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ABSTRACT 
Formal dipolar cycloadditions of cyclopropanes and aziridines are useful methods for 
the formation of carbo- and heterocycles.  Given our group’s previous interest in this 
area, we sought to expand the scope of strained ring cycloadditions by employing 
heterocumulenes as dipolarophiles.  This thesis describes our development of Lewis acid 
catalyzed formal (3 + 2) cycloadditions between donor–acceptor cyclopropanes and 
isocyanates, isothiocyanates, and carbodiimides to furnish various five-membered 
heterocycles.  Enantioenriched cycloadducts can be accessed through a stereospecific 
reaction if enantiopure substrates are employed.  We also present a method to access 
more highly nitrogenated heterocycles by replacing donor–acceptor cyclopropanes with 
activated aziridines.  These aziridines react smoothly with isothiocyanates and 
carbodiimides in the presence of zinc Lewis acids to afford iminothiazolidine and 
iminoimidazolidine products in good yields.  Our efforts to apply a cyclopropane 
cycloaddition toward the total synthesis of the indole alkaloid calophyline A are also 
described 
In addition, a method for the activation of sterically hindered allylic C–H bonds is 
presented.  Despite numerous recent advances in the functionalization of allylic C–H 
bonds and the general utility of these transformations, reactions of sterically hindered 
substrates remain challenging.  In this thesis we describe the development of a novel 
system for the palladium(II)-catalyzed allylic C–H acetoxylation of α-allyl lactams.  We 
believe the lactam moiety may act as a directing group to aid in the palladation of these 
generally unreactive substrates.  During optimization, we also discovered enal products 
were formed if water was added.  These conditions represent the first example of a 
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Synthetic Applications and Methodological Developments of Donor–Acceptor 
Cyclopropanes and Related Compounds in the Stoltz Laboratory 
 
 
1.1  INTRODUCTION 
Donor–acceptor cyclopropanes (1, Scheme 1.1), or those possessing one or more 
electron-donating groups and electron-withdrawing groups on adjacent carbons, are 
useful building blocks in organic synthesis.1  Due to the presence of these vicinal charge-
stabilizing groups and the strain inherent to the cyclopropane core, ring opening can 
occur under mild conditions.  Typically, treatment with a Lewis acid at room temperature 
is sufficient to induce carbon–carbon bond cleavage, leading to an all-carbon 1,3-dipole 
(2).  These dipoles are quite versatile, having been shown to undergo nucleophilic 
trapping, electrophilic trapping, or dipolar cycloadditions to form a wide array of 
products (3–6, Scheme 1.1). 
                                                
† Portions of this chapter have been adapted with permission from O’Connor, N. R.; Wood, J. L.; 
Stoltz, B. M. Isr. J. Chem. 2016, 56, 431–444.  Copyright 2016 WILEY-VCH. 
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Scheme 1.1  Basic reactivity modes of donor–acceptor cyclopropanes 
  
 
The acceptor groups are often carbonyl derivatives (with esters, ketones, and 
nitriles most common), although other electron-withdrawing groups, including 
sulfonyl, sulfinyl, and phosphoryl, are occasionally used.  Traditional donor groups 
are alkoxy, silyloxy, and amino substituents.  Over the past decade, however, the 
use of aryl donor groups has become widespread, pioneered by the work of Kerr2 
and Johnson.3  Aryl-substituted cyclopropanes are readily available in one or two 
steps from styrenes or benzaldehydes using straightforward methods.1a  These 
compounds are typically more stable than cyclopropanes with heteroatom-based 
donors, and in some circumstances are capable of undergoing stereospecific 
reactions.4 
The Stoltz laboratory’s interest in donor–acceptor cyclopropanes was sparked 
during Brian M. Stoltz’s use of cyclopropane fragmentations (classified as 
electrophilic trapping in Scheme 1.1) as a method of ring expansion in the synthesis 
of K252a and the welwitindolinone C isothiocyanate core during his graduate 
studies in the John L. Wood research laboratory at Yale University.  This chapter 
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the independent Stoltz laboratory’s continued use of donor–acceptor cyclopropane 
fragmentations and cycloadditions toward the total synthesis of natural products.  
Our endeavours in natural products synthesis have also resulted in the development 
of several novel synthetic methodologies involving strained ring intermediates.  
Two examples of such methods are summarized in this chapter, and two others are 
described in detail in the following chapters of this thesis. 
 
1.2   USE OF DONOR–ACCEPTOR CYCLOPROPANES AS 
INTERMEDIATES IN NATURAL PRODUCTS SYNTHESIS 
The following sections describe the use of donor–acceptor cyclopropanes as 
intermediates in natural products synthesis from the Wood research laboratory in the 
1990s and the Stoltz research laboratory over the past 16 years.  The donor–acceptor 
cyclopropanes featured in the examples below include both isolable intermediates and 
transient, highly reactive transient species. 
 
1.2.1   TOTAL SYNTHESIS OF K252a 
Our interest in the use of donor–acceptor cyclopropanes as intermediates in natural 
products total synthesis began with the synthesis of K252a (7, Scheme 1.2) by Brian M. 
Stoltz while a graduate student in the Wood laboratory at Yale.5  Isolated in 1985 by 
Sezaki and co-workers from a culture of the soil bacterium Actinomadura sp. SF-2370,6 
(+)-K252a was found to possess nanomolar inhibitory activity against protein kinase C.7  
Subsequent studies showed that structurally related compounds possess similar activity, 
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and suggested these indolocarbazole alkaloids may have potential in the treatment of 
cancers8 and neurodegenerative diseases.9 
Stoltz, Wood, and co-workers envisioned accessing K252a (7) by late stage 
glycosylation of an indolocarbazole precursor 8, itself constructed by coupling of 
diazolactam 1010 and 2,2’-biindole11  (11, Scheme 1.2).  Rationale for this 
disconnection was provided by several reports of indole C3-functionalization 
through reactions with carbenes or metal carbenoids.12  These functionalizations 
were proposed to occur by cyclopropanation of the indole C2–C3 bond and 
subsequent cyclopropane fragmentation. 
 
Scheme 1.2  Retrosynthetic analysis of K252a 
 
Extensive experimentation revealed that treatment of a mixture of 10 and 11 
with 1 mol % rhodium(II) acetate in pinacolone at 120 °C furnished the desired 
indolocarbazole 8 in 62% yield.13  Although no intermediates could be observed by 
TLC or NMR, the reaction is presumed to proceed via the transient donor–acceptor 
cyclopropane 12, produced by cyclopropanation of the rhodium carbenoid onto an 
indole C2–C3 bond (Scheme 1.3).  This cyclopropane is expected to rapidly 
fragment to form the more stable enol biindole 13, which can undergo a 6π 
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amounts of hemiaminal 15 were also obtained in the reaction, and subjection of this 
material to xylenes at reflux or CSA resulted in quantitative conversion to 8.  It was 
postulated that this byproduct was formed from adduct 13, supporting the proposed 
mechanism outlined in Scheme 1.3. 
 
Scheme 1.3  Total synthesis of K252a 
 
Indolocarbazole 8 was advanced to K252a by coupling with furanose 9 
(synthesized in four steps from methyl diazoacetoacetate) using conditions inspired 
by McCombie.14  The desired isomer of the two glycosylated indolocarbazoles (16) 
was then deprotected using TFA and thioanisole to provide the target with a longest 
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1.2.2   SYNTHESIS OF THE WELWITINDOLINONE CARBON SKELETON 
Stoltz, Wood, and co-workers continued to pursue their interest in donor–acceptor 
cyclopropane intermediates in their efforts toward the carbon skeleton of the 
welwitindolinone alkaloids.15  Isolated in the 1990s from various cyanobacteria, some 
welwitindolinone alkaloids act as P-glycoprotein P-170 inhibitors with multidrug-
resistance reversing activity.16  Stoltz and Wood planned to form the carbon skeleton of 
the most potent member of the family, N-methylwelwitindolinone C isothiocyanate (17, 
Scheme 1.4) by elaboration of oxindole 18, itself formed by ring opening and further 
functionalization of a donor–acceptor cyclopropane derived from compound 19. Diazo 19 
was to be synthesized from isatin (20). 
 
Scheme 1.4  Retrosynthetic analysis of N-methylwelwitindolinone C isothiocyanate 
 
In the forward direction, Wittig homologation of isatin (20) and 
cyclopropanation of the resulting olefin using a phosphorus ylide, followed by N-
methylation produced stable cyclopropane 21, containing one aryl donor group and 
two vicinal carbonyl acceptor groups (Scheme 1.5).  The ethyl ester was converted 
to α-diazo ketone 22, which upon treatment with rhodium(II) trifluoroacetate and 
Montmorillonite K-10 clay underwent an aryl C–H insertion step to afford tetracycle 
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Scheme 1.5  Synthesis of the carbon skeleton of N-methylwelwitindolinone C isothiocyanate 
 
 Benzylic oxidation, tosylhydrazone formation, and elimination selectively formed 
the desired α-diazo ketone (19).  Exposure of the corresponding rhodium carbenoid to 
allyl alcohol furnished cycloheptenone 25 in nearly quantitative yield.  This reaction 
proceeds by initial insertion of the rhodium carbenoid into the O–H bond of allyl alcohol 
to form transient cyclopropane 24, which features a strong enol donor substituent at one 
position and a carbonyl acceptor group at a vicinal position.  This unstable intermediate 
undergoes fragmentation to produce cycloheptenone 25.  Addition of ethynylmagnesium 
bromide and Claisen rearrangement gave enyne 26, which was advanced to the 
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1.2.3   APPROACH TOWARD THE SYNTHESIS OF BIELSCHOWSKYSIN 
The independent Stoltz laboratory continued to investigate the strategy of 
cyclopropane fragmentation en route to larger carbocyclic rings in their approach 
toward the total synthesis of bielschowskysin (27, Scheme 1.6A).17  Isolated in 2004 
from a Caribbean coral, 27 was found to possesses potent anticancer activity.18  The 
simplified scaffold of 28 was chosen as a model system. 
Stoltz and co-workers planned to construct the highly functionalized core 
cyclobutane ring of 28 from donor–acceptor cyclopropane 30 by a ring opening-
Michael addition cascade sequence proceeding through intermediate 29 (Scheme 
1.6B).  Cyclopropane 30 would be synthesized from diazoacetoacetate 31, which in 
turn would be accessed from simple aryl bromide (32)19 and enone (33)20 building 
blocks. 
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Scheme 1.6  A) Bielschowskysin and a simplified scaffold and B) Retrosynthetic analysis of 
bielschowskysin 
 
In the forward direction, alcohol 34 was synthesized from 32 using a three-step 
sequence consisting of borylation,21 Suzuki cross-coupling with vinyl iodide 33,22 
and diastereoselective Luche reduction (Scheme 1.7).  At this stage, optically pure 
material could be optained by the oxidative kinetic resolution protocol previously 
developed in the Stoltz laboratory.23  Advancement to diazoacetoacetate 31 was 
achieved through another three step sequence.24  The key donor–acceptor 
cyclopropane 37 was obtained in moderate yield upon heating 30 with Cu(TBS)2 
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Scheme 1.7  Synthesis of donor–acceptor cyclopropane 37 
 
At this point, it was envisioned that acetate cleavage and oxidation of the 
resulting hydroxyl group would afford cyclopropane 30, which would undergo the 
fragmentation-Michael addition cascade upon exposure to a Lewis acid.  
Unfortunately, acetate cleavage, oxidation, and treatment with lanthanum triflate in 
methanol produced cyclopentanol 42 (Scheme 1.8) rather than desired cyclobutane 
28.  This occurs as the result of an undesired translactonization following acetate 
hydrolysis to give 39.  Oxidation and exposure to Lewis acid induces fragmentation 
of the cyclopropane to form a stabilized enolate and an extended oxocarbenium 
cation (40).  Addition of one equivalent of methanol provides presumed 
intermediate 41, which proceeds through two transesterifications and hemiketal 
formation to provide the observed cyclopentanol (42).  Unfortunately, all attempts 
to avoid this undesired translactonization were unsuccessful, and synthetic efforts 
concluded at this point.  This effort highlights the tenuous nature of such reactive, 









































1. Ac2O, DMAP, CH2Cl2
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Chapter 1 – Applications of Donor–Acceptor Cyclopropanes in the Stoltz Laboratory 11 
Scheme 1.8  Cyclopropane fragmentation 
 
 
1.2.4   SYNTHESIS OF THE CORE OF THE GAGUNIN DITERPENOIDS 
Stoltz and co-workers again chose to investigate a donor–acceptor cyclopropane 
fragmentation strategy in their construction of the carbocyclic core structure of the 
gagunin diterpenoids.25  The gagunin family of natural products, isolated in 2002 
from the sea sponge Phorbas sp., are characterized by a highly oxygenated 5–6–7 
tricyclic core containing two all-carbon quaternary stereocenters. Depending on the 
extent of core oxygenation, these diterpenoids exhibit varying levels of 
cytotoxicity.26  
Retrosynthetically, access to these natural products (exemplified by gagunin E, 
43, Scheme 1.9) would proceed via fragmentation of donor–acceptor cyclopropane 
44.  This compound would be reached from triflate 45, itself accessed from 
symmetrical precursor 46, a key intermediate in our previously reported total 





















1. DMP, CH2Cl2, 23 °C
MeOH, 0 °C
(80% yield)
2. La(OTf)3, MeOH, 55 °C
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Scheme 1.9  Retrosynthetic analysis of gagunin E 
 
In the forward direction (Scheme 1.10), compound 46 was synthesized from 
diallyl succinate in two steps as a mixture of diastereomers.27a  Subjection of this 
material to a double enantioselective decarboxylative allylic alkylation reaction28 
using conditions developed in the Stoltz laboratory gave bis-allylated cyclohexane-
1,4-dione 47 in excellent yield, good diastereoselectivity, and excellent 
enantioselectivity.  Enol triflate formation afforded 45, which was converted to 
tetraene 48 over four steps.  Ring-closing metathesis produced 49, containing the 
seven-membered ring of the gagunin core.  A four-step sequence consisting of 
enone carbonate protection and allyl functional group interconversions delivered α-
diazo ketone 50. 
 Treatment of 50 with rhodium(II) acetate in dichloromethane gave 
cyclopropane 44 in good yield, and ring fragmentation with potassium carbonate in 
methanol furnished 51, which contains the 5–6–7 tricyclic core of the gagunin 
diterpenoids, in 31% yield.  This appears to be an uncommon example of the 
reactivity of a donor–acceptor cyclopropane with a transiently formed enolate acting 
as the donor.29  Interestingly, cyclopropane 54 was also isolated from the 
fragmentation step in 27% yield.  This unexpected compound is presumed to arise 
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Scheme 1.10  Synthesis of the gagunin core 
 
 
1.2.5   SYNTHESIS OF THE ABCD RING SYSTEM OF SCANDINE 
Having gained an appreciation for the utility of donor–acceptor cyclopropanes in 
synthesis, Stoltz and co-workers planned to use a cyclopropane-olefin cycloaddition 
to construct the central C ring of scandine (55, Scheme 1.11), the parent compound 
of the Melodinus alkaloids.31,32  Although they possess no known biological activity, 
these compounds are of interest due to their structural complexity, specifically in 
regard to the highly congested cyclopentane (C) ring. 
The original retrosynthesis is shown in Scheme 1.11.  Incorporation of a late-
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56, which could arise from cyclopentane 57 by nitro reduction, lactam ring closure, 
allylation, and diastereoselective ring-closing metathesis.33  This cyclopentane could 
be formed by a palladium-catalyzed formal (3 + 2) cycloaddition between donor–
acceptor cyclopropane 58 and nitroolefin 59.34 
 
Scheme 1.11  Retrosynthetic analysis of scandine 
 
Unfortunately, despite significant effort, the synthesis of divinyl cyclopropane 
58 proved elusive.35  A revised retrosynthesis was developed, beginning with a 
monovinyl cyclopropane in the (3 + 2) reaction, and relying on a late-stage C–H 
vinylation to install the second vinyl group.  The use of stable vinylcyclopropane 60 
(Scheme 1.12) relied upon the known reactivity of such compounds to unveil their 
donor–acceptor reactivity upon treatment with palladium(0) complexes.34 
In the forward sense, exposure of monovinyl cyclopropane 6036 and commercially 
available dinitrostyrene 59 to a palladium(0) phosphine complex afforded 
nitrocyclopentane 61 in good yield as a mixture of diastereomers (Scheme 1.12).  
Treatment of the mixture with zinc dust in acetic acid resulted in reduction of both nitro 
groups and subsequent lactamization (with exclusive cis ring fusion) to afford the 
quinolone products as a 2:1 mixture of vinyl diastereomers.  The desired minor 
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Amine protection and ring-closing metathesis furnished tetracycle 65 in good yield.  
Although 65 does not contain the vinyl group present in the natural product, Stoltz’s 
route assembled four out of the five rings in only six steps from commercial sources. 
 
Scheme 1.12  Synthesis of the ABCD ring system of scandine 
 
1.3   DEVELOPMENT OF NOVEL REACTIONS OF TRANSIENT 
DONOR–ACCEPTOR CYCLOPROPANES AND CYCLOBUTANES 
The following sections describe methodologies developed in the Stoltz research 
laboratory inspired by their efforts in the total synthesis of natural products.  These 
methods are believed to proceed through transient donor–acceptor cyclopropane or 


































1. Ac2O, pyridine, CH2Cl2, 25 °C
2. HG II cat., CH2Cl2, TBME, 60 °C
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1.3.1   SYNTHESIS OF FUSED CARBOCYCLES BY A TANDEM WOLFF–
COPE REARRANGEMENT 
Natural products containing fused 5–7 and 6–7 ring systems are of considerable 
interest to the synthetic community due to their biological potential.37  Inspired by 
complex seven-membered-ring-containing natural products like guanacastepene A 
(66, Scheme 1.13),38 Stoltz and co-workers devised a novel approach to the fused 
cycloheptadienone scaffold 67, which could be viewed as a synthetic intermediate 
en route to these targets.  This scaffold could conceivably arise through a ketene-
Cope rearrangement of a divinyl cyclopropane such as 68.  While compounds like 
68 do not fit the typical structural motif of a donor–acceptor cyclopropane, they are 
nevertheless quite reactive.  For any asynchronous reactions of these compounds, it 
is possible to envision the transition state featuring vicinal positive and negative 
charge stabilization, as is the case for most reactions of traditional donor–acceptor 
cyclopropanes.  If the ketene moiety of 87 were to be accessed from an α-diazo 
ketone (69), it may be possible to form the desired cycloheptadienones in a single 
pot through a tandem Wolff–Cope rearrangement.39 
 
Scheme 1.13  Synthetic inspiration for the tandem Wolff–Cope rearrangement 
 
Donor–acceptor cyclopropane 72 was synthesized from methyl acetoacetate and 
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rearrangements.  Extensive optimization revealed that the use of silver benzoate and 
triethylamine with sonication in THF at 45 °C resulted in nearly quantitative yield 
of the desired fused cycloheptadienone product 75 as a single diastereomer (Scheme 
1.14). 
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 The substrate scope of the reaction is shown in Scheme 1.14.  A range of 
hydroxyl protecting groups were tolerated (72–74).  Compounds containing a 1,1-
disubstituted olefin (78) or a monosubstituted olefin (80 and 84) were also 
competent substrates.  Finally, a tricyclic product (83) and a 6–7 ring system (85) 
could be formed in excellent yields.  Interestingly, photochemical conditions were 
necessary to achieve high yields with the substrates containing monosubstituted 
olefins (80 and 84). 
Treatment of substrate 72 with the photochemical conditions shown in Scheme 
1.15 resulted in the isolation of the fused cyclopentenone product 88 in good yield 
after a prolonged reaction time.  This product is proposed to arise from a Norrish 
type I fragmentation of cycloheptadienone 75, followed by intramolecular radical 
recombination, resulting in a net 1,3-acyl migration process.40 
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Scheme 1.15  Selected scope of the tandem Wolff–Cope–1,3-acyl shift reaction 
 
The substrate scope of the tandem Wolff–Cope–1,3-acyl shift process is shown in 
Scheme 1.15.  As with the simpler Wolff–Cope rearrangement, this reaction is successful 
on substrates incorporating a variety of hydroxyl protecting groups (72–74) and olefin 
substitutions (91 and 93).  This method is able to deliver α-quaternary cyclopentenone 92 
in excellent diastereoselectivity.  Finally, access to  both the 5–5 (88–90, 92) and 5–6 
(94) fused ring systems is possible in good yields and diastereoselectivities. 
 
1.3.2   THE ACYL-ALKYLATION OF ARYNES WITH β-KETOESTERS 
During efforts directed toward the arylation of enolates with benzyne to form 
all-carbon quaternary stereocenters (e.g. 97), we found that treatment of β-ketoester 
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in the formation of disubstituted arene 98 in moderate yield (Scheme 1.16).41  This 
represented the first mild and direct example of the insertion of benzyne into a β-
ketoester carbon–carbon bond,42 and is likely produced by fragmentation of 
transiently generated donor–acceptor cyclobutane 102. 
 
Scheme 1.16  Unexpected aryne C–C insertion and mechanistic proposal 
 
This reactivity of benzyne with β-ketoesters proved to be quite general, and the scope 
of acyl-alkylation products produced is shown in Scheme 1.17.  A variety of β-ketoesters 
were tolerated, including those with branching or heteroatom-containing groups at the γ-
position (providing products 107–111).  β-Ketoesters derived from bulky and complex 
alcohols also afforded the acyl-alkylation products in good yield (112 and 113).  
Substituted arynes could also be used, furnishing 114–116 in good to excellent yields.  
Finally, cyclic β-ketoesters were also capable substrates, reacting to give ring expansion 
products 117–121, in moderate yields, representing a novel route to medium-sized rings. 
The Stoltz laboratory has demonstrated the utility of this transformation as well as related 
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hypothesis has been invoked by  numerous groups in recent disclosures of aryne insertion 
reactions.44 
 
Scheme 1.17  Scope of the acyl-alkylation of arynes 
 
 
1.4   SUMMARY 
Donor–acceptor cyclopropanes have been used for decades to rapidly transform 
simple starting materials to complex products.  Recent developments in the use of aryl 
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This chapter has described the Stoltz laboratory’s use of donor–acceptor 
cyclopropanes and related compounds in both natural products synthesis and 
methodological developments over the past 15 years with inspiration dating into the 
early 1990s.  As is the case in many laboratories, endeavors in total synthesis often 
inspire the development of new methods.45  In this case, application of a donor–
acceptor cyclopropane (3 + 2) cycloaddition toward the synthesis of scandine 
initiated further investigations into related reactivity, culminating the development 
of novel cycloadditions of cyclopropanes and aziridines described in Chapters 2 and 
3 of this thesis.  Additionally, the laboratory’s interest in cyclopropane 
cycloadditions inspired the initial approach to the total synthesis of calophyline A, 
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Lewis Acid Mediated (3 + 2) Cycloadditions of 
Donor–Acceptor Cyclopropanes with Heterocumulenes 
 
 
2.1  INTRODUCTION 
Donor–acceptor cyclopropanes (1), or those possessing one or more electron-donating 
groups and electron-withdrawing groups on vicinal carbons, have found utility in organic 
synthesis due to their ease of construction and unique reactivity profiles.1  Upon 
treatment with a Lewis acid, these cyclopropanes are converted to reactive 1,3-dipoles 
(2), which can undergo nucleophilic trapping, electrophilic trapping, or dipolar 
cycloadditions to give a wide array of useful products (3–6, Scheme 2.1).  Dipolar 
cycloadditions of donor–acceptor cyclopropanes (i.e. 1→6) are a particularly powerful 
                                                
† This work was performed in collaboration with Dr. Alexander F. G. Goldberg and Dr. Robert A. 
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with permission from Goldberg, A. F. G.; O’Connor, N. R.; Craig, R. A., II; Stoltz, B. M. Org. 
Lett. 2012, 14, 5314–5317.  Copyright 2012 American Chemical Society. 
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method for the construction of five- and six-membered rings, and this approach has been 
used in several recent total syntheses of natural products.2 
Scheme 2.1  Basic reactivity modes of donor–acceptor cyclopropanes 
 
The first reports of dipolar cycloadditions of donor–acceptor cyclopropanes were 
limited to cyclopropanes with alkoxy and silyloxy donor groups.  In recent years, 
however, several groups have been investigating the use of aryl donor groups.  Work by 
Kerr, Johnson, and others have shown that aryl-substituted cyclopropane 1,1-diesters are 
capable of undergoing formal cycloadditions with a variety of dipolarophiles, including 
nitrones,3 aldehydes,4 imines,5 and silyl enol ethers.6 Unlike with alkoxy and silyloxy 
donor groups, cyclopropanes with aryl donor groups can undergo enantiospecific 
reactions with proper choice of Lewis acid.  It is believed that a correctly tuned Lewis 
acid can activate these aryl-substituted cyclopropanes (131, Scheme 2.2) toward 
nucleophilic attack by a dipolarophile without complete cleavage of the carbon–carbon 
bond, allowing the stereochemical information of the starting material to be transferred to 
the product through an SN2-like nucleophilic attack of the dipolarophile upon activated 
intermediate 132.  The resulting zwitterion (133) then undergoes ring closure to give the 
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Scheme 2.2  Mechanistic rationale for the stereospecific cycloadditions of donor–acceptor 
cyclopropanes with aryl donor groups 
 
Our research group has had a longstanding interest in the application of donor–
acceptor cyclopropanes toward the construction of complex natural products.7  Our recent 
use of a cyclopropane-olefin cycloaddition in the construction of the core of the 
Melodinus alkaloids furthered our interest in this area.2e  We were interested in extending 
Kerr and Johnson’s methodolgies for the cycloadditions of aryl-substituted donor–
acceptor cyclopropanes to include heterocumulene dipolarophiles.  Specifically, we 
hoped to use isocyanates as electrophiles to access 5-aryl γ-lactam derivatives (135, 
Scheme 2.3), as they form part of the core of many natural products such as trolline 
(136),8 crispine A (137),9 and many of the Erythrina alkaloids (138).10  Although 
isocyanates and isothiocyanates have been shown to undergo (3 + 2) cycloadditions with 
alkoxy-substituted donor–acceptor cyclopropanes, yields were low and the reaction 
stereochemistry was controlled by existing stereocenters in the reactants, rather than 
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Scheme 2.3  A) Proposed reactions of donor–acceptor cyclopropanes with heterocumulenes and B) 
Potential synthetic targets containing the 5-aryl γ-lactam motif 
 
 
2.2  INITIAL EFFORTS: REACTIONS OF DONOR–ACCEPTOR 
CYCLOPROPANES WITH ISOCYANATES 
We chose to focus our initial efforts on the reactions of donor–acceptor 
cyclopropanes with isocyanates, as the product lactams could be most directly 
applied toward the synthesis of alkaloids such as those shown in Scheme 2.3. 
 
2.2.1  CYCLOADDITIONS OF DONOR–ACCEPTOR CYCLOPROPANES 
WITH POTASSIUM CYANATE AND TRIMETHYLSILYL ISOCYANATE 
We began our studies by investigating the reactivity of potassium cyanate with aryl-
substituted donor–acceptor cyclopropane 139 (Scheme 2.4).  Although the reactivity of 
inorganic cyanates with cyclopropanes was not known, the analogous reactivity with 
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methodology to the synthesis of secondary γ-lactams, and use of an inorganic cyanate 
would allow for direct and economical access to the desired heterocycles. 
Scheme 2.4  Initial screening of cyclopropane reactivity with potassium cyanate 
 
We screened for reactivity of cyclopropane 139 with potassium cyanate in DMF, 
THF, and dichloromethane, at temperatures ranging from 50 to 140 °C, but detected no 
product by LCMS analysis (Scheme 2.4).  Use of additives such as tetra(n-
butyl)ammonium bromide and 18-crown-6 also failed to produce the desired reactivity.  
In all cases, the results were either a lack of reactivity or isomerization of the starting 
material to styrene 143 (see Scheme 2.5).  In order to increase the reactivity of the 
cyclopropane, we attempted the use of a stronger donating group (140), but this was also 
unsuccessful.  We hypothesized that a Lewis acid might assist in the reaction by further 
activating the cyclopropane, but addition of tin(II) triflate and zinc(II) triflate made no 
difference, possibly due to cyanate coordination to and deactivation of the Lewis acids. 
We investigated the use of trimethylsilyl isocyanate as an alternative that may be 
less likely to coordinate to and deactivate the Lewis acid, and we were able to observe the 
desired lactam product in 10% yield when 20 mol % tin(II) triflate was used in 
dichloromethane (Scheme 2.5).  A screen of various Lewis acids, solvents, and relative 
stoichiometries was unable to identify conditions to reliably afford the lactam product in 










139   R = Me
140   R = OMe
141   R = Me
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reaction, but phenyl and tosyl isocyanate were not successful, and isopropyl isocyanate 
gave only a trace of the desired product. 
 
Scheme 2.5  Initial observation of desired reactivity with trimethylsilylisocyanate 
 
 
2.2.2  CYCLOADDITIONS OF DONOR–ACCEPTOR CYCLOPROPANES 
WITH ALKYL ISOCYANATES 
After our lack of success with potassium cyanate, trimethylsilyl isocyanate, tosyl 
isocyanate, and phenyl isocyanate, we proceeded to study more robust and reactive 
alkyl isocyanates, such as benzyl- and isopropyl isocyanate.  These alkyl 
dipolarophiles displayed sluggish reactivity with tin(II) triflate, but a study of 
stronger Lewis acids and a reinvestigation of the other reaction parameters found 
that the tertiary lactam products could be obtained in good to moderate yields using 
stoichiometric iron(III) chloride in dichloromethane.  The scope of the reaction is 
shown in Scheme 2.6.  Lactams arising from cyclopropanes with both electron-rich 
(145) and electron-poor (146) donor groups are easily accessed, as is the product 
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Notably, secondary lactam 149 can be accessed if trimethylsilyl isocyanate is used, 
with the trimethylsilyl group being lost during reaction workup. 
 




2.3  REACTIONS OF DONOR–ACCEPTOR CYCLOPROPANES WITH 
ISOTHIOCYANATES 
Having established the desired reactivity with isocyanate dipolarophiles, we 
subsequently investigated the reactions of isothiocyanates in order to furnish 





























































a Glovebox FeCl3 used.  b Benchtop FeCl3 used. c Trimethylsilyl isocyanate used.
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2.3.1  INITIAL REACTIVITY AND STRUCTURAL REASSIGNMENT 
When cyclopropane 140 was subjected to an excess of allyl isothiocyanate in the 
presence of 30 mol % tin(II) triflate in wet ethyl acetate, we isolated 18% yield of a 
product with the formula and mass of our expected thioamide product (Scheme 2.7).  
Upon closer examination of the 13C NMR and infrared spectra, we were surprised to find 
that our isolated product was in fact thioimidate 150, rather than thioamide 151. 
 
Scheme 2.7  Initial observation of desired reactivity with allyl isothiocyanate 
 
During this time, Li and coworkers reported an iron(III) chloride mediated (3 + 2) 
cycloaddition of aryl-substituted donor–acceptor cyclopropanes and aryl isothiocyanates 
giving thioamide products (Scheme 2.8A).13  We suspected Li’s products may have been 
misassigned due to the close similarities between the proton NMR spectra of the two 
compounds and Li’s lack of inclusion of IR spectra in their characterization data.  We 
treated cyclopropane 152 with phenyl isothiocyanate under Li’s conditions with slight 
modifications (Scheme 2.8B), and obtained a product with identical proton and 13C NMR 
spectra as those reported by Li for compound 153.  The 13C NMR showed a peak 
consistent with a thioimidate carbon (approximately 160 ppm), rather than a thioamide 
(approximately 200 ppm).  Additionally, the IR spectrum showed a C=N stretch 
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believe these data, in combination with a crystal structure of one of our other thioimidate 
products (155, Scheme 2.8C) provide sufficient support for our reassignment of Li’s 
products as thioimidates rather than thioamides. 
 
Scheme 2.8  Structural reassignment of Li’s products15 
 
 
2.3.2  OPTIMIZATION AND SCOPE OF CYCLOADDITIONS WITH 
ISOTHIOCYANATES 
Upon further optimization of our initial isothiocyanate hit, we found that use of 
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dichloromethane gave the best yields.  Furthermore, the products slowly decompose 
under the reaction conditions so prompt workup and purification was necessary.  The 
substrate scope of the reaction is displayed in Scheme 2.9.  Cyclopropanes bearing 
electron-rich aryl rings were the most reactive, whereas those with electron-withdrawing 
or ortho substituents were less reactive.  A vinyl group could replace the aryl group as a 
donor, giving vinyl thioimidate 165 in quantitative yield.  Finally, cyclohexyl 
isothiocyanate also worked well in the reaction.  Crystallographic analysis of compound 
155 confirmed our assignments of these products as thioimidates (other products assigned 
by analogy). 
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2.4  REACTIONS OF DONOR–ACCEPTOR CYCLOPROPANES WITH 
CARBODIIMIDES 
We next examined carbodiimides as dipolarophiles in the (3 + 2) cycloaddition 
reaction.  Our initial attempt in benchtop ethyl acetate formed the desired product in 22% 
yield but suffered from the formation of a large amount of urea byproduct due to 
hydrolysis of the carbodiimide in the wet solvent.  Further optimization studies resulted 








































150 OMe 98%, 1.5 h
159 Ph 80%, 1.5 h
160 Cl 66%, 6 h
161 Me 99%, 4 h
162 t-Bu 57%, 5 h
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used in dry dichloromethane.  The scope of the reaction is shown in Scheme 2.10.  In 
general, these reactions were faster than the reactions with isothiocyanates, forming the 
amidine products in as little as 10 minutes.  The primary amidines 174 and 175 could be 
formed in good yields using bis(trimethylsilyl)carbodiimide.  Highly substituted amidine 
176 could be prepared in moderate yield, and an aryl carbodiimide also underwent the 
reaction to give amidine 177 in good yield. 
 




2.5  INVESTIGATIONS INTO THE REACTION STEREOCHEMISTRY 
After concluding our study of the reaction scope, we investigated the possible transfer 
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R3 =
171 OMe 98%, 10 min
172 Ph 92%, 75 min
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products.  Although treatment of enantioenriched cyclopropane (S)-152 with an 
isocyanate in the presence of iron(III) chloride resulted in complete racemization of the 
benzylic stereocenter (Scheme 2.11A),16 we observed transfer of chirality in the case of 
the tin(II) triflate mediated cycloadditions (Scheme 2.11B,C).  Notably, substrates that 
required longer reaction times resulted in increased erosion of enantiomeric excess.17  The 
absolute configuration of an amidine product was confirmed by crystallographic analysis 
of the hydrobromide salt (Figure 2.1), which revealed an inversion of configuration at the 
benzylic position during the course of the reaction. 
 
Scheme 2.11  Stereochemical investigations of the reaction of enantioenriched cyclopropane (S)-
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Figure 2.1  Absolute configuration of an amidine product determined by X-ray crystallography18 
 
 
2.6  PROPOSED MECHANISM 
We propose the mechanism of the isothiocyanate and carbodiimide reactions 
involves coordination of the Lewis acid to the cyclopropane to weaken the polarized C–C 
bond, forming intermediate 178.  Attack of the nucleophilic dipolarophile in an SN2-like 
fashion followed by ring closure affords heterocyclic product 180 (Scheme 2.12).  This 
mechanism is supported by our observations of the reaction stereochemistry and the 
greater reactivity of electron-rich dipolarophiles and of cyclopropanes with electron-rich 
aryl donor groups.  Our mechanism is analogous to that proposed by Johnson and Kerr 
for the (3 + 2) cycloadditions of donor–acceptor cyclopropanes with aldehydes and 
nitrones, respectively.3d,4c,19  We propose a similar mechanism for the reactions of 
isocyanates, however the stronger Lewis acid iron(III) chloride likely promotes the 
formation of a zwitterionic intermediate, preventing the transfer of stereochemical 
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Scheme 2.12  Proposed mechanism of reactions of donor–acceptor cyclopropanes with 
isothiocyanates and carbodiimides 
 
 
2.7  CONCLUSIONS AND FUTURE DIRECTIONS 
In conclusion, we have developed a novel method for the formation of five-
membered heterocycles from simple and readily accessible precursors.  Our studies 
suggest that carbodiimides are more reactive than isothiocyanates, which in turn are more 
reactive than isocyanates.  Furthermore, with tin(II) triflate as a Lewis acid, a highly 
stereselective reaction is possible, allowing for the synthesis of enantioenriched 
heterocycles from enantioenriched cyclopropanes.  Investigations to apply this 
methodology toward the total synthesis of natural products are described in Appendix 2. 
 
2.8  EXPERIMENTAL SECTION 
2.8.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed in flame-dried or oven-dried 
glassware under an argon or nitrogen atmosphere using dry, deoxygenated solvents 
(distilled or passed over a column of activated alumina).20  Diazodimethylmalonate was 
prepared according to the method of Davies and coworkers.21  Potassium cyanate and all 
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reagents were used as received with the exception of tin(II) triflate and iron(III) chloride, 
which were stored in a nitrogen-filled glovebox.  A separate bottle of iron(III) chloride 
was stored in a calcium sulfate desiccator on the benchtop.  Thin-layer chromatography 
(TLC) was performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm) and 
visualized by UV fluorescence quenching, potassium permanganate, or p-anisaldehyde 
staining.  SiliaFlash P60 Academic Silica gel (particle size 0.040–0.063 mm) was used 
for flash chromatography.  1H and 13C NMR spectra were recorded on a Varian 400 (at 
400 MHz and 100 MHz, respectively) or on a Varian Mercury 500 (at 500 MHz and 126 
MHz, respectively) and are reported relative to CHCl3 (δ 7.26 & 77.16 ppm, respectively) 
or tetramethylsilane (0.00 ppm).  Data for 1H NMR spectra are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration).  Abbreviations 
are used as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, hept = 
heptet, m = complex multiplet, app = apparent br = broad.  IR spectra were recorded on a 
Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of absorption 
(cm–1).  HRMS were acquired using an Agilent 6200 Series TOF with an Agilent 
G1978A Multimode source in electrospray ionization (ESI), atmospheric pressure 
chemical ionization (APCI) or mixed (MM) ionization mode; HRMS were also acquired 
using a JEOL JMS-600H with fast atom bombardment (FAB).  Optical rotations were 
recorded on a JASCO P-2000 Polarimeter.  Enantiomeric excesses were determined by 
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2.8.2   GENERAL AND MISCELLANEOUS EXPERIMENTAL PROCEDURES 
 
General Procedure A. Knoevenagel condensation. 
A round-bottom flask was charged with the appropriate aldehyde (181, 14.4 mmol), 
followed by benzene (85 mL), dimethyl malonate (15.8 mmol), piperidine (1.44 mmol), 
and acetic acid (1.44 mmol).  The flask was equipped with a Dean-Stark trap and 
condenser and the solution heated to reflux.  Upon completion (as determined by TLC 
analysis), evaporation of the solvent gave the crude product, which was purified by silica 
gel column chromatography. 
 
 
General Procedure B. Corey–Chaykovsky cyclopropanation. 
Sodium hydride (2.56 mmol, 60% dispersion in mineral oil) was suspended in 
anhydrous DMF (4 mL) in a flame-dried round-bottom flask under nitrogen.  
Trimethylsulfoxonium iodide (2.56 mmol) was added, and the solution stirred at ambient 
temperature for 1 hour.  A solution of the appropriate benzylidene malonate (182, 2.13 
mmol) in anhydrous DMF (2 mL) was added, and the reaction mixture allowed to stir at 
room temperature.  Upon completion (as determined by TLC analysis), the solution was 
poured onto a mixture of ice and aqueous 2 M HCl (10 mL) and extracted with diethyl 
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magnesium sulfate, filtered, and concentrated in vacuo to give the crude product, which 
was purified by silica gel column chromatography. 
 
 
General Procedure C. Styrene cyclopropanation. 
Rh2(esp)2 (0.3 mg) was added to a flame-dried round-bottom flask, which was then 
evacuated and backfilled with nitrogen three times. The appropriate styrene (183, 5.0 
mmol) and anhydrous dichloromethane (5 mL) were then added and the solution was 
stirred under nitrogen and cooled in an ice bath.  A solution of diazodimethylmalonate 
(6.0 mmol) in anhydrous dichloromethane (5 mL) was added dropwise over 20 minutes.  
The reaction solution was then allowed to warm to ambient temperature.  Upon 
completion (as determined by TLC analysis), the crude product was adsorbed onto silica 
gel and purified by column chromatography. When traces of the rhodium catalyst 
remained after chromatography (as determined by a blue discoloration), the product was 
dissolved in anhydrous benzene (1.5 mL) in a flame-dried round-bottom flask.  A 
solution of tetrakis(hydroxymethyl)phosphonium hydroxide (10 mL, 1 M in isopropanol) 
was added,22 and the mixture was stirred at 60 °C for 12 hours.  The solution was then 
cooled to room temperature, diluted with diethyl ether (20 mL), washed once with water 
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General Procedure D. Isocyanate (3 + 2) reaction with D-A cyclopropanes, Method A. 
To a flame-dried 10 mL flask equipped with a magnetic stir bar was added iron(III) 
chloride (0.44 mmol) in an inert atmosphere glovebox. The flask was sealed with a 
Teflon septum, removed from the glovebox, and placed under a nitrogen atmosphere. To 
an oven-dried 1 dram vial were added the appropriate cyclopropane (131, 0.4 mmol) and 
isocyanate (1.2 mmol). The vial was sealed with a screw cap fitted with a Teflon septum, 
and this mixture was transferred to the reaction flask as a solution in anhydrous 
dichloromethane (1 mL + 0.33 mL rinse). The solution was then allowed to stir at 
ambient temperature under nitrogen.  Upon consumption of the cyclopropane (as 
determined by TLC analysis), the reaction solution was diluted with dichloromethane, 
adsorbed onto Celite, and purified by silica gel column chromatography. 
 
General Procedure E. Isocyanate (3 + 2) reaction with D-A cyclopropanes, Method B. 
To an oven-dried 1 dram vial equipped with a magnetic stir bar was added iron (III) 
chloride (0.44 mmol) and oven-dried 4Å molecular sieves (50 mg). The vial was sealed 
with a screw cap fitted with a rubber septum, and was placed under a nitrogen 
atmosphere. To a second oven-dried 1 dram vial was added the appropriate cyclopropane 
(131, 0.4 mmol) and isocyanate (1.2 mmol). The vial was sealed with a screw cap fitted 
with a Teflon septum and this mixture was transferred to the first vial as a solution in 
anhydrous dichloromethane (1 mL + 0.33 mL rinse). The mixture was then allowed to 
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determined by TLC analysis), the reaction mixture was partitioned between 
dichloromethane and saturated aqueous sodium bicarbonate. The layers were separated 
and the aqueous phase was washed twice with dichloromethane. The combined organic 
layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated 
in vacuo. The crude product was purified by silica gel column chromatography. 
 
 
General Procedure F. Isothiocyanate (3 + 2) reaction with D-A cyclopropanes. 
To an oven-dried 1 dram vial equipped with a magnetic stir bar was added tin(II) 
trifluoromethanesulfonate (0.44 mmol) in an inert atmosphere glovebox. The vial was 
sealed with a screw cap fitted with a Teflon® septum, removed from the glovebox, and 
placed under a nitrogen atmosphere. To a separate, oven-dried 1 dram vial were added 
the appropriate cyclopropane (131, 0.4 mmol) and isothiocyanate (0.8 mmol). The vial 
was sealed with a screw cap fitted with a Teflon® septum, and the mixture was transferred 
to the first vial as a solution in anhydrous dichloromethane (1 mL + 0.33 mL rinse). The 
heterogeneous reaction mixture was then allowed to stir at ambient temperature under 
nitrogen.  Upon consumption of the cyclopropane (as determined by TLC analysis), the 
reaction solution was diluted with dichloromethane (3 mL) and methanol (1 mL), 
adsorbed onto Celite, and purified by silica gel column chromatography. The products of 
this reaction were often found to be unstable during prolonged storage (~1 week) at 
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General Procedure G. Carbodiimide (3 + 2) reaction with D-A cyclopropanes. 
To an oven-dried 1 dram vial equipped with a magnetic stir bar was added tin(II) 
trifluoromethanesulfonate (0.44 mmol) in an inert atmosphere glovebox. The vial was 
sealed with a screw cap fitted with a Teflon® septum, removed from the glovebox and 
placed under a nitrogen atmosphere. To a separate, oven-dried 1 dram vial were added 
the appropriate cyclopropane (131, 0.4 mmol) and carbodiimide (0.44 mmol). The vial 
was sealed with a screw cap fitted with a Teflon® septum, and the mixture was transferred 
to the first vial as a solution in anhydrous dichloromethane (1 mL + 0.33 mL rinse). The 
heterogeneous reaction mixture was then allowed to stir at ambient temperature under 
nitrogen.  Upon consumption of the cyclopropane (as determined by TLC analysis), the 
reaction solution was diluted with dichloromethane (3 mL) and methanol (1 mL), 
adsorbed onto Celite, and purified by silica gel column chromatography. The product 
obtained after column chromatography is an amidinium salt, which is dissolved in DCM, 
and washed with aqueous sodium hydroxide (0.1 M) and brine, then dried over sodium 
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Preparation of Styrene 143. 
A 1 dram vial, equipped with a magnetic stir bar, was charged with tin(II) triflate 
(16.7 mg, 0.04 mmol, 0.2 equiv), then cyclopropane 140 (54.1 mg, 0.2 mmol, 1 equiv) 
was added as a solution in chloroform (1 mL). Stirring was initiated and a heterogeneous 
mixture with a yellow supernatant resulted.  Consumption of starting material was 
observed by LCMS after 35 minutes.  The reaction mixture was dry-loaded onto SiO2 (~1 
mL) and purified by silica gel column chromatography (3:1 hexanes:EtOAc) to afford 
styrene 143 as a colorless solid.  Characterization data match those reported in the 
literature.23 
 
2.8.3   CYCLOPROPANE CHARACTERIZATION DATA 
 
dimethyl 2-(p-tolyl)cyclopropane-1,1-dicarboxylate (139): 
Benzylidene dimethylmalonate 185 was prepared according to General Method A:  
30% yield. Rf = 0.19 (3:1 Heaxanes:EtOAc eluent). Characterization data matches those 
reported in the literature.24 Cyclopropane 139 was prepared according to General Method 
B:  77% yield. Rf = 0.60 (3:1 Hexanes:EtOAc). Characterization data match those 
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dimethyl 2-(4-methoxyphenyl)cyclopropane-1,1-dicarboxylate (140): 
Benzylidene dimethylmalonate 187 was prepared according to General Method A: 
92% yield. Rf = 0.27 (3:1 Hexanes:EtOAc eluent). Characterization data match those 
reported in the literature.26 Cyclopropane 140 was prepared according to General Method 
B: 95% yield. Rf = 0.40 (3:1 Hexanes:EtOAc eluent). Characterization data match those 
reported in the literature.27 
 
 
dimethyl 2-phenylcyclopropane-1,1-dicarboxylate (152): 
Benzylidene dimethylmalonate 189 was prepared according to General Method A: 
99% yield. Rf = 0.60 (3:1 Hexanes:EtOAc eluent). Characterization data match those 
reported in the literature.28 Cyclopropane 152 was prepared according to General Method 
B: 66% yield. Rf = 0.60 (3:1 Hexanes:EtOAc eluent). Characterization data match those 
reported in the literature.29 
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Cyclopropane (S)-152 was prepared according to literature methods.30 [α]D25.0 –
133.17° (c 0.99, CHCl3, >98% ee). 
 
 
dimethyl 2-([1,1'-biphenyl]-4-yl)cyclopropane-1,1-dicarboxylate (191): 
Cyclopropane 191 was prepared according to General Method C: 99% yield. Rf = 




dimethyl 2-(4-chlorophenyl)cyclopropane-1,1-dicarboxylate (193): 
Cyclopropane 193 was prepared according to General Method C:  99% yield. Rf = 
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Cyclopropane 195 was prepared according to General Method C: 60% yield. Rf = 
0.50 (3:1 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.39–7.33 (m, 1H), 
7.22–7.15 (m, 2H), 7.11–7.07 (m, 1H), 3.81 (s, 3H), 3.36 (s, 4H), 2.26 (dd, J = 8.3, 5.2 
Hz, 1H), 1.79 (dd, J = 9.1, 5.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 170.0, 167.1, 
136.6, 132.8, 129.3, 129.0, 128.9, 126.5, 53.0, 52.4, 36.5, 31.3, 19.0; IR (Neat Film, 
NaCl) 3001, 2953, 1732, 1483, 1435, 1377, 1331, 1288, 1219, 1131, 1055, 894, 785, 754 
cm-1; HRMS (ESI) m/z calc’d for C13H1435ClO4 [M+H]+: 269.0575, found 269.0573.  
 
 
dimethyl 2-mesitylcyclopropane-1,1-dicarboxylate (197): 
Cyclopropane 197 was prepared according to General Method C:  71% yield. Rf = 
0.40 (3:1 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 6.81 (s, 2H), 3.83 (s, 
3H), 3.34 (s, 3H), 3.10–3.02 (app t, J = 9.3 Hz, 1H), 2.42–2.36 (dd, J = 8.9, 4.9 Hz, 1H), 
2.32 (s, 6H), 2.22 (s, 3H), 1.97–1.89 (dd, J = 9.6, 4.9 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ 170.8, 168.0, 136.6, 129.2, 128.5, 52.9, 52.2, 35.3, 32.0, 24.0, 21.0; IR (Neat 
Film, NaCl) 2953, 2921, 1728, 1612, 1437, 1372, 1328, 1287, 1224, 1196, 1128, 1096, 
1032, 1015, 992, 894, 852, 782, 718 cm-1; HRMS (Low Voltage MM: ESI-APCI) m/z 
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dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (199): 
Cyclopropane 199 was prepared according to the method of Johnson and coworkers.32 
 
 
dimethyl 2-(4-(tert-butyl)phenyl)cyclopropane-1,1-dicarboxylate (201): 
Cyclopropane 201 was prepared according to General Method C:  89% yield. Rf = 




dimethyl 2-(4-acetoxyphenyl)cyclopropane-1,1-dicarboxylate (203): 
Cyclopropane 203 was prepared according to General Method C: 67% yield. Rf = 
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Cyclopropane 205 was prepared according to General Method C: 41% yield. Rf = 




dimethyl 2-(1-tosyl-1H-indol-3-yl)cyclopropane-1,1-dicarboxylate (209): 
N-Tosylindole-3-carboxaldehyde (207) was prepared according to literature methods 
from indole-3-carbodaldehyde (206).35  Benzylidene dimethylmalonate 208 was prepared 
according to General Method A: 75% yield. Rf = 0.20 (3:1 Hexanes:EtOAc eluent). 
Characterization data match those reported in the literature.36  Cyclopropane 209 was 
prepared according to General Method B:  95% yield. Rf = 0.30 (3:1 Hexanes:EtOAc 
eluent).  Characterization data match those reported in the literature.35  
 
2.8.4   LACTAM CHARACTERIZATION DATA  
 
 
dimethyl 1-isopropyl-2-oxo-5-phenylpyrrolidine-3,3-dicarboxylate (144):  
Prepared according to General Method F. 72% yield. Rf = 0.46 (1:1 Hexanes:EtOAc 
eluent); 1H NMR (500 MHz, CDCl3) δ 7.39–7.26 (m, 5H), 4.64 (t, J = 7.3 Hz, 1H), 3.83 
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13.8, 6.9 Hz, 1H), 1.25 (d, J = 6.9 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 168.3, 168.1, 167.2, 141.0, 129.0, 128.6, 127.2, 63.4, 59.7, 53.7, 53.5, 
47.1, 38.4, 19.8, 19.7; IR (Neat Film, NaCl) 2954, 1735, 1703, 1495, 1457, 1434, 1367, 
1342, 1259, 1218, 1130, 1090, 1065, 998, 966, 919, 894, 774 cm-1; HRMS (MM: ESI-
APCI) m/z calc’d for C17H22NO5 [M+H]+: 320.1492, found 320.1490. 
 
 
dimethyl 1-butyl-2-oxo-5-(4-methoxyphenyl)pyrrolidine-3,3-dicarboxylate (145): 
Prepared according to General Method F. 62% yield. Rf = 0.39 (1:1 Hexanes:EtOAc 
eluent); 1H NMR (500 MHz, CDCl3) δ 7.30–7.23 (m, 3H), 7.08–7.02 (m, 4H), 6.94–6.87 
(m, 2H), 5.11 (d, J = 14.5 Hz, 1H), 4.31 (t, J = 7.6 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 
3.81 (s, 3H), 3.46 (d, J = 14.6 Hz, 1H), 2.94 (dd, J = 13.8, 7.2 Hz, 1H), 2.65 (dd, J = 13.8, 
8.1 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 168.1, 167.9, 167.1, 160.0, 135.5, 130.4, 
128.8, 128.7, 128.6, 127.9, 114.6, 63.4, 58.3, 55.5, 53.7, 53.6, 45.2, 38.1; IR (Neat Film, 
NaCl) 2953, 1735, 1705, 1513, 1434, 1281, 1247 cm-1; HRMS (MM: ESI-APCI) m/z 
calc’d for C22H24NO6 [M+H]+: 398.1598, found 398.1581. 
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Prepared according to General Method F. 78% yield. Rf = 0.41 (1:1 Hexanes:EtOAc 
eluent); 1H NMR (500 MHz, CDCl3) δ 7.39–7.33 (m, 2H), 7.29–7.24 (m, 3H), 7.10–7.05 
(m, 2H), 7.04–7.00 (m, 2H), 5.13 (d, J = 14.6 Hz, 1H), 4.33 (t, J = 7.6 Hz, 1H), 3.87 (s, 
3H), 3.83 (s, 3H), 3.46 (d, J = 14.6 Hz, 1H), 2.97 (dd, J = 13.9, 7.4 Hz, 1H), 2.60 (dd, J = 
13.9, 7.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 167.9, 167.7, 167.2, 137.3, 135.1, 
134.7, 129.5, 128.8, 128.7, 128.6, 128.0, 63.2, 58.1, 53.8, 53.7, 45.3, 37.9; IR (Neat Film, 
NaCl) 2953, 1736, 1708, 1435, 1242, 1204, 1090 cm-1; HRMS (MM: ESI-APCI) m/z 
calc’d for C21H2135ClNO5 [M+H]+: 402.1103, found 402.1084. 
 
 
dimethyl 1-allyl-2-oxo-5-phenylpyrrolidine-3,3-dicarboxylate (147): 
Prepared according to General Method G. 42% yield. Rf = 0.52 (1:1 Hexanes:EtOAc 
eluent);1H NMR (500 MHz, CDCl3) δ 7.42–7.29 (m, 3H), 7.24–7.18 (m, 2H), 5.71–5.52 
(m, 1H), 5.12 (ddt, J = 10.1, 1.3, 0.7 Hz, 1H), 4.99–4.91 (m, 1H), 4.64 (t, J = 7.5 Hz, 
1H), 4.40 (m, 1H), 3.90–3.84 (m, 3H), 3.82 (d, J = 0.9 Hz, 3H), 3.15–3.02 (m, 2H), 2.62 
(dd, J = 13.8, 7.4 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 168.0, 167.9, 166.8, 138.9, 
131.0, 129.2, 128.8, 127.3, 118.9, 63.1, 59.1, 53.8, 53.6, 44.1, 38.0; IR (Neat Film, NaCl) 
2953, 1735, 1707, 1433, 1245, 1214, 1070 cm-1; HRMS (FAB+) m/z calc’d for 
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dimethyl 1-butyl-2-oxo-5-phenylpyrrolidine-3,3-dicarboxylate (148): 
Prepared according to General Method G. 58% yield. Rf = 0.10  (4:1 Hexanes:EtOAc 
eluent); 1H NMR (500 MHz, CDCl3) δ 7.40–7.31 (m, 3H), 7.25–7.20 (m, 2H), 4.63 (t, J = 
7.5 Hz, 1H), 3.84 (s, 3H), 3.81 (s, 3H), 3.70 (dt, J = 13.7, 7.9 Hz, 1H), 3.06 (dd, J = 13.7, 
7.3 Hz, 1H), 2.57–2.53 (m, 2H), 1.43–1.30 (m, 2H), 1.29–1.10 (m, 2H), 0.82 (t, J = 7.3 
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 168.1, 168.0, 166.9, 139.1, 129.2, 128.7, 127.1, 
63.2, 59.5, 53.7, 53.6, 41.1, 38.3, 28.6, 19.8, 13.7; IR (Neat Film, NaCl) 2957, 2873, 
1732, 1708, 1495, 1456, 1435, 1370, 1278, 1242, 1202, 1108, 1090, 1070, 893, 771 cm-1; 
HRMS (FAB+) m/z calc’d for C18H24NO5 [M+H]+: 334.1654, found 334.1646.  
 
 
dimethyl 2-oxo-5-phenylpyrrolidine-3,3-dicarboxylate (149): 
Prepared according to General Method G. 49% yield. Rf = 0.48 (1:1 Hexanes:EtOAc 
eluent); 1H NMR (500 MHz, CDCl3) δ 7.40–7.33 (m, 2H), 7.33–7.28 (m, 3H), 6.93–6.69 
(br s, 1H), 4.75 (t, J = 7.4 Hz, 1H), 3.85 (d, J = 1.6 Hz, 3H), 3.77 (dd, J = 2.1, 0.9 Hz, 
3H), 3.18 (ddt, J = 13.6, 7.2, 0.8 Hz, 1H), 2.63 (ddd, J = 13.5, 7.8, 1.8 Hz, 1H); 13C NMR 
(126 MHz, CDCl3) δ 169.5, 167.5, 167.4, 140.3, 129.0, 128.4, 126.0, 63.2, 55.4, 53.7, 
53.6, 40.4; IR (Neat Film, NaCl) 3251, 2955, 1729, 1435, 1250, 1208, 1060 cm-1; HRMS 
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2.8.5   THIOIMIDATE CHARACTERIZATION DATA 




(Z)-dimethyl 2-(allylimino)-5-phenyldihydrothiophene-3,3(2H)-dicarboxylate (158): 
92% yield. Rf = 0.45 (7:3 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.46–
7.40 (m, 2H), 7.39–7.34 (m, 2H), 7.33–7.29 (m, 1H), 5.99 (ddt, J = 17.1, 10.4, 5.2 Hz, 
1H), 5.26 (dq, J = 17.2, 1.8 Hz, 1H), 5.13 (dq, J = 10.4, 1.7 Hz, 1H), 4.73 (dd, J = 11.7, 
4.9 Hz, 1H), 4.00 (dtd, J = 5.5, 1.8, 0.7 Hz, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 3.12 (dd, J = 
13.0, 4.9 Hz, 1H), 2.90 (dd, J = 13.0, 11.7 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 168.4, 
168.1, 166.0, 138.2, 134.0, 129.0, 128.5, 127.8, 116.0, 71.0, 59.8, 53.8, 53.6, 50.9, 44.3; 
IR (Neat Film, NaCl) 3010, 2952, 1738, 1652, 1495, 1435, 1269, 1227, 1169, 1098, 
1064, 977, 921, 862, 842, 799, 765 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for 
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Characterization data are same as above; [α]D25.0 +8.8° (c 0.445, CHCl3, 95% ee). 
 
 
dimethyl 1-allyl-5-(4-methoxyphenyl)-2-thioxopyrrolidine-3,3-dicarboxylate (150): 
98% yield. Rf = 0.49 (7:3 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.38–
7.32 (m, 2H), 6.90–6.85 (m, 2H), 6.03–5.92 (m, 1H), 5.24 (dq, J = 17.2, 1.8 Hz, 1H), 
5.12 (dq, J = 10.4, 1.7 Hz, 1H), 4.71 (dd, J = 11.8, 4.8 Hz, 1H), 3.99 (dt, J = 5.2, 1.8 Hz, 
2H), 3.87 (s, 3H), 3.81 (s, 3H), 3.80 (s, 3H), 3.07 (dd, J = 13.0, 4.9 Hz, 1H), 2.87 (dd, J = 
13.0, 11.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 168.4, 168.1, 166.5, 159.7, 134.0, 
130.0, 129.0, 116.0, 114.3, 71.1, 59.7, 55.5, 53.8, 53.6, 50.6, 44.5; IR (Neat Film, NaCl) 
3003, 2953, 2837, 1736, 1638, 1610, 1513, 1435, 1305, 1250, 1175, 1098, 1070, 1032, 
922, 831, 792 cm-1; HRMS (Low Voltage MM: ESI-APCI) m/z calc’d for C18H22NO5S 




dicarboxylate (159):  
80% yield. Rf = 0.53 (7:3 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.62–
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17.2, 10.4, 5.2 Hz, 1H), 5.27 (dq, J = 17.1, 1.8 Hz, 1H), 5.14 (dq, J = 10.3, 1.7 Hz, 1H), 
4.79 (dd, J = 11.7, 4.9 Hz, 1H), 4.02 (dt, J = 5.2, 1.8 Hz, 2H), 3.89 (s, 3H), 3.83 (s, 3H), 
3.16 (dd, J = 13.0, 4.9 Hz, 1H), 2.94 (dd, J = 13.0, 11.7 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ 168.3, 168.0, 166.2, 141.4, 140.4, 137.0, 133.8, 128.9, 128.2, 127.6, 127.1, 
116.0, 71.0, 59.6, 53.7, 53.5, 50.6, 44.2; IR (Neat Film, NaCl) 3029, 2952, 1736, 1651, 
1639, 1487, 1435, 1412, 1279, 1263, 1226, 1168, 1099, 1070, 1008, 977, 920, 836, 799, 
767, 738 cm-1; HRMS (Low Voltage MM: ESI-APCI) m/z calc’d for C23H24NO4S 




dicarboxylate (160):  
66% yield. Rf = 0.49 (7:3 Hexanes:EtOAc eluent); 1H NMR (400 MHz, CDCl3) δ 7.42 – 
7.19 (m, 4H), 5.97 (ddt, J = 17.1, 10.4, 5.1 Hz, 1H), 5.23 (dq, J = 17.2, 1.9 Hz, 1H), 5.12 
(dq, J = 10.4, 1.7 Hz, 1H), 4.69 (dd, J = 11.6, 4.9 Hz, 1H), 3.98 (dt, J = 5.1, 1.8 Hz, 2H), 
3.86 (s, 3H), 3.79 (s, 3H), 3.09 (dd, J = 13.0, 5.0 Hz, 1H), 2.82 (dd, J = 13.0, 11.6 Hz, 
1H).; 13C NMR (101 MHz, CDCl3) δ 168.1, 167.8, 165.3, 136.7, 134.2, 133.8, 129.0, 
129.0, 115.9, 70.8, 59.7, 53.7, 53.4, 50.0, 44.1; IR (Neat Film, NaCl) 2953, 1733, 1652, 
1637, 1491, 1434, 1266, 1221, 1167, 1090, 1068, 1011 cm-1; HRMS (MM: ESI-APCI) 








Chapter 2 – (3 + 2) Cycloadditions of Cyclopropanes with Heterocumulenes  64 
  
(Z)-dimethyl 2-(allylimino)-5-(p-tolyl)dihydrothiophene-3,3(2H)-dicarboxylate (161): 
99% yield. Rf = 0.47 (7:3 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.33–
7.29 (m, 2H), 7.19–7.15 (m, 2H), 5.98 (ddt, J = 17.2, 10.4, 5.2 Hz, 1H), 5.25 (dq, J = 
17.2, 1.8 Hz, 1H), 5.14 (dq, J = 10.4, 1.7 Hz, 1H), 4.72 (dd, J = 11.8, 4.8 Hz, 1H), 4.01 
(dt, J = 5.2, 1.8 Hz, 2H), 3.88 (s, 3H), 3.82 (s, 3H), 3.10 (dd, J = 13.1, 4.9 Hz, 1H), 2.88 
(dd, J = 13.0, 11.8 Hz, 1H), 2.35 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 168.2, 168.0, 
138.5, 134.9, 133.7, 129.7, 127.7, 116.3, 71.1, 59.5, 53.9, 53.7, 51.1, 44.5, 21.3; IR (Neat 
Film, NaCl) 3011, 2952, 1737, 1652, 1639, 1515, 1435, 1278, 1269, 1257, 1228, 1169, 
1071, 1018, 978, 921, 864, 848, 818, 790 cm-1; HRMS (Low Voltage MM: ESI-APCI) 





41% yield. Rf = 0.30 (3:1 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.41–
7.32 (m, 4H), 5.98 (ddt, J = 17.1, 10.4, 5.2 Hz, 1H), 5.25 (dq, J = 17.2, 1.8 Hz, 1H), 5.13 
(dq, J = 10.4, 1.7 Hz, 1H), 4.71 (dd, J = 11.8, 4.9 Hz, 1H), 3.99 (dt, J = 5.1, 1.7 Hz, 2H), 
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1H) 1.31 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 168.5, 168.2, 166.3, 151.6, 135.1, 134.1, 
127.5, 125.9, 116.0, 71.1, 59.8, 53.8, 53.6, 50.7, 44.3, 34.8, 31.4; IR (Neat Film, NaCl) 
2955, 2904, 2868, 1737, 1652, 1639, 1509, 1435, 1363, 1280, 1267, 1227, 1168, 1111, 
1070, 1016, 978, 920, 828 cm-1; HRMS (Low Voltage MM: ESI-APCI) m/z calc’d for 




dicarboxylate (163):  
84% yield. Rf = 0.20 (3:1 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.49–
7.41 (m, 2H), 7.12–7.05 (m, 2H), 5.97 (ddt, J = 17.2, 10.3, 5.2 Hz, 1H), 5.25 (dq, J = 
17.2, 1.8 Hz, 1H), 5.13 (dq, J = 10.4, 1.7 Hz, 1H), 4.72 (dd, J = 11.6, 4.9 Hz, 1H), 3.99 
(ddd, J = 7.0, 1.7, 1.0 Hz, 2H), 3.87 (s, 3H), 3.80 (s, 3H), 3.11 (dd, J = 13.1, 4.9 Hz, 1H), 
2.85 (dd, J = 13.1, 11.6 Hz, 1H), 2.30 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 169.5, 
168.4, 168.0, 165.8, 150.6, 135.8, 134.0, 129.0, 122.2, 116.0, 71.0, 59.8, 53.8, 53.6, 50.3, 
44.5, 21.3; IR (Neat Film, NaCl) 2953, 1736, 1649, 1639, 1507, 1436, 1370, 1280, 1257, 
1194, 1167, 1099, 1016, 911, 851 cm-1; HRMS (Low Voltage MM: ESI-APCI) m/z calc’d 
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(Z)-dimethyl 2-(allylimino)-5-mesityldihydrothiophene-3,3(2H)-dicarboxylate (155): 
85% yield. White, translucent crystals were obtained by slow diffusion of 1% benzene in 
heptane into a solution of thioimidate 155 in EtOAc, M.P.: 89–91 °C; Rf = 0.52 (7:3 
Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 6.87–6.84 (m, 2H), 5.99 (ddt, J = 
17.2, 10.4, 5.2 Hz, 1H), 5.32 (dd, J = 12.5, 5.3 Hz, 1H), 5.24 (dq, J = 17.2, 1.8 Hz, 1H), 
5.13 (dq, J = 10.4, 1.7 Hz, 1H), 4.02 (dtd, J = 5.2, 1.8, 0.8 Hz, 2H), 3.90 (s, 3H), 3.84 (s, 
3H), 3.24 (dd, J = 13.3, 12.5 Hz, 1H), 2.93 (dd, J = 13.3, 5.3 Hz, 1H), 2.46 (s, 6H), 2.25 
(s, 3H); 13C NMR (126 MHz, CDCl3) δ 168.5, 168.3, 166.8, 137.9, 134.0, 130.9, 129.2, 
116.0, 71.1, 59.8, 53.8, 53.6, 46.2, 40.0, 21.3, 20.9; IR (Neat Film, NaCl) 3010, 2952, 
2918, 1737, 1649, 1638, 1611, 1435, 1267, 1230, 1203, 1167, 1097, 1073, 1015, 976, 
921, 954, 822, 799, 774, 739 cm-1; HRMS (Low Voltage MM: ESI-APCI) m/z calc’d for 




dicarboxylate (164):  
84% yield. Rf = 0.48 (7:3 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.65 
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7.23 (td, J = 7.6, 1.7, 1H), 5.98 (ddt, J = 17.2, 10.4, 5.2 Hz, 1H), 5.30–5.22 (m, 2H), 5.14 
(dq, J = 10.4, 1.7 Hz, 1H), 4.03 (td, J = 4.4, 2.0 Hz, 2H), 3.88 (s, 3H), 3.77 (s, 3H), 3.19 
(dd, J = 13.0, 5.1 Hz, 1H), 2.84 (dd, J = 13.0, 11.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) 
δ 168.1, 168.0, 165.7, 135.8, 134.0, 133.9, 130.0, 129.5, 128.5, 127.5, 116.1, 70.6, 59.7, 
53.8, 53.6, 47.0, 42.6; IR (Neat Film, NaCl) 3011, 2953, 1737, 1651, 1639, 1435, 1279, 
1256, 1228, 1171, 1130, 1100, 1069, 1051, 1038, 977, 921, 760 cm-1; HRMS (Low 




(Z)-dimethyl 2-(allylimino)-5-vinyldihydrothiophene-3,3(2H)-dicarboxylate (165): 
99% yield. Rf = 0.45 (7:3 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 5.95 
(ddt, J = 17.2, 10.4, 5.2 Hz, 1H), 5.80 (ddd, J = 16.9, 10.0, 8.4 Hz, 1H), 5.33 (dq, J = 
16.9, 0.8 Hz, 1H), 5.23 (ddd, J = 17.3, 1.8, 0.6 Hz, 1H), 5.19 (d, J = 10.1. 1H), 5.13 (ddd, 
J = 10.4, 1.7, 0.7 Hz, 1H), 4.22 (m, 1H), 3.98 (dd, J = 5.2, 2.0 Hz, 2H), 3.84 (s, 3H), 3.81 
(d, J = 0.6 Hz, 3H), 2.97 (ddd, J = 13.1, 5.1, 0.8 Hz, 1H), 2.61 (dd, J = 13.1, 10.6 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 168.1, 168.0, 135.7, 133.6, 118.9, 116.3, 70.5, 59.4, 
53.8, 53.7, 50.3, 42.2; IR (Neat Film, NaCl) 2952, 1735, 1649, 1638, 1434, 1328, 1272, 
1254, 1169, 1139, 1097, 1068, 987, 923, 859, 787, 728 cm-1; HRMS (Low Voltage MM: 











91% yield. Rf = 0.40 (3:1 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.46–
7.42 (m, 2H), 7.36 (ddd, J = 8.2, 7.1, 0.9 Hz, 2H), 7.30 (m, 1H), 4.69 (dd, J = 11.7, 4.9 
Hz, 1H), 3.87 (s, 3H), 3.78 (s, 3H), 3.08 (dd, J = 13.0, 4.9 Hz, 1H), 2.98 (tt, J = 10.1, 3.6 
Hz, 1H), 2.85 (dd, J = 13.0, 11.7 Hz, 1H), 1.85–1.72 (m, 4H), 1.65–1.57 (m, 1H), 1.57–
1.44 (m, 2H), 1.37–1.20 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 168.6, 168.3, 161.5, 
138.6, 128.9, 128.4, 127.8, 70.8, 67.1, 53.7, 53.4, 50.6, 44.0, 32.8, 31.7, 25.8, 24.7, 24.6; 
IR (Neat Film, NaCl) 2930, 2854, 1738, 1651, 1435, 1168, 1067, 973, 912, 764 cm-1; 





99% yield. Rf = 0.63 (2:1 Hexanes: EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.35–
7.29 (m, 2H), 7.18–7.14 (m, 2H), 4.67 (dd, J = 11.8, 4.8 Hz, 1H), 3.86 (s, 3H), 3.78 (s, 
3H), 3.05 (dd, J = 13.0, 4.9 Hz, 1H), 2.98 (tt, J = 10.1, 3.6 Hz, 1H), 2.83 (dd, J = 13.0, 
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1.38–1.21 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 168.7, 168.3, 161.5, 138.2, 135.5, 
129.6, 127.6, 70.9, 67.0, 53.6, 53.4, 50.4, 44.0, 32.8, 31.7, 25.8, 24.7, 24.5, 21.2; IR (Neat 
Film, NaCl) 2929, 2853, 1735, 1648, 1434, 1255, 1167, 1071, 973, 818 cm-1; HRMS 




dicarboxylate (168):  
77% yield. Rf = 0.80 (1:1 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 168.1, 
167.9, 166.2, 145.4, 135.5, 135.1, 133.6, 130.2, 128.9, 127.1, 125.5, 123.9, 123.5, 119.9, 
116.3, 114.0, 77.4, 70.5, 59.7, 53.9, 53.7, 42.7, 41.7, 21.7; 13C NMR (126 MHz, CDCl3) δ 
168.1, 167.9, 166.2, 145.4, 135.5, 135.1, 133.6, 130.2, 128.9, 127.1, 125.5, 123.9, 123.5, 
119.9, 116.3, 114.0, 77.4, 70.5, 59.7, 53.9, 53.7, 42.7, 41.7, 21.7; IR (Neat Film, NaCl) 
2953, 1738, 1639, 1447, 1372, 1275, 1175, 1126, 1095, 974, 912, 733 cm-1; HRMS (ESI) 
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Prepared using General Procedure D, using phenylisothiocyanate. 89% yield. Rf = 
0.60 (3:1 Hexanes:EtOAc eluent); 1H NMR (500 MHz, CDCl3) δ 7.41–7.37 (m, 2H), 
7.36–7.31 (m, 4H), 7.30–7.27 (m, 1H), 7.16–7.11 (m, 1H), 7.05–7.01 (m, 2H), 4.76 (dd, J 
= 11.7, 4.9 Hz, 1H), 3.97 (s, 3H), 3.87 (s, 3H), 3.19 (dd, J = 13.1, 4.9 Hz, 1H), 2.99 (dd, J 
= 13.1, 11.7 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 168.3, 167.9, 167.8, 151.0, 137.8, 
129.1, 129.0, 128.5, 127.8, 125.3, 120.2, 71.4, 54.0, 53.8, 51.2, 43.9; IR (Neat Film, 
NaCl) 3030, 2952, 1735, 1638, 1593, 1486, 1434, 1268, 1224, 1170, 1063, 973, 763 cm-1; 
HRMS (ESI) m/z calc’d for C20H20NO4S [M+H]+: 370.1108, found 370.1098. 
 
2.8.6   AMIDINE CHARACTERIZATION DATA 





98% yield. Rf = 0.39 (9:1 CH2Cl2:MeOH eluent); 1H NMR (400 MHz, CDCl3) δ 7.37–
7.18 (m, 5H), 4.52 (t, J = 7.1 Hz, 1H), 3.99 (p, J = 6.8 Hz, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 
3.50 (hept, J = 6.0 Hz, 1H), 2.95 (dd, J = 12.8, 7.0 Hz, 1H), 2.33 (dd, J = 12.8, 7.2 Hz, 
1H), 1.15 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 6.0 Hz, 3H), 1.05 (d, J = 5.9 Hz, 3H), 0.88 (d, 
J = 6.9 Hz, 3H).; 13C NMR (101 MHz, CDCl3) δ 169.7, 169.2, 151.3, 143.8, 128.5, 127.8, 
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NaCl) 2963, 1731, 1659, 1436, 1261, 1212, 1063, 969 cm-1; HRMS (MM: ESI-APCI) m/z 




dicarboxylate ((R)-170•HBr):   
Acetyl bromide (22 mL, 0.3 mmol) was dissolved in dichloromethane (3 mL) in a 10 
mL round bottom flask. Methanol (41 mL, 1 mmol) was added to the solution and this 
mixture was transferred into a second flask containing a solution of amidine (R)-170 (72 
mg, 0.2 mmol). The mixture was concentrated in vacuo and crystallized by vapor 
diffusion of diethyl ether into dichloromethane to produce fine colorless needles suitable 




dicarboxylate (171):  
98% yield. Rf = 0.42 (9:1 CH2Cl2:MeOH eluent); 1H NMR (400 MHz, CDCl3) δ 7.25–
7.16 (m, 2H), 6.89–6.79 (m, 2H), 4.50 (br t, J = 6.9 Hz, 1H), 4.07–3.95 (br m, 1H), 3.79 
(s, 3H), 3.77 (s, 3H), 3.72 (s, 3H), 3.49 (p, J = 6.0 Hz, 1H), 2.93 (br dd, J = 12.8, 6.9 Hz, 
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2H), 1.05 (d, J = 6.0 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H).; 13C NMR (101 MHz, CDCl3) δ 
169.5, 169.0, 159.3, 151.6, 135.2, 128.2, 113.9, 60.7, 59.6, 55.3, 53.2, 53.0, 51.4, 47.4, 
43.4, 24.5, 24.1, 19.7, 19.2.; IR (Neat Film, NaCl) 2963, 2928, 1736, 1654, 1612, 1513, 
1249, 1214, 1172, 1081 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C21H31N2O5 




dicarboxylate (172):  
92% yield. Rf = 0.42 (9:1 CH2Cl2:MeOH eluent); 1H NMR (500 MHz, CDCl3) δ 7.63–
7.53 (m, 4H), 7.47–7.38 (m, 4H), 7.37–7.32 (m, 1H), 4.59 (t, J = 7.1 Hz, 1H), 4.04 (hept, 
J = 6.9 Hz, 1H), 3.83 (s, 3H), 3.74 (s, 3H), 3.53 (hept, J = 5.9 Hz, 1H), 3.00 (dd, J = 12.8, 
7.0 Hz, 1H), 2.37 (dd, J = 12.8, 7.3 Hz, 1H), 1.20 (d, J = 6.8 Hz, 3H), 1.15 (d, J = 6.0 Hz, 
3H), 1.08 (d, J = 5.9 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
169.7, 169.2, 151.4, 142.9, 140.8, 140.7, 128.9, 127.5, 127.4, 127.2, 127.1, 60.6, 59.6, 
53.2, 53.0, 51.5, 47.4, 43.4, 24.7, 24.4, 19.8, 19.2; IR (Neat Film, NaCl) 2964, 1733, 
1658, 1486, 1435, 1375, 1358, 1264, 1216, 1165, 1126, 1076, 1008, 973, 841, 767, 733 
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(E)-dimethyl 5-(4-chlorophenyl)-1-isopropyl-2-(isopropylimino)pyrrolidine-3,3-
dicarboxylate (173):  
78% yield. Rf = 0.40 (9:1 CH2Cl2:MeOH eluent); 1H NMR (500 MHz, CDCl3) δ 7.30–
7.23 (m, 4H), 4.50 (t, J = 7.1 Hz, 1H), 4.00 (hept, J = 6.9 Hz, 1H), 3.80 (s, 3H), 3.71 (s, 
3H), 3.48 (hept, J = 5.9 Hz, 1H), 2.95 (dd, J = 12.8, 7.1 Hz, 1H), 2.27 (dd, J = 12.9, 7.1 
Hz, 1H), 1.13 (d, J = 6.7 Hz, 3H), 1.09 (d, J = 6.0 Hz, 3H), 1.04 (d, J = 5.9 Hz, 3H), 0.86 
(d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 169.6, 169.1, 151.2, 142.6, 133.4, 
128.7, 128.3, 60.4, 59.1, 53.2, 53.0, 51.5, 47.3, 43.3, 24.7, 24.3, 19.9, 19.1; IR (Neat 
Film, NaCl) 2965, 1733, 1658, 1489, 1435, 1376, 1359, 1269, 1214, 1165, 1126, 1088, 
1014, 974, 831 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C20H2835ClN2O4 [M+H]+: 
395.1732, found 395.1755.  
 
 
dimethyl 2-imino-5-phenylpyrrolidine-3,3-dicarboxylate (174):  
78% yield. Rf = 0.45 (9:1 CH2Cl2:MeOH eluent); 1H NMR (500 MHz, CDCl3) δ7.34–
7.27 (m, 3H), 7.25–7.21 (m, 2H), 4.99 (dd, J = 8.2, 6.9 Hz, 1H), 3.83 (s, 3H), 3.77 (s, 
3H), 3.10 (dd, J = 13.6, 7.0 Hz, 1H), 2.37 (dd, J = 13.6, 8.1 Hz, 1H); 13C NMR (126 
MHz, CDCl3) δ 168.9, 168.3, 160.2, 144.2, 128.6, 127.1, 126.4, 68.4, 67.4, 53.6, 53.4, 
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1201, 1154, 1114, 1075, 765 cm-1; HRMS (FAB+) m/z calc’d for C14H17N2O4 [M+H]+: 
277.1188, found 277.1176. 
 
 
dimethyl 2-imino-5-(4-methoxyphenyl)pyrrolidine-3,3-dicarboxylate (175):  
68% yield. Rf = 0.47 (9:1 CH2Cl2:MeOH eluent); 1H NMR (500 MHz, CDCl3) δ 7.23–
7.16 (m, 2H), 6.84 (dd, J = 6.8, 1.9 Hz, 2H), 4.97–4.88 (m, 1H), 3.82 (s, 3H), 3.78 (s, 
3H), 3.76 (s, 3H), 3.06 (dd, J = 13.6, 6.9 Hz, 1H) 2.34 (dd, J = 13.6, 8.1 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ 168.9, 168.3, 160.1, 158.7, 136.3, 127.5, 113.9, 113.9, 67.8, 
67.4, 55.4, 53.6, 53.4, 42.9; IR (Neat Film, NaCl) 3464, 3374, 3102, 2955, 2838, 1738, 
1662, 1612, 1514, 1439, 1351, 1247, 1213, 1175, 1105, 1077, 1034, 831, 733 cm-1; 




dicarboxylate (176):  
58% yield. Rf =0.35 (10:1 CHCl3:MeOH eluent); 1H NMR (500 MHz, CDCl3) δ 7.48–
7.44 (m, 2H), 7.38–7.33 (m, 2H), 7.29–7.24 (m, 1H), 3.85 (s, 3H), 3.71 (s, 3H), 3.44 (dt, 
J = 11.8, 5.9 Hz, 1H), 3.09–2.99 (hept, J = 6.7 Hz, 1H), 2.83–2.72 (m, 2H), 1.61 (s, 3H), 
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CDCl3) δ 170.5, 170.2, 148.5, 146.8, 128.3, 127.2, 126.7, 64.8, 60.3, 53.2, 53.1, 51.4, 
50.5, 47.1, 24.9, 24.8, 24.5, 19.9, 19.1; IR (Neat Film, NaCl) 2963, 1731, 1654, 1375, 
1251, 1217, 1090 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C21H31N2O4 [M+H]+: 
375.2278, found 375.2297. 
 
 
(E)-dimethyl 1,5-diphenyl-2-(phenylimino)pyrrolidine-3,3-dicarboxylate (177):   
79% yield. Rf =0.32 (10:1 CH2Cl2:MeOH eluent); 1H NMR (400 MHz, DMSO-d6, 80 °C) 
δ 7.34–7.16 (m, 8H), 7.10 (dt, J = 15.2, 7.6 Hz, 5H), 6.95 (t, J = 7.4 Hz, 1H), 6.80 (t, J = 
7.3 Hz, 1H), 6.71 (d, J = 7.7 Hz, 2H), 5.28 (t, J = 7.0 Hz, 1H), 3.66 (s, 3H) 3.45 (s, 3H), 
3.17 (dd, J = 13.0, 7.2 Hz, 1H), 3.05 (s, 1H), 2.71 (dd, J = 13.0, 6.9 Hz, 1H); 13C NMR 
(101 MHz, DMSO-d6, 100 °C) δ 168.5, 168.2, 152.0, 148.4, 148.3, 140.9, 129.6, 129.5, 
129.4, 129.3, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.2, 128.2, 128.1, 128.0, 127.7, 
127.5, 127.4, 127.3, 127.2, 126.6, 125.9, 124.6, 122.0, 121.9, 120.9, 64.1, 63.1, 62.7, 
55.3, 54.5, 54.3, 53.4, 52.6, 52.4, 51.9, 43.0; IR (Neat Film, NaCl) 3062, 3027, 2948, 
1730, 1661, 1592, 1493, 1372, 1263, 1051 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for 
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(R,E)-dimethyl 1,5-diphenyl-2-(phenylimino)pyrrolidine-3,3-dicarboxylate ((R)-177): 
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Supplementary Synthetic Information for Chapter 2 
 
 
A1.1  INTRODUCTION 
This appendix discusses cyclopropanes and heterocumulenes that did not successfully 
react to form the desired heterocycles.  Efforts to use a tin-phenanthroline complex as the 
catalyst are also presented.  Finally, two attempts at product derivitization are included. 
 
A1.2  UNREACTIVE CYCLOPROPANES 
During our investigations of the substrate scope of these reactions, we 
encountered a number of cyclopropanes that did not undergo the desired reactivity 
(Figure A1.1).  Cyclopropanes with aryl substitutents incorporating coordinating 
groups such as pyridine rings (210 and 211) failed to produce the desired 
heterocycles even in the presence of additional sacrificial Lewis acid to coordinate 
to the pyridine nitrogen atom.  Attempts to replace the aryl or vinyl donor groups of 
successful substrates with alkyl groups (212 and 213) were also unsuccessful.  An 
                                                      
† This work was performed in collaboration with Dr. Alexander F. G. Goldberg and Dr. Robert A. 
Craig, II, alumni of the Stoltz group.  
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examination of the acceptor groups revealed both ester functionalities to be critical, 
as cyclopropanes with one (214) or zero (215) carboxylate groups were completely 
unreactive under our conditions.  Finally, highly functionalized cyclopropane 216 
did not react under our carbodiimide conditions, likely due to its lack of a clearly 
polarized C–C bond. 
 





A1.3  PROBLEMATIC HETEROCUMULENES 
A variety of heterocumulenes were also found to lack the desired reactivity.  
Treatment of cyclopropanes with tosylisocyanate (217) or phenylisocyanate (218) 
resulted in no formation of the desired lactams (Figure A1.2).  Aryl isothiocyanates (219) 
were also unreactive under our tin-mediated conditions, although we were able to obtain 
reactivity using conditions similar to those reported by Li (see Scheme 2.8).1  Finally, the 






























Figure A1.2  Problematic heterocumulenes 
 
 
A1.4  TESTING FOR PRODUCT INHIBITION 
The requirement for stoichiometric Lewis acid in all reactions, regardless of 
dipolarophile identity is a practical drawback for which a solution has not yet been 
discovered.  Product inhibition of the catalyst does not appear to play a role, as 
experiments showed the reaction to proceed smoothly in the presence of a slight excess of 
an amidine product (Scheme A1.1).  Attempts to catalyze the reaction with 
phenanthroline-ligated tin complexes were also unsuccessful. 
 
Scheme A1.1  Testing for product inhibition 
 
 
A1.5  PRODUCT DERIVATIZATIONS 
To demonstrate the utility of the thioimidate products produced by our method, we 
attempted several derivatizations.  Decarboxylation using Krapcho’s protocol2 was 
successful, delivering monocarboxylate 221 in good yield as a single diastereomer 
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easily at room temperature, heating to achieve a double decarboxylation gave a complex 
mixture.  Unfortunately, an attempt to form a thiolactam from lactam 148 using 
Lawesson’s reagent was unsuccessful (Scheme A1.2B), as were several attempts to 
hydrolyze thioimidates or amidines to thioester or lactam products (Scheme A1.2C).  
 
Scheme A1.2  Derivatization of the cycloadducts 
 
 
A1.6  EXPERIMENTAL SECTION 
A1.6.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed in flame-dried or oven-dried 
glassware under an argon or nitrogen atmosphere using dry, deoxygenated solvents 
(distilled or passed over a column of activated alumina).3  Diazodimethylmalonate was 
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potassium cyanate, and all organic heterocumulenes except phenylisopropylcarbodiimide 
were obtained from commercial suppliers.  Cyclopropane 233 was obtained upon request 
from the research laboratories of Professor John L. Wood at Colorado State University 
(currently at Baylor University).  Commercially obtained reagents were used as received 
with the exception of tin(II) triflate and iron(III) chloride, which were stored in a 
nitrogen-filled glovebox.  A separate bottle of iron(III) chloride was stored in a calcium 
sulfate desiccator on the benchtop.  Thin-layer chromatography (TLC) was performed 
using E. Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized by UV 
fluorescence quenching, potassium permanganate, or p-anisaldehyde staining.  SiliaFlash 
P60 Academic Silica gel (particle size 0.040-–0.063 mm) was used for flash 
chromatography.  1H and 13C NMR spectra were recorded on a Varian 400 (at 400 MHz 
and 100 MHz, respectively) or on a Varian Mercury 500 (at 500 MHz and 126 MHz, 
respectively) and are reported relative to CHCl3 (δ 7.26 & 77.16 ppm, respectively) or 
tetramethylsilane (0.00 ppm).  Data for 1H NMR spectra are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration).  Abbreviations 
are used as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, hept = 
heptet, m = complex multiplet, app = apparent.  IR spectra were recorded on a Perkin 
Elmer Paragon 1000 Spectrometer and are reported in frequency of absorption (cm–1).  
HRMS were acquired using an Agilent 6200 Series TOF with an Agilent G1978A 
Multimode source in electrospray ionization (ESI), atmospheric pressure chemical 
ionization (APCI), or mixed (MM) ionization mode. 
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A1.6.2  SYNTHESIS OF UNREACTIVE CYCLOPROPANES 
 
dimethyl 2-(pyridin-2-yl)cyclopropane-1,1-dicarboxylate (210): 
Benzylidene dimethylmalonate 226 was prepared according to the method described 
in General Procedure A, Experimental Section, Chapter 2: 97% yield. Rf = 0.81 (3:1 
Hexanes:EtOAc eluent). Characterization data match those reported in the literature.5  
Cyclopropane 210 was prepared according to the method described in General Procedure 
B, Experimental Section, Chapter 2 using saturated aqueous ammonium chloride in the 
workup instead of 2 M HCl:  95% yield.  Rf = 0.30 (3:1 Hexanes:EtOAc eluent); 1H NMR 
(500 MHz, CDCl3) δ 8.45–8.34 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 7.62–7.53 (tdd, J = 7.3, 
4.9, 1.1 Hz, 1H), 7.29–7.26 (dt, J = 7.9, 1.1 Hz, 1H), 7.12–7.05 (ddt, J = 7.3, 4.9, 1.1 Hz, 
1H), 3.82–3.68 (m, 3H), 3.53–3.43 (m, 3H), 3.12–3.06 (ddd, J = 8.8, 7.4, 1.1 Hz, 1H), 
2.36–2.31 (ddd, J = 7.4, 4.5, 1.1 Hz, 1H), 1.84–1.78 (ddd, J = 9.0, 4.5, 1.1 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ 170.3, 167.3, 155.4, 149.0, 136.3, 124.0, 122.0, 53.0, 52.4, 
38.0, 33.0, 20.5; IR (Neat Film, NaCl) 3011, 2952, 1734, 1593, 1570, 1477, 1437, 1379, 
1334, 1301, 1275, 1210, 1132, 1085, 998, 970, 924, 878, 807, 759, 749 cm-1; HRMS 
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dimethyl 2-(pyridin-2-yl)cyclopropane-1,1-dicarboxylate (211): 
Benzylidene dimethylmalonate 228 was prepared according to the method described 
in General Procedure A, Experimental Section, Chapter 2: 76% yield.  Rf = 0.58 (1:1 
Hexanes:EtOAc eluent); 1H NMR (400 MHz, CDCl3) δ 8.72–8.60 (m, 2H), 7.68 (s, 1H), 
7.29–7.21 (m, 2H), 3.87 (s, 3H), 3.83 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 166.0, 
163.8, 150.7, 140.4, 140.0, 129.9, 122.8, 53.2, 53.1; IR (Neat Film, NaCl) 2954, 1732, 
1638, 1596, 1437, 1374, 1269, 1225, 1067, 813 cm-1; HRMS (MM: ESI-APCI) m/z calc’d 
for C11H12NO4 [M+H]+: 222.0761, found 222.0750.  Cyclopropane 211 was prepared 
according to the method described in General Procedure B, Experimental Section, 
Chapter 2:  81% yield.  Rf = 0.13 (3:1 Hexanes:EtOAc eluent); 1H NMR (500 MHz, 
CDCl3) δ 8.42 (d, J = 5.6 Hz, 2H), 7.02 (dd, J = 4.4, 1.7 Hz, 2H), 3.73 (s, 3H), 3.35 (s, 
3H), 3.07 (dd, J = 9.1, 7.9, 1H), 2.11 (dd, J = 8.0, 5.4 Hz, 1H), 1.71 (dd, J = 9.1, 5.4 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 169.5, 166.4, 149.6, 144.1, 123.3, 53.0, 52.5, 37.7, 
30.9, 18.7; IR (Neat Film, NaCl) 3029, 2954, 1732, 1601, 1437, 1335, 1282, 1212, 1133, 




dimethyl spiro[2.5]octane-1,1-dicarboxylate (212): 
Cyclopropane 212 was prepared according to the method described in General 
Procedure C, Experimental Section, Chapter 2:  40% yield.  Rf = 0.20 (9:1 










dimethyl 2-isopropylcyclopropane-1,1-dicarboxylate (213): 
Isopropylidene dimethylmalonate 231 was prepared according to the method 
described in General Procedure A, Experimental Section, Chapter 2: 94% yield.  Rf = 
0.30 (9:1 Hexanes:EtOAc eluent).  Characterization data match those reported in the 
literature.7  Cyclopropane 213 was prepared according to the method described in 
General Procedure B, Experimental Section, Chapter 2: Rf = 0.40 (9:1 Hexanes:EtOAc 
eluent).  Characterization data match those reported in the literature.8 
 
 
methyl 2-phenylcyclopropanecarboxylate (214): 
Cyclopropane 214 was prepared according to the method described in General 
Procedure B, Experimental Section, Chapter 2: 24% yield.  Rf = 0.60 (3:1 
Hexanes:EtOAc eluent).  Characterization data match those reported in the literature.9 
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To a flame-dried round-bottomed flask equipped with a magnetic stir bar were added 
carboxylic acid 233 (200 mg, 0.77 mmol) and potassium carbonate (131 mg, 0.95 mmol).  
Acetone (8.75 mL) and dimethylsulfate (90 μL) were added and the heterogeneous 
mixture was stirred at ambient temperature for 1 hour.  The mixture was poured into 
water (20 mL) and ether (20 mL).  The ether layer was separated, dried over magnesium 
sulfate, and filtered and concentrated in vacuo to give the crude product, which was 
purified by silica gel column chromatography (3:1 hexanes:EtOAc) to afford 
cyclopropane 216 as a colorless oil (179 mg, 84% yield).  Rf = 0.60 (3:1 Hexanes:EtOAc 
eluent).  1H NMR (500 MHz, CDCl3) δ 7.64 (ddd, J = 7.7, 1.2, 0.6 Hz, 1H), 7.30 (td, J = 
7.7, 1.2 Hz, 1H), 7.06 (td, J = 7.7, 1.1 Hz, 1H), 6.90 (ddd, J = 7.8, 1.2, 0.5 Hz, 1H), 3.67 
(s, 3H), 3.27 (s, 3H), 2.79 (s, 1H), 1.61 (s, 3H), 1.60 (s, 3H).  13C NMR (126 MHz, CDCl-
3) δ 173.8, 169.3, 144.3, 127.1, 125.6, 125.0, 121.6, 107.9, 51.7, 41.9, 40.8, 35.0, 26.6, 
20.6, 17.0. 
 
A1.6.3  SYNTHESIS OF MIXED CARBODIIMIDE 220 
 
Thiourea 235.  Prepared according to the method of Zhou and coworkers.10  To a 
flame-dried round-bottom flask, equipped with a magnetic stir bar and fitted with a 
rubber septum was added phenyl isothiocyanate (1.2 mL, 10 mmol, 1 equiv) and 
anhydrous THF (32 mL) under an inert atmosphere.  To the stirring solution was added 
isopropylamine (1.64 mL, 20 mmol, 2 equiv) dropwise.  The rubber septum was quickly 
N
CPh
S i-PrNH2 (2 equiv)
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replaced with a reflux condenser fitted with a hose adapter, connected to an inert 
atmosphere manifold.  The resulting solution was heated to reflux with stirring for 40 
minutes.  The reaction mixture was then cooled to ambient temperature and the solvent 
was removed in vacuo.  The residue was dissolved in ethyl acetate (60 mL) and washed 
with aqueous hydrochloric acid (10 mL, 1 N) and brine (10 mL), and the organic phase 
was dried over sodium sulfate, filtered, and concentrated in vacuo to afford crude 
thiourea 235 (1.89 g, 97%) as a white solid which was carried forward directly to the next 
step in the synthesis. 
Carbodiimide 220.  Prepared according to the method of Fell and Coppola.11  To a 
flame-dried, round-bottom flask, equipped with a magnetic stir bar was added crude 
thiourea 235 (971 mg, 5 mmol, 1 equiv).  The flask was sealed with a rubber septum and 
placed under an inert atmosphere.  To the flask was added dry dichloromethane (50 mL, 
0.1 M) and freshly distilled triethylamine (2.1 mL, 15 mmol, 3 equiv), followed by a 
dropwise addition of mesyl chloride (0.78 mL, 10 mmol, 2 equiv).  Complete 
consumption of starting material was observed within 5 minutes, as determined by TLC.  
The volatiles were removed in vacuo, and a precipitate was observed.  The mixture was 
filtered twice through silica gel (100 mL), eluting with dichloromethane, then purified by 
silica gel column chromatography (10:1 hexanes:EtOAc) to afford carbodiimide 220 
(332.2 mg, 41% yield) as a yellow oil: Rf = 0.81 (3:1 Hexanes:EtOAc eluent); 1H NMR 
(300 MHz, CDCl3) δ 7.38–7.20 (m, 2H), 7.21–7.02 (m, 3H), 3.80 (hept, J = 6.4 Hz, 1H), 
1.35 (d, J = 6.5 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 140.9, 136.6, 129.4, 124.7, 123.4, 
50.3, 24.9; IR (Neat Film, NaCl) 3419, 3067, 2973, 2129, 1637, 1592, 1501, 1454, 1367, 
1320 cm-1; HRMS (ESI) m/z calc’d for C10H13N2 [M+H]+: 161.1073, found 161.1077. 
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A1.6.4  INVESTIGATION OF PRODUCT INHIBITION 
 
 
To an oven-dried 1 dram vial equipped with a magnetic stir bar was added tin(II) 
trifluoromethanesulfonate (0.44 mmol) in an inert atmosphere glovebox.  The vial was 
sealed with a screw cap fitted with a Teflon® septum, removed from the glovebox, and 
placed under a nitrogen atmosphere. To a separate, oven-dried 1 dram vial were added 
cyclopropane 140 (106 mg, 0.4 mmol), carbodiimide (68 µL, 0.44 mmol), and amidine 
171 (195 mg, 0.5 mmol).  The vial was sealed with a screw cap fitted with a Teflon® 
septum, and the mixture was transferred to the first vial as a solution in anhydrous 
dichloromethane (1 mL + 0.33 mL rinse). The heterogeneous reaction mixture was then 
allowed to stir at ambient temperature under nitrogen for 10 minutes.  TLC and LCMS 
analysis showed complete conversion of the starting material and an increase in 
concentration of product amidine 171. 
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Krapcho decarboxylation.  To a 1 dram vial equipped with a magnetic stir bar were 
added thioimidate 166 (100 mg, 0.27 mmol) and sodium cyanide (132 mg, 2.7 mmol).  
DMSO (2.3 mL) and water (2 drops) were added, the vial was capped, and the mixture 
was stirred vigorously at ambient temperature for 48 hours.  The reaction mixture was 
partitioned between ether (5 mL) and water (5 mL), and the aqueous layer was extracted 
with ether (3 x 10 mL).  The organic layers were combined and washed with water (3 x 
10 mL), brine (1 x 10 mL), dried over magnesium sulfate, and filtered and concentrated 
in vacuo to give the crude product, which was purified by silica gel column 
chromatography (95:5 hexanes:EtOAc) to afford thioimidate 221 as a colorless oil (65 
mg, 95% yield).  1H NMR (500 MHz, CDCl3) δ 8.14 (s, 1H), 7.48–7.40 (m, 2H), 7.37–
7.31 (m, 2H), 7.31 (m, 1H), 4.84 (t, J = 8.1 Hz, 1H), 3.69 (s, 3H), 3.39 (dd, J = 13.9, 8.5 
Hz, 1H), 3.20 (dp, J = 9.3, 5.1 Hz, 1H), 3.14 (dd, J = 14.0, 7.7 Hz, 1H), 2.01 (m, 2H), 
1.83–1.70 (m, 2H), 1.69–1.54 (m, 2H), 1.41–1.28 (m, 3H), 1.28–1.17 (m, 1H).  13C NMR 
(126 MHz, CDCl3) δ 167.0, 165.2, 141.7, 128.7, 127.7, 127.2, 86.5, 56.6, 51.6, 50.2, 
40.8, 34.1, 33.9, 25.3, 24.6, 24.6. 
 
 
Attempted synthesis of a thiolactam.  To an oven-dried 1 dram vial equipped with a 
magnetic stir bar were added lactam 140 (12 mg, 0.035 mmol), Lawesson’s reagent (56 
mg, 0.140 mmol), and dichloromethane (70 μL).  The mixture was stirred at room 
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Application of Cyclopropane Cycloadditions toward the Synthesis 
of Tetrahydroisoquinoline Alkaloids and Discovery of a 
Novel Route to Isoindolones 
 
 
A2.1  INTRODUCTION AND INITIAL RETROSYNTHETIC ANALYSIS 
The tetrahydroisoquinoline (THIQ) alkaloids are a large class of natural products 
which have attracted attention from the synthetic community due to their potentially 
useful biological activities and structural diversity.1  Our research laboratory has 
completed total syntheses of the antitumor bis-THIQ alkaloids lemonomycin (236)2 and 
quinocarcin (237)3 using Pictet–Spengler and aryne annulation strategies, respectively 
(Figure A2.1A).  Simpler THIQ alkaloids, such as those shown in Figure A2.1B,4 also 
possess notable bioactivities, and our ability to rapidly access 5-aryl γ-lactams by 
cycloadditions of donor–acceptor cyclopropanes and isocyanates inspired us to work 
toward a concise route to these targets. 
 
                                                      
† This work was performed in collaboration with Dr. Alexander F. G. Goldberg and Moriam Masha, 
alumni of the Stoltz group.  
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Figure A2.1  A) Tetrahydroisoquioline alkaloids previously synthesized in our laboratory.  B) 
Tetrahydroisoquinoline alkaloids targeted for application of a cyclopropane-isocyanate 
cycloaddition. 
 
We envisioned these alkaloids could be accessed from common intermediate 239 by 
double Krapcho decarboxylation and either demethylation (to afford trolline and 
oleracein E) or lactam reduction (to afford crispine A).  Lactam 239 was to be 
constructed using an intramolecular cycloaddition of isocyanate 240, which in turn would 
be accessed from acid 241.  This carboxylic acid would be assembled by a cross coupling 
between aryl halide (242) and cyclopropylmetal (243) components (Scheme A2.1). 
 
lemonomycin
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Scheme A2.1  Retrosynthetic analysis of 136, 238, and 137 
 
 
A2.2  TOWARD THE SYNTHESIS OF AN INTRAMOLECULAR 
CYCLOADDITION SUBSTRATE 
In the forward direction, aryl halides 244–247 were synthesized according to reported 
methods or standard procedures.  Cyclopropylboronate ester 248 was synthesized using 
the method developed by Gevorgyan.5  Although the enantioenriched product is known, 
we chose to probe initial reactivity using the racemic compound, which would also allow 
access to both trolline and oleracein E through a divergent synthesis.  Unfortunately, 
various attempts to hydrolyze the boronate ester of 248 were unsuccessful, leaving us 
unable to evaluate the presumably more reactive boronic acid in the coupling reaction.  
However, we were able to synthesize cyclopropylstannane 249 using conditions reported 
by Gevorgyan,6 which allowed for an alternative organometallic coupling partner to be 
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Figure A2.2  Cross-coupling partners prepared 
 
Unfortunately, despite extensive screening of conditions using the coupling partners 
shown above, we were unable to achieve the desired transformation, with all attempts 
displaying either significant protodehalogenation or a total lack of reactivity.  However, 
we were able to couple bromide 246 with vinyltributylstannane to afford styrene 250 in 
moderate yield.  Although not pursued due to concerns about step count, a conceivable 
route forward would involve styrene cyclopropanation, cleavage of the tert-butyl ester 
group, formation of the isocyanate by Curtius rearrangement, and subsequent 
cycloaddition to afford the desired lactam 239. 
 
Scheme A2.2  Successful cross-coupling of aryl bromide 246 with vinyltributylstannane 
 
 
A2.3  REVISED RETROSYNTHETIC ANALYSIS 
Given our inability to construct cyclopropane 241 in a concise fashion, we turned our 
attention to the use of an intermolecular cycloaddition, which would allow for the joining 
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common intermediate 239, but this tricycle would be formed by an intramolecular 
Friedel–Crafts alkylation of lactam 251.  The Friedel–Crafts substrate would be 
constructed by an intermolecular cycloaddition between known cyclopropane 2527 and 
commercially available isocyanate 253. 
 
Scheme A2.3  Revised retrosynthetic analysis 
 
 
A2.4  ATTEMPTED INTERMOLECULAR CYCLOADDITION 
Cyclopropane 252 was prepared using known methods and exposed to isocyanate 253 
in the presence of either iron(III) chloride or tin(II) triflate.  Unfortunately both cases 
resulted in decoposition (Scheme A2.4A).  In order to determine the problematic 
component, we conducted control reactions between isocyanate 253 and a cyclopropane 
known to be competent in cycloadditions with isocyanates (195).  These experiments 
resulted in decomposition, suggesting 253 is not compatible with the reaction conditions 
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(tert-butyldimethysiloxy)ethylisocyanate, and trimethylsilylisocyanate (planning future 
lactam N-alkylation) were also unsuccessful, we suspected the cyclopropane partner 
(252) may also be problematic. 
 




To investigate the viability of cyclopropane 252 in cycloadditions with dipolarophiles 
known to be competent (Scheme A2.5).  Reaction of 252 with allyl isothiocyanate 
afforded only decomposition products, but cycloaddition with diisopropylcarbodiimide 
smoothly provided amidine 256.  The use of benzyl isocyanate gave rise to a mixture of 
expected lactam 257 in 47% yield as well as isoindolone 258 in 40% yield.  These results 
suggested cyclopropane 252 is a problematic substrate in the desired cycloaddition 
reaction, which combined with the uncooperative reactivity of isocyanate 253 
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Scheme A2.5  Control experiments with competent dipolarophiles 
 
 
A2.5  INVESTIGATION OF THE ISOINDOLONE FORMATION  
We did not observe the formation of isoindolone products or byproducts during our 
previous studies of cyclopropane cycloadditions with isocyanates (see Chapter 2).  
However, we believe this can be accounted for by considering the mechanisms by which 
the 5-aryl lactam and isoindolone products are formed, which are shown in Scheme A2.6.  
In both cases, coordination of the Lewis acid to the ester functional groups is thought to 
fully cleave the polarized C–C bond in the cyclopropane, giving rise to zwitterionic 
intermediate 259.8  Subsequent attack of the isocyanate at the benzylic carbocation 
produces 260.  At this stage, the highly electrophilic carbon atom is typically attacked by 
the malonate group to deliver 5-aryl lactam product 257 (pathway a, red).  In substrates 































































Appendix 2 – Application of Cyclopropane Cycloadditions to Alkaloid Synthesis  
 
104
the electrophilic carbon (and subsequent rearomatization) furnishes isoindolone 258 
(pathway b, blue).  The requirement for a highly electron-rich aryl ring accounts for the 
lack of isoindolone formation in our earlier studies, as only less electron-rich substrates 
were used.  Indeed, similar reactivity between cyclopropanes and olefins9 and alkynes,10 
as well as dimerization7,11 and intramolecular rearrangement12 reactions all require very 
electron-rich aryl groups. 
 
Scheme A2.6  Proposed mechanism for the formation of 5-aryl γ-lactam 257 and isoindolone 258 
 
Despite the similar methods mentioned above,7–10 isocyanates (or any other 
heteroatom-containg dipolarophiles) were not reported to undergo such reactions.  Given 
the prevalence of isoindolones in biologically active compounds13 and our discovery of a 
novel method for their synthesis, we attempted to optimize conditions for their formation.  
Unfortunately, screening a number of Lewis acids, solvents, and isocyanate equivalents 
provided no useful insights, with only low conversion or decomposition being observed. 
We next investigated the influence of the aryl donor group on the cyclopropane, 
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better compete with the malonate moiety in attacking the electrophilic carbon atom.  
While the use of heteroaryl donor groups such as furyl (261) and indolyl (209) 
cyclopropanes resulted in only decomposition, use of a 3,4,5-trimethoxyphenyl donor 
group (264) afforded the isoindolone product as the exclusive product in moderate yield. 
 
Scheme A2.7  Attempts at isoindolone formation from cyclopropanes with strongly electron-
donating groups 
 
Similarly, more strongly electron-withdrawing acceptor groups on the cyclopropane 
should shift the product distribution to favor the isoindolones.  Unfortunately attempts to 
synthesize cyclopropanes with acceptor groups derived from Meldrum’s acid or 1,3-
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A2.6  FUTURE DIRECTIONS 
A2.6.1  THIQ ALKALOID SYNTHESIS 
Although the use of an intermolecular cyclopropane-isocyanate cycloaddition in the 
THIQ alkaloid synthesis does not appear promising, the success of a carbodiimide 
dipolarophile in the cycloaddition reaction (Scheme A2.5B) suggests a different approach 
may be feasible.  Utilization of bis(2-chloroethyl)carbodiimide (or a more stable 
analogue) would enable the synthesis of amidine 266, which could undergo a sequence of 
Fridel–Crafts alkylation and amidine hydrolysis15 to afford lactam 239 (Scheme A2.8).  
This common intermediate could be advanced to the target molecules as described above. 
 
Scheme A2.8  Proposed synthetic route utilizing a cyclopropane-carbodiimide cycloaddition 
 
 
A2.6.2  SYNTHESIS OF ISOINDOLONES 
Our newly discovered route to isoindolones requires further optimization, but the 
demonstrated ability of a 3,4,5-trimethoxyphenyl donor group to suppress formation of 
the typical dipolar cycloadduct is a promising starting point.  Future studies may include 
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Figure A2.3) and re-screening of Lewis acids and solvents with the 3,4,5-
trimethoxyphenyl cyclopropane substrate. 
 
Figure A2.3  Cyclopropanes bearing slighly more electron-withdrawing acceptor groups 
 
 
A2.7  EXPERIMENTAL SECTION 
A2.7.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed in flame-dried or oven-dried 
glassware under an argon or nitrogen atmosphere using dry, deoxygenated solvents 
(distilled or passed over a column of activated alumina).16  All heterocumulenes were 
obtained from commercial suppliers.  Commercially obtained reagents were used as 
received with the exception of tetrakis(triphenylphospine)palladium(0), tin(II) triflate, 
and iron(III) chloride, which were stored in a nitrogen-filled glovebox.  
Diazodimethylmalonate was prepared according to the method of Davies and 
coworkers.17  Cyclopropanes 195 and 209 were prepared as described in Chapter 2.  Thin-
layer chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated 
plates (0.25 mm) and visualized by UV fluorescence quenching, potassium 
permanganate, or p-anisaldehyde staining.  SiliaFlash P60 Academic Silica gel (particle 
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were recorded on a Varian 400 (at 400 MHz and 100 MHz, respectively) or on a Varian 
Mercury 500 (at 500 MHz and 126 MHz, respectively) and are reported relative to CHCl3 
(δ 7.26 & 77.16 ppm, respectively) or tetramethylsilane (0.00 ppm).  Data for 1H NMR 
spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant 
(Hz), integration).  Abbreviations are used as follows: s = singlet, d = doublet, t = triplet, 
q = quartet, hept = heptet, m = complex multiplet, app = apparent. 
 
A2.7.2  PREPARATION OF ARYL HALIDES AND CYCLOPROPANES 
 
3-(2-bromo-3,4-dimethoxyphenyl)propionic acid (244): 
Prepared according to the method of Lebel and coworkers18 with minor 
modifications: pre-cooling the acetic acid solution in an ice-water bath resulted in a 
frozen mixture; therefore, the solution was cooled until it began to freeze, and bromine 
was added thereafter, with continued cooling in the ice-water bath.  The characterization 
data matched those reported by Lebel and coworkers.17 
  
 
3-(2-iodo-3,4-dimethoxyphenyl)propionic acid (245):   
Carboxylic acid 271 (1.08 g, 5.14 mmol, 1 equiv) was dissolved in acetic acid (6 mL) 
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added in portions at ambient temperature to afford an orange solution.  After at least 20 
minutes, a precipitate was observed.  After 85 minutes, the suspension was poured over 
water (10 mL) and a saturated solution of aqueous sodium thiosulfate was slowly added 
until the orange color disappeared.  The suspension was filtered, washed with water, and 
air-dried to afford iodide 245 (1.5503 g, 90% yield) as a white amorphous solid: 1H NMR 
(300 MHz, CDCl3) δ 7.21 (s, 1H), 6.80 (s, 1H), 3.85 (s, 6H), 3.00 (t, J = 7.8 Hz, 2H), 
2.66 (t, J = 7.8 Hz, 2H). 
 
 
tert-butyl 3-(2-bromo-4,5-dimethoxyphenyl)propanoate (246): 
According to the procedure of Takeda and coworkers.19  To a suspension of acid 244 
(1.00 g, 3.4 mmol, 1 equiv) and di-tert-butyl dicarbonate (2.2544 g, 10.4 mmol, 3 equiv) 
in tert-butanol (8.5 mL, 0.4 M) was added 4-(N,N-dimethylamino)pyridine (127 mg, 1.02 
mmol, 0.3 equiv). Vigorous bubbling was observed and the solution became yellow.  
After one hour, the reaction mixture was dry-loaded directly onto SiO2 (~10 mL) and 
purified by silica gel column chromatography (20:1 → 10:1 hexanes:EtOAc) to afford 
tert-butyl ester 246 (581.6 mg, 49% yield): 1H NMR (300 MHz, CDCl3) δ 6.99 (s, 1H), 
6.77 (s, 1H), 3.85 (s, 6H), 2.95 (t, J = 7.7 Hz,  2H), 2.52 (t, J = 7.7 Hz, 2H), 1.43 (s, 9H). 
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To a flame-dried round bottom flask equipped with a magnetic stir bar were added 
aryl bromide 244 (500 mg, 1.73 mmol), sodium bicarbonate (291 mg, 3.46 mmol), para-
methoxybenzyl chloride (258 μL, 1.90 mmol), and DMF (1 mL).  The mixture was 
stirred under nitrogen at 45 °C for 29 hours.  Upon completion (as determined by TLC 
analysis), the mixture was cooled to room temperature, diluted with ethyl acetate (5 mL), 
washed with water (2 x 10 mL) and brine (1 x 10 mL), dried over sodium sulfate, and 
filtered and evaporated to give the crude product as a yellow oil.  The oil was purified by 
silica gel column chromatography (9:1 hexanes:EtOAc) to give ester 247 (594 mg, 91% 
yield).  1H NMR (300 MHz, CDCl3) δ 7.29–7.18 (m, 2H), 6.96 (s, 1H), 6.88–6.80 (m, 
2H), 6.71 (s, 1H), 5.03 (s, 2H), 3.80 (s, 3H), 3.76 (s, 3H), 3.76 (s, 3H), 2.98 (t, J = 8.2, 
2H), 2.63 (t, J = 8.2, 2H). 
 
 
dimethyl 2-(trimethylsilyl)cycloprop-2-ene-1,1-dicarboxylate (274):   
Prepared by an improved procedure based on that reported by Gevorgyan and 
coworkers.5 To a flame-dried round-bottom flask equipped with a magnetic stir bar was 
added bis[rhodium(α,α,α’,α’-tetramethyl-1,3-benzenedipropionic acid)] (0.7 mg, 0.9 
µmol, 0.016 mol %) and trimethylsilylacetylene (272, 0.82 mL, 5.75 mmol, 1 equiv).  
The flask was sealed with a rubber septum, then evacuated and backfilled with argon 
three times.  Dichloromethane was then added (10 mL, 0.6 M) and the flask was cooled 
in an ice-water bath with stirring.  Diazodimethylmalonate (0.9982 g, 6.3 mmol, 1.1 
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warm to ambient temperature, stirring overnight (13 h).  Complete consumption of the 
starting material was observed (TLC), and the solvent was evaporated in vacuo.  The 
residue was purified by silica gel column chromatography (20:1 → 6:1 hexanes:EtOAc) 
to afford cyclopropene 273 as a blue oil which was carried forward directly to the next 
stage.  Cyclopropene 273 was dissolved in tetrahydrofuran (30 mL) in a round-bottom 
flask, and the solution was cooled in an ice-water bath.  To this solution was added 
K2CO3 (10 mL, 10% in water) with stirring.  After 10 minutes, TLC indicated complete 
consumption of starting material (Rf: 3:1 hexanes:EtOAc, SM = 0.62, prod = 0.21).  The 
phases were separated and the organic phase was concentrated to an approximate volume 
of 5 mL.  The aqueous and organic phases were recombined and diluted with water (10 
mL) and diethyl ether (25 mL).  The phases were separated and the aqueous layer was 
extracted with additional diethyl ether (25 mL).  The  combined organics were dried over 
sodium sulfate, filtered, and concentrated in vacuo.  The residue was purified by silica gel 
column chromatography (9:1 hexanes:EtOAc) to afford cyclopropene 274 (634.1 mg, 
70% yield) as an amorphous white solid.  The characterization data matched those 





In a nitrogen filled glove-box, an oven-dried scintillation vial was charged with 
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and dppb (6.0 mg, 0.014 mmol, 0.022 equiv), and the solids were dissolved in 
dichloromethane, affording an orange solution.  A separate one dram vial was charged 
with cyclopropene 274 (99.5 mg, 0.64 mmol, 1 equiv) and pinacolborane (100 μL, 0.7 
mmol, 1.1 equiv).  The mixture was dissolved in dichloromethane (0.5 mL) and 
transferred into the first vial; the second vial was then washed with additional 
dichloromethane (0.3 mL) and transferred into the first vial.  The reaction was stirred for 
17 hours and complete conversion of the starting material was observed (TLC: 3:1 
hexanes:EtOAc, Rf: SM = 0.21, product: 0.46).  The reaction mixture was dry-loaded 
onto SiO2 (~1 mL) and purified by silica gel column chromatography (8:1 
hexanes:EtOAc) to afford cyclopropane 248 (160.7 mg, 89% yield).  The characterization 
data matched those reported by Gevorgyan.5 
 
 
dimethyl 2-(tributylstannyl)cyclopropane-1,1-dicarboxylate (249): 
Prepared by a procedure reported by Gevorgyan and coworkers.6  In a nitrogen filled 
glove-box, an oven-dried scintillation vial was charged with 
tetrakis(triphenylphosphine)palladium(0) (10 mg, 0.002 mmol).  The vial was capped 
with a screw cap fitted with a Teflon septum and removed from the glovebox.  THF (1.55 
mL) was added and the mixture was stirred until the catalyst dissolved.  The solution was 
then cooled to –78 °C under nitrogen and tributyltin hydride (460 μL, 0.34 mmol) was 
added.  Finally, a solution of the starting material (274, 250 mg, 0.31 mmol) in THF (0.5 
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(as determined by TLC analysis), the mixture was concentrated and purified by silica gel 
column chromatography (hexanes) to afford cyclopropylstannane 249  (510 mg, 72% 
yield).  The characterization data match those reported by Gevorgyan.6 
 
 
dimethyl 2-(3,4-dimethoxyphenyl)cyclopropane-1,1-dicarboxylate (252): 
Cyclopropane 252 was synthesized following our standard procedures.  See General 
Proceedures A and B, Experimental Section, Chapter 2.  The characterization data match 
those reported by Müller.20 
 
 
dimethyl 2-(furan-3-yl)cyclopropane-1,1-dicarboxylate (261) 
Cyclopropane 261 was synthesized following our standard procedures.  See General 
Proceedures A and B, Experimental Section, Chapter 2.  The characterization data match 
those reported by Skvorcova.21 
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Cyclopropane 264 was synthesized following our standard procedures.  See General 
Proceedures A and B, Experimental Section, Chapter 2.  The characterization data match 
those reported by Melnikov.7 
 
A2.7.3  SYNTHESIS OF STYRENE 250 VIA STILLE COUPLING 
 
 
tert-butyl 3-(4,5-dimethoxy-2-vinylphenyl)propanoate (250):   
In a nitrogen-filled glovebox, a flame-dried Schlenk bomb was charged with 
tetrakis(triphenylphosphine)palladium(0) (30 mg, 0.03 mmol, 0.02 equiv).  The bomb 
was sealed, removed from the glovebox, and placed under an atmosphere of argon.  To a 
vial containing bromide 246 (455.1 mg, 1.30 mmol, 1 equiv) was added dry toluene, 
which was then removed in vacuo; this procedure was repeated twice to remove traces of 
water from the substrate.  Under an atmosphere of argon, the bromide was dissolved in 
toluene (3 mL) and transferred to the Schlenk bomb under a high flow of argon.  Finally, 
vinyl tributyltin (0.4 mL, 1.37 mmol, 1.05 equiv) was added as a neat oil to the Schlenk 
bomb under a high flow of argon.  The bomb was sealed and lowered into an oil bath 
which was preheated to 100 °C.  After 17 hours, the bomb was cooled to ambient 
temperature, and a crude product was obtained by a workup procedure that was not 
properly recorded. The crude product was purified by column chromatography to afford 
styrene 250 as a yellow solid (253.1 mg, 66% yield).  1H NMR of the crude material 











Appendix 2 – Application of Cyclopropane Cycloadditions to Alkaloid Synthesis  
 
115
the vinyl group: 5.87 (dd, J = 17.2, 10.5 Hz, 1H), 5.09 (d, J = 10.5 Hz, 1H), 5.04 (d, J = 
17.2 Hz, 1 H). 1H NMR of the purified product was poorly shimmed or had paramagnetic 
impurities. 
 
A2.7.4  PROCEDURE FOR ATTEMPTED REACTIONS WITH 2-
(CHLOROETHYL)ISOCYANATE 
 
These reactions were carried out using our standard procedure.  See General 
Procedure D, Experimental Section, Chapter 2.  In no case did analysis of the reaction 
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A2.7.5  CONTROL REACTIONS WITH CYCLOPROPANE 252 
 
The reaction of cyclopropane 252 with allyl isothiocyanate was carried out using our 
standard procedure.  See General Proceedure F, Experimental Section, Chapter 2.  






The reaction of cyclopropane 252 with diisopropylcarbodiimide was carried out using 
our standard procedure.  See General Proceedure G, Experimental Section, Chapter 2.  
Analysis of the reaction mixture and crude product by TLC, LCMS, and NMR showed 
only decomposition.  1H NMR analysis (300 MHz, CDCl3) of the crude product (256) 
showed signals correponsing to the 5-arylamidine ring: δ 5.19 (dd, J = 8.4, 3.7, 1H), 3.23 






































The reaction of cyclopropane 252 with benzyl isocyanate was carried out using our 
standard procedure.  See General Proceedure D, Experimental Section, Chapter 2.  A 
mixture of 257 and 258 was obtained, and the following characterization data was 
collected.  257 (47% yield): 1H NMR (300 MHz, CDCl3) δ 7.31–7.27 (m, 3H), 7.10–7.06 
(m, 2H), 6.87 (d, J = 8.2, 1H), 6.72 (dd, J = 8.2, 2.1, 1H), 6.63 (d, J = 2.1, 1H), 5.11 (d, J 
= 14.5, 1H), 4.33 (t, J = 7.6, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.85 (s, 3H), 3.84 (s, 3H), 
3.55 (d, J = 14.6, 1H), 2.97 (dd, J = 13.9, 7.3, 1H), 2.69 (dd, J = 13.9, 7.9, 1H).  13C NMR 
(126 MHz, CDCl3) δ 167.9, 167.8, 167.0, 149.6, 149.2, 135.5, 130.7, 128.7, 128.5, 127.8, 
120.1, 111.1, 109.7, 63.3, 58.6, 56.0, 55.9, 53.6, 53.5, 45.2, 37.8.  258 (40% yield): 1H 
NMR (300 MHz, CDCl3) δ 7.37 (s, 1H), 7.35–7.24 (m, 5H), 6.80 (d, J = 0.6, 1H), 5.33 
(d, J = 15.3, 1H), 4.42 (dd, J = 4.2, 3.3, 1H), 4.09 (d, J = 15.3, 1H), 3.98 (s, 3H), 3.94 (s, 
3H), 3.72 (s, 3H), 3.49 (s, 3H), 2.88 (dd, J = 6.9, 6.3, 1H), 2.77 (ddd, J = 15.1, 7.0, 4.4, 
1H), 2.60 (ddd, J = 15.0, 6.2, 3.2, 1H).  13C NMR (126 MHz, CDCl3) δ 169.5, 169.5, 
169.0, 152.7, 150.0, 137.0, 136.6, 128.8, 128.1, 127.6, 125.0, 105.4, 104.9, 56.4, 56.3, 
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A2.7.6  REACTION OF CYCLOPROPANE 264 WITH BENZYL ISOCYANATE 
 
The reaction of cyclopropane 264 with benzyl isocyanate was carried out using our 
standard procedure.  See General Proceedure D, Experimental Section, Chapter 2.  
Isoindolone 265 was obtained in approximately 49% yield, although purification was 
difficult.  1H NMR analysis (300 MHz, CDCl3) of showed signals corresponding to the 5-
malonyl-containing side chain off the isoindoline ring: δ 3.03–2.94 (m, 1H), 2.83–2.70 
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Figure A3.3 13C NMR (126 MHz, CDCl3) of compound 195. 
Figure A3.2 Infrared spectrum (thin film/NaCl) of compound 195. 



















































Figure A3.6 13C NMR (126 MHz, CDCl3) of compound 197. 
 
Figure A3.5 Infrared spectrum (thin film/NaCl) of compound 197. 
 

















































Figure A3.9 13C NMR (126 MHz, CDCl3) of compound 144. 
 
Figure A3.8 Infrared spectrum (thin film/NaCl) of compound 144. 
 



















































Figure A3.11 Infrared spectrum (thin film/NaCl) of compound 145. 
 
Figure A3.12 13C NMR (126 MHz, CDCl3) of compound 145. 
 


















































Figure A3.15 13C NMR (126 MHz, CDCl3) of compound 146. 
 
Figure A3.14 Infrared spectrum (thin film/NaCl) of compound 146. 
 


















































Figure A3.18. 13C NMR (126 MHz, CDCl3) of compound 147. 
 
Figure A3.17 Infrared spectrum (thin film/NaCl) of compound 147. 
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Figure A3.21 13C NMR (126 MHz, CDCl3) of compound 148. 
 
Figure A3.20 Infrared spectrum (thin film/NaCl) of compound 148. 
 
















































Figure A3.24 13C NMR (126 MHz, CDCl3) of compound 149. 
 
Figure A3.23 Infrared spectrum (thin film/NaCl) of compound 149. 
 
















































































































Figure A3.27 13C NMR (126 MHz, CDCl3) of compound 158. 
 
Figure A3.26 Infrared spectrum (thin film/NaCl) of compound 158. 
 


















































Figure A3.30 13C NMR (126 MHz, CDCl3) of compound 150. 
 
Figure A3.29 Infrared spectrum (thin film/NaCl) of compound 150. 
 

















































Figure A3.33 13C NMR (126 MHz, CDCl3) of compound 159. 
 
Figure A3.32 Infrared spectrum (thin film/NaCl) of compound 159. 
 

















































Figure A3.36 13C NMR (126 MHz, CDCl3) of compound 160. 
 
Figure A3.35 Infrared spectrum (thin film/NaCl) of compound 160. 
 


















































Figure A3.39 13C NMR (126 MHz, CDCl3) of compound 161. 
 
Figure A3.38 Infrared spectrum (thin film/NaCl) of compound 161. 
 


















































Figure A3.42 13C NMR (126 MHz, CDCl3) of compound 162. 
 
Figure A3.41 Infrared spectrum (thin film/NaCl) of compound 162. 
 




















































Figure A3.45 13C NMR (126 MHz, CDCl3) of compound 163. 
 
Figure A3.44 Infrared spectrum (thin film/NaCl) of compound 163. 
 






















































Figure A3.48 13C NMR (126 MHz, CDCl3) of compound 155. 
 
Figure A3.47 Infrared spectrum (thin film/NaCl) of compound 155. 
 
















































Figure A3.51 13C NMR (126 MHz, CDCl3) of compound 164. 
 
Figure A3.50 Infrared spectrum (thin film/NaCl) of compound 164. 
 
















































Figure A3.54 13C NMR (126 MHz, CDCl3) of compound 165. 
 
Figure A3.53 Infrared spectrum (thin film/NaCl) of compound 165. 
 

















































Figure A3.57 13C NMR (126 MHz, CDCl3) of compound 166. 
 
Figure A3.56 Infrared spectrum (thin film/NaCl) of compound 166. 
 


















































Figure A3.60 13C NMR (126 MHz, CDCl3) of compound 167. 
 
Figure A3.59 Infrared spectrum (thin film/NaCl) of compound 167. 
 


















































Figure A3.63 13C NMR (126 MHz, CDCl3) of compound 168. 
 
Figure A3.62 Infrared spectrum (thin film/NaCl) of compound 168. 
 
















































Figure A3.66 13C NMR (126 MHz, CDCl3) of compound 154. 
 
Figure A3.65 Infrared spectrum (thin film/NaCl) of compound 154. 
 




















































Figure A3.69 13C NMR (101 MHz, CDCl3) of compound 170. 
 
Figure A3.68 Infrared spectrum (thin film/NaCl) of compound 170. 
 





















































Figure A3.72 13C NMR (101 MHz, CDCl3) of compound 171. 
Figure A3.71 Infrared spectrum (thin film/NaCl) of compound 171. 
 




















































Figure A3.75 13C NMR (126 MHz, CDCl3) of compound 172. 
 
Figure A3.74 Infrared spectrum (thin film/NaCl) of compound 172. 
 




















































Figure A3.78 13C NMR (126 MHz, CDCl3) of compound 173. 
 
Figure A3.77 Infrared spectrum (thin film/NaCl) of compound 173. 
 


















































Figure A3.81 13C NMR (126 MHz, CDCl3) of compound 174. 
 
Figure A3.80 Infrared spectrum (thin film/NaCl) of compound 174. 
 




















































Figure A3.84 13C NMR (126 MHz, CDCl3) of compound 175. 
 
Figure A3.83 Infrared spectrum (thin film/NaCl) of compound 175. 
 






















































Figure A3.87 13C NMR (126 MHz, CDCl3) of compound 176. 
 
Figure A3.86 Infrared spectrum (thin film/NaCl) of compound 176. 
 





















































Figure A3.90 13C NMR (101 MHz, DMSO-d6, 100 °C) of compound 177. 
Figure A3.89 Infrared spectrum (thin film/NaCl) of compound 177. 
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A4.1   X-RAY CRYSTAL STRUCTURE ANALYSIS OF THIOIMIDATE 155 
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Table A4.1.1 Crystal data and structure refinement for thioimidate 155 
Caltech Identification Number rac13 
CCDC Deposition Number 911991 
Empirical formula  C20 H25 N O4 S 
Formula weight  375.47 
Crystallization solvent  Benzene/Heptane/Ethyl Acetate  
Crystal color  colourless  
Crystal size 0.08 x 0.19 x 0.46 mm 
  
 Data Collection  
Preliminary photograph(s)  rotation  
Type of diffractometer  Bruker KAPPA APEX II 
Wavelength  0.71073 ≈ MO K 
Data collection temperature  100.15 K 
Theta range for 5787 reflections used 
in lattice determination  2.521 to 31.600° 
Unit cell dimensions a = 14.5982(10) ≈ α= 90° 
 b = 16.1620(12) ≈ β= 92.145(4)° 
 c = 8.2014(6) ≈ γ = 90° 
Volume 1933.7(2) ≈3 
Z 4 
Crystal system  monoclinic 
Space group  P 1 21/c 1   (# 14) 
Density (calculated) 1.290 g/cm3 
F(000) 800 
Theta range for data collection 1.4 to 37.4∞ 
Completeness to theta = 25.00° 100.0%  
Index ranges –24 ≤ h ≤ 24, 0 ≤ k ≤ 27, 0 ≤ l ≤ 13 
Data collection scan type  narrow and scans 
Reflections collected 15085 
Independent reflections 15085 [Rint= 0.0000] 
Reflections > 2s(I) 10418  
Average s(I)/(net I) 0.0676 
Absorption coefficient 0.19 mm–1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9848 and 0.9170 
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Table A4.1.1 (cont’d) 
Reflections monitored for decay  0 
Decay of standards  0%  
 
 Structure Solution and Refinement  
Primary solution method  direct 
Secondary solution method  difmap 
Hydrogen placement  geom 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15085 / 0 / 241 
Treatment of hydrogen atoms  constr 
Goodness-of-fit on F2 1.06 
Final R indices [I>2s(I), 10418 reflections] R1 = 0.0592, wR2 = 0.1221 
R indices (all data) R1 = 0.1034, wR2 = 0.1431 
Type of weighting scheme used calc 
Weighting scheme used calc w=1/[^2^(Fo^2^)+(0.0645P)^2^+0.3700P] where 
P=(Fo^2^+2Fc^2^)/3 
Max shift/error  0.001 
Average shift/error  0.000 
Largest diff. peak and hole 0.49 and -0.37 e∑≈-3 
  
 Programs Used  
Cell refinement   SAINT V8.18C (Bruker-AXS, 2007) 
Data collection   APEX2 2012.2-0 (Bruker-AXS, 2007) 
Data reduction   SAINT V8.18C (Bruker-AXS, 2007) 
Structure solution   SHELXS-97 (Sheldrick, 1990) 
Structure refinement   SHELXL-97 (Sheldrick, 1997) 
Graphics  DIAMOND 3 (Crystal Impact, 1999) 
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Table A4.1.2 Atomic coordinates (x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for thioimidate 155.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________________________________ 
 x y z Ueq 
________________________________________________________________________ 
S(1) 7001(1) 6892(1) 2895(1) 22(1) 
O(1) 8360(1) 6282(1) 6404(1) 27(1) 
O(2) 7480(1) 5212(1) 7100(1) 22(1) 
O(3) 7866(1) 4219(1) 2706(1) 26(1) 
O(4) 8857(1) 4560(1) 4768(1) 22(1) 
N(1) 8660(1) 6157(1) 2476(1) 20(1) 
C(1) 6183(1) 6259(1) 4018(2) 18(1) 
C(2) 6567(1) 5375(1) 4014(2) 18(1) 
C(3) 7607(1) 5456(1) 4275(2) 17(1) 
C(4) 7894(1) 6152(1) 3131(2) 18(1) 
C(5) 5192(1) 6358(1) 3430(1) 15(1) 
C(6) 4890(1) 6274(1) 1789(1) 18(1) 
C(7) 3969(1) 6418(1) 1363(2) 20(1) 
C(8) 3336(1) 6643(1) 2493(2) 20(1) 
C(9) 3634(1) 6687(1) 4121(2) 19(1) 
C(10) 4541(1) 6543(1) 4608(1) 17(1) 
C(11) 5514(1) 6056(1) 420(2) 26(1) 
C(12) 2354(1) 6831(1) 1995(2) 29(1) 
C(13) 4795(1) 6554(1) 6414(1) 24(1) 
C(14) 7874(1) 5710(1) 6034(2) 18(1) 
C(15) 7719(1) 5383(1) 8800(2) 26(1) 
C(16) 8111(1) 4667(1) 3805(2) 18(1) 
C(17) 9433(1) 3862(1) 4390(2) 29(1) 
C(18) 8876(1) 6851(1) 1424(2) 23(1) 
C(19) 9690(1) 6694(1) 428(2) 27(1) 
C(20) 10218(1) 6036(1) 521(2) 31(1) 
________________________________________________________________________
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Table A4.1.3      Bond lengths [Å] and angles [°] for thioimidate 155 
______________________________________________________________________  
S(1)-C(1)  1.8457(13) 
S(1)-C(4)  1.7750(12) 
O(1)-C(14)  1.1975(14) 
O(2)-C(14)  1.3343(15) 
O(2)-C(15)  1.4511(15) 
O(3)-C(16)  1.1997(14) 
O(4)-C(16)  1.3320(15) 
O(4)-C(17)  1.4486(16) 
N(1)-C(4)  1.2587(17) 
N(1)-C(18)  1.4571(16) 
C(1)-H(1)  1.0000 
C(1)-C(2)  1.5343(16) 
C(1)-C(5)  1.5167(17) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(2)-C(3)  1.5308(17) 
C(3)-C(4)  1.5333(17) 
C(3)-C(14)  1.5361(17) 
C(3)-C(16)  1.5297(16) 
C(5)-C(6)  1.4066(16) 
C(5)-C(10)  1.4121(18) 
C(6)-C(7)  1.3959(18) 
C(6)-C(11)  1.5136(19) 
C(7)-H(7)  0.9500 
C(7)-C(8)  1.3812(19) 
C(8)-C(9)  1.3904(17) 
C(8)-C(12)  1.5075(18) 
C(9)-H(9)  0.9500 
C(9)-C(10)  1.3892(17) 
C(10)-C(13)  1.5126(16) 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
C(11)-H(11C)  0.9800 
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Table A4.1.3 (cont’d) 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
C(13)-H(13A)  0.9800 
C(13)-H(13B)  0.9800 
C(13)-H(13C)  0.9800 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9900 
C(18)-H(18B)  0.9900 
C(18)-C(19)  1.489(2) 
C(19)-H(19)  0.9500 
C(19)-C(20)  1.313(2) 
C(20)-H(20A)  0.9500 
















Appendix 4 – X-Ray Crystallography Reports Relevant to Chapter 2  
 
191



































Appendix 4 – X-Ray Crystallography Reports Relevant to Chapter 2  
 
192



































Appendix 4 – X-Ray Crystallography Reports Relevant to Chapter 2  
 
193











Symmetry transformations used to generate equivalent atoms:  
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Table A4.1.4 Anisotropic displacement parameters  (Å2x103) for thioimidate 155.  The 
anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________  
S(1) 146(1)  147(1) 372(2)  67(1) -20(1)  19(1) 
O(1) 275(6)  192(4) 326(5)  -16(4) -66(4)  -65(4) 
O(2) 204(5)  218(4) 232(4)  -6(3) -28(3)  -45(3) 
O(3) 261(5)  201(4) 313(5)  -57(4) -71(4)  32(4) 
O(4) 175(5)  176(4) 300(5)  -10(3) -55(3)  60(3) 
N(1) 170(5)  157(4) 275(5)  8(4) -34(4)  -1(4) 
C(1) 140(6)  152(5) 228(5)  21(4) -52(4)  -1(4) 
C(2) 142(6)  134(5) 259(6)  23(4) -55(4)  -3(4) 
C(3) 136(6)  125(5) 245(5)  10(4) -47(4)  5(4) 
C(4) 160(6)  127(5) 256(6)  6(4) -50(5)  11(4) 
C(5) 138(5)  139(5) 181(5)  20(4) -28(4)  4(4) 
C(6) 174(6)  184(5) 173(5)  13(4) -19(4)  7(4) 
C(7) 185(6)  211(6) 210(5)  35(4) -70(5)  -12(5) 
C(8) 145(6)  157(5) 286(6)  54(4) -41(5)  -6(4) 
C(9) 177(6)  168(5) 237(5)  19(4) 25(5)  20(4) 
C(10) 192(6)  127(5) 180(5)  16(4) -14(4)  13(4) 
C(11) 258(7)  331(7) 186(5)  -2(5) 10(5)  35(6) 
C(12) 152(6)  289(7) 436(8)  87(6) -65(6)  12(5) 
C(13) 311(8)  249(6) 171(5)  -12(5) -13(5)  31(5) 
C(14) 130(6)  132(5) 272(6)  0(4) -39(4)  27(4) 
C(15) 236(7)  302(7) 241(6)  -38(5) -11(5)  -12(5) 
C(16) 158(6)  137(5) 248(6)  31(4) -22(5)  14(4) 
C(17) 232(7)  237(7) 401(8)  -37(6) -48(6)  116(5) 
C(18) 207(7)  182(5) 301(6)  22(5) -30(5)  -21(5) 
C(19) 219(7)  292(7) 309(7)  32(5) -34(5)  -87(5) 
C(20) 211(7)  391(8) 323(7)  -5(6) 2(6)  -20(6) 
________________________________________________________________________
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Table A4.1.5      Hydrogen coordinates (x103) and isotropic  displacement parameters (Å2x103)  
for thioimidate 155 
________________________________________________________________________  
 x  y  z  Uiso 
________________________________________________________________________  
  
H(1) 622 645 518 21 
H(2A) 631 504 490 22 
H(2B) 641 510 296 22 
H(7) 377 636 25 24 
H(9) 320 682 492 23 
H(11A) 516 576 -44 39 
H(11B) 601 570 84 39 
H(11C) 578 656 -2 39 
H(12A) 227 677 81 44 
H(12B) 221 740 230 44 
H(12C) 195 645 255 44 
H(13A) 424 663 704 37 
H(13B) 522 701 665 37 
H(13C) 509 603 672 37 
H(15A) 839 538 896 39 
H(15B) 745 496 949 39 
H(15C) 748 593 910 39 
H(17A) 907 335 441 44 
H(17B) 994 382 520 44 
H(17C) 968 394 330 44 
H(18A) 899 735 211 28 
H(18B) 834 697 68 28 
H(19) 984 711 -34 33 
H(20A) 1009 561 128 37 
H(20B) 1072 599 -17 37 
________________________________________________________________________  
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A4.2   X-RAY CRYSTAL STRUCTURE ANALYSIS OF AMIDINE (R)-170•HBr 
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Table A4.2.1 Crystal data and structure refinement for amidine (R)-170•HBr 
Caltech Identification Number afg04 
CCDC Deposition Number 911990 
Empirical formula  C20 H31 Br N2 O5 
Formula weight  459.38 
Crystallization solvent  diethyl ether / dichloromethane  
Crystal shape  prism 
Crystal color  colourless  
Crystal size 0.17 x 0.18 x 0.47 mm 
 
 Data Collection  
Preliminary photograph(s)  rotation  
Type of diffractometer  Bruker KAPPA APEX II 
Wavelength  0.71073 ≈ MO K 
Data collection temperature  100.15 K 
Theta range for 9397 reflections used 
in lattice determination  2.620 to 31.334∞ 
Unit cell dimensions a = 8.0748(6) ≈ α= 98.815(5)∞ 
 b = 15.1323(12) ≈ β= 92.189(5)∞ 
 c = 29.190(2) ≈ γ = 105.250(4)∞ 
Volume 3388.9(5) ≈3 
Z 6 
Crystal system  triclinic 
Space group  P 1   (# 1) 
Density (calculated) 1.351 g/cm3 
F(000) 1440 
Theta range for data collection 1.7 to 35.3∞ 
Completeness to theta = 25.00∞ 99.7%  
Index ranges –12 ≤ h ≤ 12, –24 ≤ k ≤ 24, –46 ≤ l ≤ 45 
Data collection scan type  narrow and scans 
Reflections collected 161414 
Independent reflections 54469 [Rint= 0.0430] 
Reflections > 2σ(I) 44420  
Average σ(I)/(net I) 0.0781 
Absorption coefficient 1.85 mm-1 
Absorption correction Semi-empirical from equivalents 
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Table A4.2.1 (cont’d) 
Max. and min. transmission 1.0000 and 0.8047 
Reflections monitored for decay  0 
Decay of standards  0%  
 
 Structure Solution and Refinement  
Primary solution method  direct 
Secondary solution method  difmap 
Hydrogen placement  geom 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 54469 / 21 / 1585 
Treatment of hydrogen atoms  mixed 
Goodness-of-fit on F2 1.65 
Final R indices [I>2σ(I), 44420 reflections] R1 = 0.0568, wR2 = 0.1138 
R indices (all data) R1 = 0.0743, wR2 = 0.1159 
Type of weighting scheme used calc 
Weighting scheme used calc w=1/[^2^(Fo^2^)+(0.0000P)^2^+0.0000P] where 
P=(Fo^2^+2Fc^2^)/3 
Max shift/error  0.001 
Average shift/error  0.000 
Absolute structure parameter 0.029(3) 
Largest diff. peak and hole 3.05 and -1.34 e∑≈-3 
 
 Programs Used  
Cell refinement   SAINT V8.18C (Bruker-AXS, 2007) 
Data collection   APEX2_2011.2-3 (Bruker-AXS, 2007) 
Data reduction   SAINT V8.18C (Bruker-AXS, 2007) 
Structure solution   SHELXS-97 (Sheldrick, 1990) 
Structure refinement     
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Table A4.2.2 Atomic coordinates (x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for amidine (R)-170•HBr.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
_______________________________________________________________________________  
 x y z Ueq 
________________________________________________________________________________   
O(1A) 5205(3) 3297(1) 8553(1) 18(1) 
O(2A) 8042(3) 3464(1) 8523(1) 23(1) 
O(3A) 7013(3) 1830(2) 9013(1) 23(1) 
O(4A) 6394(3) 573(1) 8452(1) 19(1) 
N(1A) 4511(3) 1542(2) 7520(1) 13(1) 
N(2A) 2967(3) 1288(2) 8164(1) 14(1) 
C(1A) 6285(4) 1836(2) 7379(1) 14(1) 
C(2A) 7391(4) 1877(2) 7827(1) 14(1) 
C(3A) 6203(4) 1976(2) 8227(1) 12(1) 
C(4A) 4428(4) 1573(2) 7975(1) 14(1) 
C(5A) 2951(4) 1256(2) 7188(1) 16(1) 
C(6A) 3358(5) 925(2) 6694(1) 24(1) 
C(7A) 2076(4) 2039(2) 7207(1) 23(1) 
C(8A) 6672(4) 2728(2) 7175(1) 15(1) 
C(9A) 7542(4) 2761(2) 6775(1) 18(1) 
C(10A) 8003(4) 3575(2) 6590(1) 21(1) 
C(11A) 7600(4) 4364(2) 6807(1) 23(1) 
C(12A) 6731(4) 4340(2) 7206(1) 22(1) 
C(13A) 6259(4) 3527(2) 7390(1) 18(1) 
C(14A) 6408(4) 2992(2) 8455(1) 14(1) 
C(15A) 8393(5) 4430(2) 8746(1) 34(1) 
C(16A) 6583(4) 1461(2) 8621(1) 14(1) 
C(17A) 6827(5) 27(2) 8784(1) 25(1) 
C(18A) 2705(4) 1332(2) 8666(1) 18(1) 
C(19A) 1333(5) 1853(2) 8773(1) 26(1) 
C(20A) 2143(4) 350(2) 8781(1) 23(1) 
O(1B) 2761(3) 3136(1) 5141(1) 17(1) 
O(2B) 5580(3) 3478(1) 5045(1) 21(1) 
O(3B) 5020(3) 2039(1) 5691(1) 20(1) 
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Table A4.2.2 (cont’d) 
O(4B) 4388(3) 642(1) 5224(1) 15(1) 
N(1B) 2497(3) 1144(2) 4168(1) 13(1) 
N(2B) 861(3) 1029(2) 4810(1) 13(1) 
C(1B) 4227(4) 1579(2) 4036(1) 12(1) 
C(2B) 5323(4) 1771(2) 4507(1) 14(1) 
C(3B) 4061(4) 1890(2) 4879(1) 11(1) 
C(4B) 2345(4) 1315(2) 4624(1) 10(1) 
C(5B) 1134(4) 495(2) 3828(1) 16(1) 
C(6B) 1108(6) -489(2) 3872(1) 34(1) 
C(7B) 1377(5) 664(2) 3331(1) 25(1) 
C(8B) 4279(4) 2426(2) 3819(1) 16(1) 
C(9B) 5329(4) 2597(2) 3455(1) 20(1) 
C(10B) 5427(5) 3384(2) 3252(1) 27(1) 
C(11B) 4507(5) 4012(2) 3411(1) 27(1) 
C(12B) 3444(5) 3838(2) 3769(1) 29(1) 
C(13B) 3321(4) 3048(2) 3970(1) 21(1) 
C(14B) 4016(4) 2910(2) 5039(1) 14(1) 
C(15B) 5731(5) 4454(2) 5218(1) 35(1) 
C(16B) 4545(4) 1538(2) 5321(1) 11(1) 
C(17B) 4834(4) 217(2) 5610(1) 19(1) 
C(18B) 562(4) 1128(2) 5308(1) 16(1) 
C(19B) -769(4) 1662(2) 5395(1) 24(1) 
C(20B) 24(5) 159(2) 5438(1) 23(1) 
O(1C) 7414(3) 3248(1) 1843(1) 18(1) 
O(2C) 10170(3) 3462(1) 1676(1) 20(1) 
O(3C) 9486(3) 1908(1) 2270(1) 18(1) 
O(4C) 8375(3) 559(1) 1779(1) 17(1) 
N(1C) 6577(3) 1420(2) 803(1) 12(1) 
N(2C) 5107(3) 1248(2) 1469(1) 14(1) 
C(1C) 8322(4) 1713(2) 645(1) 14(1) 
C(2C) 9463(4) 1764(2) 1090(1) 14(1) 
C(3C) 8351(4) 1926(2) 1498(1) 12(1) 
C(4C) 6541(4) 1503(2) 1260(1) 12(1) 
C(5C) 4995(4) 1095(2) 474(1) 16(1) 
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Table A4.2.2 (cont’d) 
C(6C) 5401(5) 735(2) -8(1) 25(1) 
C(7C) 4090(4) 1873(2) 480(1) 23(1) 
C(8C) 8674(4) 2610(2) 448(1) 14(1) 
C(9C) 9607(4) 2662(2) 57(1) 17(1) 
C(10C) 10051(4) 3492(2) -124(1) 22(1) 
C(11C) 9592(4) 4260(2) 85(1) 21(1) 
C(12C) 8658(4) 4211(2) 475(1) 19(1) 
C(13C) 8190(4) 3389(2) 650(1) 17(1) 
C(14C) 8566(4) 2959(2) 1696(1) 15(1) 
C(15C) 10528(5) 4459(2) 1838(1) 28(1) 
C(16C) 8817(4) 1481(2) 1902(1) 13(1) 
C(17C) 8809(5) 56(2) 2138(1) 24(1) 
C(18C) 4905(4) 1339(2) 1975(1) 15(1) 
C(19C) 3653(5) 1915(2) 2094(1) 24(1) 
C(20C) 4316(4) 374(2) 2103(1) 20(1) 
O(1D) 1240(3) 5108(1) 6240(1) 20(1) 
O(2D) 3700(3) 4743(1) 6402(1) 20(1) 
O(3D) 4660(3) 6149(1) 5724(1) 18(1) 
O(4D) 5282(3) 7583(1) 6158(1) 16(1) 
N(1D) 3160(3) 7177(2) 7194(1) 15(1) 
N(2D) 1547(3) 7222(2) 6524(1) 14(1) 
C(1D) 4426(4) 6735(2) 7354(1) 16(1) 
C(2D) 5261(4) 6488(2) 6909(1) 15(1) 
C(3D) 3823(4) 6343(2) 6516(1) 13(1) 
C(4D) 2718(4) 6949(2) 6737(1) 12(1) 
C(5D) 2529(5) 7876(2) 7495(1) 21(1) 
C(6D) 3492(7) 8846(2) 7419(1) 44(1) 
C(7D) 2737(6) 7782(3) 8001(1) 40(1) 
C(8D) 3631(4) 5924(2) 7600(1) 16(1) 
C(9D) 4577(4) 5780(2) 7978(1) 19(1) 
C(10D) 3931(5) 5037(2) 8204(1) 24(1) 
C(11D) 2319(5) 4419(2) 8048(1) 24(1) 
C(12D) 1365(4) 4564(2) 7676(1) 24(1) 
C(13D) 2023(4) 5321(2) 7453(1) 19(1) 
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Table A4.2.2 (cont’d) 
C(14D) 2742(4) 5328(2) 6366(1) 14(1) 
C(15D) 2805(5) 3759(2) 6283(1) 26(1) 
C(16D) 4603(4) 6663(2) 6069(1) 18(1) 
C(17D) 6055(4) 7985(2) 5766(1) 20(1) 
C(18D) 1059(4) 7056(2) 6019(1) 16(1) 
C(19D) -850(4) 6519(2) 5928(1) 22(1) 
C(20D) 1460(5) 7990(2) 5849(1) 23(1) 
O(1E) 8189(3) 5002(1) 2884(1) 17(1) 
O(2E) 10789(3) 4812(1) 3084(1) 20(1) 
O(3E) 11510(3) 6349(1) 2459(1) 19(1) 
O(4E) 11784(3) 7706(1) 2936(1) 16(1) 
N(1E) 9306(3) 6863(2) 3901(1) 14(1) 
N(2E) 7912(3) 7004(2) 3214(1) 13(1) 
C(1E) 10840(4) 6612(2) 4078(1) 15(1) 
C(2E) 11850(4) 6544(2) 3643(1) 16(1) 
C(3E) 10485(4) 6346(2) 3224(1) 13(1) 
C(4E) 9125(4) 6767(2) 3441(1) 12(1) 
C(5E) 8093(4) 7202(2) 4207(1) 17(1) 
C(6E) 8924(5) 7597(2) 4695(1) 24(1) 
C(7E) 6434(4) 6429(2) 4205(1) 25(1) 
C(8E) 10401(4) 5743(2) 4298(1) 14(1) 
C(9E) 11448(4) 5716(2) 4684(1) 18(1) 
C(10E) 11196(5) 4923(2) 4890(1) 24(1) 
C(11E) 9887(4) 4130(2) 4696(1) 25(1) 
C(12E) 8829(4) 4150(2) 4313(1) 22(1) 
C(13E) 9087(4) 4951(2) 4113(1) 20(1) 
C(14E) 9677(4) 5308(2) 3044(1) 13(1) 
C(15E) 10098(5) 3806(2) 2945(1) 28(1) 
C(16E) 11305(4) 6788(2) 2820(1) 13(1) 
C(17E) 12685(5) 8211(2) 2588(1) 22(1) 
C(18E) 7528(4) 6881(2) 2704(1) 14(1) 
C(19E) 5668(4) 6298(2) 2585(1) 19(1) 
C(20E) 7882(4) 7829(2) 2556(1) 20(1) 
O(1F) 3235(3) 5134(1) -412(1) 19(1) 
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Table A4.2.2 (cont’d) 
O(2F) 5671(3) 4755(1) -225(1) 18(1) 
O(3F) 6672(3) 6143(1) -899(1) 18(1) 
O(4F) 7152(3) 7587(1) -500(1) 16(1) 
N(1F) 5150(3) 7135(2) 573(1) 13(1) 
N(2F) 3519(3) 7236(2) -81(1) 12(1) 
C(1F) 6479(4) 6698(2) 719(1) 14(1) 
C(2F) 7291(4) 6503(2) 261(1) 14(1) 
C(3F) 5819(4) 6356(2) -119(1) 12(1) 
C(4F) 4727(4) 6948(2) 117(1) 12(1) 
C(5F) 4508(5) 7803(2) 905(1) 21(1) 
C(6F) 5459(6) 8792(2) 852(1) 36(1) 
C(7F) 4692(5) 7654(2) 1401(1) 27(1) 
C(8F) 5722(4) 5850(2) 939(1) 16(1) 
C(9F) 6733(5) 5676(2) 1296(1) 21(1) 
C(10F) 6146(5) 4885(2) 1498(1) 26(1) 
C(11F) 4527(5) 4264(2) 1334(1) 32(1) 
C(12F) 3517(5) 4448(2) 988(1) 30(1) 
C(13F) 4112(4) 5250(2) 793(1) 22(1) 
C(14F) 4735(4) 5344(2) -269(1) 14(1) 
C(15F) 4757(5) 3776(2) -342(1) 23(1) 
C(16F) 6572(4) 6673(2) -552(1) 11(1) 
C(17F) 7860(4) 7967(2) -903(1) 20(1) 
C(18F) 3033(4) 7127(2) -582(1) 15(1) 
C(19F) 1129(4) 6619(2) -683(1) 21(1) 
C(20F) 3407(5) 8094(2) -714(1) 23(1) 
Br(1A) 8079(1) 123(1) 6649(1) 21(1) 
Br(1B) 6474(1) 134(1) 3290(1) 18(1) 
Br(1C) 137(1) -30(1) -14(1) 21(1) 
Br(1D) 8418(1) 8234(1) 7949(1) 23(1) 
Br(1E) 4521(1) 8396(1) 4618(1) 20(1) 
Br(1F) 358(1) 8210(1) 1391(1) 21(1) 
O(5A) 9657(3) 349(1) 7734(1) 19(1) 
O(5B) 7574(3) 112(2) 4381(1) 21(1) 
O(5C) 1767(3) 255(2) 1077(1) 20(1) 
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Table A4.2.2 (cont’d) 
O(5D) 9265(3) 8257(2) 6859(1) 25(1) 
O(5E) 5655(3) 8046(1) 3544(1) 18(1) 
O(5F) 1187(3) 8178(2) 296(1) 24(1) 
________________________________________________________________________________ 
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Table A4.2.3      Bond lengths [Å] and angles [°] for amidine (R)-170•HBr 
___________________________________________________________________________________  
O(1A)-C(14A)  1.207(4) 
O(2A)-C(14A)  1.316(4) 
O(2A)-C(15A)  1.456(3) 
O(3A)-C(16A)  1.189(3) 
O(4A)-C(16A)  1.326(3) 
O(4A)-C(17A)  1.454(4) 
N(1A)-C(1A)  1.479(4) 
N(1A)-C(4A)  1.327(3) 
N(1A)-C(5A)  1.483(4) 
N(2A)-H(2A)  0.8800 
N(2A)-C(4A)  1.319(4) 
N(2A)-C(18A)  1.482(4) 
C(1A)-H(1A)  1.0000 
C(1A)-C(2A)  1.539(4) 
C(1A)-C(8A)  1.521(4) 
C(2A)-H(2AA)  0.9900 
C(2A)-H(2AB)  0.9900 
C(2A)-C(3A)  1.555(4) 
C(3A)-C(4A)  1.513(4) 
C(3A)-C(14A)  1.541(4) 
C(3A)-C(16A)  1.548(4) 
C(5A)-H(5A)  1.0000 
C(5A)-C(6A)  1.531(4) 
C(5A)-C(7A)  1.527(4) 
C(6A)-H(6AA)  0.9800 
C(6A)-H(6AB)  0.9800 
C(6A)-H(6AC)  0.9800 
C(7A)-H(7AA)  0.9800 
C(7A)-H(7AB)  0.9800 
C(7A)-H(7AC)  0.9800 
C(8A)-C(9A)  1.386(4) 
C(8A)-C(13A)  1.401(4) 
C(9A)-H(9A)  0.9500 
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Table A4.2.3 (cont’d) 
C(9A)-C(10A)  1.388(4) 
C(10A)-H(10A)  0.9500 
C(10A)-C(11A)  1.386(5) 
C(11A)-H(11A)  0.9500 
C(11A)-C(12A)  1.382(4) 
C(12A)-H(12A)  0.9500 
C(12A)-C(13A)  1.385(4) 
C(13A)-H(13A)  0.9500 
C(15A)-H(15G)  0.9800 
C(15A)-H(15H)  0.9800 
C(15A)-H(15I)  0.9800 
C(17A)-H(17G)  0.9800 
C(17A)-H(17H)  0.9800 
C(17A)-H(17I)  0.9800 
C(18A)-H(18A)  1.0000 
C(18A)-C(19A)  1.535(5) 
C(18A)-C(20A)  1.529(4) 
C(19A)-H(19G)  0.9800 
C(19A)-H(19H)  0.9800 
C(19A)-H(19I)  0.9800 
C(20A)-H(20G)  0.9800 
C(20A)-H(20H)  0.9800 
C(20A)-H(20I)  0.9800 
O(1B)-C(14B)  1.186(4) 
O(2B)-C(14B)  1.325(3) 
O(2B)-C(15B)  1.456(4) 
O(3B)-C(16B)  1.204(3) 
O(4B)-C(16B)  1.314(3) 
O(4B)-C(17B)  1.458(3) 
N(1B)-C(1B)  1.473(4) 
N(1B)-C(4B)  1.332(3) 
N(1B)-C(5B)  1.485(3) 
N(2B)-H(2B)  0.8800 
N(2B)-C(4B)  1.330(4) 
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Table A4.2.3 (cont’d) 
N(2B)-C(18B)  1.473(3) 
C(1B)-H(1B)  1.0000 
C(1B)-C(2B)  1.552(4) 
C(1B)-C(8B)  1.505(4) 
C(2B)-H(2BA)  0.9900 
C(2B)-H(2BB)  0.9900 
C(2B)-C(3B)  1.540(4) 
C(3B)-C(4B)  1.524(4) 
C(3B)-C(14B)  1.552(4) 
C(3B)-C(16B)  1.544(4) 
C(5B)-H(5B)  1.0000 
C(5B)-C(6B)  1.509(5) 
C(5B)-C(7B)  1.523(4) 
C(6B)-H(6BA)  0.9800 
C(6B)-H(6BB)  0.9800 
C(6B)-H(6BC)  0.9800 
C(7B)-H(7BA)  0.9800 
C(7B)-H(7BB)  0.9800 
C(7B)-H(7BC)  0.9800 
C(8B)-C(9B)  1.398(4) 
C(8B)-C(13B)  1.401(4) 
C(9B)-H(9B)  0.9500 
C(9B)-C(10B)  1.395(4) 
C(10B)-H(10B)  0.9500 
C(10B)-C(11B)  1.391(5) 
C(11B)-H(11B)  0.9500 
C(11B)-C(12B)  1.391(5) 
C(12B)-H(12B)  0.9500 
C(12B)-C(13B)  1.393(4) 
C(13B)-H(13B)  0.9500 
C(15B)-H(15D)  0.9800 
C(15B)-H(15E)  0.9800 
C(15B)-H(15F)  0.9800 
C(17B)-H(17D)  0.9800 
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Table A4.2.3 (cont’d) 
C(17B)-H(17E)  0.9800 
C(17B)-H(17F)  0.9800 
C(18B)-H(18B)  1.0000 
C(18B)-C(19B)  1.513(5) 
C(18B)-C(20B)  1.527(4) 
C(19B)-H(19D)  0.9800 
C(19B)-H(19E)  0.9800 
C(19B)-H(19F)  0.9800 
C(20B)-H(20D)  0.9800 
C(20B)-H(20E)  0.9800 
C(20B)-H(20F)  0.9800 
O(1C)-C(14C)  1.194(4) 
O(2C)-C(14C)  1.327(4) 
O(2C)-C(15C)  1.457(3) 
O(3C)-C(16C)  1.192(3) 
O(4C)-C(16C)  1.334(3) 
O(4C)-C(17C)  1.470(4) 
N(1C)-C(1C)  1.476(4) 
N(1C)-C(4C)  1.322(3) 
N(1C)-C(5C)  1.492(4) 
N(2C)-H(2C)  0.8800 
N(2C)-C(4C)  1.324(4) 
N(2C)-C(18C)  1.481(3) 
C(1C)-H(1C)  1.0000 
C(1C)-C(2C)  1.544(4) 
C(1C)-C(8C)  1.517(4) 
C(2C)-H(2CA)  0.9900 
C(2C)-H(2CB)  0.9900 
C(2C)-C(3C)  1.546(4) 
C(3C)-C(4C)  1.524(4) 
C(3C)-C(14C)  1.544(4) 
C(3C)-C(16C)  1.525(4) 
C(5C)-H(5C)  1.0000 
C(5C)-C(6C)  1.510(4) 
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Table A4.2.3 (cont’d) 
C(5C)-C(7C)  1.539(4) 
C(6C)-H(6CA)  0.9800 
C(6C)-H(6CB)  0.9800 
C(6C)-H(6CC)  0.9800 
C(7C)-H(7CA)  0.9800 
C(7C)-H(7CB)  0.9800 
C(7C)-H(7CC)  0.9800 
C(8C)-C(9C)  1.392(4) 
C(8C)-C(13C)  1.391(4) 
C(9C)-H(9C)  0.9500 
C(9C)-C(10C)  1.403(4) 
C(10C)-H(10C)  0.9500 
C(10C)-C(11C)  1.373(5) 
C(11C)-H(11C)  0.9500 
C(11C)-C(12C)  1.390(4) 
C(12C)-H(12C)  0.9500 
C(12C)-C(13C)  1.383(4) 
C(13C)-H(13C)  0.9500 
C(15C)-H(15A)  0.9800 
C(15C)-H(15B)  0.9800 
C(15C)-H(15C)  0.9800 
C(17C)-H(17A)  0.9800 
C(17C)-H(17B)  0.9800 
C(17C)-H(17C)  0.9800 
C(18C)-H(18C)  1.0000 
C(18C)-C(19C)  1.516(5) 
C(18C)-C(20C)  1.522(4) 
C(19C)-H(19A)  0.9800 
C(19C)-H(19B)  0.9800 
C(19C)-H(19C)  0.9800 
C(20C)-H(20A)  0.9800 
C(20C)-H(20B)  0.9800 
C(20C)-H(20C)  0.9800 
O(1D)-C(14D)  1.197(4) 
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Table A4.2.3 (cont’d) 
O(2D)-C(14D)  1.333(4) 
O(2D)-C(15D)  1.454(3) 
O(3D)-C(16D)  1.184(4) 
O(4D)-C(16D)  1.335(3) 
O(4D)-C(17D)  1.462(3) 
N(1D)-C(1D)  1.460(4) 
N(1D)-C(4D)  1.335(3) 
N(1D)-C(5D)  1.478(4) 
N(2D)-H(2D)  0.8800 
N(2D)-C(4D)  1.300(4) 
N(2D)-C(18D)  1.477(4) 
C(1D)-H(1D)  1.0000 
C(1D)-C(2D)  1.529(4) 
C(1D)-C(8D)  1.525(4) 
C(2D)-H(2DA)  0.9900 
C(2D)-H(2DB)  0.9900 
C(2D)-C(3D)  1.549(4) 
C(3D)-C(4D)  1.531(4) 
C(3D)-C(14D)  1.541(4) 
C(3D)-C(16D)  1.559(4) 
C(5D)-H(5D)  1.0000 
C(5D)-C(6D)  1.523(5) 
C(5D)-C(7D)  1.514(4) 
C(6D)-H(6DA)  0.9800 
C(6D)-H(6DB)  0.9800 
C(6D)-H(6DC)  0.9800 
C(7D)-H(7DA)  0.9800 
C(7D)-H(7DB)  0.9800 
C(7D)-H(7DC)  0.9800 
C(8D)-C(9D)  1.394(4) 
C(8D)-C(13D)  1.384(4) 
C(9D)-H(9D)  0.9500 
C(9D)-C(10D)  1.385(4) 
C(10D)-H(10D)  0.9500 
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Table A4.2.3 (cont’d) 
C(10D)-C(11D)  1.400(5) 
C(11D)-H(11D)  0.9500 
C(11D)-C(12D)  1.384(5) 
C(12D)-H(12D)  0.9500 
C(12D)-C(13D)  1.397(4) 
C(13D)-H(13D)  0.9500 
C(15D)-H(15P)  0.9800 
C(15D)-H(15Q)  0.9800 
C(15D)-H(15R)  0.9800 
C(17D)-H(17P)  0.9800 
C(17D)-H(17Q)  0.9800 
C(17D)-H(17R)  0.9800 
C(18D)-H(18D)  1.0000 
C(18D)-C(19D)  1.533(4) 
C(18D)-C(20D)  1.527(4) 
C(19D)-H(19P)  0.9800 
C(19D)-H(19Q)  0.9800 
C(19D)-H(19R)  0.9800 
C(20D)-H(20P)  0.9800 
C(20D)-H(20Q)  0.9800 
C(20D)-H(20R)  0.9800 
O(1E)-C(14E)  1.215(4) 
O(2E)-C(14E)  1.325(4) 
O(2E)-C(15E)  1.462(3) 
O(3E)-C(16E)  1.200(3) 
O(4E)-C(16E)  1.325(3) 
O(4E)-C(17E)  1.465(3) 
N(1E)-C(1E)  1.485(4) 
N(1E)-C(4E)  1.327(3) 
N(1E)-C(5E)  1.486(4) 
N(2E)-H(2E)  0.8800 
N(2E)-C(4E)  1.317(4) 
N(2E)-C(18E)  1.481(4) 
C(1E)-H(1E)  1.0000 
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Table A4.2.3 (cont’d) 
C(1E)-C(2E)  1.541(4) 
C(1E)-C(8E)  1.515(4) 
C(2E)-H(2EA)  0.9900 
C(2E)-H(2EB)  0.9900 
C(2E)-C(3E)  1.553(4) 
C(3E)-C(4E)  1.520(4) 
C(3E)-C(14E)  1.533(4) 
C(3E)-C(16E)  1.532(4) 
C(5E)-H(5E)  1.0000 
C(5E)-C(6E)  1.514(4) 
C(5E)-C(7E)  1.528(4) 
C(6E)-H(6EA)  0.9800 
C(6E)-H(6EB)  0.9800 
C(6E)-H(6EC)  0.9800 
C(7E)-H(7EA)  0.9800 
C(7E)-H(7EB)  0.9800 
C(7E)-H(7EC)  0.9800 
C(8E)-C(9E)  1.394(4) 
C(8E)-C(13E)  1.394(4) 
C(9E)-H(9E)  0.9500 
C(9E)-C(10E)  1.396(4) 
C(10E)-H(10E)  0.9500 
C(10E)-C(11E)  1.398(5) 
C(11E)-H(11E)  0.9500 
C(11E)-C(12E)  1.390(5) 
C(12E)-H(12E)  0.9500 
C(12E)-C(13E)  1.396(4) 
C(13E)-H(13E)  0.9500 
C(15E)-H(15M)  0.9800 
C(15E)-H(15N)  0.9800 
C(15E)-H(15O)  0.9800 
C(17E)-H(17M)  0.9800 
C(17E)-H(17N)  0.9800 
C(17E)-H(17O)  0.9800 
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Table A4.2.3 (cont’d) 
C(18E)-H(18E)  1.0000 
C(18E)-C(19E)  1.525(4) 
C(18E)-C(20E)  1.520(4) 
C(19E)-H(19M)  0.9800 
C(19E)-H(19N)  0.9800 
C(19E)-H(19O)  0.9800 
C(20E)-H(20M)  0.9800 
C(20E)-H(20N)  0.9800 
C(20E)-H(20O)  0.9800 
O(1F)-C(14F)  1.209(4) 
O(2F)-C(14F)  1.328(4) 
O(2F)-C(15F)  1.451(3) 
O(3F)-C(16F)  1.212(3) 
O(4F)-C(16F)  1.321(3) 
O(4F)-C(17F)  1.459(3) 
N(1F)-C(1F)  1.481(4) 
N(1F)-C(4F)  1.329(3) 
N(1F)-C(5F)  1.497(4) 
N(2F)-H(2F)  0.8800 
N(2F)-C(4F)  1.316(4) 
N(2F)-C(18F)  1.473(3) 
C(1F)-H(1F)  1.0000 
C(1F)-C(2F)  1.533(4) 
C(1F)-C(8F)  1.517(4) 
C(2F)-H(2FA)  0.9900 
C(2F)-H(2FB)  0.9900 
C(2F)-C(3F)  1.542(4) 
C(3F)-C(4F)  1.526(4) 
C(3F)-C(14F)  1.537(4) 
C(3F)-C(16F)  1.513(4) 
C(5F)-H(5F)  1.0000 
C(5F)-C(6F)  1.526(5) 
C(5F)-C(7F)  1.506(4) 
C(6F)-H(6FA)  0.9800 
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Table A4.2.3 (cont’d) 
C(6F)-H(6FB)  0.9800 
C(6F)-H(6FC)  0.9800 
C(7F)-H(7FA)  0.9800 
C(7F)-H(7FB)  0.9800 
C(7F)-H(7FC)  0.9800 
C(8F)-C(9F)  1.398(4) 
C(8F)-C(13F)  1.383(4) 
C(9F)-H(9F)  0.9500 
C(9F)-C(10F)  1.394(4) 
C(10F)-H(10F)  0.9500 
C(10F)-C(11F)  1.410(5) 
C(11F)-H(11F)  0.9500 
C(11F)-C(12F)  1.381(6) 
C(12F)-H(12F)  0.9500 
C(12F)-C(13F)  1.397(4) 
C(13F)-H(13F)  0.9500 
C(15F)-H(15J)  0.9800 
C(15F)-H(15K)  0.9800 
C(15F)-H(15L)  0.9800 
C(17F)-H(17J)  0.9800 
C(17F)-H(17K)  0.9800 
C(17F)-H(17L)  0.9800 
C(18F)-H(18F)  1.0000 
C(18F)-C(19F)  1.521(4) 
C(18F)-C(20F)  1.527(4) 
C(19F)-H(19J)  0.9800 
C(19F)-H(19K)  0.9800 
C(19F)-H(19L)  0.9800 
C(20F)-H(20J)  0.9800 
C(20F)-H(20K)  0.9800 
C(20F)-H(20L)  0.9800 
O(5A)-H(5AA)  0.846(17) 
O(5A)-H(5AB)  0.830(17) 
O(5B)-H(5BA)  0.863(17) 
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Table A4.2.3 (cont’d) 
O(5B)-H(5BB)  0.845(17) 
O(5C)-H(5CA)  0.882(17) 
O(5C)-H(5CB)  0.850(17) 
O(5D)-H(5DA)  0.874(18) 
O(5D)-H(5DB)  0.895(17) 
O(5E)-H(5EA)  0.857(17) 
O(5E)-H(5EB)  0.891(17) 
O(5F)-H(5FA)  0.866(19) 
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Symmetry transformations used to generate equivalent atoms:  
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Table A4.2.4 Anisotropic displacement parameters  (Å2x103) for amidine (R)-170•HBr.  The 
anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1A) 246(12)  132(9) 182(10)  11(8) 35(9)  80(8) 
O(2A) 202(12)  132(9) 284(12)  -45(8) -6(10)  -9(8) 
O(3A) 331(14)  195(10) 173(11)  39(8) -26(9)  90(9) 
O(4A) 285(12)  137(9) 176(10)  71(8) 42(9)  65(8) 
N(1A) 177(13)  123(10) 105(10)  40(8) 46(9)  41(9) 
N(2A) 155(12)  152(11) 102(10)  1(8) 21(9)  42(9) 
C(1A) 149(14)  90(11) 175(13)  15(9) 50(11)  44(10) 
C(2A) 140(14)  140(12) 166(13)  42(10) 68(11)  49(10) 
C(3A) 147(14)  99(11) 127(12)  30(9) 28(10)  48(9) 
C(4A) 192(15)  94(11) 134(12)  6(9) 48(11)  67(10) 
C(5A) 163(15)  194(13) 128(13)  75(10) 35(11)  34(11) 
C(6A) 268(18)  294(16) 135(14)  33(12) 30(13)  16(14) 
C(7A) 220(17)  257(16) 255(16)  115(13) -14(13)  95(13) 
C(8A) 149(14)  127(12) 145(13)  25(10) 14(11)  4(10) 
C(9A) 168(15)  212(14) 163(13)  51(11) 30(11)  29(11) 
C(10A) 199(16)  235(15) 212(15)  95(12) 31(12)  45(12) 
C(11A) 228(17)  202(14) 290(17)  162(12) 62(14)  43(12) 
C(12A) 259(17)  168(13) 260(16)  73(11) 35(13)  94(12) 
C(13A) 190(16)  203(13) 187(14)  96(11) 63(12)  100(11) 
C(14A) 140(14)  141(12) 161(13)  67(10) 21(11)  28(10) 
C(15A) 360(20)  110(13) 450(20)  -96(14) 49(18)  -22(13) 
C(16A) 117(14)  129(12) 180(13)  69(10) 40(11)  3(10) 
C(17A) 302(19)  203(14) 296(17)  153(13) 75(14)  93(13) 
C(18A) 193(16)  232(14) 115(13)  25(11) 59(11)  65(12) 
C(19A) 259(18)  254(16) 277(17)  30(13) 97(14)  104(14) 
C(20A) 185(16)  288(16) 213(16)  120(12) 7(13)  4(13) 
O(1B) 177(11)  139(9) 201(11)  -4(8) 21(9)  82(8) 
O(2B) 154(11)  78(8) 366(13)  -25(8) 34(10)  -8(7) 
O(3B) 257(12)  180(10) 138(10)  -21(8) -66(9)  43(9) 
O(4B) 246(12)  108(8) 107(9)  31(7) -2(8)  55(8) 
N(1B) 116(12)  124(10) 121(10)  30(8) 7(9)  -3(8) 
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Table A4.2.4 (cont’d) 
N(2B) 113(12)  158(11) 100(10)  4(8) 13(9)  1(9) 
C(1B) 119(13)  108(11) 130(12)  20(9) 38(10)  4(9) 
C(2B) 114(13)  121(11) 168(13)  28(10) 7(11)  21(10) 
C(3B) 104(13)  107(11) 104(11)  5(9) -30(10)  13(9) 
C(4B) 115(13)  72(10) 113(12)  21(9) 9(10)  35(9) 
C(5B) 144(14)  199(13) 96(12)  -27(10) 6(10)  -10(11) 
C(6B) 490(20)  151(14) 245(17)  -70(12) -74(17)  -43(15) 
C(7B) 207(17)  349(18) 140(14)  29(12) 38(12)  -12(14) 
C(8B) 162(15)  128(12) 167(13)  19(10) -22(11)  -9(10) 
C(9B) 205(16)  190(14) 179(14)  59(11) 19(12)  -31(12) 
C(10B) 277(19)  219(15) 241(16)  117(12) 7(14)  -80(13) 
C(11B) 350(20)  161(14) 267(17)  92(12) -67(15)  -32(13) 
C(12B) 400(20)  211(15) 274(18)  68(13) -41(15)  112(14) 
C(13B) 270(18)  165(13) 208(15)  52(11) 16(13)  69(12) 
C(14B) 155(14)  87(11) 158(13)  29(9) 11(11)  16(10) 
C(15B) 340(20)  73(13) 550(20)  -81(14) 87(18)  -24(13) 
C(16B) 122(13)  81(11) 116(12)  1(9) 15(10)  -4(9) 
C(17B) 277(17)  193(13) 122(13)  67(10) 20(12)  100(12) 
C(18B) 198(16)  172(13) 74(12)  -18(10) 23(11)  7(11) 
C(19B) 122(15)  279(16) 282(17)  -48(13) 56(13)  44(12) 
C(20B) 232(17)  285(16) 180(15)  103(12) 63(13)  32(13) 
O(1C) 224(12)  106(9) 222(11)  35(8) 32(9)  54(8) 
O(2C) 191(12)  114(9) 264(11)  14(8) 58(9)  -16(8) 
O(3C) 211(12)  148(9) 152(10)  8(7) -45(8)  31(8) 
O(4C) 276(12)  117(9) 126(9)  37(7) 7(8)  61(8) 
N(1C) 160(12)  110(10) 107(10)  28(8) 49(9)  39(9) 
N(2C) 150(12)  162(11) 83(10)  17(8) 14(9)  30(9) 
C(1C) 205(15)  133(12) 116(12)  57(10) 76(11)  71(11) 
C(2C) 175(15)  139(12) 130(12)  40(9) 53(11)  63(10) 
C(3C) 117(13)  100(11) 131(12)  9(9) 13(10)  27(9) 
C(4C) 156(14)  80(11) 120(12)  33(9) 20(10)  37(10) 
C(5C) 183(15)  176(13) 95(12)  27(10) 4(11)  27(11) 
C(6C) 291(19)  258(16) 136(14)  -22(12) 0(13)  3(13) 
C(7C) 197(17)  208(14) 280(17)  79(12) -25(13)  51(12) 
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Table A4.2.4 (cont’d) 
C(8C) 176(15)  122(12) 119(12)  32(9) 19(11)  39(10) 
C(9C) 222(16)  183(13) 124(13)  54(10) 83(11)  51(11) 
C(10C) 269(18)  221(14) 201(15)  137(12) 107(13)  49(13) 
C(11C) 280(18)  154(13) 213(15)  108(11) 56(13)  43(12) 
C(12C) 275(17)  124(12) 199(14)  51(10) 31(12)  73(11) 
C(13C) 246(17)  155(13) 161(13)  49(10) 98(12)  102(11) 
C(14C) 205(15)  111(12) 96(12)  29(9) 1(11)  -5(10) 
C(15C) 320(20)  139(13) 348(19)  12(12) 154(16)  -19(13) 
C(16C) 98(14)  131(12) 192(14)  64(10) 31(11)  54(10) 
C(17C) 350(20)  200(14) 228(15)  150(12) 56(14)  115(13) 
C(18C) 160(15)  214(13) 83(12)  53(10) 0(10)  29(11) 
C(19C) 311(19)  283(16) 89(13)  -87(11) 12(12)  92(14) 
C(20C) 206(16)  223(15) 157(14)  76(11) 13(12)  10(12) 
O(1D) 206(12)  167(10) 223(11)  30(8) 2(9)  26(8) 
O(2D) 223(12)  110(9) 280(12)  53(8) 49(9)  69(8) 
O(3D) 225(12)  131(9) 181(10)  15(8) 12(9)  35(8) 
O(4D) 216(11)  87(8) 170(10)  36(7) 16(8)  4(8) 
N(1D) 224(14)  153(11) 80(10)  19(8) -16(9)  79(9) 
N(2D) 181(13)  132(10) 105(10)  19(8) 5(9)  63(9) 
C(1D) 184(15)  166(13) 128(13)  35(10) -17(11)  64(11) 
C(2D) 134(14)  177(13) 175(13)  64(10) -15(11)  77(11) 
C(3D) 118(13)  113(11) 148(13)  17(9) 2(10)  22(10) 
C(4D) 167(14)  70(10) 127(12)  23(9) -21(10)  26(10) 
C(5D) 310(18)  229(14) 132(13)  -30(11) -18(12)  167(13) 
C(6D) 750(30)  164(15) 360(20)  -54(14) 0(20)  124(18) 
C(7D) 780(30)  490(20) 120(15)  39(14) 63(17)  510(20) 
C(8D) 174(15)  148(12) 171(13)  43(10) -12(11)  77(11) 
C(9D) 209(16)  158(13) 192(14)  28(11) -26(12)  59(11) 
C(10D) 312(19)  235(15) 202(15)  74(12) -17(14)  108(13) 
C(11D) 308(19)  221(15) 211(15)  116(12) 57(14)  76(13) 
C(12D) 223(17)  249(15) 206(15)  93(12) -12(13)  -12(13) 
C(13D) 159(15)  240(14) 152(14)  86(11) -33(11)  2(12) 
C(14D) 174(15)  132(12) 115(12)  57(9) 36(11)  20(10) 
C(15D) 330(20)  115(13) 308(18)  33(12) 31(15)  43(12) 
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Table A4.2.4 (cont’d) 
C(16D) 137(15)  141(13) 296(17)  48(12) 79(13)  57(11) 
C(17D) 227(17)  170(13) 199(15)  86(11) 30(12)  31(12) 
C(18D) 166(15)  187(13) 120(13)  29(10) -25(11)  64(11) 
C(19D) 229(17)  246(15) 180(15)  49(12) -67(13)  67(13) 
C(20D) 274(18)  202(14) 207(15)  74(12) -23(13)  51(12) 
O(1E) 127(11)  105(9) 242(11)  17(8) -31(9)  -22(7) 
O(2E) 186(11)  130(9) 271(12)  11(8) -32(9)  54(8) 
O(3E) 205(12)  141(9) 192(10)  5(8) 50(9)  13(8) 
O(4E) 206(11)  121(9) 142(9)  41(7) -18(8)  -3(8) 
N(1E) 182(13)  111(10) 108(11)  17(8) -20(9)  32(9) 
N(2E) 147(12)  147(11) 117(11)  22(8) 4(9)  62(9) 
C(1E) 146(14)  134(12) 139(13)  24(10) -37(11)  -6(10) 
C(2E) 113(14)  146(12) 192(14)  63(10) -21(11)  -20(10) 
C(3E) 118(13)  97(11) 149(12)  26(9) -8(10)  -6(9) 
C(4E) 113(13)  91(11) 131(12)  15(9) -13(10)  -22(9) 
C(5E) 233(16)  159(13) 131(13)  39(10) 28(11)  78(11) 
C(6E) 330(20)  286(16) 104(13)  37(11) -32(13)  89(14) 
C(7E) 231(18)  286(17) 260(17)  79(13) 89(14)  70(13) 
C(8E) 150(14)  136(12) 139(12)  34(10) -17(10)  33(10) 
C(9E) 159(15)  203(13) 176(14)  60(11) -20(11)  35(11) 
C(10E) 284(19)  223(15) 235(16)  93(12) -43(13)  83(13) 
C(11E) 278(18)  203(14) 275(17)  115(12) -25(14)  54(13) 
C(12E) 209(17)  175(13) 258(16)  114(12) -28(13)  -8(12) 
C(13E) 185(16)  198(14) 208(15)  85(11) -32(12)  43(12) 
C(14E) 168(14)  113(11) 108(12)  32(9) 3(10)  30(10) 
C(15E) 330(20)  83(12) 420(20)  14(12) -59(16)  79(12) 
C(16E) 115(13)  116(11) 167(13)  44(10) 15(11)  15(10) 
C(17E) 259(18)  179(14) 194(15)  105(11) 14(13)  -8(12) 
C(18E) 173(15)  177(13) 87(12)  35(10) -15(10)  75(11) 
C(19E) 150(15)  196(14) 222(15)  -15(11) -45(12)  65(11) 
C(20E) 226(17)  224(14) 194(15)  100(12) 23(12)  93(12) 
O(1F) 190(12)  151(10) 243(11)  61(8) 13(9)  47(8) 
O(2F) 231(12)  101(9) 213(11)  20(8) 15(9)  35(8) 
O(3F) 243(12)  163(9) 150(10)  -4(8) 55(9)  67(8) 
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Table A4.2.4 (cont’d) 
O(4F) 257(12)  107(8) 99(9)  34(7) 29(8)  12(8) 
N(1F) 168(13)  136(10) 110(10)  33(8) -17(9)  80(9) 
N(2F) 141(12)  133(10) 98(10)  20(8) -12(9)  52(9) 
C(1F) 147(14)  163(12) 135(12)  46(10) 1(11)  71(10) 
C(2F) 167(14)  134(12) 121(12)  35(9) 7(11)  39(10) 
C(3F) 126(13)  91(11) 132(12)  27(9) -2(10)  16(9) 
C(4F) 140(14)  81(11) 132(12)  26(9) 10(10)  17(9) 
C(5F) 326(18)  192(14) 160(14)  0(11) 9(13)  160(13) 
C(6F) 630(30)  219(16) 240(17)  2(13) 13(18)  172(17) 
C(7F) 380(20)  330(17) 125(14)  -28(12) -34(14)  192(15) 
C(8F) 225(16)  146(12) 131(13)  35(10) 39(11)  85(11) 
C(9F) 310(18)  229(15) 174(14)  68(11) 42(13)  174(13) 
C(10F) 430(20)  278(16) 180(15)  111(12) 94(14)  237(15) 
C(11F) 550(30)  199(15) 261(17)  104(13) 208(17)  145(15) 
C(12F) 430(20)  203(15) 258(17)  91(13) 153(16)  59(15) 
C(13F) 246(18)  229(15) 183(15)  69(12) 45(13)  60(13) 
C(14F) 157(14)  123(12) 128(12)  21(9) 13(11)  24(10) 
C(15F) 350(20)  72(11) 238(15)  8(10) 62(14)  23(12) 
C(16F) 132(14)  155(12) 50(11)  17(9) -21(10)  62(10) 
C(17F) 238(17)  216(14) 155(14)  107(11) 27(12)  22(12) 
C(18F) 177(15)  168(12) 99(12)  22(10) -28(11)  61(11) 
C(19F) 215(17)  139(13) 200(15)  -5(11) -47(13)  -39(11) 
C(20F) 351(19)  240(15) 129(13)  76(11) -9(13)  130(13) 
Br(1A) 265(2)  205(1) 172(1)  6(1) -6(1)  118(1) 
Br(1B) 212(2)  209(1) 143(1)  38(1) 18(1)  89(1) 
Br(1C) 286(2)  173(1) 186(2)  -11(1) -24(1)  92(1) 
Br(1D) 242(2)  223(2) 175(2)  45(1) 22(1)  -12(1) 
Br(1E) 225(2)  166(1) 142(1)  0(1) 31(1)  -40(1) 
Br(1F) 212(2)  228(2) 157(1)  45(1) -2(1)  10(1) 
O(5A) 202(12)  160(10) 207(11)  8(8) 11(9)  47(8) 
O(5B) 155(11)  210(10) 200(11)  29(8) -5(9)  -74(9) 
O(5C) 189(12)  159(10) 246(12)  43(8) 21(9)  55(9) 
O(5D) 342(15)  272(12) 219(12)  50(9) 23(10)  202(11) 
O(5E) 200(12)  176(10) 162(10)  29(8) 54(9)  63(8) 
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Table A4.2.4 (cont’d) 
O(5F) 253(13)  291(12) 214(12)  35(9) 37(10)  159(10) 
______________________________________________________________________________ 
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Table A4.2.5     Hydrogen coordinates (x103) and isotropic  displacement parameters (Å2x103)  
for amidine (R)-170•HBr 
________________________________________________________________________________  
 x  y  z  Uiso 
________________________________________________________________________________  
  
H(2A) 204 104 797 17 
H(1A) 646 133 714 16 
H(2AA) 842 242 787 17 
H(2AB) 776 130 782 17 
H(5A) 213 72 729 19 
H(6AA) 404 146 657 37 
H(6AB) 228 64 650 37 
H(6AC) 402 47 670 37 
H(7AA) 186 224 753 35 
H(7AB) 98 182 702 35 
H(7AC) 282 256 709 35 
H(9A) 782 222 663 22 
H(10A) 859 359 632 25 
H(11A) 792 492 668 27 
H(12A) 646 488 735 26 
H(13A) 565 351 766 21 
H(15G) 784 477 855 51 
H(15H) 964 472 878 51 
H(15I) 794 446 905 51 
H(17G) 691 -57 862 37 
H(17H) 593 -8 900 37 
H(17I) 793 36 896 37 
H(18A) 381 168 885 21 
H(19G) 173 248 870 38 
H(19H) 114 190 910 38 
H(19I) 25 151 859 38 
H(20G) 99 3 863 35 
H(20H) 211 38 912 35 
H(20I) 296 1 867 35 
H(2B) -4 75 461 16 
H(1B) 460 112 381 15 
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Table A4.2.5 (cont’d) 
H(2BA) 580 124 454 16 
H(2BB) 628 234 453 16 
H(5B) 0 59 391 20 
H(6BA) 226 -58 383 50 
H(6BB) 27 -92 363 50 
H(6BC) 78 -61 418 50 
H(7BA) 134 130 331 37 
H(7BB) 45 22 312 37 
H(7BC) 249 58 324 37 
H(9B) 598 218 334 25 
H(10B) 613 349 300 32 
H(11B) 460 456 328 33 
H(12B) 280 426 388 35 
H(13B) 258 293 421 25 
H(15D) 494 467 503 53 
H(15E) 692 482 520 53 
H(15F) 543 453 554 53 
H(17D) 488 -42 549 28 
H(17E) 396 20 584 28 
H(17F) 596 58 576 28 
H(18B) 166 149 549 19 
H(19D) -33 229 532 36 
H(19E) -101 171 572 36 
H(19F) -183 134 520 36 
H(20D) -108 -19 527 35 
H(20E) -10 21 577 35 
H(20F) 90 -16 536 35 
H(2C) 416 99 128 16 
H(1C) 849 121 40 17 
H(2CA) 1052 228 112 17 
H(2CB) 979 118 109 17 
H(5C) 419 57 59 19 
H(6CA) 606 125 -15 37 
H(6CB) 432 43 -20 37 
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Table A4.2.5 (cont’d) 
H(6CC) 608 29 1 37 
H(7CA) 386 208 80 34 
H(7CB) 300 164 28 34 
H(7CC) 483 240 36 34 
H(9C) 994 214 -9 21 
H(10C) 1067 352 -39 26 
H(11C) 991 482 -4 25 
H(12C) 834 474 62 23 
H(13C) 753 336 91 21 
H(15A) 1026 476 158 42 
H(15B) 1175 471 195 42 
H(15C) 982 457 209 42 
H(17A) 855 -61 201 36 
H(17B) 813 14 240 36 
H(17C) 1004 30 224 36 
H(18C) 605 167 215 18 
H(19A) 412 254 202 36 
H(19B) 349 197 243 36 
H(19C) 254 161 192 36 
H(20A) 317 5 195 30 
H(20B) 427 43 244 30 
H(20C) 513 2 200 30 
H(2D) 98 754 670 16 
H(1D) 531 721 758 19 
H(2DA) 563 591 691 18 
H(2DB) 628 700 687 18 
H(5D) 128 777 740 26 
H(6DA) 471 898 753 65 
H(6DB) 300 931 760 65 
H(6DC) 339 888 709 65 
H(7DA) 236 712 803 60 
H(7DB) 204 812 818 60 
H(7DC) 395 804 812 60 
H(9D) 568 620 808 22 
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Table A4.2.5 (cont’d) 
H(10D) 458 495 846 29 
H(11D) 188 390 820 28 
H(12D) 26 415 757 28 
H(13D) 136 542 720 23 
H(15P) 229 362 596 38 
H(15Q) 190 360 649 38 
H(15R) 363 339 631 38 
H(17P) 515 793 552 30 
H(17Q) 688 765 564 30 
H(17R) 665 864 587 30 
H(18D) 176 667 586 19 
H(19P) -101 589 600 33 
H(19Q) -123 649 560 33 
H(19R) -153 684 613 33 
H(20P) 67 834 598 34 
H(20Q) 132 788 551 34 
H(20R) 265 834 596 34 
H(2E) 725 727 339 16 
H(1E) 1153 714 432 18 
H(2EA) 1241 603 363 19 
H(2EB) 1274 713 364 19 
H(5E) 778 772 408 20 
H(6EA) 909 709 485 36 
H(6EB) 818 791 487 36 
H(6EC) 1004 804 468 36 
H(7EA) 600 615 388 38 
H(7EB) 557 669 436 38 
H(7EC) 667 595 437 38 
H(9E) 1236 625 481 22 
H(10E) 1190 492 516 29 
H(11E) 972 358 483 30 
H(12E) 792 362 419 26 
H(13E) 836 496 385 23 
H(15M) 935 367 266 42 
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Table A4.2.5 (cont’d) 
H(15N) 943 355 319 42 
H(15O) 1105 352 290 42 
H(17M) 1192 808 230 32 
H(17N) 1372 801 252 32 
H(17O) 1302 888 271 32 
H(18E) 830 654 255 17 
H(19M) 557 566 263 29 
H(19N) 533 629 226 29 
H(19O) 491 656 279 29 
H(20M) 708 816 269 30 
H(20N) 772 775 222 30 
H(20O) 907 819 266 30 
H(2F) 294 753 11 15 
H(1F) 736 716 95 17 
H(2FA) 771 594 25 17 
H(2FB) 827 704 23 17 
H(5F) 326 770 82 25 
H(6FA) 669 891 94 54 
H(6FB) 499 923 105 54 
H(6FC) 530 887 53 54 
H(7FA) 413 700 142 40 
H(7FB) 415 806 160 40 
H(7FC) 592 780 150 40 
H(9F) 782 610 140 26 
H(10F) 683 477 174 31 
H(11F) 413 372 146 38 
H(12F) 242 403 88 35 
H(13F) 341 538 56 26 
H(15J) 426 364 -66 34 
H(15K) 383 363 -14 34 
H(15L) 556 340 -30 34 
H(17J) 696 780 -116 30 
H(17K) 882 771 -100 30 
H(17L) 828 864 -82 30 
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Table A4.2.5 (cont’d) 
H(18F) 373 676 -76 18 
H(19J) 93 599 -62 31 
H(19K) 78 660 -101 31 
H(19L) 45 695 -49 31 
H(20J) 267 844 -55 34 
H(20K) 318 804 -105 34 
H(20L) 462 843 -62 34 
H(5AA) 998(5) -14(2) 771(1) 29 
H(5AB) 915(5) 48(2) 797(1) 29 
H(5BA) 681(4) -35(2) 445(1) 32 
H(5BB) 758(5) 62(1) 454(1) 32 
H(5CA) 145(5) -29(1) 117(1) 29 
H(5CB) 114(4) 59(2) 119(1) 29 
H(5DA) 897(5) 875(2) 681(1) 38 
H(5DB) 901(5) 820(2) 715(1) 38 
H(5EA) 601(5) 860(2) 349(1) 26 
H(5EB) 528(5) 808(2) 383(1) 26 
H(5FA) 230(2) 832(3) 35(1) 35 










Stereoselective Lewis Acid Mediated (3 + 2) Cycloadditions of  
N-H- and N-Sulfonylaziridines with Heterocumulenes 
 
 
3.1   INTRODUCTION 
Having studied the cycloadditions of donor–acceptor cyclopropanes with 
heterocumulenes, we sought to expand the reactivity by replacing cyclopropanes with 
activated aziridines in order to access more highly nitrogenated heterocycles.  Aziridines 
are versatile intermediates and reaction partners for the preparation of a structurally 
diverse assortment of nitrogen-containing architectures. 1   These heterocycles are 
characterized by a unique reactivity profile, in part due to the large strain energy (27 kcal 
mol–1) contained within their three-membered rings,2  rendering them susceptible to 
nucleophilic ring opening,3 carbonylation,4 and ring expansion.5  Previous work has 
shown the utility of 2-arylaziridines in transition-metal-mediated and -catalyzed (3 + 2) 
cycloadditions with heterocumulenes for the formation of imidazolines, 6 a–e !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
† This work was performed in collaboration with Dr. Robert A. Craig, II, and Dr. Alexander F. G. 
Goldberg, alumni of the Stoltz group.  This work has been published, with portions of this chapter adapted 
with permission from Craig, R. A., II; O’Connor, N. R.; Goldberg, A. F. G.; Stoltz, B. M. Chem. Eur. J. 
2014, 20, 4806–4813.  Copyright 2015 WILEY–VCH. 
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oxazolidines,6d–e iminoazolidinones,6f–i iminothiazolidines,6i–k and iminoimidazolidines.6f,l  
Iminothiazolidines and iminoimidazolidines have seen use as effective organic catalysts 
in asymmetric transformations including Strecker reactions,7a O- and N-acylations,7b–c and 
Michael additions,7d and as highly active pharmacophores for the treatment of a wide 
range of medical conditions including obesity, diabetes, cancer, and arthritis.8 
The critical limitation of the majority of existing (3 + 2) cycloaddition manifolds is 
the requirement that the aziridine starting materials bear either alkyl or aryl N-
substitution.  The harsh conditions necessary for the removal of such robust groups 
severely limits the potential for derivatization and, thus, the utility of the products.  
Despite this, the use of N-sulfonyl-protected aziridines in (3 + 2) cycloadditions has been 
explored minimally.6a–e,k  Prior to our studies, the work of Nadir and co-workers stood as 
the only previous study of (3 + 2) cycloadditions of N-sulfonyl-2-arylaziridines with 
heterocumulenes.6k,9  Their reaction system has a narrow scope and is only able to 
accommodate aryl isocyanates and aryl isothiocyanates, resulting in similarly limited 
product derivatization options.  This transformation depends on the use of an alkali metal 
iodide as a noninnocent reaction partner; Nadir and co-workers explicitly demonstrate the 
formation of the ring-opened iodide intermediate prior to product formation. 
Additionally, only a single example of the synthesis of enantioenriched 
iminothiazolidines by a stereoselective (3 + 2) cycloaddition is known6i despite readily 
available enantiopure aziridine starting materials.1,2,6h  This method, however, has an 
extremely narrow substrate scope, requiring the use of N-alkyl- or N-arylaziridines and 
aryl heterocumulenes.  There are no examples of this transformation with N-sulfonyl-
protected aziridines or more synthetically versatile heterocumulenes. 
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3.2  DEVELOPMENT OF THE RACEMIC (3 + 2) CYCLOADDITION 
From this foundation, we sought to develop the first stereoselective Lewis acid 
mediated (3 + 2) cycloaddition reaction of N-sulfonyl-2-substituted aziridines and alkyl 
heterocumulenes.  The Lewis acid mediated conditions would likely enable the use of a 
broad variety of heterocumulenes and consequently furnish readily derivatizable, highly 
enantioenriched heterocyclic building blocks. 
 
3.2.1  OPTIMIZATION OF THE REACTION CONDITIONS 
Initial reaction development focused on the cycloaddition of N-tosyl-2-
phenylaziridine (291) with allyl isothiocyanate (Scheme 3.1).  In contrast to our previous 
work on (3 + 2) cycloadditions of donor–acceptor cyclopropanes with heterocumulenes,10 
tin(II) triflate was found to be an ineffective Lewis acid mediator for the desired 
transformation (entry 1).  Alternatively, zinc(II) salts proved competent for the formation 
of iminothiazolidine 292. While zinc(II) triflate furnished the product in good yield, the 
reaction times were greatly reduced when zinc(II) halides were employed (entries 2–5).  
Lithium bromide mediated reaction conditions resulted in low conversion (entry 6).  
Attempts to develop a catalytic system with zinc(II) bromide proved unsuccessful, even 
in the presence of an additional bromide ion (entry 7).  Ultimately, the use of 1.25 
equivalents of zinc(II) bromide and 2.00 equivalents of allyl isothiocyanate in 
dichloromethane at ambient temperature proved optimal (entry 5).11 
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Scheme 3.1 Optimization of the reaction conditions 
 
 
3.2.2  EXPLORATION OF 2-AZIRIDINE AND HETEROCUMULENE 
SUBSTITUTION 
With optimized conditions identified, we examined the substrate scope of the 
reaction.  We found that a variety of N-tosyl-2-aryl-substituted aziridines participated 
effectively in the zinc(II) bromide mediated (3 + 2) cycloaddition with allyl 
isothiocyanate to yield the corresponding iminothiazolidine products with complete 
chemo- and regioselectivity (Scheme 3.2).12,13  Altering the C-aryl substitution from 
phenyl to mesityl allowed for the formation of the corresponding heterocycle (296) in a 
shorter reaction time despite the increased steric bulk.14  Similarly, (p-tolyl)thiazolidine 
297 was successfully furnished with a slightly decreased yield.  Acetoxy substitution was 
compatible with the reaction conditions as well, generating 298 in excellent yield.  
Compared to the p-chlorophenyl- or o-chlorophenylthiazolidines (299 and 301, 
respectively), the more electronically deactivated m-chlorophenylthiazolidine 302 was 
produced more slowly, albeit without any significant reduction in yield.15  The highly 
electron-deficient p-nitrophenyl-thiazolidine 300 was formed in modest yield, with a 
Conditions: aziridine 291 (0.40 mmol), isothiocyanate (0.80 mmol), Lewis 
acid (0.50 mmol), CH2Cl2 (0.80 mL).  a Isolated yield. b 1.00 mmol of LiBr.        
c Starting material was not fully consumed. d 0.12 mmol of ZnBr2 with 0.40 
mmol of tetra(n-buty)lammonium bromide additive.
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significant portion of starting material lost to nucleophilic ring opening of the aziridine 
by the bromide counterion.16  Substrates bearing coordinating C-aryl! substituents served 
to slow the rate of reaction (e.g. 298 and 300) or require additional ZnBr2 to drive the 
reaction to completion (303).  Styrenyl thiazolidine 304 could also be synthesized in 
approximately the same reaction time as phenyl product 292.  Additionally, primary and 
secondary alkyl isothiocyanates were found to be highly compatible under the reaction 
conditions as were electron-neutral, -rich, and -deficient aryl isothiocyanates, all 
furnishing the desired iminothiazolidines in excellent yields (305–309, respectively). 
 
Scheme 3.2 Substrate scope of the isothiocyanate (3 + 2) cycloaddition 
 
In contrast to the C-aryl-substituted aziridines, C-alkyl-substituted aziridine 310 
reacted with allyl isothiocyanate under the reaction conditions to furnish two isomeric    
Conditions: aziridine 293 (0.40 mmol), isothiocyanate (0.80 mmol), ZnBr2 (0.50 mmol), CH2Cl2 (0.80 mL). a Isolated yield.      
b The product of nucleophilic ring opening of the starting material by a bromide ion was isolated in 35% yield. c 0.90 mmol 
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(3 + 2) adducts (Scheme 3.3).  Formation of 5-alkyl-substituted iminothiazolidine 311 
was accomplished in only 18% yield, whereas 4-alkyl-substituted product 312 was 
furnished in 56% yield.  While C-alkyl-substituted aziridines are suitable reaction 
partners in the (3 + 2) cycloaddition and the heterocyclic products are formed with 
complete chemoselectivity, they are not formed with the regiofidelity exhibited by 
aziridines substituted at carbon with aryl groups or other conjugated systems. 
 
Scheme 3.3 (3 + 2) cycloaddition with 2-alkylaziridine 310 
 
 
3.2.3   EFFECT OF AZIRIDINE N-SUBSTITUTION 
As an extension of the substrate scope, we investigated the effect of N-substitution on 
the aziridine (Scheme 3.4).  Aziridines protected with N-sulfonyl groups provided the 
desired iminothiazolidines (292, 315–317) in excellent yields, generally showing reaction 
times that were slightly shorter for electron-deficient sulfonyl groups (entry 2) and 
slightly longer for more electron-rich sulfonyl groups (entries 3–4) in comparison to the 
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Scheme 3.4 Scope of N-substitution in the isothiocyanate (3 + 2) cycloaddition reaction 
 
Interestingly, unprotected 2-phenylaziridine showed an improved reaction time yet a 
partially decreased yield of the heterocyclic product 318, whereas N-(n-decyl)-substituted 
aziridine was unreactive under the reaction conditions (entries 5–6).  N-Acyl aziridines 
also failed to furnish any of the desired heterocycles 320 and 321 (entries 7–8). 
 
3.2.4  EXTENSION OF HETEROCUMULENE SCOPE 
Subsequently, we turned our attention to broadening the scope of competent 
heterocumulenes.  We found that isocyanates gave only trace yields of the (3 + 2) 
cycloaddition adducts, 17  but carbodiimides were compatible with the conditions, 
furnishing iminoimidazolidines (Scheme 3.5).18  Unlike previously known systems,6,9 our 
unique zinc-mediated conditions enabled the (3 + 2) cycloadditions of N-
sulfonylaziridines with dialkyl- and disilylcarbodiimides systems, allowing access to 
diisopropyliminoimidazolidine 323 and secondary imidazolidine 324.  In accordance with 
our observations of the isothiocyanate (3 + 2) cycloadditions, a variety of 2-arylaziridines 
were suitable reaction partners with diphenylcarbodiimide (325–327). 
 
Conditions: aziridine 313 (0.40 mmol), isothiocyanate (0.80 mmol), ZnBr2 
(0.50 mmol), CH2Cl2 (0.80 mL). a Isolated yield. b Starting material was not 
fully consumed.
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Scheme 3.5 Substrate scope of carbodiimide (3 + 2) cycloaddition 
 
 
3.2.5  CYCLOADDITION OF DISUBSTITUTED N-SULFONYLAZIRIDINES 
During our investigation of the substrate scope of the (3 + 2) cycloaddition of N-
sulfonylaziridines with isothiocyanates, we discovered that trans-2,3-disubstituted 
aziridine 328 was an acceptable reaction partner, furnishing cis-thiazolidine 329 in high 
yield and with the shortest reaction time observed for any N-tosyl-substituted substrate 
(Scheme 3.6).  Iminothiazolidine 329 was formed as a single diastereomer, and the 
relative stereochemistry was confirmed by single-crystal X-ray diffraction.  The cis 
configuration of 329 led to the hypothesis that the mechanism of the reaction involves 
inversion at the benzylic position of the aziridine starting material.19 
 
Conditions: aziridine 293 (0.40 mmol), carbodiimide (0.41 mmol), ZnBr2 (0.50 mmol), 
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Scheme 3.6 Diastereoselective (3 + 2) cycloaddition with aziridine 328 
 
To confirm that the chemo-, regio-, and diastereoselective formation of cis-
thiazolidine 329 was not substrate dependent, we exposed trans-2,3-disubstituted 
acroylaziridine 330 to identical reaction conditions and were pleased to find that cis-
acroylthiazolidine 331 was formed as the sole product and as a single diastereomer 
(Scheme 3.7). 
 
Scheme 3.7 Diastereoselective (3 + 2) cycloaddition with aziridine 330  
 
In contrast, the (3 + 2) cycloaddition of allyl isothiocyanate with cis-2,3-disubstituted 
aziridine 333 resulted in the nondiastereoselective formation of both trans-thiazolidine 
334 and the cis isomer 335 (Scheme 3.8A).  Interestingly, exposure of cis-aziridine 333 
to the reaction conditions in the absence of heterocumulene resulted in the rapid 
formation of pyrrolines 336 and 337 (Scheme 3.8B).20  Finally, we found that geminally 
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Scheme 3.8 (3 + 2) Cycloaddition with aziridine 333 
 
 
3.3  DEVELOPMENT OF THE STEREOSELECTIVE (3 + 2) 
CYCLOADDITION 
The formation of cis-thiazolidines 329 and 331 with excellent chemo-, regio-, and 
diastereoselectivity intimated the potential to develop a stereoselective reaction manifold. 
 
3.3.1  DEVELOPMENT OF A STERESELECTIVE (3 + 2) CYCLOADDITION 
Initial development focused on the (3 + 2) cycloaddition of (R)-N-tosyl-2-
phenylaziridine ((R)-291) with allyl isothiocyanate (Scheme 3.9). 22   The optimized 
zinc(II) bromide mediated reaction conditions furnished (S)-292 in excellent yield and 
with 42% enantiomeric excess (ee) (entry 1).  Other zinc(II) halide salts furnished the 
desired product in similar yield, with zinc(II) chloride giving the best ee (entries 2–3). 
Zinc(II) triflate provided no improvement in the ee of (S)-292 (entry 4).  Lithium 
bromide mediated and catalytic zinc(II) bromide conditions both exhibited incomplete 
conversion of (R)-291 (entries 5–6).  Interestingly, while the lithium bromide conditions 
furnished the opposite enantiomer (R)-292, the catalytic zinc(II) bromide conditions 





               
ZnBr2

















               
ZnBr2




















Chapter 3 – (3+2) Cycloadditions of Aziridines with Heterocumulenes  256
find that increasing the equivalents of isothiocyanate in the presence of stoichiometric 
zinc(II) bromide could provide a similar boost in ee while maintaining full conversion of 
the starting material (entry 7).  Ultimately, the use of 1.25 equivalents of zinc(II) chloride 
and 10.0 equivalents of allyl isothiocyanate in dichloromethane at ambient temperature 
proved optimal, furnishing (S)-292 in 99% yield and with 94% ee (entry 8). 
 
Scheme 3.9 Optimization of the stereoselective reaction conditions 
 
 
3.3.2  EXPLORATION OF ISOTHIOCYANATE SUBSTITUTION 
With optimal conditions identified, we examined the scope of heterocumulene 
substitution in the reaction.23  We found that, along with allyl isothiocyanate, primary and 
secondary alkyl isothiocyanates were all highly compatible under the reaction conditions, 
furnishing desired enantioenriched iminothiazolidines (S)-292, (S)-305, and (S)-306 in 
uniformly excellent yields and ee (Scheme 3.10).13  The use of a tertiary isothiocyanate, 
however, extended the reaction time and provided thiazolidine (S)-338 in decreased yield 
and ee.  Additionally, aryl isothiocyanates were competent cycloaddition reaction 
Conditions: aziridine (R)-291 (0.40 mmol, 99% ee), isothiocyanate (0.80 
mmol), Lewis acid (0.50 mmol), CH2Cl2 (0.80 mL). a Isolated yield. b 
Determined by analytical chiral SFC. c Starting material was not fully 
consumed. d 0.12 mmol of ZnBr2. e 6.00 equiv allyl isothiocyanate. f 10.0 
equiv allyl isothiocyanate.
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partners under the zinc(II) chloride mediated conditions, providing thiazolidine products 
(S)-307, (S)-308, and (S)-309 in excellent yields.  While phenyliminothiazolidine (S)-307 
was isolated with good ee, the use of a more electron-rich isothiocyanate resulted in the 
formation of a thiazolidine product ((S)-308) with an excellent 90% ee, whereas the use 
of a more electron-deficient isothiocyanate provided a product with a significantly lower 
ee ((S)-309). 
 





Conditions: aziridine (R)-293 (0.40 mmol, 99% ee), isothiocyanate (4.00 
mmol), ZnCl2 (0.50 mmol), CH2Cl2 (0.80 mL). a Isolated yield. b Determined 









yield (%)a, reaction time
ee (%)b



















































Chapter 3 – (3+2) Cycloadditions of Aziridines with Heterocumulenes  258
3.3.3  EFFECT OF AZIRIDINE N-SUBSTITUTION ON THE TRANSFER OF 
CHIRAL INFORMATION 
We subsequently investigated the effect of N-substitution on the aziridine in the 
stereoselective (3 + 2) cycloaddition.  Aziridines with N-sulfonyl substitutions were 
extremely well tolerated under the reaction conditions, furnishing the desired 
thiazolidines ((S)-292, (S)-315–(S)-317) in excellent yields and with uniformly high ee’s, 
and reaction times that increased slightly when moving from more electron-deficient 
(Scheme 3.11, entry 2) to more electron-rich (entry 4) sulfonyl groups.  While 
unprotected 2-phenylaziridine showed an improved reaction time, unfortunately both the 
yield and ee of thiazolidine (S)-318 were reduced (entry 5). 
 
Scheme 3.11 Scope of N-substitution in the stereoselective isothiocyanate (3 + 2) 
 
 
3.3.4  PROPOSED MECHANISM OF STEREOSELECTIVE (3 + 2) 
CYCLOADDITION 
We hypothesize that the mechanism of the (3 + 2) cycloadditions presented herein 
proceeds through a stereoselective intimate-ion-pair mechanism similar to that invoked in 
Conditions: aziridine (R)-313 (0.40 mmol, 99% ee), isothiocyanate (4.00 
mmol), ZnCl2 (0.50 mmol), CH2Cl2 (0.80 mL). a Isolated yield. b Determined 
by analytical chiral SFC.
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our previous work10 and by Johnson24 and Kerr25 in related work on the cycloadditions of 
donor–acceptor cyclopropanes (Scheme 3.12).  Our observations including lack of 
reactivity in the absence of Lewis acid,11,26 inversion at the benzylic position, greater 
reactivity of aziridines with electron-rich aryl substituents, and shorter reaction times of 
N-substituted aziridines with more electron-withdrawing groups are all consistent with 
this mechanistic hypothesis.  The formation of (R)-292 under lithium bromide mediated 
conditions strongly suggests we have developed a Lewis acid mediated process in 
contrast to the related alkali metal halide mediated system reported by Nadir and co-
workers,6k,9 who observe overall stereoretention as a result of a double inversion pathway, 
which proceeds through an iodinated intermediate.  It also suggests a distinct mechanism 
from the palladium(II)-catalyzed reaction reported Alper and co-workers,6i who observe 
the stereoretentive product as the major enantiomer.  Our hypothesis accounts for the 
observed nondiastereoselective formation of thiazolidines 334 and 335 and pyrrolines 
336 and 337, considering the fully separated ion-pair intermediate that likely results from 
destabilization of the polarized C–N bond by the steric interaction between the cis 
substituents on aziridine 333 (see Scheme 3.8). 
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3.4  CYCLOADDITION OF AN AZIRIDINE DICARBOXYLATE 
Noting the apparent mechanistic similarities with our previous work,10 we synthesized 
aziridine dicarboxylate 342 to assess the potential for selective activation of the C–C or 
C–N bond under either our tin(II)- or zinc(II)-mediated conditions, respectively. 27  
Unfortunately, Sn(OTf)2 failed to provide any cycloaddition product.28 Alternatively, use 
of ZnBr2 provided thiolactam 343 as the sole (3 + 2) adduct (Scheme 3.13A).  
 
Scheme 3.13 (3 + 2) Cycloaddition with aziridine dicarboxylate 342 
 
This is the only thiolactam (3 + 2) cycloaddition product observed during our 
studies.13  The ability of the malonate group to stabilize the negative charge and the 
nitrogen to further stabilize the benzylic positive charge allows for the formation of 
zwitterion 345, likely resulting in the observed divergent reactivity (Scheme 3.13B).29 
 
3.5  DEPROTECTION OF IMINOTHIAZOLIDINE PRODUCTS  
Having explored a range of substrates, heterocumulenes, and N-protecting groups, we 
next sought to assess the potential to derivatize our heterocyclic products.  As expected, 
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318 could be accessed rapidly in an excellent 91% yield without any loss of enantiomeric 
excess through detosylation of thiazolidine (S)-292 (Scheme 3.14A).30  Alternatively, (S)-
318 could be reached by the desulfonylation of p-nosyl-protected thiazolidine (S)-315 
(Scheme 3.41B), furnishing thiazolidine (S)-318 in 87% yield and with 94% ee over two 
steps from (R)-N-(p-nitrobenzenesulfonyl)-2-phenylaziridine.31 
 
Scheme 3.14 Desulfonylation and deallylation of iminothiazolidine products 
 
Alternatively, cleavage of the allyl imine C–N bond of heterocycle (S)-292 in the 
presence of palladium(0) enabled access to secondary iminothiazolidine (S)-344 with 
some loss of enantiomeric excess (Scheme 3.14C).  While the deallylation of various 
nitrogen groups, including amines32 and amides,33 is known, this is the first example of 
imino N-allyl bond cleavage. 
Iminothiazolidines (S)-318 and (S)-344 are extremely versatile heterocycles. 
Derivatization and synthetic manipulations of the imine, allyl group, and secondary 
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oxothiazolidines, thiazoles, and a variety of polycyclic scaffolds.34  Critically, access to 
the enantioenriched secondary thiazolidine and imidazolidine products enabled by our   
(3 + 2) cycloaddition allows for their use as asymmetric organic catalysts, as the free 
secondary nitrogen functions as a necessary hydrogen bond donor for the majority of 
these applications.7a–d 
 
3.6  CONCLUSIONS 
We have disclosed the first stereoselective Lewis acid mediated (3 + 2) cycloaddition 
of N-H- and N-sulfonylaziridines with alkyl heterocumulenes. These zinc(II)-mediated 
conditions offer broad tolerance of alkyl, silyl, and aryl heterocumulenes, as well as 
aziridine substitution, enabling the formation of iminoimidazolidines and enantioenriched 
iminothiazolidines in overall excellent yields from enantioenriched aziridines, which are 
easily accessible from their amino acid precursors.  Combined with the exhibited ability 
to simply and orthogonally remove the sulfonyl and allyl protecting groups, this reaction 
system enables the installation of a broad number of functional group handles for further 
derivatization of these biologically and catalytically important heterocyclic scaffolds. 
 
3.7  EXPERIMENTAL SECTION 
3.7.1   MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) in 
flame-dried or oven-dried glassware under an argon or nitrogen atmosphere using dry, 
deoxygenated solvents (distilled or passed over a column of activated alumina).35  
Commercially obtained reagents were used as received with the exception of tetra(n-
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butyl)ammonium bromide (TBAB), zinc(II) chloride, zinc(II) bromide, zinc(II) iodide, 
zinc(II) triflate, tin(II) triflate, lithium bromide, tetrakis(acetonitrile)copper(I) 
hexafluorophosphate, and tetrakis(triphenylphosphine)palladium(0), which were stored in 
a nitrogen-filled glovebox.  Triethylamine and pyridine were distilled from calcium 
hydride immediately prior to use.  Methanol was distilled from magnesium methoxide 
immediately prior to use.  Iodosobenzene36 and diphenylcarbodiimide37were prepared by 
known methods.  Reactions requiring external heat were modulated to the specified 
temperatures using an IKAmag temperature controller.  Reaction progress was monitored 
by thin-layer chromatography (TLC) or Agilent 1290 UHPLC-LCMS.  TLC was 
performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized 
by UV fluorescence quenching, potassium permanganate, or p-anisaldehyde staining.  
SiliaFlash P60 Academic Silica gel (particle size 0.040-0.063 mm) was used for flash 
chromatography.  1H and 13C NMR spectra were recorded on a Varian Inova 500 
spectrometer (500 MHz and 126 MHz, respectively) and are reported in terms of 
chemical shift relative to residual CHCl3 (δ 7.26 and δ 77.16 ppm, respectively), 
D3CS(O)CHD2 (δ 2.50 and δ 39.52 ppm, respectively), or CHDCl2 (δ 5.32 and δ 53.84 
ppm, respectively).  Data for 1H NMR spectra are reported as follows: chemical shift (δ 
ppm) (multiplicity, coupling constant (Hz), integration).  Abbreviations are used as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, m = complex multiplet, bs = 
broad singlet.  Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 
spectrometer and are reported in frequency of absorption (cm–1).  High-resolution mass 
spectra (HRMS) were obtained from the Caltech Mass Spectral Facility using a JEOL 
JMS-600H High Resolution Mass Spectrometer with fast atom bombardment (FAB+) 
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ionization mode or were acquired using an Agilent 6200 Series TOF with an Agilent 
G1978A Multimode source in atmospheric pressure chemical ionization (APCI+), 
electrospray ionization (ESI+), or mixed (MultiMode: ESI-APCI) ionization mode. 
Optical rotations were measured on a JASCO P-2000 polarimeter using a 100 mm path 
length cell at 589 nm.  Analytical supercritical fluid chromatography (SFC) was 
performed with a Mettler SFC supercritical CO2 analytical chromatography system 
utilizing Chiralpak (AD-H or AS-H) or Chiralcel (OB-H or OD-H) columns (4.6 mm x 
25 cm) obtained from Daicel Chemical Industries, Ltd. 
 
3.7.2   GENERAL EXPERIMENTAL PROCEDURES 
 
General Procedure A. Direct aziridination of olefins.38 
To a flame-dried round-bottom flask with a stir bar were added p-toluenesulfonamide 
(5.60 mmol, 1.40 equiv), tetrakis(acetonitrile)copper(I) hexafluorophosphate (0.40 mmol, 
0.10 equiv), the appropriate olefin (183, 4.00 mmol, 1.00 equiv), activated 3 Å molecular 
sieves (2.40 g, 600 mg/mmol olefin), and acetonitrile (10 mL).  The stirred suspension 
was cooled to 0 °C (ice/H2O bath), and iodosobenzene (5.60 mmol, 1.40 equiv) was 
added as a solid in one portion.  The bath was immediately removed and the reaction 
mixture was allowed to warm to ambient temperature.  Upon consumption of starting 
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through Celite, washing with acetonitrile (50 mL) and ethyl acetate (50 mL).  The filtrate 
was concentrated in vacuo to give the crude product, which was purified by silica gel 
column chromatography (EtOAc in hexanes eluent). 
 
 
General Procedure B.  Ring closure of amino alcohols.39 
A flame-dried round-bottom flask with a stir bar was charged with 2-phenylglycinol 
(345, 0.73 mmol, 1.00 equiv), which was then suspended in CH2Cl2 (500 µL) and 
pyridine (250 µL).  The stirred suspension was cooled to 0 °C (ice/H2O bath) at which 
time the appropriate sulfonyl chloride (2.19 mmol, 3.00 equiv) was added in one portion.  
The bath was immediately removed and the reaction mixture was allowed to warm to 
ambient temperature.  Upon completion (determined by TLC or LCMS analysis, ca. 1–5 
h), the mixture was diluted with CH2Cl2 (12 mL), and washed with aqueous 2 N HCl (3 x 
4 mL).  The combined acidic aqueous layers were extracted with CH2Cl2 (1 x 4 mL).  
The organic layers were combined and carefully washed with aqueous 2 N KOH (6 x 8 
mL).  The combined basic aqueous layers were then extracted with CH2Cl2 (1 x 12 mL) 
and the combined organic layers were dried over sodium sulfate, filtered, and 
concentrated in vacuo.  The crude residue was purified by silica gel column 
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General Procedure C. Isothiocyanate (3 + 2) cycloaddition with 2-subsituted aziridines.  
To an oven-dried 1-dram vial equipped with a magnetic stir bar was added zinc(II) 
bromide (113 mg, 0.50 mmol, 1.25 equiv), freshly powdered with a mortar and pestle, in 
an inert atmosphere glovebox.  The vial was sealed with a screw cap fitted with a Teflon 
septum, removed from the glovebox, and placed under an inert atmosphere. To a 
separate, oven-dried 1-dram vial was added the appropriate aziridine (346, 0.40 mmol, 
1.00 equiv). The vial was sealed with a screw cap fitted with a Teflon septum and 
anhydrous CH2Cl2 (0.60 mL) and isothiocyanate (0.80 mmol, 2.00 equiv) were added. 
The mixture was transferred to the first vial with a rinse of anhydrous CH2Cl2 (0.20 mL).  
The heterogeneous reaction mixture was then allowed to stir at ambient temperature.  
Upon consumption of the aziridine (determined by TLC or LCMS analysis), the reaction 
solution was diluted with CH2Cl2 (3 mL) and CH3OH (1 mL), adsorbed onto Celite, and 




General Procedure D. Carbodiimide (3 + 2) cycloaddition with 2-subsituted aziridines.  
To an oven-dried 1-dram vial equipped with a magnetic stir bar was added zinc(II) 
bromide (113 mg, 0.50 mmol, 1.25 equiv), freshly powdered with a mortar and pestle, in 
R1
N
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an inert atmosphere glovebox.  The vial was sealed with a screw cap fitted with a Teflon 
septum, removed from the glovebox, and placed under an inert atmosphere. To a 
separate, oven-dried 1-dram vial was added the appropriate aziridine (346, 0.40 mmol, 
1.00 equiv). The vial was sealed with a screw cap fitted with a Teflon septum and 
anhydrous CH2Cl2 (0.60 mL) and carbodiimide (0.41 mmol, 1.02 equiv) were added. The 
mixture was transferred to the first vial with a rinse of anhydrous CH2Cl2 (0.20 mL). The 
heterogeneous reaction mixture was then allowed to stir at ambient temperature.  Upon 
consumption of the aziridine (determined by TLC or LCMS analysis), the reaction 
solution was diluted with CH2Cl2 (3 mL) and CH3OH (1 mL), adsorbed onto Celite, and 




General Procedure E. Stereoselective Isothiocyanate (3 + 2) cycloaddition with 2-
subsituted aziridines.  
To an oven-dried 1-dram vial equipped with a magnetic stir bar was added powdered 
zinc(II) chloride (68 mg, 0.50 mmol, 1.25 equiv) in an inert atmosphere glovebox.  The 
vial was sealed with a screw cap fitted with a Teflon septum, removed from the 
glovebox, and placed under an inert atmosphere. To a separate, oven-dried 1-dram vial 
was added the appropriate aziridine ((R)-346, 0.40 mmol, 1.00 equiv). The vial was 
sealed with a screw cap fitted with a Teflon septum and anhydrous CH2Cl2 (0.60 mL) and 
isothiocyanate (4.00 mmol, 10.0 equiv) were added. The mixture was transferred to the 
R1
N
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first vial with a rinse of anhydrous CH2Cl2 (0.20 mL). The heterogeneous reaction 
mixture was then allowed to stir at ambient temperature.  Upon consumption of the 
aziridine (determined by TLC or LCMS analysis), the reaction solution was diluted with 
CH2Cl2 (3 mL) and CH3OH (1 mL), adsorbed onto Celite, and purified by silica gel 
column chromatography (acetone in hexanes). 
 




Aziridine 291 was prepared according to General Procedure B from 2-phenylglycinol 
(345): 85% yield; Rf = 0.25 (1:4 Acetone:Hexanes eluent); characterization data match 




Aziridine (R)-291 was prepared according to a procedure modified from literature 
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phenylglycinol ((R)-345, 5.00 g, 36.4 mmol, 1.00 equiv), p-toluenesulfonyl chloride 
(17.4 g, 91.1 mmol, 2.50 equiv), and 4-(dimethylamino)pyridine (DMAP, 445 mg, 3.64 
mmol, 0.10 equiv).  The solids were suspended in dichloromethane under nitrogen, and 
the flask was cooled in an ice-water bath.  Triethylamine (Et3N, 15.2 mL, 109 mmol, 3.00 
equiv) was added dropwise, and the reaction mixture became clear and colorless.  The 
flask was allowed to warm to room temperature and stir under nitrogen.  Upon 
completion (as determined by LCMS analysis, ca. 8 h), the reaction was quenched by 
addition of saturated aqueous NH4Cl (80 mL).  The organic layer was removed and the 
aqueous layer extracted with dichloromethane (3 x 60 mL).  The combined organic layers 
were dried over sodium sulfate, filtered, and concentrated in vacuo.  The crude solid was 
purified by silica gel column chromatography (10% EtOAc in hexanes eluent) to give 
aziridine (R)-291 (6.34 g, 64% yield) as a fluffy white solid: characterization data are the 
same as above; [α]D 25.0 –108.6° (c 0.950, CHCl3); enantiomeric excess was determined 
by analytical SFC (Chiralcel OB-H column, 10% isopropyl alcohol in CO2, 2.5 mL/min, 
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Aziridine 349 was prepared according to General Procedure A: 40% yield; Rf = 0.29 (1:9 




Aziridine 351 was prepared according to General Procedure A: 75% yield; Rf = 0.34 (1:4 




Aziridine 352 was prepared according to General Procedure A: 76% yield; Rf = 0.32 (3:7 
EtOAc:Hexanes eluent); characterization data for 1H NMR, 13C NMR, and IR spectra 
match those reported in the literature;42a HRMS (ESI+) m/z calc’d for C17H18NO4S 
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N-tosyl-2-(p-chlorophenyl)aziridine (353): 
Aziridine 353 was prepared according to General Procedure A: 82% yield; Rf = 0.30 





Aziridine 355 was prepared according to General Procedure A: 31% yield; Rf = 0.27 (1:4 
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Aziridine 356 was prepared according to General Procedure A: 90% yield; Rf = 0.45 (1:3 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.93–7.87 (m, 2H), 7.37–7.34 (m, 
2H), 7.34–7.31 (m, 1H), 7.23–7.14 (m, 3H), 4.04 (dd, J = 7.2, 4.4 Hz, 1H), 3.03 (d, J = 
7.2 Hz, 1H), 2.45 (s, 3H), 2.29 (d, J = 4.4 Hz, 1H); 13C NMR (CDCl3, 126 MHz) δ 145.0, 
134.8, 133.9, 133.2, 129.9, 129.4, 129.3, 128.2, 127.6, 127.1, 39.1, 35.8, 21.8; IR (Neat 
Film, NaCl) 3065, 1596, 1444, 1328, 1163, 1093, 913, 815, 759, 732 cm–1; HRMS 




Aziridine 358 was prepared according to General Procedure A: 97% yield; Rf = 0.46 (1:3 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.89–7.84 (m, 2H), 7.37–7.32 (m, 
2H), 7.26–7.17 (m, 3H), 7.12 (dtd, J = 7.1, 1.5, 0.5 Hz, 1H), 3.73 (dd, J = 7.1, 4.4 Hz, 
1H), 2.97 (d, J = 7.2 Hz, 1H), 2.44 (s, 3H), 2.35 (d, J = 4.4 Hz, 1H); 13C NMR (CDCl3, 
126 MHz) δ 145.0, 137.4, 134.9, 134.7, 130.0, 129.9, 128.6, 128.1, 126.7, 125.0, 40.2, 
36.3, 21.8; IR (Neat Film, NaCl) 3062, 1597, 1451, 1326, 1161, 1092, 919, 786, 723   
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N-tosyl-2-(o-pyridyl)aziridine (360):44 
Aziridine 360 was prepared according to General Procedure A: 68% yield; Rf = 0.34 (1:1 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.52 (ddd, J = 4.8, 1.8, 0.9 Hz, 
1H), 7.89–7.83 (m, 2H), 7.62 (td, J = 7.7, 1.8 Hz, 1H), 7.34–7.30 (m, 2H), 7.26 (dt, J = 
7.8, 1.1 Hz, 1H), 7.19 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 3.90 (dd, J = 7.2, 4.4 Hz, 1H), 2.97 
(d, J = 7.2 Hz, 1H), 2.65 (d, J = 4.4 Hz, 1H), 2.42 (s, 3H); 13C NMR (CDCl3, 126 MHz) 
δ 154.4, 149.7, 144.9, 136.9, 134.6, 129.9, 128.2, 123.4, 121.9, 41.4, 35.1, 21.8; IR (Neat 
Film, NaCl) 3064, 1594, 1477, 1437, 1326, 1204, 1161, 1092, 915, 804, 715 cm–1; 




Aziridine 362 was prepared according to General Procedure A: 11% yield; Rf = 0.18 (1:9 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.90–7.82 (m, 2H), 7.36–7.23 (m, 
7H), 6.73 (d, J = 15.9 Hz, 1H), 5.84 (dd, J = 15.9, 7.9 Hz, 1H), 3.46 (dddd, J = 7.8, 7.1, 
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NMR (CDCl3, 126 MHz) δ 144.8, 135.9, 135.2, 129.9, 128.8, 128.4, 128.0, 126.6, 126.6, 
124.2, 41.4, 34.8, 21.8; IR (Neat Film, NaCl) 3287, 3028, 2924, 1597, 1494, 1450, 1323, 
1160, 1090, 964, 939, 884, 815, 753, 714 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for 




Aziridine 310 was prepared according to General Procedure A: 32% yield; Rf = 0.44 (1:3 




Aziridine 364 was prepared according to General Procedure B from 2-phenylglycinol 
(345); 88% yield; Rf = 0.29 (3:7 Acetone:Hexanes eluent); characterization data match 
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(R)-N-mesyl-2-phenylaziridine ((R)-364): 
Aziridine (R)-364 was prepared according to General Procedure B from (R)-(–)-2-
phenylglycinol ((R)-345): characterization data are the same as above; [α]D 25.0 –194.5° (c 
0.500, CHCl3); enantiomeric excess was determined by analytical SFC (Chiralpak AS-H 
column, 10% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major retention time: 




Aziridine 365 was prepared according to General Procedure B from 2-phenylglycinol 
(345): 81% yield; Rf = 0.39 (3:7 Acetone:Hexanes eluent); characterization data match 




Aziridine (R)-365 was prepared according to General Procedure B from (R)-(–)-2-
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0.850, CHCl3); enantiomeric excess was determined by analytical SFC (Chiralpak AS-H 
column, 10% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major retention time: 




Aziridine 366 was prepared according to General Procedure B from 2-phenylglycinol 
(345): 76% yield; Rf = 0.24 (1:4 Acetone:Hexanes eluent); characterization data match 




Aziridine (R)-366 was prepared according to General Procedure B from (R)-(–)-2-
phenylglycinol ((R)-345): characterization data are the same as above; [α]D 25.0 –58.4° (c 
0.600, CHCl3); enantiomeric excess was determined by analytical SFC (Chiralcel OD-H 
column, 10% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major retention time: 





























Aziridine 367 was prepared according to literature methods from N-tosyl-2-
phenylaziridine (291).30 To a suspension of magnesium metal shavings (474 mg, 19.5 
mmol, 5.33 equiv) in CH3OH (37 mL) was added a solution of aziridine 291 (1.00 g, 3.66 
mmol, 1.00 equiv) in CH3OH (24 mL) quickly dropwise.  The reaction mixture was then 
sonicated at ambient temperature until consumption of the starting material was complete 
(determined by TLC analysis, ca. 30 min).  The resulting white suspension was poured 
over brine (200 mL) and extracted with CH2Cl2 (4 x 150 mL).  The combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo to generate a white 
solid.  The crude residue was purified by column chromatography (85% EtOAc and 3% 
Et3N in hexanes→3%Et3N in EtOAc eluent) to afford aziridine 367 (342 mg, 78% yield) 
as a clear, colorless oil: Rf = 0.42 (EtOAc eluent); characterization data match those 
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Aziridine (R)-367 was prepared according to literature methods from (R)-N-tosyl-2-
phenylaziridine ((R)-291) as described above: characterization data are the same as 
above; [α]D 25.0 –59.4° (c 0.750, CHCl3); enantiomeric excess was determined by 
analytical SFC (Chiralcel OD-H column, 10% isopropyl alcohol in CO2, 2.5 mL/min, λ = 





Aziridine 368 was prepared according to a procedure modified from literature methods.5c 
To an oven-dried vial with a stir bar were added aziridine 367 (113 mg, 0.95 mmol, 1.20 
equiv) and acetonitrile (1.2 mL).  Potassium carbonate (130 mg, 0.95 mmol, 1.20 equiv) 
and decyl iodide (170 µL, 0.79 mmol, 1.00 equiv) were then added, and the vial was 
sealed and heated to 55 °C.  Upon consumption of starting material (determined by 
LCMS analysis, ca. 17 h), the reaction mixture was allowed to cool to room temperature, 
concentrated in vacuo, and the residue partitioned between diethyl ether and brine.  The 
organic layer was separated and concentrated in vacuo to afford a gold oil.  The crude 
residue was purified by column chromatography (5% EtOAc in hexanes eluent) to furnish 
alkylated aziridine 368 (138 mg, 67% yield) as a clear, colorless oil: Rf = 0.33 (1:19 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.33–7.18 (m, 5H), 2.52–2.44 (m, 
1H), 2.36–2.26 (m, 2H), 1.89 (dd, J = 3.4, 0.7 Hz, 1H), 1.65 (dd, J = 6.5, 0.7 Hz, 1H), 
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MHz) δ 140.7, 128.4, 126.9, 126.3, 62.1, 41.4, 37.9, 32.1, 30.0, 29.8, 29.7, 29.7, 29.5, 
27.6, 22.8, 14.3; IR (Neat Film, NaCl) 3036, 2925, 2853, 1606, 1495, 1467, 1377, 1207, 





To a stirred solution of 2-phenylaziridine (367, 568 mg, 4.77 mmol, 1.00 equiv) in 
CH2Cl2 (12 mL) were added triethylamine (Et3N, 0.39 mL, 5.25 mmol, 1.10 equiv) and 
trimethylacetyl chloride (1.17 mL, 9.54 mmol, 2.00 equiv) dropwise. The reaction 
mixture was cooled to 0 °C (ice/H2O bath) at which time 4-(dimethylamino)pyridine 
(DMAP, 59 mg, 0.49 mmol, 0.10 equiv) was added as a solid in one portion. The bath 
was immediately removed and the reaction mixture was allowed to warm to ambient 
temperature. Upon consumption of starting material (determined by TLC analysis, ca. 1 
h), the reaction mixture was concentrated in vacuo to afford a gold oil. The crude residue 
was purified by column chromatography (20% EtOAc in hexanes eluent) to afford 
aziridine 369 (204 mg, 21% yield) as a clear, colorless oil: Rf = 0.31 (1:4 EtOAc:Hexanes 
eluent); 1H NMR (CDCl3, 500 MHz) δ 7.38–7.33 (m, 2H), 7.32–7.28 (m, 1H), 7.27–7.24 
(m, 2H), 5.44 (dd, J = 10.3, 7.8 Hz, 1H), 4.24 (dd, J = 14.2, 10.3 Hz, 1H), 3.74 (dd, J = 
14.2, 7.8 Hz, 1H), 1.30 (s, 9H); 13C NMR (CDCl3, 126 MHz) δ 174.2, 141.8, 128.8, 











0 °C → 23°C
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1265, 1132, 988, 954, 759 cm–1; HRMS (FAB+) m/z calc’d for C13H18NO [M+H]+: 




To a stirred solution of 2-phenylaziridine (367, 119 mg, 1.00 mmol, 1.00 equiv) in 
CH2Cl2 (2.5 mL) were added triethylamine (Et3N, 0.16 mL, 1.10 mmol, 1.10 equiv) and 
benzoyl chloride (0.23 mL, 2.00 mmol, 2.00 equiv) dropwise. The reaction mixture was 
cooled to 0 °C (ice/H2O bath) at which time 4-(dimethylamino)pyridine (12 mg, 0.10 
mmol, 0.10 equiv) was added as a solid in one portion. The bath was immediately 
removed and the reaction mixture was allowed to warm to ambient temperature. Upon 
consumption of starting material (determined by TLC analysis, ca. 1 h), the reaction 
mixture was concentrated in vacuo to afford a gold oil. The crude residue was purified by 
column chromatography (10% EtOAc with 1% Et3N in hexanes eluent) to afford 
aziridine 370 (222 mg, 99% yield) as a white amorphous solid: Rf = 0.40 (1:9 
EtOAc:Hexanes eluent); characterization data match those reported in the literature.46 
 
 



















Chapter 3 – (3+2) Cycloadditions of Aziridines with Heterocumulenes  281
Aziridine 328 was prepared according to General Procedure A: 52% yield; Rf = 0.29 (3:7 
Acetone:Hexanes eluent); characterization data match those reported in the literature.42  
 
 
trans-N-tosyl-2-((E)-2-(methoxycarbonyl)ethenyl)-3-phenylaziridine (330) and cis-
methyl N-tosyl-3-((E)-styryl)aziridine-2-carboxylate (333): 
Aziridines 330 and 333 were prepared according to General Procedure A:  
 
trans-N-tosyl-2-((E)-2-(methoxycarbonyl)ethenyl)-3-phenylaziridine (330): 
20% yield; Rf = 0.42 (3:7 EtOAc:Hexanes eluent); characterization data for 1H and 13C 
NMR  spectra match those reported in the literature;47 IR (Neat Film, NaCl) 3032, 2952, 
2256, 1722, 1651, 1597, 1495, 1435, 1407, 1329, 1268, 1162, 1089, 1034, 980, 900, 865, 
815, 766, 733 cm–1; HRMS (ESI+) m/z calc’d for C19H20NO4S [M+H]+: 358.1108, found 
358.1108. 
cis-methyl N-tosyl-3-((E)-styryl)aziridine-2-carboxylate (333): 
30% yield; Rf = 0.45 (3:7 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ  7.90–
7.83 (m, 2H), 7.37–7.24 (m, 7H), 6.81 (d, J = 16.0 Hz, 1H), 6.06 (dd, J = 16.0, 8.5 Hz, 
1H), 3.74 (s, 3H), 3.72 (ddd, J = 8.5, 7.4, 0.6 Hz, 1H), 3.62 (d, J = 7.3 Hz, 1H), 2.44 (s, 
3H); 13C NMR (CDCl3, 126 MHz) δ 166.0, 145.3, 137.8, 135.7, 134.3, 130.1, 128.8, 
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2256, 1747, 1597, 1445, 1329, 1207, 1161, 1090, 1035, 969, 915, 802, 761, 734 cm–1; 




dimethyl N-tosyl-3-phenylaziridine-2,2-dicarboxylate (342): 
Aziridine 342 was prepared according to literature methods from benzaldehyde over two 
steps. Procedure for the condensation of p-toluenesulfonamide onto benzaldehyde (188) 
was followed from the literature.48 A stirred suspension of benzaldehyde (188, 1.02 mL, 
10.0 mmol, 1.00 equiv), p-toluenesulfonamide (1.71 g, 10.0 mmol, 1.00 equiv), and 
montmorillonite K 10 (900 mg) in toluene (50 mL) was heated to reflux under a Dean-
Stark apparatus. After 2.5 h, the consumption of starting material was complete (as 
determined by TLC analysis) and the reaction mixture was allowed to cool and filtered 
through Celite rinsing with toluene eluent (30 mL). The filtrate was concentrated in 
vacuo and the crude solids were purified by silica gel column chromatography (40% Et2O 
in hexanes eluent), ensuring the product was eluted quickly,49 to furnish imine 372 (2.13 
g, 82% yield) as a white solid: Rf = 0.32 (2:3 Et2O:Hexanes eluent); characterization data 
matches those reported in the literature.50 
Procedure for the oxidative cycloaddition of dimethyl malonate with imine 372 was 
























Chapter 3 – (3+2) Cycloadditions of Aziridines with Heterocumulenes  283
1.00 equiv) and dimethyl malonate (0.32 mL, 2.75 mmol, 1.10 equiv) in acetonitrile (5 
mL) were added iodosobenzene (1.10 g, 5.00 mmol, 2.00 equiv) and potassium iodide 
(85 mg, 0.50 mmol, 0.20 equiv) as solids, each in a single portion. After 10 minutes, the 
consumption of starting material was complete (as determined by TLC analysis) and the 
reaction mixture was diluted with dichloromethane (20 mL), dry loaded onto Celite (2.5 
g), and purified by silica gel column chromatography (25% EtOAc in hexanes eluent) to 
afford aziridine 342 (658 mg, 68% yield) as a viscous clear, colorless oil; Rf = 0.17 (1:4 
EtOAc:Hexanes eluent); characterization data for 1H and 13C NMR and HRMS spectra 
match those reported in the literature;52 IR (Neat Film, NaCl) 3281, 2956, 1749, 1435, 




Aziridine 373 was prepared according to General Procedure A: 32% yield; Rf = 0.44 (1:3 
EtOAc:Hexanes eluent); characterization data match those reported in the literature.42  
 
3.7.4   IMINOTHIAZOLIDINE SYNTHESIS AND CHARACTERIZATION 
DATA 
Unless otherwise stated, all iminothiazolidines were prepared according to General 
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(Z)-5-phenyl-3-tosyl-2-(allylimino)thiazolidine (292): 
99% yield; Rf = 0.28 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.94–
7.89 (m, 2H), 7.40–7.32 (m, 5H), 7.32–7.28 (m, 2H), 5.84 (ddt, J = 17.1, 10.3, 5.1 Hz, 
1H), 5.12–4.98 (m, 2H), 4.80 (dd, J = 8.4, 6.3 Hz, 1H), 4.50 (dd, J = 10.3, 6.3 Hz, 1H), 
3.94 (dd, J = 10.3, 8.5 Hz, 1H), 3.86 (ddt, J = 15.9, 5.1, 1.8 Hz, 1H), 3.77 (ddt, J = 15.9, 
5.2, 1.8 Hz, 1H), 2.44 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 151.2, 144.6, 136.8, 135.0, 
134.9, 129.2, 129.1, 129.0, 128.8, 127.6, 115.3, 58.0, 56.6, 47.1, 21.8; IR (Neat Film, 
NaCl) 2923, 1653, 1596, 1355, 1168, 1108, 810, 764 cm–1; HRMS (APCI+) m/z calc’d 




Thiazolidine (S)-292 was prepared according to General Procedure E: 99% yield; Rf = 
0.28 (1:4 Acetone:Hexanes eluent); characterization data match those above; [α]D 25.0      
–13.1° (c 1.600, CHCl3); enantiomeric excess was determined by analytical SFC 
(Chiralpak AD-H, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major 





















97% yield; Rf = 0.23 (1:4 Et2O:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.99–7.91 
(m, 2H), 7.31 (d, J = 8.0 Hz, 2H), 6.85 (s, 2H), 5.83 (ddt, J = 17.2, 10.3, 5.1 Hz, 1H), 
5.43 (dd, J = 11.0, 7.6 Hz, 1H), 5.11–4.97 (m, 2H), 4.41 (dd, J = 10.4, 7.6 Hz, 1H), 4.14 
(t, J = 10.7 Hz, 1H), 3.85 (ddt, J = 16.0, 5.1, 1.8 Hz, 1H), 3.73 (ddt, J = 16.0, 5.2, 1.7 Hz, 
1H), 2.45 (s, 3H), 2.40 (s, 6H), 2.25 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 151.9, 144.6, 
138.4, 138.0, 135.4, 135.2, 131.0, 129.3, 129.1, 127.3, 115.2, 58.0, 52.3, 42.4, 21.8, 21.6, 
20.9; IR (Neat Film, NaCl) 2920, 1656, 1637, 1450, 1357, 1170, 1106, 1090, 858, 789 




92% yield; Rf = 0.38 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.95–
7.89 (m, 2H), 7.32–7.28 (m, 2H), 7.28–7.24 (m, 2H), 7.19–7.13 (m, 2H), 5.84 (ddt, J = 
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4.77 (dd, J = 8.6, 6.3 Hz, 1H), 4.48 (dd, J = 10.3, 6.3 Hz, 1H), 3.91 (dd, J = 10.3, 8.7 Hz, 
1H), 3.85 (ddt, J = 15.9, 5.1, 1.8 Hz, 1H), 3.76 (ddt, J = 15.9, 5.2, 1.8 Hz, 1H), 2.44 (s, 
3H), 2.35 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 151.4, 144.6, 138.7, 135.1, 135.0, 
133.7, 129.8, 129.2, 129.1, 127.5, 115.2, 58.0, 56.6, 47.0, 21.8, 21.2; IR (Neat Film, 
NaCl) 3007, 2922, 1657, 1639, 1597, 1514, 1358, 1170, 1110, 915, 814, 774, 732 cm–1; 




95% yield; Rf = 0.37 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.93–
7.87 (m, 2H), 7.42–7.34 (m, 2H), 7.32–7.27 (m, 2H), 7.10–7.04 (m, 2H), 5.83 (ddt, J = 
17.1, 10.3, 5.1 Hz, 1H), 5.12–4.97 (m, 2H), 4.78 (dd, J = 8.3, 6.3 Hz, 1H), 4.47 (dd, J = 
10.3, 6.3 Hz, 1H), 3.91 (dd, J = 10.3, 8.3 Hz, 1H), 3.84 (ddt, J = 15.9, 5.1, 1.8 Hz, 1H), 
3.76 (ddt, J = 15.9, 5.2, 1.8 Hz, 1H), 2.43 (s, 3H), 2.30 (s, 3H); 13C NMR (CDCl3, 126 
MHz) δ 169.4, 151.0, 150.8, 144.7, 135.0, 134.9, 134.5, 129.2, 129.1, 128.8, 122.3, 
115.3, 58.0, 56.6, 46.5, 21.8, 21.2; IR (Neat Film, NaCl) 2922, 1760, 1657, 1505, 1360, 
1202, 1169, 1107, 912, 811 cm–1; HRMS (APCI+) m/z calc’d for C21H23N2O4S2 [M+H]+: 
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(Z)-5-(p-chlorophenyl)-3-tosyl-2-(allylimino)thiazolidine (299): 
93% yield; Rf = 0.29 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.92–
7.87 (m, 2H), 7.32–7.27 (m, 6H), 5.83 (ddt, J = 17.1, 10.3, 5.1 Hz, 1H), 5.10–4.99 (m, 
2H), 4.75 (dd, J = 7.8, 6.3 Hz, 1H), 4.45 (dd, J = 10.3, 6.3 Hz, 1H), 3.93 (dd, J = 10.3, 
7.8 Hz, 1H), 3.84 (ddt, J = 15.9, 5.1, 1.8 Hz, 1H), 3.77 (ddt, J = 15.9, 5.2, 1.8 Hz, 1H), 
2.44 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 150.7, 144.7, 135.7, 135.0, 134.9, 134.7, 
129.3, 129.2, 129.1, 129.0, 115.4, 58.1, 56.4, 46.4, 21.8; IR (Neat Film, NaCl) 2924, 
1651, 1597, 1493, 1354, 1168, 1090, 1014, 917, 809, 731 cm–1; HRMS (APCI+) m/z 




59% yield; Rf = 0.20 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.25–
8.19 (m, 2H), 7.93–7.87 (m, 2H), 7.59–7.53 (m, 2H), 7.34–7.28 (m, 2H), 5.84 (ddt, J = 
17.1, 10.3, 5.1 Hz, 1H), 5.12–5.01 (m, 2H), 4.84 (t, J = 6.5 Hz, 1H), 4.47 (dd, J = 10.5, 
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13C NMR (CDCl3, 126 MHz) δ 149.8, 148.1, 145.0, 134.8, 134.7, 129.4, 129.1, 128.6, 
124.4, 115.6, 58.3, 55.9, 46.0, 21.8; IR (Neat Film, NaCl) 1656, 1597, 1521, 1347, 1169, 
1107, 857, 813 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C19H20N3O4S2 [M+H]+: 




91% yield; Rf = 0.35 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.92–
7.87 (m, 2H), 7.60–7.56 (m, 1H), 7.43–7.38 (m, 1H), 7.31–7.26 (m, 4H), 5.83 (ddt, J = 
17.1, 10.3, 5.1 Hz, 1H), 5.19 (dd, J = 6.3, 5.2 Hz, 1H), 5.09–5.00 (m, 2H), 4.39 (dd, J = 
10.5, 6.3 Hz, 1H), 4.20 (dd, J = 10.5, 5.2 Hz, 1H), 3.85 (ddt, J = 15.9, 5.1, 1.8 Hz, 1H), 
3.79 (ddt, J = 15.9, 5.2, 1.8 Hz, 1H), 2.44 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 150.8, 
144.7, 135.6, 135.0, 134.9, 133.6, 130.0, 129.7, 129.3, 129.1, 128.1, 127.7, 115.3, 58.1, 
54.9, 42.8, 21.8; IR (Neat Film, NaCl) 3067, 2881, 1657, 1597, 1470, 1444, 1361, 1284, 
1171, 1109, 919, 811, 750 cm–1; HRMS (APCI+) m/z calc’d for C19H2035ClN2O2S2 
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(Z)-5-(m-chlorophenyl)-3-tosyl-2-(allylimino)thiazolidine (302): 
90% yield; Rf = 0.35 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.92–
7.86 (m, 2H), 7.37–7.34 (m, 1H), 7.33–7.25 (m, 5H), 5.83 (ddt, J = 17.1, 10.3, 5.1 Hz, 
1H), 5.09–5.00 (m, 2H), 4.74 (dd, J = 7.8, 6.3 Hz, 1H), 4.48 (dd, J = 10.4, 6.3 Hz, 1H), 
3.94 (dd, J = 10.4, 7.8 Hz, 1H), 3.85 (ddt, J = 15.9, 5.1, 1.8 Hz, 1H), 3.77 (ddt, J = 15.9, 
5.2, 1.8 Hz, 1H), 2.44 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 150.6, 144.8, 139.3, 135.0, 
134.9, 134.8, 130.5, 129.3, 129.1, 129.0, 127.8, 125.9, 115.4, 58.1, 56.4, 46.4, 21.8; IR 
(Neat Film, NaCl) 2923, 1656, 1596, 1479, 1360, 1169, 1110, 917, 812 cm–1; HRMS 




General Procedure C followed using 2.25 equivalents of zinc(II) bromide: 42% yield; Rf 
= 0.28 (1:1 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.58 (ddd, J = 4.8, 
1.8, 0.9 Hz, 1H), 7.86–7.79 (m, 2H), 7.64 (td, J = 7.7, 1.8 Hz, 1H), 7.38 (dq, J = 7.9, 0.9 
Hz, 1H), 7.26–7.21 (m, 3H), 5.98–5.93 (m, 1H), 5.85 (ddt, J = 17.2, 10.3, 5.1 Hz, 1H), 
5.10 (dq, J = 17.1, 1.8 Hz, 1H), 5.03 (dq, J = 10.3, 1.7 Hz, 1H), 3.88 (ddt, J = 15.9, 5.2, 
1.8 Hz, 1H), 3.77 (ddt, J = 15.9, 5.1, 1.8 Hz, 1H), 3.69 (dd, J = 11.0, 7.2 Hz, 1H), 3.53 
(dd, J = 11.0, 1.3 Hz, 1H), 2.43 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 158.5, 152.2, 
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21.8; IR (Neat Film, NaCl) 2921, 1655, 1638, 1590, 1352, 1169, 1110, 1088, 792 cm–1; 




47% yield; Rf = 0.34 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.94–
7.90 (m, 2H), 7.38–7.26 (m, 7H), 6.64 (dd, J = 15.6, 0.8 Hz, 1H), 6.13 (dd, J = 15.6, 8.9 
Hz, 1H), 5.82 (ddt, J = 17.1, 10.3, 5.1 Hz, 1H), 5.09–4.97 (m, 2H), 4.42 (dddd, J = 8.9, 
7.4, 6.0, 0.8 Hz, 1H), 4.34 (dd, J = 10.2, 6.0 Hz, 1H), 3.87 (dd, J = 10.2, 7.5 Hz, 1H), 
3.82 (ddt, J = 15.8, 5.1, 1.8 Hz, 1H), 3.75 (ddt, J = 15.9, 5.2, 1.8 Hz, 1H), 2.44 (s, 3H); 
13C NMR (CDCl3, 126 MHz) δ 151.2, 144.7, 135.6, 135.0, 134.9, 134.4, 129.3, 129.1, 
128.9, 128.6, 126.8, 124.6, 115.3, 58.1, 54.9, 46.2, 21.8; IR (Neat Film, NaCl) 2925, 
2254, 1645, 1452, 1353, 1259, 1168, 1090, 1019, 915, 811, 753 cm–1; HRMS (APCI+) 
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>99% yield; Rf = 0.36 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 
7.92–7.87 (m, 2H), 7.40–7.32 (m, 5H), 7.31–7.27 (m, 2H), 4.78 (dd, J = 8.4, 6.3 Hz, 1H), 
4.48 (dd, J = 10.2, 6.3 Hz, 1H), 3.91 (dd, J = 10.2, 8.4 Hz, 1H), 3.20 (dt, J = 12.6, 6.7 Hz, 
1H), 3.08 (dt, J = 12.7, 6.8 Hz, 1H), 2.44 (s, 3H), 1.50 (dddd, J = 13.5, 8.7, 6.7, 2.2 Hz, 
2H), 1.23–1.13 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 149.4, 
144.5, 137.1, 135.1, 129.1, 129.1, 129.1, 128.8, 127.7, 56.4, 56.1, 47.0, 32.9, 21.8, 20.5, 
14.0; IR (Neat Film, NaCl) 2955, 2928, 2870, 1658, 1455, 1357, 1170, 1096, 811, 765 





Thiazolidine (S)-305 was prepared according to General Procedure E: 94% yield; Rf = 
0.36 (1:4 Acetone:Hexanes eluent); characterization data match those above; [α]D 25.0      
–6.45° (c 2.800, CHCl3); enantiomeric excess was determined by analytical SFC 
(Chiralpak AD-H column, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, 
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(Z)-5-phenyl-3-tosyl-2-(cyclohexylimino)thiazolidine (306): 
94% yield; Rf = 0.41 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.95–
7.89 (m, 2H), 7.41–7.31 (m, 5H), 7.31–7.27 (m, 2H), 4.76 (dd, J = 8.5, 6.3 Hz, 1H), 4.46 
(dd, J = 10.3, 6.3 Hz, 1H), 3.87 (dd, J = 10.2, 8.5 Hz, 1H), 2.77 (tt, J = 9.5, 3.9 Hz, 1H), 
2.44 (s, 3H), 1.79–1.62 (m, 3H), 1.58 (dddd, J = 12.8, 5.9, 3.6, 1.7 Hz, 2H), 1.40 (ddtd, J 
= 22.7, 16.6, 9.5, 4.6 Hz, 2H), 1.33–1.18 (m, 3H); 13C NMR (CDCl3, 126 MHz) δ 147.2, 
144.4, 137.2, 135.0, 129.3, 129.1, 129.0, 128.7, 127.6, 65.5, 56.1, 47.0, 33.6, 33.4, 25.8, 
24.5, 24.5, 21.8; IR (Neat Film, NaCl) 2928, 2853, 1652, 1450, 1362, 1171, 1100, 812, 





Thiazolidine (S)-306 was prepared according to General Procedure E: 98% yield; Rf = 
0.41 (1:4 Acetone:Hexanes eluent); characterization data match those above; [α]D 25.0 
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(Chiralpak AS-H column, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major 




95% yield; Rf = 0.23 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.03–
7.96 (m, 2H), 7.41–7.29 (m, 7H), 7.30–7.22 (m, 2H), 7.12–7.03 (m, 1H), 6.83–6.75 (m, 
2H), 4.80 (dd, J = 8.5, 6.4 Hz, 1H), 4.60 (dd, J = 10.4, 6.4 Hz, 1H), 4.06 (dd, J = 10.4, 
8.5 Hz, 1H), 2.49 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 152.3, 150.1, 145.0, 136.6, 
134.7, 129.3, 129.2, 129.1, 129.0, 128.9, 127.6, 124.4, 120.9, 56.9, 47.1, 21.9; IR (Neat 
Film, NaCl) 3030, 1640, 1591, 1487, 1360, 1171, 1135, 1100, 763 cm–1; HRMS (APCI+) 




Thiazolidine (S)-307 was prepared according to General Procedure E: >99% yield; Rf = 
0.23 (1:4 Acetone:Hexanes eluent); characterization data match those above; [α]D 25.0 
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(Chiralpak AS-H column, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major 




98% yield; Rf = 0.31 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.03–
7.94 (m, 2H), 7.39–7.28 (m, 7H), 6.85–6.79 (m, 2H), 6.79–6.73 (m, 2H), 4.79 (dd, J = 
8.4, 6.4 Hz, 1H), 4.59 (dd, J = 10.4, 6.4 Hz, 1H), 4.05 (dd, J = 10.4, 8.5 Hz, 1H), 3.76 (s, 
3H), 2.48 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 156.6, 151.9, 144.9, 143.4, 136.7, 
134.8, 129.3, 129.2, 129.1, 128.8, 127.6, 121.9, 114.2, 56.7, 55.5, 47.0, 21.8; IR (Neat 
Film, NaCl) 2949, 1640, 1505, 1455, 1360, 1290, 1242, 1168, 1101, 1033, 910, 832, 811, 





Thiazolidine (S)-308 was prepared according to General Procedure E: 97% yield; Rf = 
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61.6° (c 2.800, CHCl3); enantiomeric excess was determined by analytical SFC 
(Chiralpak AS-H column, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major 




92% yield; Rf = 0.29 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.01–
7.93 (m, 2H), 7.39–7.30 (m, 7H), 7.25–7.18 (m, 2H), 6.76–6.70 (m, 2H), 4.81 (dd, J = 
8.4, 6.4 Hz, 1H), 4.60 (dd, J = 10.4, 6.5 Hz, 1H), 4.07 (dd, J = 10.4, 8.5 Hz, 1H), 2.48 (s, 
3H); 13C NMR (CDCl3, 126 MHz) δ 153.0, 148.5, 145.2, 136.4, 134.6, 129.7, 129.4, 
129.2, 129.2, 129.1, 129.0, 127.6, 122.3, 56.9, 47.2, 21.9; IR (Neat Film, NaCl) 2924, 
1634, 1588, 1486, 1360, 1172, 1139, 1088, 833, 812 cm–1; HRMS (APCI+) m/z calc’d 




Thiazolidine (S)-309 was prepared according to General Procedure E: 99% yield; Rf = 
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44.7° (c 4.950, CHCl3); enantiomeric excess was determined by analytical SFC 
(Chiralpak AS-H column, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major 




39% yield; Rf = 0.38 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.88–
7.83 (m, 2H), 7.42–7.31 (m, 5H), 7.30–7.26 (m, 2H), 4.79 (dd, J = 8.4, 6.2 Hz, 
1H), 4.47 (dd, J = 10.3, 6.2 Hz, 1H), 3.88 (dd, J = 10.3, 8.4 Hz, 1H), 2.44 (s, 3H), 
1.17 (s, 9H); 13C NMR (CDCl3, 126 MHz) δ 144.2, 142.9, 137.3, 135.7, 129.4, 129.1, 
128.8, 128.7, 127.7, 55.0, 54.7, 48.3, 28.9, 21.8; IR (Neat Film, NaCl) 2971, 1653, 1600, 
1496, 1454, 1360, 1167, 1092, 810, 771, 701 cm–1; HRMS (APCI+) m/z calc’d for 
C20H25N2O2S2 [M+H]+: 389.1352, found 389.1362; [α]D 25.0 3.33° (c 1.900, CHCl3); 
enantiomeric excess was determined by analytical SFC (Chiralpak IC-3 column, 30% 
isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major retention time: 6.2 minutes, 
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(Z)-5-(n-butyl)-3-tosyl-2-(allylimino)thiazolidine (311):53 
18% yield; Rf = 0.44 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.94–
7.86 (m, 2H), 7.30–7.26 (m, 2H), 5.80 (ddt, J = 17.1, 10.3, 5.1 Hz, 1H), 5.04–4.96 (m, 
2H), 4.21 (dd, J = 10.0, 5.9 Hz, 1H), 3.81–3.73 (m, 2H), 3.70 (dd, J = 10.0, 7.1 Hz, 1H), 
3.59 (ddt, J = 8.4, 7.0, 6.0 Hz, 1H), 2.42 (s, 3H), 1.82–1.70 (m, 1H), 1.71–1.60 (m, 1H), 
1.42–1.27 (m, 4H), 0.90 (td, J = 7.4, 3.7 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 151.6, 
144.5, 135.2, 130.0, 129.2, 129.0, 115.1, 58.0, 55.0, 44.0, 33.9, 30.1, 22.5, 21.8, 14.0; IR 
(Neat Film, NaCl) 2957, 2928, 2871, 1652, 1598, 1456, 1357, 1170, 1106, 918, 812 cm–1; 
HRMS (APCI+) m/z calc’d for C17H25N2O2S2 [M+H]+: 353.1352, found 353.1364. 
 
 
(Z)-4-(n-butyl)-3-tosyl-2-(allylimino)thiazolidine (312):53  
56% yield; Rf = 0.44 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.95–
7.85 (m, 2H), 7.29–7.24 (m, 2H), 5.80 (ddt, J = 17.1, 10.3, 5.2 Hz, 1H), 5.03 (dq, J = 
17.2, 1.9 Hz, 1H), 4.99 (dq, J = 10.3, 1.8 Hz, 1H), 4.82–4.74 (m, 1H), 3.81 (ddt, J = 15.9, 
5.2, 1.8 Hz, 1H), 3.70 (ddt, J = 15.9, 5.1, 1.8 Hz, 1H), 3.33 (dd, J = 11.0, 6.8 Hz, 1H), 
2.94 (dd, J = 11.1, 0.8 Hz, 1H), 2.41 (s, 3H), 1.88–1.73 (m, 2H), 1.47–1.27 (m, 4H), 0.91 
(t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 151.8, 144.2, 136.8, 135.1, 129.2, 
128.9, 115.1, 61.2, 58.2, 33.1, 32.3, 28.7, 22.5, 21.7, 14.1; IR (Neat Film, NaCl) 2957, 
2928, 2860, 1651, 1598, 1455, 1351, 1164, 1117, 1088, 918, 813 cm–1; HRMS (APCI+) 














94% yield; Rf = 0.28 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.37–
8.28 (m, 2H), 8.26–8.16 (m, 2H), 7.42–7.31 (m, 5H), 5.82 (ddt, J = 17.1, 10.4, 5.2 Hz, 
1H), 5.11–5.03 (m, 2H), 4.86 (dd, J = 8.3, 6.3 Hz, 1H), 4.54 (dd, J = 10.3, 6.3 Hz, 1H), 
3.98 (dd, J = 10.3, 8.4 Hz, 1H), 3.83 (ddt, J = 15.9, 5.2, 1.8 Hz, 1H), 3.75 (ddt, J = 15.8, 
5.3, 1.7 Hz, 1H); 13C NMR (CDCl3, 126 MHz) δ 151.1, 150.6, 143.6, 136.3, 134.6, 130.4, 
129.2, 129.1, 127.6, 123.7, 115.7, 57.9, 56.5, 47.5; IR (Neat Film, NaCl) 3106, 1656, 
1530, 1349, 1314, 1175, 1109, 854, 740 cm–1; HRMS (APCI+) m/z calc’d for 




Thiazolidine (S)-315 was prepared according to General Procedure E and was isolated as 
a white crystalline solid: 95% yield; Rf = 0.28 (1:4 Acetone:Hexanes eluent); 
characterization data match those above; colorless, translucent X-ray quality crystals 
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iminothiazolidine (S)-315 in ethyl acetate, mp: 70–72 °C; [α]D 25.0 1.7° (c 2.250, CHCl3); 
enantiomeric excess was determined by analytical SFC (Chiralcel OD-H column, 30% 
isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major retention time: 6.6 minutes, 




Thiazolidine 316 was isolated as a clear, colorless oil: 91% yield; Rf = 0.40 (3:7 
Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.46–7.31 (m, 5H), 5.97 (ddt, J 
= 17.1, 10.3, 5.2 Hz, 1H), 5.27 (dq, J = 17.1, 1.8 Hz, 1H), 5.13 (dq, J = 10.3, 1.7 Hz, 1H), 
4.84 (dd, J = 8.6, 6.3 Hz, 1H), 4.41 (dd, J = 10.4, 6.3 Hz, 1H), 3.99–3.90 (m, 3H), 3.38 
(s, 3H); 13C NMR (CDCl3, 126 MHz) δ 153.0, 136.6, 134.9, 129.2, 129.0, 127.7, 115.8, 
58.1, 55.6, 47.6, 40.5; IR (Neat Film, NaCl) 3011, 1656, 1651, 1346, 1163, 1113, 964, 
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Thiazolidine (S)-316 was prepared according to General Procedure E and was isolated as 
a clear, colorless oil: 95% yield; Rf = 0.40 (3:7 Acetone:Hexanes eluent); characterization 
data match those reported above; [α]D 25.0 –55.5° (c 2.200, CHCl3); enantiomeric excess 
was determined by analytical SFC (Chiralpak AD-H column, 7% isopropyl alcohol in 
CO2, 2.5 mL/min, λ = 254 nm, major retention time: 12.6 minutes, minor retention time: 




90% yield; Rf = 0.40 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.01–
7.93 (m, 2H), 7.42–7.29 (m, 5H), 6.98–6.93 (m, 2H), 5.85 (ddt, J = 17.1, 10.3, 5.2 Hz, 
1H), 5.08 (dq, J = 17.1, 1.8 Hz, 1H), 5.03 (dq, J = 10.3, 1.7 Hz, 1H), 4.79 (dd, J = 8.4, 
6.3 Hz, 1H), 4.49 (dd, J = 10.3, 6.3 Hz, 1H), 3.92 (dd, J = 10.3, 8.4 Hz, 1H), 3.88 (s, 3H), 
3.88–3.83 (m, 1H), 3.77 (ddt, J = 15.9, 5.2, 1.8 Hz, 1H); 13C NMR (CDCl3, 126 MHz) 
δ 163.8, 151.3, 136.9, 135.1, 131.4, 129.5, 129.2, 128.8, 127.7, 115.3, 113.8, 58.1, 56.6, 
55.8, 47.1; IR (Neat Film, NaCl) 2927, 1655, 1595, 1497, 1356, 1262, 1162, 1110, 1090, 
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(S,Z)-5-phenyl-3-(p-methoxybenzenesulfonyl)-2-(allylimino)thiazolidine ((S)-317): 
Thiazolidine (S)-317 was prepared according to General Procedure E: 94% yield; Rf = 
0.40 (3:7 Acetone:Hexanes eluent); characterization data match those reported above; 
[α]D 25.0 –6.6° (c 2.000, CHCl3); enantiomeric excess was determined by analytical SFC 
(Chiralpak AD-H column, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, 




75% yield; Rf = 0.19 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.40–
7.36 (m, 2H), 7.35–7.30 (m, 2H), 7.29–7.26 (m, 1H), 5.94 (ddt, J = 17.2, 10.2, 5.5 Hz, 
1H), 5.27 (dq, J = 17.1, 1.6 Hz, 1H), 5.18 (dq, J = 10.3, 1.4 Hz, 1H), 5.02 (dd, J = 7.8, 
6.3 Hz, 1H), 4.34 (dd, J = 13.4, 7.8 Hz, 1H), 4.10 (dd, J = 13.4, 6.3 Hz, 1H), 3.97 (dt, J = 
5.5, 1.6 Hz, 2H); 13C NMR (CDCl3, 126 MHz) δ 160.7, 141.3, 134.5, 128.9, 127.9, 127.4, 
116.6, 68.4, 56.7, 47.3; IR (Neat Film, NaCl) 2924, 2853, 1612, 1454, 1260, 1023, 802, 
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(S,Z)-5-phenyl-2-(allylimino)thiazolidine ((S)-318): 
Thiazolidine (S)-318 was prepared according to General Procedure E: 31% yield; Rf = 
0.19 (3:7 Acetone:Hexanes eluent); characterization data match those reported above; 
[α]D 25.0 26.4° (c 0.200, CHCl3); enantiomeric excess was determined by analytical SFC 
(Chiralcel OB-H column, 10% methanol in CO2, 2.5 mL/min, λ = 254 nm, major 
retention time: 3.9 minutes, minor retention time: 8.4 minutes, 34% ee). 
 
 
cis-methyl (Z)-5-phenyl-3-tosyl-2-(allylimino)thiazolidine-4-carboxylate (329): 
Thiazolidine 329 was isolated as a white crystalline solid and colorless, translucent X-ray 
quality crystals were obtained by slow diffusion of 1% benzene in heptane into a solution 
of iminothiazolidine 329 in ethyl acetate, mp: 107–109 °C: 88% yield; Rf = 0.32 (3:7 
Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.96–7.90 (m, 2H), 7.38–7.31 
(m, 5H), 7.30–7.25 (m, 2H), 5.86 (ddt, J = 17.1, 10.3, 4.9 Hz, 1H), 5.33 (d, J = 8.0 Hz, 
1H), 5.26 (d, J = 8.0 Hz, 1H), 5.07 (dq, J = 17.1, 1.9 Hz, 1H), 5.03 (dq, J = 10.4, 1.8 Hz, 
1H), 3.91 (ddt, J = 16.1, 4.9, 1.8 Hz, 1H), 3.83 (ddt, J = 16.1, 4.8, 1.9 Hz, 1H), 3.25 (s, 
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132.9, 129.7, 129.3, 128.9, 128.8, 128.4, 115.1, 65.7, 57.9, 52.1, 49.8, 21.8; IR (Neat 
Film, NaCl) 2952, 2253, 1748, 1660, 1595, 1444, 1353, 1166, 1107, 915, 811 cm–1; 






62% yield; Rf = 0.43 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.93–
7.87 (m, 2H), 7.36–7.27 (m, 5H), 7.26–7.23 (m, 2H), 6.60 (dd, J = 15.6, 7.4 Hz, 1H), 
5.88 (ddt, J = 17.1, 10.2, 5.0 Hz, 1H), 5.80 (dd, J = 15.7, 1.1 Hz, 1H), 5.42 (ddd, J = 7.5, 
6.5, 1.1 Hz, 1H), 5.22 (d, J = 6.5 Hz, 1H), 5.11 (dq, J = 17.1, 1.9 Hz, 1H), 5.06 (dq, J = 
10.3, 1.7 Hz, 1H), 3.90 (ddt, J = 16.0, 4.9, 1.8 Hz, 1H), 3.84 (ddt, J = 16.0, 5.1, 1.8 Hz, 
1H), 3.66 (s, 3H), 2.42 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 165.6, 149.6, 144.7, 
140.3, 135.9, 134.9, 132.2, 129.6, 129.2, 129.1, 129.0, 128.7, 125.8, 115.4, 65.3, 58.1, 
52.8, 51.9, 21.8; IR (Neat Film, NaCl) 2951, 1726, 1659, 1436, 1360, 1276, 1168, 1109, 




















42% yield; Rf = 0.39 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.98–
7.93 (m, 2H), 7.34 (m, 4H), 7.32–7.27 (m, 1H), 7.25–7.20 (m, 2H), 6.62 (dd, J = 15.7, 
0.9 Hz, 1H), 6.22 (dd, J = 15.6, 8.5 Hz, 1H), 5.84 (ddt, J = 17.1, 10.1, 4.9 Hz, 1H), 5.20 
(d, J = 1.7 Hz, 1H), 5.07–4.99 (m, 2H), 4.57 (ddd, J = 8.5, 1.8, 1.0 Hz, 1H), 3.82 (ddd, J 
= 5.1, 3.5, 1.8 Hz, 2H), 3.80 (s, 3H), 2.41 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 169.4, 
149.2, 144.6, 135.7, 135.5, 134.8, 133.2, 129.7, 128.9, 128.8, 128.6, 126.9, 125.9, 115.2, 
66.9, 58.0, 53.4, 48.3, 21.8; IR (Neat Film, NaCl) 2954, 1756, 1661, 1597, 1495, 1435, 
1354, 1167, 1113, 1089, 916, 813, 781, 754 cm–1; HRMS (APCI+) m/z calc’d for 
C23H25N2O4S2 [M+H]+: 457.1250, found 457.1252. 
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31% yield; Rf = 0.39 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.97–
7.92 (m, 2H), 7.36–7.27 (m, 7H), 6.66 (dd, J = 15.6, 0.9 Hz, 1H), 6.00 (dd, J = 15.5, 9.1 
Hz, 1H), 5.84 (ddt, J = 17.1, 10.3, 4.9 Hz, 1H), 5.27 (d, J = 7.6 Hz, 1H), 5.09–4.98 (m, 
2H), 4.80 (ddd, J = 9.1, 7.6, 0.9 Hz, 1H), 3.85 (ddt, J = 16.1, 4.9, 1.9 Hz, 1H), 3.80 (ddt, 
J = 16.1, 4.8, 1.9 Hz, 1H), 3.68 (s, 3H), 2.43 (s, 3H); 13C NMR (CDCl3, 126 MHz) 
δ 168.2, 150.2, 144.7, 135.7, 135.5, 135.5, 134.8, 129.7, 129.0, 128.9, 128.8, 126.9, 
121.2, 115.2, 64.5, 58.0, 52.6, 48.3, 21.8; IR (Neat Film, NaCl) 2952, 1750, 1661, 1597, 
1495, 1450, 1354, 1206, 1169, 1121, 1089, 966, 916, 841, 813, 751 cm–1; HRMS 
(APCI+) m/z calc’d for C23H25N2O4S2 [M+H]+: 457.1250, found 457.1253. 
 
3.7.5   IMINOIMIDAZOLIDINE SYNTHESIS AND CHARACTERIZATION 
DATA 
Unless otherwise stated, all iminothiazolidines were prepared according to General 




Product was initially prepared according to General Procedure D, isolating the product as 
a salt after column chromatography (2%→5% CH3OH in CH2Cl2eluent). The resulting 
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10 mL).  The organic layer was dried over sodium sulfate, filtered, and concentrated in 
vacuo to give imidazolidine 323 (88 mg, 55% yield) as a colorless oil. 
 
 
For the purpose of characterization, to a portion of iminoimidazolidine 323 (ca. 0.20 
mmol) as a neat oil was added 4 N HCl in dioxane (3 mL) immediately followed by Et2O 
(40 mL) causing a white precipitate to form. The supernatant was decanted and the 
residual white solid was washed with Et2O (3 x 10 mL) and dried in vacuo furnishing 
iminoimidazolidinium hydrochloride 323•HCl as a white solid: Rf = 0.39 (1:9 
CH3OH:CH2Cl2 eluent); 1H NMR (CDCl3, 500 MHz) δ 10.95 (bs, 1H), 7.69–7.59 (m, 
2H), 7.30–7.24 (m, 3H), 7.18 (dd, J = 8.2, 6.9 Hz, 2H), 6.96–6.85 (m, 2H), 5.52–5.32 (m, 
1H), 4.82–4.75 (m, 1H), 4.48–4.26 (m, 2H), 4.03 (dd, J = 12.0, 3.0 Hz, 1H), 2.46 (s, 3H), 
1.70 (d, J = 6.4 Hz, 3H), 1.51 (d, J = 6.4 Hz, 3H), 1.28–1.21 (m, 3H), 0.95 (d, J = 6.5 Hz, 
3H); 13C NMR (CDCl3, 126 MHz) δ 154.7, 146.9, 137.9, 133.7, 130.8, 129.3, 128.8, 
127.7, 125.9, 57.0, 56.1, 54.0, 51.3, 24.3, 22.2, 21.9, 21.3, 20.8; IR (Neat Film, NaCl) 
2972, 1636, 1457, 1435, 1367, 1260, 1172, 1088, 1036, 907, 814, 729 cm–1; HRMS 





















4 N HCl in dioxane
Cl
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4-phenyl-1-tosyl-2-iminoimidazolidine (324): 
Prepared according to General Procedure D followed by purification by column 
chromatography using deactivated silica gel (1% Me2NEt and 1% MeOH in CH2Cl2 
eluent): 61% yield; Rf = 0.41 (1:9 CH3OH:CH2Cl2 eluent); 1H NMR (DMSO-d6, 500 
MHz) δ 7.86–7.79 (m, 2H), 7.46 (dd, J = 8.4, 0.9 Hz, 2H), 7.21–7.16 (m, 3H), 6.92 (dd, J 
= 6.7, 2.9 Hz, 2H), 4.77 (dd, J = 9.2, 6.5 Hz, 1H), 4.14 (t, J = 9.6 Hz, 1H), 3.35 (bs, 2H), 
3.26 (dd, J = 9.9, 6.5 Hz, 1H), 2.43 (s, 3H); 13C NMR (DMSO-d6, 126 MHz) δ 151.2, 
145.0, 143.6, 132.9, 130.1, 128.2, 127.5, 126.9, 125.9, 61.4, 55.2, 21.1; IR (Neat Film, 
NaCl) 3445, 2920, 1683, 1397, 1350, 1161, 1091, 1002 cm–1; HRMS (APCI+) m/z calc’d 




96% yield; Rf = 0.22 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.03–
7.96 (m, 2H), 7.37–7.28 (m, 5H), 7.24–7.15 (m, 2H), 6.82–6.73 (m, 5H), 6.60–6.48 (m, 
3H), 6.42–6.34 (m, 2H), 4.77 (dd, J = 8.2, 5.7 Hz, 1H), 4.45 (dd, J = 9.9, 8.2 Hz, 1H), 
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143.4, 139.9, 139.8, 135.0, 129.4, 129.3, 129.2, 128.8, 128.3, 127.8, 126.9, 125.8, 125.6, 
121.9, 121.4, 64.9, 52.5, 21.9; IR (Neat Film, NaCl) 3027, 2924, 1667, 1593, 1488, 1354, 
1166, 1089, 813, 759 cm–1; HRMS (APCI+) m/z calc’d for C28H26N3O2S [M+H]+: 




99% yield; Rf = 0.28 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.03–
7.96 (m, 2H), 7.37–7.29 (m, 2H), 7.22–7.18 (m, 2H), 7.08–7.02 (m, 2H), 6.82–6.75 (m, 
5H), 6.61–6.55 (m, 1H), 6.55–6.52 (m, 2H), 6.41–6.36 (m, 2H), 4.80 (dd, J = 8.1, 5.7 Hz, 
1H), 4.44 (dd, J = 9.9, 8.1 Hz, 1H), 3.92 (dd, J = 9.9, 5.7 Hz, 1H), 2.48 (s, 3H), 2.30 (s, 
3H); 13C NMR (CDCl3, 126 MHz) δ 169.4, 150.9, 146.1, 144.8, 143.5, 139.6, 137.2, 
134.7, 129.4, 129.3, 128.4, 128.0, 127.9, 126.0, 125.7, 122.5, 122.0, 121.6, 64.4, 52.4, 
21.9, 21.3; IR (Neat Film, NaCl) 3057, 2928, 1760, 1670, 1591, 1495, 1367, 1211, 1167, 
1113, 1090, 1017, 911, 813, 763, 734 cm–1; HRMS (APCI+) m/z calc’d for C30H28N3O4S 
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(E)-4-(p-chlorophenyl)-3-phenyl-1-tosyl-2-(phenylimino)imidazolidine (327): 
87% yield; Rf = 0.19 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.03–
7.95 (m, 2H), 7.35–7.31 (m, 2H), 7.30–7.27 (m, 2H), 7.16–7.12 (m, 2H), 6.83–6.75 (m, 
5H), 6.61–6.56 (m, 1H), 6.53 (dd, J = 6.8, 2.9 Hz, 2H), 6.42–6.35 (m, 2H), 4.79 (dd, J = 
8.1, 5.6 Hz, 1H), 4.44 (dd, J = 9.9, 8.1 Hz, 1H), 3.90 (dd, J = 9.9, 5.6 Hz, 1H), 2.49 (s, 
3H); 13C NMR (CDCl3, 126 MHz) δ 146.0, 144.8, 143.4, 139.4, 138.2, 134.7, 134.6, 
129.4, 129.4, 129.2, 128.4, 128.3, 127.9, 126.1, 125.7, 122.0, 121.7, 64.3, 52.3, 21.9; IR 
(Neat Film, NaCl) 3062, 1668, 1591, 1492, 1360, 1213, 1167, 1090, 1014, 910, 813, 761, 





Product was initially prepared according to General Procedure D, isolating the product as 
the H(ZnBr3•MeOH) salt after column chromatography (2%→5% MeOH in CH2Cl2 
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translucent X-ray quality crystals after slow evaporation from a solution of 374 in MeOH, 
mp: 118–120 °C. 
 
 
The remaining portion of the white foam was dissolved in 20 mL CH2Cl2 and washed 
with aqueous 0.1 N NaOH (3 x 10 mL).  The organic layer was dried over sodium sulfate, 
filtered, and concentrated in vacuo to give iminoimidazolidine 374 as a colorless oil. 
To neat 374 was then added 4 N HCl in dioxane (3 mL) immediately followed by 
Et2O (40 mL). The organics were then concentrated in vacuo to furnish 
iminoimidazolidinium hydrochloride 374•HCl as a white foam: Rf = 0.41 (1:9 
MeOH:CH2Cl2 eluent); 1H NMR (CDCl3, 500 MHz) δ  10.98 (bs, 1H), 7.88 (d, J = 7.2 
Hz, 2H), 7.52 (d, J = 7.1 Hz, 2H), 6.83 (s, 1H), 6.79 (s, 1H), 5.16 (bs, 1H), 4.56 (bs, 2H), 
4.28 (bs, 1H), 3.92–3.81 (m, 1H), 2.52 (s, 3H), 2.23 (s, 3H), 2.20 (s, 3H), 2.03 (s, 3H), 
1.72 (d, J = 6.0 Hz, 3H), 1.54 (d, J = 6.0 Hz, 3H), 0.94–0.80 (m, 6H); 13C NMR (CDCl3, 
126 MHz) δ 155.1, 147.5, 139.7, 136.7, 136.2, 133.4, 132.6, 131.1, 130.5, 128.2, 127.8, 
56.0, 54.9, 51.9, 50.9, 24.7, 22.0, 21.8, 20.9, 20.5, 20.5, 20.4, 19.7; IR (Neat Film, NaCl) 
2925, 1640, 1441, 1366, 1276, 1171, 1089, 815 cm–1; HRMS (APCI+) m/z calc’d for 
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3.7.6   PREPARATION OF THIOXOIMIDAZOLIDINE 343 
 
Imidazolidine 343 was prepared from diester aziridine 342 according to two procedures: 
Initially, imidazolidine 343 was prepared according to General Procedure C. The 
reaction mixture was an intensely neon orange-red color throughout the duration of the 
reaction (ca. 11 h). Upon purification of the reaction mixture by silica gel column 
chromatography (20% acetone in hexanes eluent), imidazolidine 343 (70 mg, 36% yield) 
and cis-oxazolidine 375 (48 mg, 24% yield) were both isolated as white crystalline solids. 
Suspecting the formation of cis-oxazolidine 375 was a result of partial hydrolysis of 
the ion-paired intermediate during the course of the reaction, imidazolidine 343 was 
subsequently prepared according to General Procedure C in the anhydrous environment 
of an inert atmosphere glovebox. The reaction mixture was an intensely neon orange-red 
color throughout the duration of the reaction (ca. 12 h) under these conditions as well. 
Upon purification of the reaction mixture by silica gel column chromatography (20% 
acetone in hexanes eluent), imidazolidine 343 (116 mg, 60% yield) was isolated in the 
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dimethyl 3-allyl-2-phenyl-4-thioxo-1-tosyl-imidazolidine-5,5-dicarboxylate (343): 
Colorless, translucent X-ray quality crystals of imidazolidine 343 were obtained by slow 
diffusion of 1% benzene in heptane into a solution of imidazolidine 343 in ethyl acetate, 
mp: 147–150 °C: Rf = 0.41 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 300 MHz) δ 
7.42–7.15 (m, 5H), 7.05–6.95 (m, 2H), 6.94–6.86 (m, 2H), 6.39 (s, 1H), 5.63 (dddd, J = 
17.4, 10.3, 7.3, 4.3 Hz, 1H), 5.24 (ddt, J = 10.3, 1.8, 1.0 Hz, 1H), 5.10 (ddt, J = 17.2, 2.1, 
1.2 Hz, 1H), 4.87–4.70 (m, 1H), 3.96 (s, 3H), 3.86 (s, 3H), 3.25 (ddt, J = 15.4, 7.4, 1.1 
Hz, 1H), 2.28 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 186.5, 164.9, 164.3, 143.9, 136.7, 
133.3, 130.6, 129.5, 129.0, 128.8, 128.3, 127.8, 120.1, 82.4, 82.3, 54.1, 53.9, 47.6, 21.6; 
IR (Neat Film, NaCl) 2952, 1794, 1771, 1489, 1354, 1257, 1162, 1090, 1061, 913, 850, 
810, 777, 731 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C23H25N2O6S2 [M+H]+: 
489.1149, found 489.1164. 
 
 
cis-dimethyl 2,5-diphenyl-3-tosyloxazolidine-4,4-dicarboxylate (375): 
Colorless, translucent X-ray quality crystals of cis-oxazolidine 375 were obtained by 
slow evaporation of a solution of cis-oxazolidine 375 in ethyl acetate, mp: 145–147 °C: 
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Imidazolidine (S)-325 was prepared according to General Procedure E using 
diphenylcarbodiimide (79 mg, 0.41 mmol, 1.02 equiv) in place of isothiocyanate:57 96% 
yield; Rf = 0.22 (1:4 Acetone:Hexanes eluent); characterization data match those reported 
above; [α]D 25.0 46.6° (c 0.550, CHCl3); enantiomeric excess was determined by 
analytical SFC (Chiralpak AS-H column, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 
254 nm, major retention time: 9.6 minutes, minor retention time: 7.0 minutes, 10% ee). 
 




Sulfonamide 376 was prepared by General Procedure C from aziridine 373: 65% 
combined yield as a 2:1 Z:E ratio of products as an amorphous white solid; Rf = 0.15 (1:4 
Acetone:Hexanes eluent); 1H and 13C NMR spectra match those reported in the 














                       
ZnCl2 (1.25 equiv)
CH2Cl2, 23 °C
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1161, 1096, 904, 817, 761 cm–1; HRMS (ESI+) m/z calc’d for C16H18NO2S [M+H]+: 




Bromide 377 was isolated as a byproduct of the reaction of aziridine 355 under the 
reaction conditions specified in General Procedure C: 35% yield as an amorphous white 
solid; Rf = 0.15 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 8.24–8.14 
(m, 2H), 7.75–7.67 (m, 2H), 7.53–7.46 (m, 2H), 7.35–7.29 (m, 2H), 5.02 (t, J = 7.1 Hz, 
1H), 4.83 (dd, J = 7.4, 5.9 Hz, 1H), 3.64–3.50 (m, 2H), 2.45 (s, 3H); 13C NMR (CDCl3, 
126 MHz) δ 148.1, 145.3, 144.3, 136.8, 130.1, 129.0, 127.1, 124.3, 50.5, 50.1, 21.7; IR 
(Neat Film, NaCl) 3278, 1598, 1522, 1423, 1346, 1157, 1092, 855, 814 cm–1; HRMS 
(FAB+) m/z calc’d for C15H1481BrN2O4S [(M–H2)+H]+: 398.9837, found 398.9834. 
 
3.7.9   DEPROTECTION OF IMINOTHIAZOLIDINES (S)-292 and (S)-315 
!
Procedure for the desulfonylation of thiazolidine (S)-292 was adapted from the 
literature.30 Iminothiazolidine (S)-292 (50 mg, 0.13 mmol, 1.00 equiv) was suspended in 
























sealed vial, 30 min
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until a homogeneous solution was formed.  Magnesium turnings (49 mg, 2.01 mmol, 15 
equiv) were then added and the vial was sealed.  The reaction mixture was stirred at 70 
°C. Upon consumption of starting material (determined by LCMS analysis, ca. 30 min), 
the reaction mixture was allowed to cool to room temperature and filtered through Celite, 
washing with CH2Cl2 (20 mL) and CH3OH (20 mL).  The filtrate was adsorbed onto 
Celite and purified by silica gel column chromatography (30% acetone and 1% Et3N in 
hexanes) to give iminothiazolidine (S)-318 (26 mg, 91% yield) as a white amorphous 
solid; characterization data match those reported above; [α]D 25.0 –61.2° (c 0.23, CHCl3); 
enantiomeric excess was determined by analytical SFC (Chiralcel OB-H column, 10% 
methanol in CO2, 2.5 mL/min, λ = 254 nm, major retention time: 3.9 minutes, minor 
retention time: 8.4 minutes, 94% ee). 
 
 
Procedure for the desulfonylation of thiazolidine (S)-315 was adapted from the 
literature.31a  To a solution of iminothiazolidine (S)-315 (120 mg, 0.30 mmol, 1.00 equiv, 
95% ee) and p-methoxythiophenol (110 µL, 0.89 mmol, 3.00 equiv) in acetonitrile (1.96 
mL) was added DMSO (40 µL), followed by potassium carbonate (164 mg, 1.18 mmol, 
4.00 equiv).  The vial was loosely capped and the heterogeneous mixture was stirred at 
room temperature until the reaction was complete (determined by TLC analysis, ca. 3 h).  
The reaction mixture was concentrated and the residue partitioned between ethyl acetate 
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sulfate, filtered, and concentrated in vacuo.  The crude residue was purified by silica gel 
column chromatography (30% acetone and 1% Et3N in hexanes eluent) to give 
iminothiazolidine (S)-318 (60 mg, 93% yield) as a white amorphous solid; 
characterization data match those reported above; [α]D 25.0 –61.2° (c 0.23, CHCl3); 
enantiomeric excess was determined by analytical SFC (Chiralcel OB-H column, 10% 
methanol in CO2, 2.5 mL/min, λ = 254 nm, major retention time: 3.9 minutes, minor 
retention time: 8.4 minutes, 94% ee). 
 
 
Procedure for the deallylation of thiazolidine (S)-292 was adapted from the 
literature.60 To a solution of iminothiazolidine (S)-292 (25 mg, 0.067 mmol, 1.00 equiv) 
in dichloroethane (750 µL) in an oven dried vial with a stir bar were added 
tetrakis(triphenylphosphine)palladium(0) (39 mg, 0.034 mmol, 0.50 equiv) and 1,3-
dimethylbarbituric acid (157 mg, 1.01 mmol, 15.0 equiv).  The vial was sealed and stirred 
at 70 °C until the reaction was complete (determined by LCMS analysis, ca. 1.5 h).  The 
reaction mixture was diluted with CH2Cl2, adsorbed onto Celite, and purified by silica gel 
column chromatography (10% acetone and 1% Et3N in hexanes) to give 
iminothiazolidine (S)-344 (20 mg, 89% yield) as a white amorphous solid; Rf = 0.30 (3:7 
Acetone:Hexanes eluent); 1H NMR (CD2Cl2, 500 MHz) δ 7.83–7.78 (m, 2H), 7.38–7.34 
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(dd, J = 10.5, 7.6 Hz, 1H), 2.46 (s, 3H); 13C NMR (CD2Cl2, 126 MHz) δ 160.3, 145.9, 
137.3, 130.4, 129.8, 129.4, 129.0, 128.1, 127.8, 58.8, 21.8; IR (Neat Film, NaCl) 3311, 
3031, 2922, 1622, 1597, 1494, 1454, 1358, 1168, 1089, 1054, 814 cm–1; HRMS (MM: 
ESI-APCI) m/z calc’d for C16H17N2O2S2 [M+H]+: 333.0726, found 333.0736; [α]D 25.0 –
10.0° (c 0.1, CHCl3); enantiomeric excess was determined by analytical SFC (Chiralpak 
AD-H column, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major retention 
time: 7.3 minutes, minor retention time: 8.4 minutes, 39% ee). 
 
3.7.10  EXPERIMENTAL PROCEDURES FOR CONTROL REACTIONS61 
3.7.10.1 Reaction in the Absence of Lewis Acid 
 
To an oven-dried 1-dram vial equipped with a magnetic stir bar were added (R)-N-tosyl-
2-phenylaziridine ((R)-291, 109 mg, 0.40 mmol, 1.00 equiv, >99% ee) and allyl 
isothiocyanate (79 µL, 0.80 mmol, 2.00 equiv). The vial was sealed with a screw cap 
fitted with a Teflon septum, placed under an inert atmosphere, and dissolved in 
anhydrous dichloromethane (0.80 mL). The heterogeneous reaction mixture was then 
allowed to stir at ambient temperature. Over the course of 96 hours, no formation of 
thiazolidine (S)-292 was observed. At 96 hours, the enantiomeric excess of the remaining 
aziridine (R)-291 was determined by analytical SFC (Chiralcel OB-H column, 10% 
isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 nm, major retention time: 7.5 minutes, 
minor retention time: 10.2 minutes, >99% ee). 
Ph
Ts















Chapter 3 – (3+2) Cycloadditions of Aziridines with Heterocumulenes  318
3.7.10.2  Isomerization of Disubstituted Aziridine 333 
 
To an oven-dried 1-dram vial equipped with a magnetic stir bar was added zinc(II) 
bromide (25 mg, 0.113 mmol, 1.25 equiv), freshly powdered with a mortar and pestle, in 
an inert atmosphere glovebox. The vial was sealed with a screw cap fitted with a Teflon 
septum, removed from the glovebox and placed under an inert atmosphere. To a separate, 
oven-dried 1-dram vial was added cis-aziridine 333 (32 mg, 0.090 mmol, 1.00 equiv). 
The vial was sealed with a screw cap fitted with a Teflon septum, and the mixture was 
transferred to the first vial as a solution in anhydrous dichloromethane (0.15 mL + 0.05 
mL rinse). The heterogeneous reaction mixture was then allowed to stir at ambient 
temperature. Upon consumption of starting material (determined by LCMS, ca. 30 min), 
the reaction mixture directly purified by silica gel column chromatography (20% acetone 
in hexanes eluent) to furnish trans-pyrroline 336 (12 mg, 38% yield) and cis-pyrroline 
337 (2 mg, 6% yield) as white amorphous solids.  
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Rf = 0.38 (3:7 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 7.21–7.16 (m, 1H), 
7.12–7.05 (m, 4H), 7.00–6.96 (m, 2H), 6.95–6.90 (m, 2H), 5.87 (dt, J = 6.2, 1.6 Hz, 1H), 
5.84 (dt, J = 6.2, 1.8 Hz, 1H), 5.76 (dt, J = 6.2, 1.6 Hz, 1H), 5.18 (dt, J = 5.7, 1.7 Hz, 
1H), 3.86 (s, 3H), 2.30 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 171.2, 142.6, 137.9, 
136.9, 134.7, 129.0, 128.9, 128.4, 128.3, 126.8, 124.0, 70.5, 69.3, 53.0, 21.5; IR (Neat 
Film, NaCl) 2953, 1747, 1598, 1456, 1343, 1262, 1200, 1158, 1100, 1018, 813, 763 cm–1; 




methyl cis-5-phenyl-1-tosyl-3-pyrroline-2-carboxylate (337): 
Rf = 0.47 (3:7 EtOAc:Hexanes eluent); characterization data match those reported in the 
literature.62 
 
3.7.10.3 Isomerization of Disubstituted Aziridine 330 
 
To an oven-dried 1-dram vial equipped with a magnetic stir bar was added zinc(II) 






























 ZnBr2 (1.25 equiv) 
CH2Cl2, 23 °C
336 337
not observed not observed
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an inert atmosphere glovebox. The vial was sealed with a screw cap fitted with a Teflon 
septum, removed from the glovebox and placed under an inert atmosphere. To a separate, 
oven-dried 1-dram vial was added trans-aziridine 330 (21 mg, 0.059 mmol, 1.00 equiv). 
The vial was sealed with a screw cap fitted with a Teflon septum, and the mixture was 
transferred to the first vial as a solution in anhydrous dichloromethane (0.15 mL + 0.05 
mL rinse). The heterogeneous reaction mixture was then allowed to stir at ambient 
temperature. The slow decomposition of aziridine 330 was complete after 96 h 
(determined by LCMS) and was characterized by the formation of no major products 
including neither trans-pyrroline 336 nor cis-pyrroline 337.63 
 
3.7.10.4 Racemization of Aziridine Starting Material (R)-291 
 
To an oven-dried 1-dram vial equipped with a magnetic stir bar was added zinc(II) 
bromide (113 mg, 0.50 mmol, 1.25 equiv), freshly powdered with a mortar and pestle, in 
an inert atmosphere glovebox. The vial was sealed with a screw cap fitted with a Teflon 
septum, removed from the glovebox and placed under an inert atmosphere. To a separate, 
oven-dried 1-dram vial was added N-tosyl-2-phenylaziridine ((R)-291, 109 mg, 0.40 
mmol, 1.00 equiv). The vial was sealed with a screw cap fitted with a Teflon septum, and 
the mixture was transferred to the first vial as a solution in anhydrous dichloromethane 
(0.60 mL + 0.20 mL rinse). The heterogeneous reaction mixture was then allowed to stir 
at ambient temperature. Racemization of the aziridine was complete after 10 minutes as 
determined by analytical SFC (Chiralcel OB-H column, 10% isopropyl alcohol in CO2, 
Ph
Ts
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2.5 mL/min, λ = 254 nm, major retention time: 7.5 minutes, minor retention time: 10.2 
minutes). 
 
3.7.10.5 Racemization of Product (S)-292 
 
To an oven-dried 1-dram vial equipped with a magnetic stir bar was added zinc(II) 
bromide (31 mg, 0.14 mmol, 1.25 equiv), freshly powdered with a mortar and pestle, in 
an inert atmosphere glovebox. The vial was sealed with a screw cap fitted with a Teflon 
septum, removed from the glovebox and placed under an inert atmosphere. To a separate, 
oven-dried 1-dram vial were added the iminothiazolidine (S)-292 (40 mg, 0.11 mmol, 
1.00 equiv, 94% ee) and allyl isothiocyanate (22 µL, 0.22 mmol, 2.00 equiv). The vial 
was sealed with a screw cap fitted with a Teflon septum, and the mixture was transferred 
to the first vial as a solution in anhydrous dichloromethane (0.15 mL + 0.10 mL rinse). 
The heterogeneous reaction mixture was then allowed to stir at ambient temperature. 
After 96 hours, the enantiomeric excess of thiazolidine (S)-292 was determined by 
analytical SFC (Chiralpak AD-H, 30% isopropyl alcohol in CO2, 2.5 mL/min, λ = 254 



















94% ee 94% ee
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3.7.10.6 Isomerization of trans-Disubstituted Thiazolidine 334 
 
To an oven-dried 1-dram vial equipped with a magnetic stir bar was added zinc(II) 
bromide (10 mg, 0.044 mmol, 1.25 equiv), freshly powdered with a mortar and pestle, in 
an inert atmosphere glovebox. The vial was sealed with a screw cap fitted with a Teflon 
septum, removed from the glovebox and placed under an inert atmosphere. To a separate, 
oven-dried 1-dram vial were added the trans-iminothiazolidine 334 (16 mg, 0.035 mmol, 
1.00 equiv) and allyl isothiocyanate (7 µL, 0.070 mmol, 2.00 equiv). The vial was sealed 
with a screw cap fitted with a Teflon septum, and the mixture was transferred to the first 
vial as a solution in anhydrous dichloromethane (0.10 mL + 0.05 mL rinse). The 
heterogeneous reaction mixture was then allowed to stir at ambient temperature. Over the 
course of 96 hours, no decomposition of trans-iminothiazolidine 334 or isomerization of 
trans-iminothiazolidine 334 to cis-iminothiazolidine 335 was observed (determined by 
LCMS). 
 
3.7.10.7 Isomerization of cis-Disubstituted Thiazolidine 335 
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To an oven-dried 1-dram vial equipped with a magnetic stir bar was added zinc(II) 
bromide (10 mg, 0.044 mmol, 1.25 equiv), freshly powdered with a mortar and pestle, in 
an inert atmosphere glovebox. The vial was sealed with a screw cap fitted with a Teflon 
septum, removed from the glovebox and placed under an inert atmosphere. To a separate, 
oven-dried 1-dram vial were added the cis-iminothiazolidine 335 (16 mg, 0.035 mmol, 
1.00 equiv) and allyl isothiocyanate (7 µL, 0.070 mmol, 2.00 equiv). The vial was sealed 
with a screw cap fitted with a Teflon septum, and the mixture was transferred to the first 
vial as a solution in anhydrous dichloromethane (0.10 mL + 0.05 mL rinse). The 
heterogeneous reaction mixture was then allowed to stir at ambient temperature. Over the 
course of 96 hours, no decomposition of cis-iminothiazolidine 335 or isomerization of 
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Figure A5.2 Infrared spectrum (thin film/NaCl) of compound 356. 
 
Figure A5.3 13C NMR (126 MHz, CDCl3) of compound 356. 
 











































































































Figure A5.5 Infrared spectrum (thin film/NaCl) of compound 358. 
 
Figure A5.6 13C NMR (126 MHz, CDCl3) of compound 358. 
 













































































































Figure A5.8 Infrared spectrum (thin film/NaCl) of compound 360. 
 
Figure A5.9 13C NMR (126 MHz, CDCl3) of compound 360. 
 













































































































Figure A5.11 Infrared spectrum (thin film/NaCl) of compound 362. 
 
Figure A5.12 13C NMR (126 MHz, CDCl3) of compound 362. 
 












































































































Figure A5.14 Infrared spectrum (thin film/NaCl) of compound 368. 
 
Figure A5.15 13C NMR (126 MHz, CDCl3) of compound 368. 
 











































































































Figure A5.17 Infrared spectrum (thin film/NaCl) of compound 369. 
 
Figure A5.18 13C NMR (126 MHz, CDCl3) of compound 369. 
 






































































































































































Figure A5.21 Infrared spectrum (thin film/NaCl) of compound 333. 
 
Figure A5.22 13C NMR (126 MHz, CDCl3) of compound 333. 
 







































































































































































Figure A5.25 Infrared spectrum (thin film/NaCl) of compound 292. 
 
Figure A5.26 13C NMR (126 MHz, CDCl3) of compound 292. 
 





















































































































Figure A5.28 Infrared spectrum (thin film/NaCl) of compound 296. 
 
Figure A5.29 13C NMR (126 MHz, CDCl3) of compound 296. 
 
 



























































































































































Figure A5.31 Infrared spectrum (thin film/NaCl) of compound 297. 
 
Figure A5.32 13C NMR (126 MHz, CDCl3) of compound 297. 
 

















































































































Figure A5.34 Infrared spectrum (thin film/NaCl) of compound 298. 
 
Figure A5.35 13C NMR (126 MHz, CDCl3) of compound 298. 
 
















































































































Figure A5.37 Infrared spectrum (thin film/NaCl) of compound 299. 
 
Figure A5.38 13C NMR (126 MHz, CDCl3) of compound 299. 
 

















































































































Figure A5.40 Infrared spectrum (thin film/NaCl) of compound 300. 
 
Figure A5.41 13C NMR (126 MHz, CDCl3) of compound 300. 
 















































































































Figure A5.43 Infrared spectrum (thin film/NaCl) of compound 301. 
 
Figure A5.44 13C NMR (126 MHz, CDCl3) of compound 301. 
 
















































































































Figure A5.46 Infrared spectrum (thin film/NaCl) of compound 302. 
 
Figure A5.47 13C NMR (126 MHz, CDCl3) of compound 302. 
 
















































































































Figure A5.49 Infrared spectrum (thin film/NaCl) of compound 303. 
 
Figure A5.50 13C NMR (126 MHz, CDCl3) of compound 303. 
 















































































































Figure A5.52 Infrared spectrum (thin film/NaCl) of compound 304. 
 
Figure A5.53 13C NMR (126 MHz, CDCl3) of compound 304. 
 

















































































































Figure A5.55 Infrared spectrum (thin film/NaCl) of compound 305. 
 
Figure A5.56 13C NMR (126 MHz, CDCl3) of compound 305. 
 















































































































Figure A5.58 Infrared spectrum (thin film/NaCl) of compound 306. 
 
Figure A5.59 13C NMR (126 MHz, CDCl3) of compound 306. 
 















































































































Figure A5.61 Infrared spectrum (thin film/NaCl) of compound 307. 
 
Figure A5.62 13C NMR (126 MHz, CDCl3) of compound 307. 
 

















































































































Figure A5.64 Infrared spectrum (thin film/NaCl) of compound 308. 
 
Figure A5.65 13C NMR (126 MHz, CDCl3) of compound 308. 
 
















































































































Figure A5.67 Infrared spectrum (thin film/NaCl) of compound 309. 
 
Figure A5.68 13C NMR (126 MHz, CDCl3) of compound 309. 
 




















































































































 Figure A5.70 Infrared spectrum (Thin Film, NaCl) of compound (S)-338. 
 
 Figure A5.71 13C NMR (126 MHz, CDCl3) of compound (S)-338. 
 
















































































































Figure A5.73 Infrared spectrum (thin film/NaCl) of compound 311. 
 
Figure A5.74 13C NMR (126 MHz, CDCl3) of compound 311. 
 
















































































































Figure A5.76 Infrared spectrum (thin film/NaCl) of compound 312. 
 
Figure A5.77 13C NMR (126 MHz, CDCl3) of compound 312. 
 















































































































Figure A5.79 Infrared spectrum (thin film/NaCl) of compound 315. 
 
Figure A5.80 13C NMR (126 MHz, CDCl3) of compound 315. 
 















































































































Figure A5.82 Infrared spectrum (thin film/NaCl) of compound 316. 
 
Figure A5.83 13C NMR (126 MHz, CDCl3) of compound 316. 
 















































































































Figure A5.85 Infrared spectrum (thin film/NaCl) of compound 317. 
 
Figure A5.86 13C NMR (126 MHz, CDCl3) of compound 317. 
 










































































































Figure A5.88 Infrared spectrum (thin film/NaCl) of compound 318. 
 
Figure A5.89 13C NMR (126 MHz, CDCl3) of compound 318. 
 



























































































































Figure A5.91 Infrared spectrum (Thin Film, NaCl) of compound 323•HCl. 
 
 Figure A5.92 13C NMR (126 MHz, CDCl3) of compound 323•HCl. 
 















































































































Figure A5.94 Infrared spectrum (thin film/NaCl) of compound 324. 
 
Figure A5.95 13C NMR (126 MHz, CDCl3) of compound 324. 
 















































































































Figure A5.97 Infrared spectrum (thin film/NaCl) of compound 325. 
 
Figure A5.98 13C NMR (126 MHz, CDCl3) of compound 325. 
 

















































































































Figure A5.100 Infrared spectrum (thin film/NaCl) of compound 326. 
 
Figure A5.101 13C NMR (126 MHz, CDCl3) of compound 326. 
 
















































































































Figure A5.103 Infrared spectrum (thin film/NaCl) of compound 327. 
 
Figure A5.104 13C NMR (126 MHz, CDCl3) of compound 327. 
 


















































































































Figure A5.106 Infrared spectrum (thin film/NaCl) of compound 329. 
 
Figure A5.107 13C NMR (126 MHz, CDCl3) of compound 329. 
 


















































































































Figure A5.109 Infrared spectrum (thin film/NaCl) of compound 331. 
 
Figure A5.110 13C NMR (126 MHz, CDCl3) of compound 331. 
 


















































































































Figure A5.112 Infrared spectrum (thin film/NaCl) of compound 334. 
 
Figure A5.113 13C NMR (126 MHz, CDCl3) of compound 334. 
 


















































































































Figure A5.115 Infrared spectrum (thin film/NaCl) of compound 335. 
 
Figure A5.116 13C NMR (126 MHz, CDCl3) of compound 335. 
 
















































































































Figure A5.118 Infrared spectrum (thin film/NaCl) of compound 336. 
 
Figure A5.119 13C NMR (126 MHz, CDCl3) of compound 336. 
 






























































































































 Figure A5.121 Infrared spectrum (Thin Film, NaCl) of compound 374•HCl. 
 
 Figure A5.122 13C NMR (126 MHz, CDCl3) of compound 374•HCl. 
 





















































































































Figure A5.124 Infrared spectrum (thin film/NaCl) of compound 343. 
 
Figure A5.125 13C NMR (126 MHz, CDCl3) of compound 343. 
 










































































































































































Figure A5.128 Infrared spectrum (thin film/NaCl) of compound 377. 
 
Figure A5.129 13C NMR (126 MHz, CDCl3) of compound 377. 
 


















































































































 Figure A5.131 Infrared spectrum (Thin Film, NaCl) of compound (S)-344. 
 
 Figure A.5.132 13C NMR (126 MHz, CDCl3) of compound (S)-344. 
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Table A6.1.1 Experimental Details 
Table A6.1.2 Crystal Data 
Table A6.1.3 Atomic Coordinates  
Table A6.1.4 Full Bond Distances and Angles 
Table A6.1.5 Anisotropic Displacement Parameters 
Table A6.1.6 Hydrogen Atomic Coordinates 
 
Figure A6.1.1     X-ray crystal structure of thiazolidine (S)-315  
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Table A6.1.1. Experimental details for X-ray structure determination of thiazolidine (S)-315 
Low-temperature diffraction data (and scans) were collected on a Bruker Kappa 
diffractometer coupled to a Apex II CCD detector with graphite monochromated Mo K 
radiation ( = 0.71073 Å) for the structure of  thiazolidine (S)-315.  The structure was 
solved by direct methods using SHELXS and refined against F2 on all data by full-matrix 
least squares with SHELXL-2013 refinement using established techniques.  All non-
hydrogen atoms were refined anisotropically.  All hydrogen atoms were included into the 
model at geometrically calculated positions and refined using a riding model.  The 
isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 times the U 
value of the atoms they are linked to (1.5 times for methyl groups).  All disordered atoms 
were refined with the help of similarity restraints on the 1,2- and 1,3- distances and 
displacement parameters as well as rigid bond restraints for anisotropic displacement 
parameters.   
 
Table A6.1.2 Crystal data and structure refinement for thiazolidine (S)-315 
Caltech Identification code  a13024 
CCDC Deposition Number 973929 
Empirical formula  C18 H17 N3 O4 S2 
Formula weight  433.95 
Crystallization solvent  Ethyl Acetate/Heptane/Benzene  
Crystal shape  blade 
Crystal color  colourless  
Crystal size 0.04 x 0.11 x 0.40 mm 
Preliminary photograph(s)  rotation  
Type of diffractometer  Bruker APEX-II CCD 
Wavelength  0.71073 Å MoK 
 
Appendix 6 – X-Ray Crystallography Reports Relevant to Chapter 3  429
Table A6.1.2 (cont’d) 
Data collection temperature  100 K 
Theta range for 9894 reflections used 
in lattice determination  2.34 to 26.36° 
Unit cell dimensions a = 29.071(2) Å α= 90° 
 b = 6.0386(5) Å β= 94.233(3)° 
 c = 23.0477(19) Å γ = 90° 
Volume 4034.9(6) Å3 
Z 8 
Crystal system  monoclinic 
Space group  C 1 2 1   (# 5) 
Density (calculated) 1.429 g/cm3 
F(000) 1802 
Theta range for data collection 1.6 to 33.0° 
Completeness to theta = 25.000° 99.9%  
Index ranges –42 ≤ h ≤ 44, –8 ≤ k ≤ 9, –35 ≤ l ≤ 35 
Reflections collected 71248 
Independent reflections 12862 [Rint= 0.0785] 
Reflections > 2s(I) 8839  
Average s(I)/(net I) 0.0814 
Absorption coefficient 0.30 mm–1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.8747   
Primary solution method  dual 
Hydrogen placement  geom 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12862 / 57 / 594 
Treatment of hydrogen atoms  constr 
Goodness-of-fit on F2 1.01 
Final R indices [I>2s(I), 8839 reflections] R1 = 0.0523, wR2 = 0.1051 
R indices (all data) R1 = 0.0985, wR2 = 0.1215 
Type of weighting scheme used calc 
Weighting scheme used w=1/[^2^(Fo^2^)+(0.0559P)^2^+1.2322P] where    
P=(Fo^2^+2Fc^2^)/3 
Max shift/error  0.001 
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Table A6.1.2 (cont’d) 
Average shift/error  0.000 
Absolute structure parameter 0.08(3) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.63 and -0.45 e·Å–3 
 
Programs Used  
Cell refinement   SAINT V8.32B (Bruker-AXS, 2007) 
Data collection   APEX2 2013.6-2 (Bruker-AXS, 2007) 
Data reduction   SAINT V8.32B (Bruker-AXS, 2007) 
Structure solution   SHELXT (Sheldrick, 2012) 
Structure refinement   SHELXL-2013/2 (Sheldrick, 2013) 
Graphics  DIAMOND 3 (Crystal Impact, 1999)  
  
 
Table A6.1.3.      Atomic coordinates (x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for thiazolidine (S)-315.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z Ueq 
________________________________________________________________________________   
S(1) 8262(1) -810(2) 7758(1) 19(1) 
S(2) 7657(1) 76(2) 9340(1) 21(1) 
O(1) 8012(1) 158(4) 7260(1) 22(1) 
O(2) 8329(1) -3134(4) 7794(1) 25(1) 
O(3) 10067(1) 5822(5) 8110(1) 40(1) 
O(4) 10425(1) 2713(5) 8234(1) 44(1) 
N(1) 7986(1) 23(5) 8320(1) 20(1) 
N(2) 10073(1) 3806(6) 8126(1) 28(1) 
N(3) 8456(1) -1870(5) 9026(1) 26(1) 
C(1) 8809(1) 482(6) 7843(1) 20(1) 
C(2) 8859(1) 2557(6) 7599(1) 20(1) 
C(3) 9278(1) 3659(6) 7690(1) 24(1) 
C(4) 9634(1) 2609(6) 8012(1) 23(1) 
C(5) 9595(1) 498(6) 8237(1) 26(1) 
C(6) 9177(1) -574(6) 8158(1) 24(1) 
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Table A6.1.3 (cont’d) 
C(7) 8098(1) -772(6) 8892(1) 21(1) 
C(8) 7276(1) 855(5) 8701(1) 18(1) 
C(9) 7616(1) 1693(6) 8273(1) 20(1) 
C(10) 8540(1) -2675(7) 9616(1) 35(1) 
C(11) 8739(1) -4949(7) 9632(1) 26(1) 
C(12) 8780(1) -6214(7) 9179(2) 38(1) 
C(13) 6914(1) 2514(6) 8844(1) 19(1) 
C(14) 6448(1) 1979(6) 8723(1) 24(1) 
C(15) 6108(1) 3500(6) 8831(1) 27(1) 
C(16) 6225(1) 5531(6) 9070(1) 26(1) 
C(17) 6686(1) 6055(6) 9207(1) 22(1) 
C(18) 7027(1) 4541(5) 9093(1) 22(1) 
S(1A) 1850(1) 2774(2) 7236(1) 24(1) 
S(2A) 2370(2) 1779(14) 5621(2) 32(1) 
S(2AA) 2253(3) 897(17) 5560(2) 29(1) 
O(1A) 2091(1) 1685(4) 7716(1) 27(1) 
O(2A) 1813(1) 5115(5) 7229(1) 31(1) 
O(3A) -335(1) -199(6) 6712(2) 52(1) 
O(4A) -13(1) -3389(5) 6842(1) 46(1) 
N(1A) 2107(1) 1906(5) 6660(1) 25(1) 
N(2A) 0(1) -1372(6) 6830(1) 33(1) 
N(3A) 1711(1) 4307(6) 5995(1) 32(1) 
C(1A) 1291(1) 1635(6) 7142(1) 22(1) 
C(2A) 1220(1) -452(6) 7371(1) 26(1) 
C(3A) 792(1) -1444(6) 7274(2) 28(1) 
C(4A) 450(1) -287(7) 6954(2) 28(1) 
C(5A) 509(1) 1817(7) 6744(2) 31(1) 
C(6A) 940(1) 2785(7) 6830(1) 28(1) 
C(7A) 1997(1) 2800(7) 6099(1) 25(1) 
C(8A) 2550(1) -700(8) 6107(2) 39(1) 
C(9A) 2328(4) -430(20) 6676(4) 32(2) 
C(9AA) 2448(5) 360(20) 6736(6) 18(3) 
C(10A) 1625(1) 5058(8) 5392(1) 38(1) 
C(11A) 1359(2) 7136(9) 5353(2) 55(1) 
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Table A6.1.3 (cont’d) 
C(12A) 1227(2) 8304(9) 5780(2) 66(2) 
C(13A) 3068(1) -809(7) 6117(1) 23(1) 
C(14A) 3272(1) -2798(6) 5960(1) 28(1) 
C(15A) 3756(1) -2909(9) 5974(2) 43(1) 
C(16A) 4014(1) -1147(10) 6144(2) 51(1) 
C(17A) 3809(2) 801(9) 6298(2) 55(1) 
C(18A) 3343(2) 954(7) 6286(2) 39(1) 
C(19) 50(20) 8890(100) 4820(20) 234(16) 
C(20) -10(17) 6960(100) 5284(17) 235(14) 
C(21) -90(18) 5080(100) 4796(17) 219(12) 
C(22) 168(14) 3320(90) 5179(15) 209(12) 
C(23) 33(10) 1280(80) 4797(11) 170(10) 
C(24) 9986(11) 1970(170) 10141(12) 340(30) 
C(25) 10106(12) 3650(130) 9638(15) 360(30) 
C(26) 10000 5830(130) 10000 360(30) 
C(27) 9890(13) 7930(120) 9647(18) 370(30) 
C(28) 9970(16) 9370(170) 10187(16) 340(30) 
________________________________________________________________________________ 
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Table A6.1.4      Bond lengths [Å] and angles [°] for thiazolidine (S)-315 
___________________________________________________________________________________  
S(1)-O(1)  1.437(2) 
S(1)-O(2)  1.418(3) 
S(1)-N(1)  1.653(3) 
S(1)-C(1)  1.767(3) 
S(2)-C(7)  1.780(3) 
S(2)-C(8)  1.839(3) 
O(3)-N(2)  1.218(4) 
O(4)-N(2)  1.228(4) 
N(1)-C(7)  1.416(4) 
N(1)-C(9)  1.473(4) 
N(2)-C(4)  1.472(4) 
N(3)-C(7)  1.253(4) 
N(3)-C(10)  1.447(4) 
C(1)-C(2)  1.386(5) 
C(1)-C(6)  1.401(4) 
C(2)-H(2)  0.9500 
C(2)-C(3)  1.389(5) 
C(3)-H(3)  0.9500 
C(3)-C(4)  1.382(4) 
C(4)-C(5)  1.384(5) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.378(5) 
C(6)-H(6)  0.9500 
C(8)-H(8)  1.0000 
C(8)-C(9)  1.533(4) 
C(8)-C(13)  1.508(4) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-H(10C)  0.9900 
C(10)-H(10D)  0.9900 
C(10)-C(11)  1.490(5) 
C(11)-H(11)  0.9500 
C(11)-C(12)  1.306(5) 
C(12)-H(12C)  0.9500 
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Table A6.1.4 (cont’d) 
C(12)-H(12D)  0.9500 
C(13)-C(14)  1.399(4) 
C(13)-C(18)  1.383(5) 
C(14)-H(14)  0.9500 
C(14)-C(15)  1.384(5) 
C(15)-H(15)  0.9500 
C(15)-C(16)  1.376(5) 
C(16)-H(16)  0.9500 
C(16)-C(17)  1.390(5) 
C(17)-H(17)  0.9500 
C(17)-C(18)  1.389(5) 
C(18)-H(18)  0.9500 
S(1A)-O(1A)  1.426(2) 
S(1A)-O(2A)  1.418(3) 
S(1A)-N(1A)  1.656(3) 
S(1A)-C(1A)  1.763(3) 
S(2A)-C(7A)  1.718(4) 
S(2A)-C(8A)  1.919(6) 
S(2AA)-C(7A)  1.886(7) 
S(2AA)-C(8A)  1.763(6) 
O(3A)-N(2A)  1.218(4) 
O(4A)-N(2A)  1.219(4) 
N(1A)-C(7A)  1.415(4) 
N(1A)-C(9A)  1.548(12) 
N(1A)-C(9AA)  1.364(14) 
N(2A)-C(4A)  1.472(5) 
N(3A)-C(7A)  1.243(5) 
N(3A)-C(10A)  1.465(4) 
C(1A)-C(2A)  1.388(5) 
C(1A)-C(6A)  1.389(5) 
C(2A)-H(2A)  0.9500 
C(2A)-C(3A)  1.384(5) 
C(3A)-H(3A)  0.9500 
C(3A)-C(4A)  1.384(5) 
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Table A6.1.4 (cont’d) 
C(4A)-C(5A)  1.375(6) 
C(5A)-H(5A)  0.9500 
C(5A)-C(6A)  1.383(5) 
C(6A)-H(6A)  0.9500 
C(8A)-H(8A)  1.0000 
C(8A)-H(8AA)  1.0000 
C(8A)-C(9A)  1.512(10) 
C(8A)-C(9AA)  1.630(13) 
C(8A)-C(13A)  1.506(5) 
C(9A)-H(9AA)  0.9900 
C(9A)-H(9AB)  0.9900 
C(9AA)-H(9AC)  0.9900 
C(9AA)-H(9AD)  0.9900 
C(10A)-H(10A)  0.9900 
C(10A)-H(10B)  0.9900 
C(10A)-C(11A)  1.473(6) 
C(11A)-H(11A)  0.9500 
C(11A)-C(12A)  1.293(6) 
C(12A)-H(12A)  0.9500 
C(12A)-H(12B)  0.9500 
C(13A)-C(14A)  1.399(5) 
C(13A)-C(18A)  1.370(5) 
C(14A)-H(14A)  0.9500 
C(14A)-C(15A)  1.409(5) 
C(15A)-H(15A)  0.9500 
C(15A)-C(16A)  1.343(7) 
C(16A)-H(16A)  0.9500 
C(16A)-C(17A)  1.378(7) 
C(17A)-H(17A)  0.9500 
C(17A)-C(18A)  1.358(7) 
C(18A)-H(18A)  0.9500 
C(19)-C(19)#1  0.90(10) 
C(19)-C(20)  1.60(2) 
C(19)-C(20)#1  1.20(4) 
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Table A6.1.4 (cont’d) 
C(19)-C(23)#2  1.45(4) 
C(19)-C(23)#3  1.72(4) 
C(20)-C(19)#1  1.20(4) 
C(20)-C(20)#1  1.31(8) 
C(20)-C(21)#1  1.19(4) 
C(20)-C(21)  1.60(2) 
C(21)-C(20)#1  1.19(4) 
C(21)-C(21)#1  1.04(7) 
C(21)-C(22)#1  1.09(4) 
C(21)-C(22)  1.54(2) 
C(22)-C(21)#1  1.09(4) 
C(22)-C(22)#1  1.23(7) 
C(22)-C(23)#1  1.37(4) 
C(22)-C(23)  1.55(2) 
C(23)-C(19)#4  1.72(4) 
C(23)-C(19)#5  1.45(4) 
C(23)-C(22)#1  1.37(4) 
C(23)-C(23)#1  0.97(4) 
C(24)-C(24)#6  0.66(5) 
C(24)-C(25)  1.60(2) 
C(24)-C(25)#6  1.18(5) 
C(24)-C(28)#5  1.57(7) 
C(24)-C(28)#7  1.75(6) 
C(25)-C(24)#6  1.18(5) 
C(25)-C(25)#6  1.82(7) 
C(25)-C(26)  1.60(2) 
C(26)-C(25)#6  1.60(2) 
C(26)-C(27)#6  1.53(2) 
C(26)-C(27)  1.53(2) 
C(27)-C(27)#6  1.70(8) 
C(27)-C(28)  1.52(2) 
C(27)-C(28)#6  1.02(6) 
C(28)-C(24)#8  1.75(6) 
C(28)-C(24)#2  1.57(7) 
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Table A6.1.4 (cont’d) 
C(28)-C(27)#6  1.02(6) 
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  ___________________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x,y,-z+1    #2 x,y+1,z    #3 -x,y+1,-z+1    #4 -x,y-1,-z+1       
#5 x,y-1,z    #6 -x+2,y,-z+2    #7 -x+2,y-1,-z+2       
#8 -x+2,y+1,-z+2       
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Table A6.1.5  Anisotropic displacement parameters  (Å2x103) for thiazolidine (S)-315.  The 
anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S(1) 238(4)  213(4) 119(3)  -6(3) 17(3)  23(3) 
S(2) 242(4)  282(4) 118(3)  15(3) 13(3)  50(3) 
O(1) 256(11)  298(13) 112(9)  4(10) 11(8)  11(10) 
O(2) 328(13)  232(13) 197(11)  -32(10) 9(10)  17(11) 
O(3) 336(15)  298(16) 559(18)  -20(14) -52(13)  -32(12) 
O(4) 236(13)  475(18) 579(18)  -18(16) -69(12)  67(14) 
N(1) 236(13)  233(14) 117(11)  37(11) 22(9)  60(12) 
N(2) 242(15)  320(20) 285(15)  -33(13) -11(11)  40(13) 
N(3) 339(16)  298(17) 139(12)  30(12) 2(11)  116(13) 
C(1) 232(15)  216(19) 140(13)  -14(12) 31(11)  28(12) 
C(2) 219(15)  213(18) 167(14)  -4(13) 9(11)  63(13) 
C(3) 260(17)  233(19) 213(15)  9(13) 21(12)  27(13) 
C(4) 212(15)  260(18) 214(15)  -36(14) 13(12)  33(14) 
C(5) 243(17)  290(20) 239(17)  4(14) -41(13)  88(14) 
C(6) 283(17)  234(19) 210(15)  33(14) 14(12)  84(14) 
C(7) 289(16)  198(16) 150(14)  2(14) 25(11)  21(14) 
C(8) 230(15)  171(15) 133(13)  3(11) 4(11)  -2(12) 
C(9) 206(15)  249(17) 130(13)  22(13) 14(11)  39(13) 
C(10) 480(20)  430(30) 142(15)  30(15) 1(14)  196(19) 
C(11) 307(17)  262(18) 198(15)  49(15) 29(13)  72(16) 
C(12) 500(20)  260(20) 390(20)  26(18) 74(18)  21(18) 
C(13) 229(15)  231(18) 113(13)  50(12) 28(11)  30(13) 
C(14) 271(17)  259(18) 170(14)  19(13) -21(12)  -16(14) 
C(15) 195(16)  380(20) 218(16)  4(15) -18(12)  29(14) 
C(16) 247(17)  330(20) 194(15)  60(14) 44(12)  81(14) 
C(17) 317(18)  165(16) 177(14)  3(13) 50(12)  8(13) 
C(18) 233(16)  236(19) 186(14)  32(12) 36(12)  -16(13) 
S(1A) 327(4)  267(5) 126(3)  -18(3) -5(3)  -33(4) 
S(2A) 324(16)  500(30) 143(9)  71(12) 55(9)  189(17) 
S(2AA) 313(19)  400(30) 162(12)  -68(14) 22(11)  50(20) 
O(1A) 313(13)  344(15) 152(11)  14(10) -14(9)  -53(11) 
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Table A6.1.5 (cont’d) 
O(2A) 425(14)  302(14) 193(11)  -37(11) -40(10)  -56(12) 
O(3A) 272(15)  510(20) 770(20)  -73(18) -53(14)  63(14) 
O(4A) 383(17)  385(19) 600(20)  13(16) -35(14)  -55(14) 
N(1A) 313(15)  304(16) 129(12)  11(12) 29(11)  -16(13) 
N(2A) 288(17)  370(20) 343(17)  -34(14) 13(13)  -2(14) 
N(3A) 427(18)  369(18) 152(13)  16(13) -6(12)  57(15) 
C(1A) 277(17)  226(18) 150(14)  -37(13) 39(12)  -15(14) 
C(2A) 272(17)  330(20) 198(15)  25(14) 51(12)  18(14) 
C(3A) 309(19)  280(20) 244(17)  29(14) 56(14)  0(14) 
C(4A) 242(17)  340(20) 281(18)  -55(16) 41(13)  6(14) 
C(5A) 303(19)  320(20) 300(19)  -35(17) -45(15)  49(16) 
C(6A) 366(19)  245(19) 239(16)  -45(16) -8(14)  13(16) 
C(7A) 248(16)  370(20) 113(13)  -1(15) -10(11)  -51(16) 
C(8A) 350(20)  620(30) 197(16)  42(18) 76(14)  120(20) 
C(9A) 360(50)  390(70) 200(30)  20(40) 80(30)  150(40) 
C(9AA) 260(60)  170(70) 110(40)  -40(40) 40(40)  60(40) 
C(10A) 510(20)  520(30) 105(14)  -12(17) -3(14)  130(20) 
C(11A) 770(30)  660(30) 204(19)  90(20) -10(20)  330(30) 
C(12A) 1110(40)  550(30) 330(20)  60(20) 70(30)  370(30) 
C(13A) 273(16)  291(18) 128(13)  27(14) 11(11)  69(15) 
C(14A) 420(20)  270(20) 139(14)  41(13) 6(13)  -3(15) 
C(15A) 370(20)  680(30) 245(18)  180(20) 48(16)  220(20) 
C(16A) 290(20)  890(40) 360(20)  340(30) -41(16)  -50(20) 
C(17A) 610(30)  580(30) 420(20)  310(20) -230(20)  -280(30) 
C(18A) 650(30)  260(20) 240(18)  41(16) -118(18)  -90(20) 
C(19) 1400(200)  2800(400) 2700(300)  0(200) -600(200)  -300(200) 
C(20) 1970(190)  2600(400) 2500(200)  -50(180) 200(200)  -100(200) 
C(21) 2200(200)  2200(300) 2200(200)  -100(160) 430(180)  70(190) 
C(22) 2300(200)  2200(300) 1810(190)  320(160) 500(160)  300(180) 
C(23) 1900(200)  2000(300) 1310(170)  170(140) 850(160)  450(190) 
C(24) 950(140)  8800(900) 600(160)  500(200) 610(130)  400(300) 
C(25) 1010(160)  8800(900) 1100(200)  300(200) -70(140)  200(200) 
C(26) 320(70)  8700(900) 1600(200)  0 -210(100)  0 
C(27) 1240(180)  8500(900) 1300(200)  100(200) 60(160)  -400(200) 
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Table A6.1.5 (cont’d) 
C(28) 1070(170)  8300(900) 860(190)  -100(300) -550(170)  -700(300) 
______________________________________________________________________________ 
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Table A6.1.6      Hydrogen coordinates (x103) and isotropic  displacement parameters (Å2x103)  
for thiazolidine (S)-315 
________________________________________________________________________________  
 x  y  z  Uiso 
________________________________________________________________________________  
  
H(2) 861 322 737 24 
H(3) 932 510 754 28 
H(5) 985 -20 844 31 
H(6) 914 -201 831 29 
H(8) 712 -51 854 21 
H(9A) 747 176 787 23 
H(9B) 774 318 839 23 
H(10C) 825 -268 981 42 
H(10D) 876 -166 984 42 
H(11) 885 -552 1000 31 
H(12C) 868 -570 880 46 
H(12D) 891 -765 923 46 
H(14) 636 57 857 28 
H(15) 579 314 874 32 
H(16) 599 657 914 31 
H(17) 677 744 938 26 
H(18) 734 490 919 26 
H(2A) 146 -119 759 32 
H(3A) 74 -288 742 33 
H(5A) 26 259 654 37 
H(6A) 100 422 668 34 
H(8A) 242 -207 591 46 
H(8AA) 243 -224 609 46 
H(9AA) 256 -55 701 38 
H(9AB) 209 -158 672 38 
H(9AC) 235 -83 700 21 
H(9AD) 273 105 692 21 
H(10A) 145 390 516 46 
H(10B) 192 528 522 46 
H(11A) 128 768 497 66 
H(12A) 130 784 617 79 
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Table A6.1.6 (cont’d) 
H(12B) 106 963 570 79 
H(14A) 309 -405 585 33 
H(15A) 390 -424 586 52 
H(16A) 434 -124 616 62 
H(17A) 400 204 641 66 
H(18A) 320 230 640 47 
________________________________________________________________________________ 
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Table A6.2.1 Experimental Details 
Table A6.2.2 Crystal Data 
Table A6.2.3 Atomic Coordinates  
Table A6.2.4 Full Bond Distances and Angles 
Table A6.2.5 Anisotropic Displacement Parameters 
Table A6.2.6 Hydrogen Atomic Coordinates 
 
Figure A6.2.1      X-ray crystal structure of thiazolidine 329  
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Table A6.2.1 Experimental details for X-ray structure determination of thiazolidine 329 
Low-temperature diffraction data (and scans) were collected on a Bruker Kappa 
diffractometer coupled to a Apex II CCD detector with graphite monochromated Mo K 
radiation (=0.71073 Å) for the structure of thiazolidine 329.  The structure was solved by 
direct methods using SHELXS and refined against F2 on all data by full-matrix least 
squares with SHELXL-2013 refinement using established techniques.  All non-hydrogen 
atoms were refined anisotropically.  All hydrogen atoms were included into the model at 
geometrically calculated positions and refined using a riding model.  The isotropic 
displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value of the 
atoms they are linked to (1.5 times for methyl groups).  All disordered atoms were 
refined with the help of similarity restraints on the 1,2- and 1,3- distances and 
displacement parameters as well as rigid bond restraints for anisotropic displacement 
parameters.   
Thiazolidine 329 crystallizes in the triclinic space group P-1 with one molecule in the 
asymmetric unit along with 0.389(2) molecules of benzene and 0.111(2) molecules of 
ethyl acetate.  The partially occupied benzene and ethyl acetate molecules are located at 
mutually exclusive positions near a crystallographic inversion center and are disordered 
accordingly.  This leads to non-integer values for the atoms in the empirical formula.  
The carbon atoms in the benzene were restrained to be flat.  The 1,2- and 1,3- distances 
for the ethyl acetate were restrained to be similar to the distances in the ester moiety of 
the main molecule.   
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Table A6.2.2 Crystal data and structure refinement for thiazolidine 329 
Caltech Identification code  rac15 
CCDC Deposition Number 956878 
Empirical formula  C23.78 H25.22 N2 O4.22 S2 
Formula weight  470.68 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 8.0719(4) Å α= 108.416(4)°. 
 b = 10.9911(6) Å β= 102.525(3)°. 
 c = 14.6381(8) Å γ = 100.436(2)°. 
Volume 1158.33(11) Å3 
Z 2 
Density (calculated) 1.349 Mg/m3 
Absorption coefficient 0.264 mm-1 
F(000) 495 
Crystal size 0.450 x 0.400 x 0.050 mm3 
Theta range for data collection 2.028 to 30.611°. 
Index ranges –11 ≤ h ≤ 11, –15 ≤ k ≤ 15, –20 ≤ l ≤ 20 
Reflections collected 73111 
Independent reflections 7117 [R(int) = 0.0401] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7461 and 0.6920 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7117 / 241 / 375 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0335, wR2 = 0.0852 
R indices (all data) R1 = 0.0411, wR2 = 0.0910 
Extinction coefficient n/a 
Largest diff. peak and hole 0.519 and -0.298 e·Å-3 
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Table A6.2.3      Atomic coordinates (x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for thiazolidine 329.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 6720(1) 912(1) 6958(1) 19(1) 
O(2) 7685(1) -166(1) 5483(1) 18(1) 
S(1) 7769(1) 1012(1) 6298(1) 14(1) 
C(1) 9977(1) 1738(1) 7028(1) 15(1) 
C(2) 10368(2) 2473(1) 8051(1) 22(1) 
C(3) 12116(2) 2931(1) 8639(1) 25(1) 
C(4) 13466(2) 2658(1) 8223(1) 21(1) 
C(5) 13041(1) 1962(1) 7189(1) 20(1) 
C(6) 11303(1) 1495(1) 6586(1) 18(1) 
C(7) 15338(2) 3066(2) 8883(1) 30(1) 
N(1) 7101(1) 1999(1) 5728(1) 14(1) 
C(8) 6907(1) 3260(1) 6257(1) 16(1) 
N(2) 7432(1) 3818(1) 7202(1) 20(1) 
C(11) 6995(2) 5071(1) 7627(1) 27(1) 
C(12) 8307(2) 6001(1) 8604(1) 30(1) 
C(13) 9751(2) 5797(2) 9062(1) 37(1) 
S(2) 5817(1) 3868(1) 5380(1) 19(1) 
C(9) 5708(1) 2434(1) 4293(1) 15(1) 
C(14) 5921(1) 2800(1) 3405(1) 17(1) 
C(15) 4955(2) 1907(1) 2438(1) 25(1) 
C(16) 5200(2) 2182(2) 1604(1) 33(1) 
C(17) 6411(2) 3338(2) 1730(1) 31(1) 
C(18) 7365(2) 4231(1) 2688(1) 24(1) 
C(19) 7112(2) 3970(1) 3524(1) 18(1) 
C(10) 7117(1) 1788(1) 4692(1) 14(1) 
C(20) 8939(1) 2443(1) 4674(1) 17(1) 
O(3) 9954(1) 3388(1) 5361(1) 27(1) 
O(4) 9225(1) 1840(1) 3801(1) 25(1) 
C(21) 10843(2) 2499(2) 3681(1) 39(1) 
C(1S) 11128(19) -483(17) 9748(10) 51(2) 
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Table A6.2.3 (cont’d) 
C(2S) 10130(17) 77(11) 9173(10) 49(2) 
C(3S) 8871(17) 592(13) 9507(10) 53(3) 
C(4S) 8570(20) 585(17) 10386(11) 58(2) 
C(5S) 9491(17) -5(13) 10916(10) 53(2) 
C(6S) 10810(18) -484(13) 10638(9) 48(2) 
C(1T) 11250(60) -420(70) 9690(20) 54(4) 
C(2T) 10990(40) -780(20) 8564(14) 69(5) 
O(1T) 12404(19) -714(14) 10186(10) 63(3) 
O(2T) 9820(20) -163(16) 9947(14) 51(3) 
C(3T) 10080(30) 210(30) 11027(16) 56(4) 
C(4T) 8270(30) 370(20) 11135(15) 62(5) 
________________________________________________________________________________ 
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Table A6.2.4      Bond lengths [Å] and angles [°] for thiazolidine 329 
_____________________________________________________  
O(1)-S(1)  1.4310(8) 
O(2)-S(1)  1.4361(8) 
S(1)-N(1)  1.6597(9) 
S(1)-C(1)  1.7533(11) 
C(1)-C(6)  1.3894(14) 
C(1)-C(2)  1.3904(15) 
C(2)-C(3)  1.3888(17) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.3931(16) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.3938(16) 
C(4)-C(7)  1.5053(16) 
C(5)-C(6)  1.3880(15) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
N(1)-C(8)  1.4129(13) 
N(1)-C(10)  1.4640(13) 
C(8)-N(2)  1.2593(14) 
C(8)-S(2)  1.7704(11) 
N(2)-C(11)  1.4617(15) 
C(11)-C(12)  1.4965(19) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(13)  1.307(2) 
C(12)-H(12)  0.9500 
C(13)-H(13A)  0.9500 
C(13)-H(13B)  0.9500 
S(2)-C(9)  1.8239(11) 
C(9)-C(14)  1.5114(14) 
C(9)-C(10)  1.5510(14) 
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Table A6.2.4 (cont’d) 
C(9)-H(9)  1.0000 
C(14)-C(15)  1.3929(15) 
C(14)-C(19)  1.3949(15) 
C(15)-C(16)  1.3908(18) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.389(2) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.3827(18) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.3898(15) 
C(18)-H(18)  0.9500 
C(19)-H(19)  0.9500 
C(10)-C(20)  1.5249(14) 
C(10)-H(10)  1.0000 
C(20)-O(3)  1.1980(14) 
C(20)-O(4)  1.3313(14) 
O(4)-C(21)  1.4494(16) 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
C(1S)-C(6S)  1.381(9) 
C(1S)-C(2S)  1.396(10) 
C(1S)-H(1S)  0.9500 
C(2S)-C(3S)  1.358(9) 
C(2S)-H(2S)  0.9500 
C(3S)-C(4S)  1.363(10) 
C(3S)-H(3S)  0.9500 
C(4S)-C(5S)  1.348(11) 
C(4S)-H(4S)  0.9500 
C(5S)-C(6S)  1.354(9) 
C(5S)-H(5S)  0.9500 
C(6S)-H(6S)  0.9500 
C(1T)-O(1T)  1.202(18) 
C(1T)-O(2T)  1.340(18) 
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Table A6.2.4 (cont’d) 
C(1T)-C(2T)  1.529(17) 
C(2T)-H(2T1)  0.9800 
C(2T)-H(2T2)  0.9800 
C(2T)-H(2T3)  0.9800 
O(2T)-C(3T)  1.458(18) 
C(3T)-C(4T)  1.539(18) 
C(3T)-H(3T1)  0.9900 
C(3T)-H(3T2)  0.9900 
C(4T)-H(4T1)  0.9800 
C(4T)-H(4T2)  0.9800 
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Symmetry transformations used to generate equivalent atoms:  
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Table A6.2.5    Anisotropic displacement parameters  (Å2x103) for thiazolidine 329.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 17(1)  20(1) 26(1)  14(1) 11(1)  6(1) 
O(2) 19(1)  13(1) 23(1)  5(1) 6(1)  5(1) 
S(1) 13(1)  13(1) 18(1)  8(1) 6(1)  4(1) 
C(1) 13(1)  17(1) 16(1)  7(1) 5(1)  5(1) 
C(2) 19(1)  32(1) 18(1)  8(1) 9(1)  9(1) 
C(3) 21(1)  38(1) 15(1)  6(1) 6(1)  7(1) 
C(4) 16(1)  27(1) 18(1)  9(1) 4(1)  4(1) 
C(5) 15(1)  25(1) 20(1)  6(1) 7(1)  6(1) 
C(6) 16(1)  19(1) 16(1)  4(1) 6(1)  6(1) 
C(7) 17(1)  46(1) 22(1)  10(1) 2(1)  4(1) 
N(1) 16(1)  12(1) 15(1)  6(1) 5(1)  5(1) 
C(8) 18(1)  14(1) 19(1)  9(1) 8(1)  6(1) 
N(2) 27(1)  17(1) 18(1)  7(1) 9(1)  9(1) 
C(11) 44(1)  21(1) 21(1)  6(1) 12(1)  17(1) 
C(12) 44(1)  21(1) 24(1)  3(1) 17(1)  8(1) 
C(13) 32(1)  32(1) 33(1)  -3(1) 11(1)  2(1) 
S(2) 27(1)  18(1) 19(1)  10(1) 9(1)  12(1) 
C(9) 14(1)  15(1) 17(1)  7(1) 4(1)  2(1) 
C(14) 16(1)  18(1) 16(1)  7(1) 4(1)  4(1) 
C(15) 25(1)  23(1) 19(1)  5(1) 3(1)  -2(1) 
C(16) 38(1)  35(1) 16(1)  4(1) 4(1)  -2(1) 
C(17) 36(1)  37(1) 19(1)  12(1) 10(1)  5(1) 
C(18) 26(1)  25(1) 22(1)  12(1) 8(1)  3(1) 
C(19) 20(1)  17(1) 17(1)  7(1) 5(1)  2(1) 
C(10) 13(1)  13(1) 15(1)  4(1) 4(1)  2(1) 
C(20) 14(1)  19(1) 21(1)  10(1) 6(1)  4(1) 
O(3) 20(1)  28(1) 24(1)  9(1) 2(1)  -7(1) 
O(4) 22(1)  28(1) 29(1)  9(1) 16(1)  8(1) 
C(21) 27(1)  51(1) 51(1)  23(1) 27(1)  11(1) 
C(1S) 55(4)  24(4) 77(4)  14(3) 33(3)  12(3) 
C(2S) 84(6)  18(3) 38(3)  9(3) 18(3)  0(3) 
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Table A6.2.5 (cont’d) 
C(3S) 54(5)  22(3) 53(4)  0(3) -16(3)  5(3) 
C(4S) 52(5)  21(3) 87(5)  -2(3) 30(3)  6(3) 
C(5S) 64(5)  35(4) 38(3)  -4(2) 16(3)  -13(3) 
C(6S) 45(4)  38(5) 50(4)  25(4) -5(3)  -5(3) 
C(1T) 64(7)  30(9) 58(6)  10(8) 14(6)  3(7) 
C(2T) 104(15)  48(10) 60(7)  23(9) 25(8)  30(10) 
O(1T) 62(7)  50(7) 56(7)  6(6) 3(6)  9(6) 
O(2T) 66(6)  25(6) 52(4)  13(4) 7(4)  8(5) 
C(3T) 63(8)  33(9) 53(5)  5(7) 12(6)  -6(8) 
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Table A6.2.6      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for thiazolidine 329 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 9455 2659 8342 27 
H(3) 12396 3439 9338 30 
H(5) 13956 1805 6891 24 
H(6) 11024 1016 5883 21 
H(7A) 15481 2462 9246 46 
H(7B) 15613 3979 9367 46 
H(7C) 16140 3022 8464 46 
H(11A) 5821 4873 7734 33 
H(11B) 6918 5519 7136 33 
H(12) 8068 6820 8923 36 
H(13A) 10049 4993 8773 44 
H(13B) 10502 6453 9683 44 
H(9) 4525 1788 4083 18 
H(15) 4130 1113 2348 30 
H(16) 4535 1575 946 40 
H(17) 6585 3514 1157 37 
H(18) 8191 5023 2775 29 
H(19) 7755 4592 4182 22 
H(10) 6777 813 4282 17 
H(21A) 11839 2619 4251 59 
H(21B) 10772 3370 3658 59 
H(21C) 11013 1953 3053 59 
H(1S) 12012 -858 9531 61 
H(2S) 10329 97 8561 59 
H(3S) 8179 967 9116 63 
H(4S) 7723 992 10623 69 
H(5S) 9209 -86 11495 64 
H(6S) 11517 -821 11054 57 
H(2T1) 12065 -360 8455 103 
H(2T2) 10010 -464 8284 103 
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Table A6.2.6 (cont’d) 
H(2T3) 10709 -1751 8229 103 
H(3T1) 11018 1056 11413 67 
H(3T2) 10402 -495 11258 67 
H(4T1) 7342 -330 10569 93 
H(4T2) 8170 1244 11135 93 
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Table A6.3.1 Experimental Details 
Table A6.3.2 Crystal Data 
Table A6.3.3 Atomic Coordinates  
Table A6.3.4 Full Bond Distances and Angles 
Table A6.3.5 Anisotropic Displacement Parameters 
Table A6.3.6 Hydrogen Atomic Coordinates 
Table A6.3.7 Hydrogen Bond Distances and Angles 
 
Figure A6.3.1     X-ray crystal structure of imidazolidinium 374•(ZnBr3•MeOH)  
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Table A6.3.1 Experimental details for X-ray structure determination of imidazolidinium 
374•(ZnBr3•MeOH) 
 
Low-temperature diffraction data (and scans) were collected on a Bruker Kappa 
diffractometer coupled to a Apex II CCD detector with graphite monochromated Mo K 
radiation ( = 0.71073 Å) for the structure of imidazolidinium 374•(ZnBr3•MeOH).  The 
structure was solved by direct methods using SHELXS and refined against F2 on all data 
by full-matrix least squares with SHELXL-2013 using established refinement techniques.  
All non-hydrogen atoms were refined anisotropically.  Unless otherwise noted, all 
hydrogen atoms were included into the model at geometrically calculated positions and 
refined using a riding model.  The isotropic displacement parameters of all hydrogen 
atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 times for 
methyl and hydroxide groups).  All disordered atoms were refined with the help of 
similarity restraints on the 1,2- and 1,3- distances and displacement parameters as well as 
rigid bond restraints for anisotropic displacement parameters.   
Imidazolidinium 374•(ZnBr3•MeOH) crystallizes in the triclinic space group P-1 
with one molecule in the asymmetric unit along with one molecule of methanol.  The 
coordinates for the hydrogen atoms on N3 and O3were taken from the difference Fourier 
synthesis and refined semi-freely with the help of a distance restraint, 0.91(2) and 0.83(2) 
Å respectively.  An additional restraint was required for the hydrogen atom bound to O3 
and the atoms Zn1, O3, C31 and H3O were restrained to be flat.  All three bromine atoms 
were disordered over two positions.  The solvent methanol had vey elongated ellipsoids 
and was disordered over two positions.  The methanol is not very stable and the C-O 
distance was restrained to 1.43(2) Å.  Additionally, the anisotropic displacement 
parameters for the two atoms in the second component of the disorder were constrained 
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to be equivalent.  Even with the disorder the methanol has elongated ellipsoids, however, 
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Table A6.3.2 Crystal data and structure refinement for imidazolidinium 374•(ZnBr3•MeOH) 
Caltech Identification code  rac14 
CCDC Deposition Number 956877 
Empirical formula  C27 H44 Br3 N3 O4 S Zn 
Formula weight  811.81 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 10.5054(14) Å α= 103.177(3)°. 
 b = 12.5274(17) Å β= 109.093(2)°. 
 c = 14.785(2) Å γ = 102.841(3)°. 
Volume 1694.7(4) Å3 
Z 2 
Density (calculated) 1.591 Mg/m3 
Absorption coefficient 4.357 mm-1 
F(000) 820 
Crystal size 0.580 x 0.380 x 0.270 mm3 
Theta range for data collection 1.764 to 30.560°. 
Index ranges –15 ≤ h ≤ 15, –17 ≤ k ≤ 17, –21 ≤ l ≤ 21 
Reflections collected 100294 
Independent reflections 10353 [R(int) = 0.0346] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.1292 and 0.0684 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10353 / 82 / 412 
Goodness-of-fit on F2 1.096 
Final R indices [I>2sigma(I)] R1 = 0.0332, wR2 = 0.0793 
R indices (all data) R1 = 0.0418, wR2 = 0.0842 
Extinction coefficient n/a 
Largest diff. peak and hole 0.878 and -0.917 e·Å-3 
Appendix 6 – X-Ray Crystallography Reports Relevant to Chapter 3  470
Table A6.3.3       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for imidazolidinium 374•(ZnBr3•MeOH).  U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 4177(2) 6547(2) 5223(1) 24(1) 
O(2) 4429(2) 8386(1) 4821(1) 24(1) 
S(1) 4213(1) 7168(1) 4530(1) 18(1) 
C(1) 2695(2) 6459(2) 3406(2) 18(1) 
C(2) 2284(2) 7039(2) 2722(2) 21(1) 
C(3) 1068(2) 6464(2) 1841(2) 24(1) 
C(4) 270(2) 5323(2) 1631(2) 24(1) 
C(7) -1077(2) 4724(3) 691(2) 33(1) 
C(5) 717(2) 4751(2) 2324(2) 24(1) 
C(6) 1922(2) 5310(2) 3212(2) 22(1) 
N(1) 5573(2) 6976(2) 4235(1) 18(1) 
C(8) 6315(2) 7626(2) 3813(2) 18(1) 
N(3) 6281(2) 8679(2) 3862(2) 22(1) 
C(11) 6662(2) 9434(2) 3284(2) 22(1) 
C(12) 5359(3) 9741(2) 2755(2) 31(1) 
C(13) 7911(3) 10511(2) 4005(2) 31(1) 
N(2) 7008(2) 7029(2) 3402(1) 18(1) 
C(14) 8269(2) 7560(2) 3202(2) 20(1) 
C(15) 7914(2) 7273(2) 2070(2) 25(1) 
C(16) 9538(2) 7195(2) 3714(2) 24(1) 
C(9) 6792(2) 5874(2) 3547(2) 17(1) 
C(21) 6427(2) 4851(2) 2623(2) 18(1) 
C(22) 7171(2) 4051(2) 2748(2) 20(1) 
C(27) 8267(2) 4165(2) 3761(2) 25(1) 
C(23) 6873(2) 3098(2) 1914(2) 25(1) 
C(24) 5860(2) 2920(2) 967(2) 28(1) 
C(28) 5587(3) 1911(3) 62(2) 44(1) 
C(25) 5097(2) 3697(2) 865(2) 26(1) 
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Table A6.3.3 (cont’d) 
C(26) 5343(2) 4650(2) 1680(2) 21(1) 
C(29) 4402(2) 5400(2) 1501(2) 28(1) 
C(10) 5663(2) 5793(2) 4001(2) 19(1) 
Zn(1) 727(1) 1039(1) 2621(1) 25(1) 
O(3) 1824(2) 1549(2) 1805(2) 42(1) 
C(31) 3303(4) 2206(4) 2288(4) 69(1) 
Br(1) -1687(2) 97(1) 1446(2) 31(1) 
Br(2) 1081(1) 2756(1) 3849(1) 16(1) 
Br(3) 1841(2) -171(2) 3374(2) 30(1) 
Br(1A) -1582(4) 220(5) 1241(6) 39(1) 
Br(2A) 1081(4) 2743(3) 3828(3) 83(3) 
Br(3A) 1793(7) -231(6) 3212(7) 47(1) 
O(1S) 10478(14) 1719(7) 9938(6) 64(2) 
C(1S) 8692(15) 1307(5) 9413(8) 65(3) 
O(1T) 11160(20) 2063(15) 10107(8) 46(3) 
C(1T) 9360(20) 1417(16) 9601(11) 46(3) 
________________________________________________________________________________ 
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Table A6.3.4      Bond lengths [Å] and angles [°] for imidazolidinium 374•(ZnBr3•MeOH) 
_____________________________________________________  
O(1)-S(1)  1.4260(16) 
O(2)-S(1)  1.4310(17) 
S(1)-N(1)  1.6740(17) 
S(1)-C(1)  1.748(2) 
C(1)-C(2)  1.387(3) 
C(1)-C(6)  1.398(3) 
C(2)-C(3)  1.387(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.392(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.397(3) 
C(4)-C(7)  1.504(3) 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
C(5)-C(6)  1.384(3) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
N(1)-C(8)  1.389(2) 
N(1)-C(10)  1.475(3) 
C(8)-N(3)  1.314(3) 
C(8)-N(2)  1.334(2) 
N(3)-C(11)  1.485(3) 
N(3)-H(3N)  0.868(17) 
C(11)-C(12)  1.518(3) 
C(11)-C(13)  1.524(3) 
C(11)-H(11)  1.0000 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
C(13)-H(13A)  0.9800 
C(13)-H(13B)  0.9800 
C(13)-H(13C)  0.9800 
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Table A6.3.4 (cont’d) 
N(2)-C(9)  1.490(3) 
N(2)-C(14)  1.497(2) 
C(14)-C(15)  1.525(3) 
C(14)-C(16)  1.526(3) 
C(14)-H(14)  1.0000 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
C(16)-H(16A)  0.9800 
C(16)-H(16B)  0.9800 
C(16)-H(16C)  0.9800 
C(9)-C(21)  1.515(3) 
C(9)-C(10)  1.538(3) 
C(9)-H(9)  1.0000 
C(21)-C(26)  1.407(3) 
C(21)-C(22)  1.409(3) 
C(22)-C(23)  1.397(3) 
C(22)-C(27)  1.514(3) 
C(27)-H(27A)  0.9800 
C(27)-H(27B)  0.9800 
C(27)-H(27C)  0.9800 
C(23)-C(24)  1.386(4) 
C(23)-H(23)  0.9500 
C(24)-C(25)  1.396(3) 
C(24)-C(28)  1.512(3) 
C(28)-H(28A)  0.9800 
C(28)-H(28B)  0.9800 
C(28)-H(28C)  0.9800 
C(25)-C(26)  1.395(3) 
C(25)-H(25)  0.9500 
C(26)-C(29)  1.512(3) 
C(29)-H(29A)  0.9800 
C(29)-H(29B)  0.9800 
C(29)-H(29C)  0.9800 
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Table A6.3.4 (cont’d) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
Zn(1)-O(3)  2.030(2) 
Zn(1)-Br(3A)  2.310(6) 
Zn(1)-Br(2A)  2.314(4) 
Zn(1)-Br(2)  2.3423(6) 
Zn(1)-Br(3)  2.369(2) 
Zn(1)-Br(1)  2.3860(13) 
Zn(1)-Br(1A)  2.408(4) 
O(3)-C(31)  1.428(4) 
O(3)-H(3O)  0.816(18) 
C(31)-H(31A)  0.9800 
C(31)-H(31B)  0.9800 
C(31)-H(31C)  0.9800 
O(1S)-C(1S)  1.680(8) 
O(1S)-H(1S)  0.8400 
C(1S)-H(1S1)  0.9800 
C(1S)-H(1S2)  0.9800 
C(1S)-H(1S3)  0.9800 
O(1T)-C(1T)  1.704(14) 
O(1T)-H(1T)  0.8400 
C(1T)-H(1T1)  0.9800 
C(1T)-H(1T2)  0.9800 
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Symmetry transformations used to generate equivalent atoms:  
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Table A6.3.5  Anisotropic displacement parameters  (Å2x103) for imidazolidinium 
374•(ZnBr3•MeOH).  The anisotropic displacement factor exponent takes the form: -2π
2[ h2a*2U11  
+ ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 21(1)  34(1) 21(1)  12(1) 12(1)  9(1) 
O(2) 23(1)  23(1) 27(1)  3(1) 15(1)  6(1) 
S(1) 16(1)  22(1) 19(1)  6(1) 11(1)  6(1) 
C(1) 15(1)  22(1) 21(1)  8(1) 10(1)  7(1) 
C(2) 21(1)  23(1) 26(1)  9(1) 13(1)  10(1) 
C(3) 24(1)  33(1) 23(1)  12(1) 13(1)  15(1) 
C(4) 17(1)  35(1) 21(1)  7(1) 10(1)  10(1) 
C(7) 20(1)  49(2) 23(1)  8(1) 7(1)  7(1) 
C(5) 18(1)  26(1) 28(1)  8(1) 10(1)  3(1) 
C(6) 18(1)  24(1) 25(1)  10(1) 10(1)  6(1) 
N(1) 15(1)  20(1) 20(1)  7(1) 11(1)  6(1) 
C(8) 15(1)  21(1) 15(1)  3(1) 7(1)  3(1) 
N(3) 26(1)  18(1) 26(1)  5(1) 19(1)  6(1) 
C(11) 26(1)  19(1) 26(1)  6(1) 17(1)  6(1) 
C(12) 35(1)  34(1) 34(1)  14(1) 19(1)  16(1) 
C(13) 32(1)  21(1) 36(1)  6(1) 18(1)  1(1) 
N(2) 15(1)  18(1) 20(1)  5(1) 10(1)  4(1) 
C(14) 17(1)  22(1) 23(1)  6(1) 12(1)  4(1) 
C(15) 28(1)  26(1) 25(1)  8(1) 17(1)  9(1) 
C(16) 17(1)  30(1) 28(1)  9(1) 13(1)  5(1) 
C(9) 14(1)  19(1) 20(1)  7(1) 8(1)  5(1) 
C(21) 14(1)  19(1) 20(1)  6(1) 8(1)  4(1) 
C(22) 16(1)  22(1) 25(1)  9(1) 12(1)  7(1) 
C(27) 22(1)  34(1) 29(1)  16(1) 12(1)  15(1) 
C(23) 24(1)  20(1) 36(1)  8(1) 18(1)  7(1) 
C(24) 23(1)  24(1) 31(1)  0(1) 14(1)  1(1) 
C(28) 38(1)  36(1) 42(2)  -11(1) 16(1)  4(1) 
C(25) 19(1)  29(1) 22(1)  3(1) 7(1)  1(1) 
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Table A6.3.5 (cont’d) 
C(26) 16(1)  23(1) 22(1)  7(1) 6(1)  4(1) 
C(29) 21(1)  34(1) 26(1)  10(1) 4(1)  12(1) 
C(10) 18(1)  22(1) 23(1)  9(1) 11(1)  8(1) 
Zn(1) 24(1)  22(1) 29(1)  9(1) 12(1)  7(1) 
O(3) 50(1)  47(1) 36(1)  19(1) 25(1)  11(1) 
C(31) 53(2)  75(3) 85(3)  35(2) 44(2)  0(2) 
Br(1) 27(1)  37(1) 25(1)  12(1) 7(1)  2(1) 
Br(2) 18(1)  14(1) 17(1)  3(1) 8(1)  4(1) 
Br(3) 31(1)  24(1) 36(1)  14(1) 12(1)  11(1) 
Br(1A) 28(1)  42(1) 36(2)  9(1) 8(1)  4(1) 
Br(2A) 85(3)  84(3) 96(4)  48(3) 40(2)  32(2) 
Br(3A) 42(2)  36(1) 85(3)  32(2) 35(2)  27(1) 
O(1S) 112(6)  44(3) 47(3)  14(3) 51(4)  17(4) 
C(1S) 118(6)  31(2) 69(5)  15(3) 71(5)  16(4) 
O(1T) 74(8)  40(5) 25(3)  15(3) 18(4)  14(5) 
C(1T) 74(8)  40(5) 25(3)  15(3) 18(4)  14(5) 
______________________________________________________________________________ 
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Table A6.3.6      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for imidazolidinium 374•(ZnBr3•MeOH) 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 2826 7815 2855 25 
H(3) 773 6857 1372 29 
H(7A) -1896 4599 880 49 
H(7B) -1048 3976 329 49 
H(7C) -1164 5207 252 49 
H(5) 187 3969 2183 29 
H(6) 2219 4918 3681 26 
H(3N) 5930(30) 8950(20) 4288(19) 26 
H(11) 6941 9000 2765 27 
H(12A) 4592 9033 2276 47 
H(12B) 5597 10263 2389 47 
H(12C) 5047 10125 3259 47 
H(13A) 7661 10915 4539 46 
H(13B) 8132 11027 3630 46 
H(13C) 8744 10285 4311 46 
H(14) 8547 8420 3501 24 
H(15A) 7648 6434 1758 37 
H(15B) 8747 7664 1967 37 
H(15C) 7118 7537 1759 37 
H(16A) 9696 7321 4426 36 
H(16B) 10389 7658 3672 36 
H(16C) 9345 6373 3372 36 
H(9) 7696 5909 4079 20 
H(27A) 8580 3481 3698 38 
H(27B) 7844 4227 4264 38 
H(27C) 9085 4860 3978 38 
H(23) 7376 2560 1999 30 
H(28A) 6006 2192 -376 66 
H(28B) 4559 1533 -317 66 
H(28C) 6019 1353 294 66 
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Table A6.3.6 (cont’d) 
H(25) 4387 3573 222 31 
H(29A) 3713 5092 795 41 
H(29B) 4989 6193 1641 41 
H(29C) 3893 5402 1951 41 
H(10A) 4736 5221 3507 23 
H(10B) 5966 5574 4621 23 
H(3O) 1370(40) 1460(30) 1211(15) 62 
H(31A) 3421 3011 2631 103 
H(31B) 3714 2180 1779 103 
H(31C) 3791 1876 2786 103 
H(1S) 10767 1332 9552 96 
H(1S1) 8373 1939 9684 98 
H(1S2) 8297 623 9573 98 
H(1S3) 8364 1119 8677 98 
H(1T) 11346 2769 10163 70 
H(1T1) 8935 1883 9964 70 
H(1T2) 9141 641 9663 70 
H(1T3) 8973 1354 8884 70 
________________________________________________________________________________ 
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Table A6.3.7  Hydrogen bonds for imidazolidinium 374•(ZnBr3•MeOH)  [Å and °] 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2)...Br(3)#1 0.95 2.97 3.584(3) 123.6 
 C(2)-H(2)...Br(3A)#1 0.95 2.90 3.519(6) 123.9 
 C(6)-H(6)...Br(2) 0.95 2.81 3.545(2) 135.1 
 N(3)-H(3N)...O(2) 0.868(17) 2.05(2) 2.767(2) 140(3) 
 C(16)-H(16A)...Br(2)#2 0.98 2.93 3.855(2) 156.7 
 C(16)-H(16B)...Br(3)#3 0.98 3.01 3.872(3) 147.4 
 C(16)-H(16B)...Br(3A)#3 0.98 3.06 3.925(7) 147.6 
 C(9)-H(9)...Br(2)#2 1.00 2.82 3.523(2) 127.7 
 C(10)-H(10B)...Br(2)#2 0.99 3.08 3.550(2) 110.5 
 O(3)-H(3O)...O(1S)#4 0.816(18) 1.95(2) 2.741(7) 164(3) 
 O(3)-H(3O)...O(1T)#4 0.816(18) 1.92(3) 2.645(11) 148(4) 
 O(1S)-H(1S)...Br(1)#5 0.84 2.61 3.440(6) 170.0 
 C(1S)-H(1S2)...Br(1)#6 0.98 2.99 3.753(8) 136.0 
 C(1S)-H(1S3)...Br(3)#5 0.98 2.91 3.845(8) 159.8 
 C(1T)-H(1T3)...Br(3A)#5 0.98 2.85 3.749(18) 153.3 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x,y+1,z    #2 -x+1,-y+1,-z+1    #3 x+1,y+1,z       
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Table A6.4.1 Experimental details for X-ray structure determination of imidazolidine 343 
Low-temperature diffraction data (and scans) were collected on a Bruker Kappa 
diffractometer coupled to a Apex II CCD detector with graphite monochromated Mo K 
radiation ( = 0.71073 Å) for the structure of imidazolidine 343.  The structure was solved 
by direct methods using SHELXS and refined against F2 on all data by full-matrix least 
squares with SHELXL-2013 using established refinement techniques.  All non-hydrogen 
atoms were refined anisotropically.  All hydrogen atoms were included into the model at 
geometrically calculated positions and refined using a riding model.  The isotropic 
displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value of the 
atoms they are linked to (1.5 times for methyl groups).   
Imidazolidine 343 crystallizes in the orthorhombic space group Pbca with one 
molecule in the asymmetric unit.  A majority of the molecule was disordered over two 
positions.  All disordered atoms were refined with the help of similarity restraints on the 
1,2- and 1,3- distances.  All atoms were refined with the help of similarity as well as rigid 












Appendix 6 – X-Ray Crystallography Reports Relevant to Chapter 3  487
Table A6.4.2 Crystal data and structure refinement for imidazolidine 343 
Caltech Identification code  rac16 
CCDC Deposition Number 973927 
Empirical formula  C23 H24 N2 O6 S2 
Formula weight  488.56 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P b c a 
Unit cell dimensions a = 7.5481(4) Å α= 90°. 
 b = 21.3568(13) Å β= 90°. 
 c = 28.1256(18) Å γ = 90°. 
Volume 4533.9(5) Å3 
Z 8 
Density (calculated) 1.431 Mg/m3 
Absorption coefficient 0.278 mm-1 
F(000) 2048 
Crystal size 0.400 x 0.250 x 0.150 mm3 
Theta range for data collection 1.907 to 30.677°. 
Index ranges –10 ≤ h ≤ 10, –30 ≤ k ≤ 30, –39 ≤ l ≤ 40 
Reflections collected 98231 
Independent reflections 7007 [R(int) = 0.0490] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7461 and 0.6817 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7007 / 1023 / 507 
Goodness-of-fit on F2 1.116 
Final R indices [I>2sigma(I)] R1 = 0.0505, wR2 = 0.1269 
R indices (all data) R1 = 0.0597, wR2 = 0.1324 
Extinction coefficient n/a 
Largest diff. peak and hole 0.662 and -0.538 e·Å-3 
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Table A6.4.3.      Atomic coordinates (x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for imidazolidine 343.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 5335(2) 1620(1) 1380(1) 26(1) 
O(2) 4409(2) 2342(1) 726(1) 31(1) 
S(1) 4127(1) 2069(1) 1184(1) 21(1) 
C(1) 3945(2) 2681(1) 1599(1) 20(1) 
C(2) 4527(2) 2582(1) 2061(1) 22(1) 
C(3) 4518(2) 3079(1) 2378(1) 24(1) 
C(4) 3935(2) 3668(1) 2242(1) 26(1) 
C(5) 3339(3) 3752(1) 1780(1) 32(1) 
C(6) 3336(3) 3263(1) 1455(1) 28(1) 
C(7) 3924(3) 4209(1) 2587(1) 37(1) 
N(1) 2138(13) 1760(4) 1128(4) 18(1) 
C(8) 877(12) 1912(3) 744(3) 21(1) 
C(11) -60(19) 2527(4) 804(4) 21(1) 
C(12) -830(30) 2682(7) 1243(5) 21(2) 
C(13) -1790(30) 3228(7) 1286(4) 21(2) 
C(14) -1950(20) 3623(6) 896(4) 33(2) 
C(15) -1186(18) 3468(5) 464(4) 32(2) 
C(16) -231(16) 2926(4) 418(4) 26(1) 
N(2) -368(12) 1385(3) 805(3) 20(1) 
C(17) -1909(11) 1330(3) 484(2) 29(2) 
C(18) -1271(4) 782(1) 140(1) 11(1) 
C(19) -1060(4) 1020(2) -290(1) 20(1) 
C(9) 88(11) 951(4) 1108(4) 21(1) 
S(2) -891(4) 277(1) 1228(1) 28(1) 
C(10) 1879(10) 1142(3) 1327(2) 18(1) 
C(20) 3219(6) 664(2) 1106(2) 23(1) 
O(3) 3612(9) 724(3) 689(2) 27(1) 
O(4) 3688(6) 201(2) 1380(2) 26(1) 
C(21) 4655(6) -280(2) 1124(2) 39(1) 
C(22) 1640(20) 1198(6) 1871(3) 21(1) 
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Table A6.4.3 (cont’d) 
O(5) 720(20) 1617(8) 2024(6) 28(2) 
O(6) 2335(18) 750(5) 2130(2) 27(1) 
C(23) 2074(14) 822(5) 2643(3) 26(1) 
N(1A) 2257(12) 1661(4) 1182(4) 17(1) 
C(8A) 967(11) 1778(3) 803(3) 16(1) 
C(11A) 53(16) 2403(4) 818(4) 17(1) 
C(12A) -880(30) 2594(7) 1223(5) 22(2) 
C(13A) -1780(30) 3161(7) 1216(4) 28(2) 
C(14A) -1815(18) 3529(5) 811(4) 31(2) 
C(15A) -907(16) 3334(4) 410(4) 31(1) 
C(16A) 12(14) 2775(4) 415(4) 23(1) 
N(2A) -258(11) 1253(3) 881(3) 17(1) 
C(17A) -1788(11) 1187(3) 566(2) 23(1) 
C(18A) -1586(8) 1051(4) 20(2) 64(2) 
C(19A) -321(12) 812(4) -170(3) 92(3) 
C(9A) 244(10) 839(3) 1203(3) 17(1) 
S(2A) -720(4) 172(1) 1345(1) 22(1) 
C(10A) 1983(9) 1075(3) 1432(2) 18(1) 
C(20A) 3358(5) 561(2) 1297(2) 19(1) 
O(3A) 4024(5) 193(2) 1558(2) 29(1) 
O(4A) 3553(8) 579(2) 823(2) 25(1) 
C(21A) 4614(4) 87(2) 615(2) 33(1) 
C(22A) 1630(20) 1207(6) 1960(2) 20(1) 
O(5A) 920(20) 1681(7) 2086(5) 33(2) 
O(6A) 2257(17) 779(5) 2248(2) 28(1) 
C(23A) 1896(15) 893(5) 2748(3) 36(2) 
________________________________________________________________________________ 
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Table A6.4.4      Bond lengths [Å] and angles [°] for imidazolidine 343 
_____________________________________________________  
O(1)-S(1)  1.4335(14) 
O(2)-S(1)  1.4295(14) 
S(1)-N(1)  1.648(9) 
S(1)-N(1A)  1.659(8) 
S(1)-C(1)  1.7562(16) 
C(1)-C(6)  1.387(2) 
C(1)-C(2)  1.387(2) 
C(2)-C(3)  1.387(2) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.388(2) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.387(3) 
C(4)-C(7)  1.508(2) 
C(5)-C(6)  1.386(3) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
N(1)-C(10)  1.446(8) 
N(1)-C(8)  1.476(8) 
C(8)-N(2)  1.476(8) 
C(8)-C(11)  1.500(8) 
C(8)-H(8)  1.0000 
C(11)-C(16)  1.385(8) 
C(11)-C(12)  1.407(9) 
C(12)-C(13)  1.378(9) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.387(9) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.383(8) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.371(7) 
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Table A6.4.4 (cont’d) 
C(15)-H(15)  0.9500 
C(16)-H(16)  0.9500 
N(2)-C(9)  1.307(6) 
N(2)-C(17)  1.477(7) 
C(17)-C(18)  1.593(5) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(18)-C(19)  1.323(4) 
C(18)-H(18)  0.9500 
C(19)-H(19A)  0.9500 
C(19)-H(19B)  0.9500 
C(9)-C(10)  1.542(8) 
C(9)-S(2)  1.653(6) 
C(10)-C(22)  1.544(8) 
C(10)-C(20)  1.567(7) 
C(20)-O(3)  1.215(6) 
C(20)-O(4)  1.301(6) 
O(4)-C(21)  1.451(6) 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
C(22)-O(5)  1.209(9) 
C(22)-O(6)  1.312(9) 
O(6)-C(23)  1.464(7) 
C(23)-H(23A)  0.9800 
C(23)-H(23B)  0.9800 
C(23)-H(23C)  0.9800 
N(1A)-C(10A)  1.450(7) 
N(1A)-C(8A)  1.466(7) 
C(8A)-N(2A)  1.469(7) 
C(8A)-C(11A)  1.503(7) 
C(8A)-H(8A)  1.0000 
C(11A)-C(16A)  1.383(7) 
C(11A)-C(12A)  1.400(9) 
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Table A6.4.4 (cont’d) 
C(12A)-C(13A)  1.387(9) 
C(12A)-H(12A)  0.9500 
C(13A)-C(14A)  1.384(9) 
C(13A)-H(13A)  0.9500 
C(14A)-C(15A)  1.384(8) 
C(14A)-H(14A)  0.9500 
C(15A)-C(16A)  1.381(6) 
C(15A)-H(15A)  0.9500 
C(16A)-H(16A)  0.9500 
N(2A)-C(9A)  1.320(5) 
N(2A)-C(17A)  1.463(7) 
C(17A)-C(18A)  1.569(6) 
C(17A)-H(17C)  0.9900 
C(17A)-H(17D)  0.9900 
C(18A)-C(19A)  1.207(7) 
C(18A)-H(18A)  0.9500 
C(19A)-H(19C)  0.9500 
C(19A)-H(19D)  0.9500 
C(9A)-C(10A)  1.546(7) 
C(9A)-S(2A)  1.649(6) 
C(10A)-C(22A)  1.535(7) 
C(10A)-C(20A)  1.557(7) 
C(20A)-O(3A)  1.187(5) 
C(20A)-O(4A)  1.342(5) 
O(4A)-C(21A)  1.444(6) 
C(21A)-H(21D)  0.9800 
C(21A)-H(21E)  0.9800 
C(21A)-H(21F)  0.9800 
C(22A)-O(5A)  1.199(9) 
C(22A)-O(6A)  1.310(8) 
O(6A)-C(23A)  1.452(7) 
C(23A)-H(23D)  0.9800 
C(23A)-H(23E)  0.9800 
C(23A)-H(23F)  0.9800 
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Symmetry transformations used to generate equivalent atoms:  
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Table A6.4.5  Anisotropic displacement parameters  (Å2x103) for imidazolidine 343.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 19(1)  26(1) 34(1)  -10(1) 3(1)  -3(1) 
O(2) 26(1)  47(1) 19(1)  -7(1) 6(1)  -12(1) 
S(1) 16(1)  27(1) 21(1)  -8(1) 5(1)  -7(1) 
C(1) 20(1)  20(1) 19(1)  -4(1) 2(1)  -5(1) 
C(2) 25(1)  19(1) 22(1)  0(1) -1(1)  -3(1) 
C(3) 28(1)  24(1) 21(1)  -4(1) -2(1)  -2(1) 
C(4) 26(1)  20(1) 31(1)  -6(1) 0(1)  -2(1) 
C(5) 41(1)  19(1) 34(1)  1(1) -7(1)  2(1) 
C(6) 36(1)  26(1) 22(1)  1(1) -6(1)  -2(1) 
C(7) 41(1)  28(1) 41(1)  -14(1) -2(1)  0(1) 
N(1) 15(2)  17(2) 22(3)  -3(2) 3(2)  -2(2) 
C(8) 18(2)  25(3) 19(2)  -4(2) -1(2)  -6(2) 
C(11) 17(2)  19(3) 26(2)  -7(2) -2(2)  0(2) 
C(12) 24(3)  20(4) 19(2)  -7(2) 3(2)  -10(3) 
C(13) 23(2)  18(3) 23(3)  -10(2) -3(3)  -1(2) 
C(14) 43(3)  24(4) 32(4)  -8(3) -3(3)  4(3) 
C(15) 38(4)  28(4) 31(3)  -1(3) -7(2)  6(2) 
C(16) 27(3)  32(4) 18(2)  -2(3) -2(2)  1(3) 
N(2) 17(2)  17(3) 26(3)  -11(2) 2(2)  2(2) 
C(17) 16(2)  51(4) 21(2)  -22(3) 0(2)  -7(2) 
C(18) 8(1)  11(1) 15(1)  -4(1) -2(1)  2(1) 
C(19) 14(1)  32(2) 14(2)  -5(1) -3(1)  10(1) 
C(9) 14(2)  15(3) 33(4)  -10(2) 2(2)  -2(2) 
S(2) 24(1)  24(1) 35(1)  -9(1) 6(1)  -9(1) 
C(10) 16(2)  19(2) 20(2)  -7(2) 4(2)  1(1) 
C(20) 14(2)  21(2) 35(3)  -8(2) 2(2)  -3(1) 
O(3) 26(2)  32(3) 24(2)  -9(2) 4(2)  3(2) 
O(4) 27(2)  21(2) 31(2)  -2(2) 10(2)  3(1) 
C(21) 34(2)  33(2) 51(3)  -5(2) 9(2)  5(2) 
C(22) 18(2)  18(2) 26(3)  -3(2) 4(3)  -6(2) 
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Table A6.4.5 (cont’d) 
O(5) 36(3)  25(3) 24(4)  -7(2) 8(3)  3(3) 
O(6) 31(2)  29(2) 21(3)  -7(2) 0(3)  1(1) 
C(23) 25(2)  27(2) 27(3)  -7(2) -1(2)  -7(2) 
N(1A) 14(2)  16(2) 21(2)  -2(2) -3(1)  -3(2) 
C(8A) 17(2)  15(2) 16(2)  -3(2) 3(1)  0(2) 
C(11A) 17(2)  15(2) 18(2)  -2(2) -2(1)  -5(2) 
C(12A) 19(3)  17(3) 29(3)  -6(2) 1(2)  -2(3) 
C(13A) 25(2)  26(3) 32(4)  -14(3) 2(3)  -4(2) 
C(14A) 31(3)  21(3) 42(4)  -10(2) -9(3)  2(2) 
C(15A) 33(4)  28(4) 31(3)  2(3) -4(2)  6(2) 
C(16A) 22(3)  20(3) 26(2)  -1(2) -6(2)  1(2) 
N(2A) 15(2)  11(2) 26(2)  -4(2) -2(1)  -1(2) 
C(17A) 18(2)  27(2) 24(2)  -6(2) -3(2)  0(1) 
C(18A) 55(3)  89(5) 50(3)  -38(3) -13(3)  3(3) 
C(19A) 107(6)  83(5) 87(6)  -44(4) 53(5)  -25(4) 
C(9A) 16(2)  15(2) 21(3)  -4(1) 3(1)  1(2) 
S(2A) 22(1)  18(1) 26(1)  0(1) -1(1)  -7(1) 
C(10A) 14(2)  14(2) 24(2)  1(2) -1(2)  -4(1) 
C(20A) 16(1)  16(2) 26(2)  0(2) -1(2)  -3(1) 
O(3A) 27(2)  22(1) 40(2)  1(2) -8(2)  3(1) 
O(4A) 24(1)  25(2) 27(2)  -11(2) 2(2)  2(1) 
C(21A) 16(1)  24(2) 59(2)  -27(2) 6(1)  0(1) 
C(22A) 18(2)  21(2) 21(2)  -2(2) 2(2)  -7(2) 
O(5A) 50(5)  23(3) 26(4)  -4(2) 6(3)  5(3) 
O(6A) 33(2)  32(2) 20(3)  -3(2) -8(3)  6(1) 
C(23A) 37(3)  53(4) 19(3)  -3(3) -6(2)  7(2) 
______________________________________________________________________________ 
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Table A6.4.6      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for imidazolidine 343 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 4925 2180 2158 26 
H(3) 4920 3014 2694 29 
H(5) 2924 4152 1683 38 
H(6) 2923 3327 1140 34 
H(7A) 2760 4236 2740 55 
H(7B) 4166 4599 2416 55 
H(7C) 4838 4142 2829 55 
H(8) 1472 1890 427 25 
H(12) -697 2412 1509 26 
H(13) -2345 3334 1579 26 
H(14) -2581 4005 926 39 
H(15) -1326 3739 199 39 
H(16) 310 2823 123 31 
H(17A) -2122 1724 307 35 
H(17B) -2996 1213 660 35 
H(18) -1076 358 229 14 
H(19A) -1288 1452 -345 24 
H(19B) -680 760 -544 24 
H(21A) 5017 -609 1346 59 
H(21B) 5708 -95 976 59 
H(21C) 3893 -459 877 59 
H(23A) 2690 483 2810 40 
H(23B) 805 803 2715 40 
H(23C) 2550 1226 2746 40 
H(8A) 1560 1725 487 19 
H(12A) -896 2339 1499 26 
H(13A) -2382 3298 1494 33 
H(14A) -2456 3912 809 38 
H(15A) -915 3585 132 37 
H(16A) 624 2643 137 27 
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Table A6.4.6 (cont’d) 
H(17C) -2485 1578 595 27 
H(17D) -2531 848 699 27 
H(18A) -2549 1167 -179 77 
H(19C) 673 689 15 111 
H(19D) -320 748 -504 111 
H(21D) 4647 139 269 50 
H(21E) 4094 -321 693 50 
H(21F) 5821 109 742 50 
H(23D) 2360 545 2938 54 
H(23E) 614 927 2797 54 
H(23F) 2470 1283 2847 54 
________________________________________________________________________________ 
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Table A6.5.1 Experimental Details 
Table A6.5.2 Crystal Data 
Table A6.5.3 Atomic Coordinates  
Table A6.5.4 Full Bond Distances and Angles 
Table A6.5.5 Anisotropic Displacement Parameters 
Table A6.5.6 Hydrogen Atomic Coordinates 
 
Figure A6.5.1      X-ray crystal structure of oxazolidine 375  
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Table A6.5.1 Experimental details for X-ray structure determination of oxazolidine 375 
Low-temperature diffraction data (and scans) were collected on a Bruker Kappa 
diffractometer coupled to a Apex II CCD detector with graphite monochromated Mo K 
radiation ( = 0.71073 Å) for the structure of oxazolidine 375.  The structure was solved 
by direct methods using SHELXS and refined against F2 on all data by full-matrix least 
squares with SHELXL-2013 refinement using established techniques.  All non-hydrogen 
atoms were refined anisotropically.  All hydrogen atoms were included into the model at 
geometrically calculated positions and refined using a riding model.  The isotropic 
displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value of the 
atoms they are linked to (1.5 times for methyl groups).  All disordered atoms were 
refined with the help of similarity restraints on the 1,2- and 1,3- distances and 
displacement parameters as well as rigid bond restraints for anisotropic displacement 
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Table A6.5.2 Crystal data and structure refinement for oxazolidine 375 
Empirical formula  C26 H25 N O7 S 
CCDC Deposition Number 973928 
Formula weight  495.53 
Crystallization solvent  Ethyl Acetate  
Crystal shape  block 
Crystal color  colourless  
Crystal size 0.34 x 0.39 x 0.41 mm 
Preliminary photograph(s)  rotation  
Type of diffractometer  Bruker APEX-II CCD 
Wavelength  0.71073 Å MoK 
Data collection temperature  100 K 
Theta range for 9033 reflections used 
in lattice determination  2.40 to 34.83° 
Unit cell dimensions a = 26.2830(13) Å α= 90° 
 b = 10.5471(5) Å β= 90° 
 c = 8.4772(4) Å γ = 90° 
Volume 2350.0(2) Å3 
Z 4 
Crystal system  orthorhombic 
Space group  P c a 21   (# 29) 
Density (calculated) 1.401 g/cm3 
F(000) 1040 
Theta range for data collection 1.9 to 35.2° 
Completeness to theta = 25.000° 99.8%  
Index ranges –42 ≤ h ≤ 41, –16 ≤ k ≤ 16, –13 ≤ l ≤ 13 
Reflections collected 85187 
Independent reflections 10087 [Rint= 0.0399] 
Reflections > 2s(I) 9439  
Average s(I)/(net I) 0.0240 
Absorption coefficient 0.19 mm-1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.9213   
Primary solution method  dual 
Hydrogen placement  geom 
Refinement method Full-matrix least-squares on F2 
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Table A6.5.2 (cont’d) 
Data / restraints / parameters 10087 / 13 / 538 
Treatment of hydrogen atoms  constr 
Goodness-of-fit on F2 1.19 
Final R indices [I>2s(I), 9439 reflections] R1 = 0.0430, wR2 = 0.1033 
R indices (all data) R1 = 0.0470, wR2 = 0.1048 
Type of weighting scheme used calc 
Max shift/error  0.001 
Average shift/error  0.000 
Absolute structure parameter 0.044(12) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.33 and -0.36 e·Å-3 
 
Programs Used  
Cell refinement   SAINT V8.32B (Bruker-AXS, 2007) 
Data collection   APEX2 2013.6-2 (Bruker-AXS, 2007) 
Data reduction   SAINT V8.32B (Bruker-AXS, 2007) 
Structure solution   SHELXT (Sheldrick, 2012) 
Structure refinement   SHELXL-2013/2 (Sheldrick, 2013) 
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Table A6.5.3       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for oxazolidine 375.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z Ueq 
________________________________________________________________________________   
S(1) 8926(1) 6201(1) 5357(1) 24(1) 
O(1) 8757(1) 5962(1) 6946(2) 28(1) 
O(2) 8828(1) 5297(2) 4131(2) 35(1) 
N(1) 8669(1) 7567(1) 4885(2) 21(1) 
C(1) 9589(1) 6443(2) 5403(3) 26(1) 
C(2) 9800(1) 7205(3) 6560(3) 36(1) 
C(3) 10325(1) 7313(3) 6651(3) 38(1) 
C(4) 10644(1) 6666(2) 5619(2) 32(1) 
C(5) 10424(1) 5912(2) 4466(3) 37(1) 
C(6) 9899(1) 5798(2) 4339(3) 32(1) 
C(7) 11214(1) 6743(3) 5801(3) 41(1) 
O(3) 8454(4) 9290(10) 3416(13) 31(2) 
O(4) 7331(1) 7845(3) 6401(4) 23(1) 
O(5) 7789(6) 6381(13) 5033(14) 20(1) 
O(6) 8103(1) 8362(3) 8651(3) 20(1) 
O(7) 8770(1) 9307(3) 7484(3) 18(1) 
C(8) 8655(4) 7986(7) 3269(11) 13(2) 
C(9) 8056(7) 9322(18) 4700(20) 22(3) 
C(10) 8209(5) 8173(18) 5850(20) 16(2) 
C(11) 9116(4) 8065(15) 2442(16) 21(2) 
C(12) 9471(3) 8980(7) 2868(7) 26(1) 
C(13) 9938(2) 9060(6) 2102(10) 40(1) 
C(14) 10053(3) 8198(8) 966(11) 44(2) 
C(15) 9701(3) 7272(7) 552(10) 44(2) 
C(16) 9233(3) 7206(6) 1270(9) 29(1) 
C(17) 8091(3) 10654(7) 5427(12) 13(1) 
C(18) 8430(3) 11443(5) 4959(11) 16(1) 
C(19) 8464(3) 12722(6) 5697(9) 24(1) 
C(20) 8107(2) 13055(4) 6806(6) 25(1) 
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Table A6.5.3 (cont’d) 
C(21) 7731(2) 12188(4) 7246(5) 19(1) 
C(22) 7720(2) 10989(4) 6570(5) 16(1) 
C(23) 7715(2) 7381(7) 5901(9) 17(1) 
C(24) 7324(6) 5619(14) 5180(20) 23(2) 
C(25) 8350(2) 8604(3) 7505(4) 14(1) 
C(26) 8860(2) 10020(4) 8925(4) 26(1) 
O(3A) 8459(2) 9216(8) 3393(7) 13(1) 
O(4A) 7556(1) 7446(3) 7202(4) 30(1) 
O(5A) 7767(6) 6217(12) 5341(14) 22(1) 
O(6A) 8992(1) 9186(3) 7025(4) 23(1) 
O(7A) 8266(1) 8980(3) 8372(3) 22(1) 
C(8A) 8668(6) 8051(11) 3175(15) 37(3) 
C(9A) 8106(5) 9189(15) 4546(18) 13(2) 
C(10A) 8303(5) 8102(13) 5730(17) 11(1) 
C(11A) 9229(3) 8166(12) 2597(11) 17(1) 
C(12A) 9556(2) 8999(5) 3331(6) 19(1) 
C(13A) 10052(2) 9131(4) 2790(6) 26(1) 
C(14A) 10225(2) 8406(6) 1527(6) 31(1) 
C(15A) 9903(3) 7558(7) 790(6) 30(1) 
C(16A) 9402(2) 7438(6) 1290(7) 25(1) 
C(17A) 8008(3) 10427(7) 5241(10) 15(1) 
C(18A) 8397(5) 11464(10) 5114(14) 45(3) 
C(19A) 8298(3) 12553(7) 5784(10) 38(2) 
C(20A) 7868(3) 12772(5) 6675(6) 39(1) 
C(21A) 7503(2) 11837(5) 6819(5) 36(1) 
C(22A) 7578(2) 10668(4) 6104(5) 26(1) 
C(23A) 7845(2) 7284(7) 6149(8) 16(1) 
C(24A) 7299(7) 5528(16) 5250(30) 41(4) 
C(25A) 8564(2) 8793(3) 7139(4) 14(1) 
C(26A) 8481(2) 9837(5) 9541(4) 31(1) 
________________________________________________________________________________ 
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Table A6.5.4       Bond lengths [Å] and angles [°] for oxazolidine 375 
___________________________________________________________________________________  
S(1)-O(1)  1.4406(16) 
S(1)-O(2)  1.4334(17) 
S(1)-N(1)  1.6401(16) 
S(1)-C(1)  1.762(2) 
N(1)-C(8)  1.440(10) 
N(1)-C(10)  1.592(12) 
N(1)-C(8A)  1.537(13) 
N(1)-C(10A)  1.326(11) 
C(1)-C(2)  1.384(3) 
C(1)-C(6)  1.393(3) 
C(2)-H(2)  0.9500 
C(2)-C(3)  1.386(3) 
C(3)-H(3)  0.9500 
C(3)-C(4)  1.390(3) 
C(4)-C(5)  1.386(4) 
C(4)-C(7)  1.510(3) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.389(4) 
C(6)-H(6)  0.9500 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
O(3)-C(8)  1.478(14) 
O(3)-C(9)  1.51(2) 
O(4)-C(23)  1.198(8) 
O(5)-C(23)  1.301(19) 
O(5)-C(24)  1.47(2) 
O(6)-C(25)  1.196(5) 
O(7)-C(25)  1.330(5) 
O(7)-C(26)  1.454(5) 
C(8)-H(8)  1.0000 
C(8)-C(11)  1.403(16) 
C(9)-H(9)  1.0000 
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Table A6.5.4 (cont’d) 
C(9)-C(10)  1.60(3) 
C(9)-C(17)  1.54(2) 
C(10)-C(23)  1.546(18) 
C(10)-C(25)  1.52(2) 
C(11)-C(12)  1.389(12) 
C(11)-C(16)  1.379(16) 
C(12)-H(12)  0.9500 
C(12)-C(13)  1.393(10) 
C(13)-H(13)  0.9500 
C(13)-C(14)  1.359(12) 
C(14)-H(14)  0.9500 
C(14)-C(15)  1.389(11) 
C(15)-H(15)  0.9500 
C(15)-C(16)  1.374(9) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.283(10) 
C(17)-C(22)  1.418(11) 
C(18)-H(18)  0.9500 
C(18)-C(19)  1.490(9) 
C(19)-H(19)  0.9500 
C(19)-C(20)  1.374(9) 
C(20)-H(20)  0.9500 
C(20)-C(21)  1.396(6) 
C(21)-H(21)  0.9500 
C(21)-C(22)  1.389(6) 
C(22)-H(22)  0.9500 
C(24)-H(24A)  0.9800 
C(24)-H(24B)  0.9800 
C(24)-H(24C)  0.9800 
C(26)-H(26A)  0.9800 
C(26)-H(26B)  0.9800 
C(26)-H(26C)  0.9800 
O(3A)-C(8A)  1.358(15) 
O(3A)-C(9A)  1.348(18) 
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Table A6.5.4 (cont’d) 
O(4A)-C(23A)  1.185(8) 
O(5A)-C(23A)  1.334(17) 
O(5A)-C(24A)  1.43(2) 
O(6A)-C(25A)  1.203(5) 
O(7A)-C(25A)  1.320(4) 
O(7A)-C(26A)  1.455(5) 
C(8A)-H(8A)  1.0000 
C(8A)-C(11A)  1.558(17) 
C(9A)-H(9A)  1.0000 
C(9A)-C(10A)  1.61(2) 
C(9A)-C(17A)  1.456(19) 
C(10A)-C(23A)  1.523(15) 
C(10A)-C(25A)  1.558(16) 
C(11A)-C(12A)  1.378(11) 
C(11A)-C(16A)  1.423(12) 
C(12A)-H(12A)  0.9500 
C(12A)-C(13A)  1.391(7) 
C(13A)-H(13A)  0.9500 
C(13A)-C(14A)  1.393(7) 
C(14A)-H(14A)  0.9500 
C(14A)-C(15A)  1.380(8) 
C(15A)-H(15A)  0.9500 
C(15A)-C(16A)  1.390(8) 
C(16A)-H(16A)  0.9500 
C(17A)-C(18A)  1.500(13) 
C(17A)-C(22A)  1.371(11) 
C(18A)-H(18A)  0.9500 
C(18A)-C(19A)  1.307(14) 
C(19A)-H(19A)  0.9500 
C(19A)-C(20A)  1.379(11) 
C(20A)-H(20A)  0.9500 
C(20A)-C(21A)  1.381(9) 
C(21A)-H(21A)  0.9500 
C(21A)-C(22A)  1.388(6) 
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Table A6.5.4 (cont’d) 
C(22A)-H(22A)  0.9500 
C(24A)-H(24D)  0.9800 
C(24A)-H(24E)  0.9800 
C(24A)-H(24F)  0.9800 
C(26A)-H(26D)  0.9800 
C(26A)-H(26E)  0.9800 
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Symmetry transformations used to generate equivalent atoms:  
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Table A6.5.5  Anisotropic displacement parameters  (Å2x103) for oxazolidine 375.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S(1) 307(2)  186(2) 231(2)  33(2) -63(2)  -10(2) 
O(1) 299(7)  260(6) 277(7)  110(5) -33(6)  3(5) 
O(2) 504(10)  189(6) 359(8)  -28(6) -108(7)  -39(6) 
N(1) 222(7)  202(6) 190(6)  63(5) -40(5)  -31(5) 
C(1) 303(8)  267(8) 212(7)  15(7) -14(8)  46(6) 
C(2) 286(10)  507(13) 276(10)  -125(9) 36(8)  -28(9) 
C(3) 307(11)  485(13) 337(11)  -73(10) 37(9)  -18(10) 
C(4) 296(9)  390(10) 257(10)  110(8) 35(7)  86(8) 
C(5) 410(12)  399(12) 294(10)  26(9) 30(9)  217(10) 
C(6) 417(11)  278(9) 275(9)  -42(7) -51(8)  135(9) 
C(7) 304(10)  553(15) 381(12)  187(11) 61(9)  93(10) 
O(3) 460(40)  160(30) 310(40)  0(20) 120(30)  110(30) 
O(4) 174(12)  241(13) 269(14)  -59(11) 87(10)  -40(10) 
O(5) 190(17)  160(30) 240(40)  -20(20) -30(20)  -50(20) 
O(6) 217(12)  216(13) 152(11)  5(9) 47(9)  -27(10) 
O(7) 153(13)  231(13) 161(11)  -15(10) -1(10)  -22(11) 
C(8) 230(30)  62(19) 100(30)  -50(18) -40(20)  -7(18) 
C(9) 150(30)  330(60) 170(40)  120(40) 70(20)  30(30) 
C(10) 160(50)  180(30) 140(20)  -39(17) 70(30)  0(30) 
C(11) 240(40)  190(20) 200(30)  0(20) -60(20)  -20(30) 
C(12) 250(30)  340(20) 200(30)  -40(20) -40(20)  -1(19) 
C(13) 240(20)  470(30) 510(40)  130(30) -50(20)  -60(20) 
C(14) 290(30)  460(40) 590(50)  160(40) 210(30)  110(30) 
C(15) 500(40)  320(30) 490(40)  40(30) 300(40)  140(30) 
C(16) 410(40)  180(20) 280(20)  -15(17) 140(30)  0(20) 
C(17) 90(30)  90(20) 200(30)  15(18) 7(19)  -23(16) 
C(18) 220(20)  15(15) 230(30)  -4(13) 16(19)  2(14) 
C(19) 320(30)  90(20) 330(20)  38(15) 50(20)  -60(18) 
C(20) 340(20)  119(15) 290(20)  -3(14) -48(18)  14(15) 
C(21) 245(17)  156(15) 180(16)  -8(13) -10(14)  27(13) 
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Table A6.5.5 (cont’d) 
C(22) 171(16)  153(15) 149(15)  -6(11) -8(12)  -31(12) 
C(23) 190(30)  180(20) 140(20)  25(15) -25(17)  -80(20) 
C(24) 220(30)  130(20) 350(50)  10(30) -40(30)  -10(30) 
C(25) 133(15)  148(13) 145(15)  4(11) 12(12)  34(12) 
C(26) 303(19)  281(18) 184(16)  -36(13) -26(13)  -96(15) 
O(3A) 140(20)  190(30) 70(20)  66(16) -31(17)  -61(18) 
O(4A) 256(14)  344(14) 299(15)  -66(12) 118(12)  -107(12) 
O(5A) 260(20)  140(30) 270(40)  0(20) -50(30)  -14(18) 
O(6A) 177(13)  288(13) 215(12)  -71(10) 12(10)  -61(10) 
O(7A) 191(11)  331(15) 125(10)  -33(10) 4(9)  -16(10) 
C(8A) 500(60)  380(50) 210(30)  200(30) -110(30)  -90(30) 
C(9A) 70(30)  190(20) 120(30)  32(17) -20(30)  -40(30) 
C(10A) 150(40)  90(20) 90(30)  0(17) 30(20)  -30(20) 
C(11A) 220(40)  210(30) 90(20)  -4(17) 10(20)  20(30) 
C(12A) 210(20)  216(16) 150(20)  -35(17) 29(16)  -32(15) 
C(13A) 225(18)  255(18) 290(20)  37(15) 101(16)  -5(14) 
C(14A) 260(20)  390(20) 290(20)  84(19) 134(17)  40(20) 
C(15A) 320(30)  390(30) 182(17)  24(19) 100(20)  120(20) 
C(16A) 310(30)  270(30) 175(16)  2(16) 17(19)  21(19) 
C(17A) 140(30)  140(30) 170(20)  58(19) -45(16)  -15(17) 
C(18A) 500(50)  630(60) 210(30)  0(30) 10(30)  250(40) 
C(19A) 540(50)  150(20) 440(30)  31(19) -160(30)  -80(30) 
C(20A) 660(40)  220(20) 290(20)  -85(19) -130(30)  210(20) 
C(21A) 550(30)  320(20) 207(17)  30(16) 42(19)  250(20) 
C(22A) 310(20)  248(18) 212(18)  64(14) 66(15)  117(16) 
C(23A) 160(30)  163(16) 140(20)  -14(14) -3(16)  -17(18) 
C(24A) 420(50)  300(50) 510(80)  -30(50) -110(50)  -210(30) 
C(25A) 146(15)  150(13) 116(12)  12(10) -2(12)  17(12) 
C(26A) 312(18)  480(20) 150(14)  -139(15) -44(13)  16(17) 
______________________________________________________________________________ 
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Table A6.5.6      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for oxazolidine 375 
________________________________________________________________________________  
 x  y  z  Uiso 
________________________________________________________________________________  
  
H(2) 959 765 728 43 
H(3) 1047 784 744 45 
H(5) 1064 546 375 44 
H(6) 975 529 354 39 
H(7A) 1131 760 612 62 
H(7B) 1138 654 479 62 
H(7C) 1133 614 661 62 
H(8) 841 745 266 16 
H(9) 771 918 425 26 
H(12) 939 956 369 31 
H(13) 1017 971 237 48 
H(14) 1037 823 45 53 
H(15) 979 667 -24 52 
H(16) 899 658 96 35 
H(18) 866 1121 414 19 
H(19) 873 1330 541 29 
H(20) 811 1387 727 30 
H(21) 748 1242 801 23 
H(22) 747 1040 687 19 
H(24A) 737 481 462 35 
H(24B) 704 608 471 35 
H(24C) 725 545 629 35 
H(26A) 909 1074 870 38 
H(26B) 902 947 971 38 
H(26C) 854 1034 933 38 
H(8A) 846 751 246 44 
H(9A) 778 889 407 15 
H(12A) 944 948 421 23 
H(13A) 1028 972 329 31 
H(14A) 1057 850 117 38 
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Table A6.5.6 (cont’d) 
H(15A) 1003 706 -6 36 
H(16A) 918 687 76 30 
H(18A) 871 1133 456 54 
H(19A) 853 1323 565 45 
H(20A) 782 1356 719 47 
H(21A) 720 1199 740 43 
H(22A) 733 1003 622 31 
H(24D) 706 597 455 62 
H(24E) 715 547 631 62 
H(24F) 736 467 485 62 
H(26D) 851 1069 909 47 
H(26E) 882 954 985 47 
H(26F) 826 986 1047 47 
________________________________________________________________________________  





Progress toward the Total Synthesis of Calophyline A 
 
 
4.1  INTRODUCTION 
Calophyline A is a monoterpenoid indole alkaloid isolated in 2012.  Although it has 
no known biological activity, we were interested in its unusual caged structure, likely the 
result of a rearrangement of an akuammaline alkaloid precursor.  This chapter briefly 
describes the isolation and proposed biosynthesis of calophyline A, summarizes a total 
synthesis recently disclosed by Zu and co-workers, and then proceeds to discuss the 
various synthetic strategies pursued by our research laboratory. 
 
4.1.1  ISOLATION AND PROPERTIES OF CALOPHYLINE A 
Calophyline A (387, Figure 4.1) is a monoterpenoid alkaloid isolated by Zou, Li, and 
co-workers in 2012 from the trunk bark of the Winchia calophylla A. DC. (Apocynaceae) 
tree of Yunnan Province and Hainan island in southern China.1  The leaves and trunk 
bark of W. calophylla have been used in traditional Chinese medicine for the treatment of 
Chapter 4 – Progress toward the Total Synthesis of Calophyline A  523 
various respiratory conditions.  The structure of 387 was determined by 
spectroscopic methods and confirmed by X-ray crystallographic analysis.  Although other 
compounds found in the bark of W. calophylla are known to posess modest activity 
against prostate and breast cancer, calophyline A displayed no such activity.  
 
Figure 4.1  Structure of calophyline A 
 
 
4.1.2  TANTILLO’S BIOSYNTHETIC PROPOSAL 
In their isolation report, Zou, Li, and co-workers recognized calophylin A as a 
rearranged monoterpenoid indole alkaloid with an unpreccedented 7/5 ring system  and 
proposed the known alkaloid rhazimol (388, Scheme 4.1) as a biosynthetic precursor.  
Their isolation report includes a proposed biosynthesis from rhazimol,1 but subsequent 
computational studies by Tantillo and co-workers found a key rearrangement step to be 
energetically unviable.2  Tantillo proposed the alternative biosynthesis shown in Scheme 
4.1, which avoids this unlikely rearrangement and relies instead upon biologically 
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oxidized to hemiaminal 389, which opens to ketone 390.  Tautomerization to the 
enol (391) and conjugate addition of the secondary amino group into the α,β-unsaturated 
imine affords enamine 392, which tautomerizes to imine 393.  Formation of the 
tetrahydrofuran ring provides 394 and oxdiation to reform the C10 ketone and N-
methylation complete the biosynthesis of calophyline A. 
 
Scheme 4.1  Tantillo’s proposal for the biosynthesis of calophyline A3 
 
 
4.1.3  ZU’S TOTAL SYNTHESIS 
In 2016, Zu and co-workers reported the first total synthesis of calophyline A.  
Retrosynthetically, they simplified calophyline A to 396 by a late-stage aldol addition 
into formaldehyde (Scheme 4.2).  This was further diconnected using a Heck cyclization 
to afford iodide 397, which would be accessed from cyclohexanol 399 via ketone 398.  In 
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the key step, 399 would be formed by an aza-pinacol rearrangement4,5 of 
spirocycle 400, itself readily available from known indoline 401.4 
 
Scheme 4.2  Zu’s retrosynthesis of calophyline A 
 
In the forward direction, 401 was advanced to aza-pinacol substrate 400 over a three step 
sequence (Scheme 4.3).  Heating triol 400 with trifluoroacetic acid promoted the key 
cascade reaction, which consists of indoline deprotection, aza-pinacol rearrangement, 
selective dehydration to form an α,β-unsaturated imine, and conjugate addition of the 
sulfonamide group, affording 399 in 76% yield.  A series of functional group 
interconversions and alkylation with bromide 402 furnished vinyl iodide 397, which was 
advanced to aldehyde 403 by an intramolecular Heck reaction.  A three step sequence 
effected indoline deprotection, indolenine formation, and ketone installation to afford 
404.  Finally, aldol reaction with formaldehyde installed the hydroxymethyl bridge and a 
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Scheme 4.3  Zu’s total synthesis of calophyline A 
 
 
4.2  INVESTIGATION OF A CYCLOPROPANE CYCLOADDITION 
ROUTE TOWARD THE SYNTHESIS OF CALOPHYLINE A 
Our initial synthetic plan was inspired by our previous studies of formal 
cycloadditions of cyclopropanes.  We predicted that a C2–C3 cyclopropanated indole 
would be reactive enough to undergo formal (3 + 3) cycloaddition with an appropriate 
1,3-dipole to construct the central cyclohexanone ring. 
 
4.2.1  RETROSYNTEHTIC ANALYSIS  
Retrosynthetically we envisioned calophyline A would arise from pentacycle 405 by 

























































(50% yield, two steps)
2. NaClO2, NaH2PO4, t-BuOH/H2O
I Me
Br 402
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salt (Scheme 4.4).  The cyclohexanone ring of 405 would be assembled by a (3 + 
3) reaction between a cyclopropanated indole such as 407 and a suitable dipole (406).  
Cyclopropane 407 would be accessed from commercially available tryptophol (408). 
 
Scheme 4.4  Initial retrosynthetic analysis 
 
 
4.2.2  ATTEMPTS TO SYNTHESIZE CYCLOPROPANATED INDOLES 
Although (3 + 3) cycloadditions between cyclopropanes and 1,3-dipoles are not 
commonly known,6 we initially approached the route with a focus on exploring the 
reactivity of cyclopropanated indoles such as 407 (Scheme 4.4).  While the synthesis and 
reactivity of several cyclopropanated indoles have been disclosed,7,8 we were interested in 
compounds posessing two geminal acceptor groups, which should increase the 
cyclopropane reactivity and would be synthetically useful in a route to calophyline A. 
We began our studies with efforts to synthesize a variety of C2–C3 cyclopropanated 
indoles beginning with those posessing geminal acceptor groups.  To investigate the 
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subjected to the two-step sequence shown in Scheme 4.5 to access diazomaloantes 
411 and 412.  Upon treatment with various cyclopropanation conditions,9 however, only 
decomposition, carbenoid dimerization, or Boc cleavage results were obtained.  
 
Scheme 4.5  Attempted syntheses of cyclopropanated indoles with two acceptor groups 
 
Suspecting that the combination of two acceptor groups and a strong nitrogen donor 
group was too polarizing for cyclopropane stability, we chose to synthesize various 
cyclopropanes with only one acceptor group in the hope they would be isolable.  
Trytophol (408) was advanced to 415 in good yield using Fukuyama’s procedure for 
diazoacetate synthesis (Scheme 4.6A).10  Protection of the indole nitrogen with a Boc 
group furnished diazoacetate 416.  A more electron-rich indole was incorporated by 
reacting N-methyl tryptophol (409) with acid chloride 417 and in situ sulfinate 
elimination (Scheme 4.6B).11  Unfortunately, despite an examination of various catalysts, 
we were unable to form the desired cyclopropanes (420 and 421), with most conditions 




R = Me, 409
R = Boc, 410
1. methyl malonyl chloride
    DMAP, Et3N, CH2Cl2, 0→23 °C
2. p-ABSA, Et3N, MeCN, 0→23 °C NR
O
R = Me, 411













R = Me, 413
R = Boc, 414
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Scheme 4.6  Attempted syntheses of cyclopropanated indoles with one acceptor group 
 
 
4.2.3  DISCOVERY OF A (3 + 2) CYCLOADDITION RESULT AND THE 
DESIGN OF A NEW SYNTHETIC STRATEGY 
In light of our inability to achieve an indole cyclopropanation using either acceptor–
acceptor diazo substrates such as 411 or 412 or acceptor diazo substrates like 416 or 419, 
we chose to investigate a donor–acceptor diazo substrate.  Reactions of donor–acceptor 
carbenoids (derived from donor–acceptor diazo compounds) are often more selective than 
those of other carbenoids due to the stabilizing effect of the electron-donating group 
(Scheme 4.7A).12  Furthermore, Qin and co-workers made use of a donor–acceptor diazo 






















OH 1. bromoacetyl bromide
    NaHCO3, MeCN, 0 °C
2. TsHN–NHTs, DBU


























































R = Me, 420
R = Boc, 421
R = Me, 419
R = Boc, 416
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Scheme 4.7  A) General classes of diazo compounds.  B) Qin’s use of a donor–acceptor 
diazo compound cyclopropanation in a total synthesis 
 
In our case, cyclopropanation with an aryldiazo compound similar to 425 would 
produce a cyclopropane likely insufficiently reactive to undergo a desired cycloaddition 
reaction.  Additionally, the aryl group would ultimately need to be removed, which we 
anticipated to be challenging.  However, Davies and co-workers have shown that styrenyl 
diazoacetates also form donor–acceptor carbenoids when treated with rhodium 
catalysts.13  If we were to use a styrenyl diazoacetate substrate in our cyclopropanation,13 
a simple oxidative cleavage of the styrene olefin could install an acceptor group where 
needed on the cyclopropane framework. 
 
4.2.4  ATTEMPTS TO FORM THE CALOPHYLINE CORE BY A (3 + 
2)/CYCLOPROPANATION/FRAGMENTATION STRATEGY 
To explore this idea, we synthesized diazoester 428 from known carboxylic acid 427 
and subjected it to cyclopropanation conditions.  Although we did not observe formation 
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dichloromethane furnished tetracycle 429 in 32% yield (Scheme 4.8 and Figure 
4.2).  This result is perhaps unsurprising, as Davies has reported the analgous rhodium-
catalyzed intermolecular (3 + 2) cyloaddition between indoles and vinyl diazoacetates.14 
 
Scheme 4.8  Synthesis and reaction of styrenyl diazoacetate 428 
 
Figure 4.2  Crystal structure of tetracycle 429  
 
 We imagined a (3 + 2) cycloaddition reaction could be productive if the phenyl 
substitutent was replaced with a group that could act as an electrofuge in a later 
fragmentation step (432→433, Scheme 4.9).  More specifically, we envisioned (3 + 2) 
cycloadduct could be cyclopropanated to afford 432, which could then be converted to 
tetracycle 433 by a cyclopropane fragmentation step.  Closure of the pyrrolidine ring by 
epoxide opening would furnish 434, which after oxidation would be advanced to 









    DCC, DMAP
    CH2Cl2, 0→23 °C
2. p-ABSA, DBU
    MeCN, 0→23 °C
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Scheme 4.9  Revised synthetic plan for calophyline A 
 
To explore the feasibility of this revised plan, we synthesized a variety of vinyl 
diazoacetates and subjected them to metal-catalyzed dediazotization conditions.  The 
results are shown in Scheme 4.10.  Unfortunately, despite investigating compounds with 
either olefin geometry containing various R2 groups which could serve as the deisred 
electrofuge (or readily be converted to an electrofugre) such as carboxylates and a furan 
rings (entries 2–8), we were unable to observe the desired cycloaddition reaction.  The 
use of a diazo enol silane substrate, which would form a cyclopentanone product 
following desilylation, was also unsuccessful.  Our attempts to investigate substrates 
containing other R2 groups, including TMS, SnBu3, and styrenyl, were frustrated by 
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Scheme 4.10  Unsuccessful (3 + 2) cycloadditions of various vinyl diazoacetates 
 
Concurrently with our efforts to indentify a (3 + 2) cycloaddition substrate, we briefly 
examined a few cyclopropanation conditions, using tetracycle 429 as a model system 
(Scheme 4.11).  To our disappointment, treatment with either standard Corey–
Chaykovsky conditions (entry 1) or a substituted sulfur ylide (entry 2) resulted in little 
reaction.  Exposure to the rhodium carbenoid derived from ethyl diazoacetate led to 
decomposition (entry 3).  At this point we concluded our studies of an indole-vinyl 
diazoacetate (3 + 2) cycloaddition/cyclopropanation/fragmentation approach in favor of 













catalyst (<1 mol %)
CH2Cl2 or 1:1 CH2Cl2/Ph
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Reactions conducted on approx. 0.05 mmol scale by adding a solution of the substrate to a solution of the catalyst over one hour.
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Scheme 4.11  Attempts to cyclopropanate tetracycle 429 
 
 
4.3  INVESTIGATION OF A [4 + 2] CYCLOADDITION ROUTE 
TOWARD THE SYNTHESIS OF CALOPHYLINE A 
After our lack of success with the initial (3 + 3) disconnection or the (3 + 
2)/cyclopropanation/fragmentation sequence, we began to consider disconnections not 
involving cyclopropane intermediates.  Our efforts toward a synthesis with a key [4 + 2] 
cycloaddition step are presented in this section.  
 
4.3.1  RETROSYNTHETIC ANALYSIS 
Preserving our endgame strategy, we envisioned that calophyline could be accessed 
by a series of transformations from a pentacycle such as 439, which itself could arise 
from enone 440 by a radical conjugate addition (Scheme 4.12).  Installation of the 
allylamino group would be accomplished by amine opening of epoxide 441, which would 
in turn be accessed from cyclohexadiene 442.15  We planned to construct the 
cyclohexadiene ring by a cascade reaction initiated by an intramolecular [4 + 2] 



















1 low conversionHMe3S(O)I, NaH, DMF, 23 °C
2 no reactionC(O)Ph[PhC(O)CH2SMe2]Br, K2CO3, MeCN, 23→80 °C
3 decompositionCO2EtEDA, Rh2(OAc)4, CH2Cl2, 23→50 °C
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or ether (X = H2) linkage.  Cycloaddition precursors would be readily aviailable 
from tryptophol. 
 
Scheme 4.12  General retrosynthetic analysis for a [4 + 2] route to calophyline A 
 
Perhaps the most common cycloddition approach for the formation of 
cyclohexadienes is a [4 + 2]/retro-[4 + 2] stragey.  This is often carried out with pyrone 
dienes, extruding carbon dioxide to afford cyclohexadiene products, a strategy commonly 
seen in complex molecule synthesis.16  While only a single report of pyrone-indole 
cycloaddition reactions is known (Scheme 4.13A),17 similar reactions of pyridazines 
(extruding nitrogen gas)18 and thiophene-1,1-dioxides (extruding sulfur dioxide)19 have 
been successfully carried out with indole dipolarophiles, leading to the fused 
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Scheme 4.13  Reaction of pyrones (A), pyridazines (B), and thiophene-1,1-dioxides (C) in [4 
+ 2]/retro [4 + 2] sequences 
 
An alternative cycloaddition-based approach could involve application of a 
cyclobutadiene cycloaddition.  Snapper and co-workers have reported that tethered 
cyclobutadienes (unmasked in situ from the cyclobutadienyliron tricarbonyl complex by 
treatment with an oxidant) readily undergo cycloadditions with proximal olefins to afford 
fused cyclobutene products (Scheme 4.14).20  Upon heating, these strained products are 
smoothly converted to the cyclohexadienes by a 4π electrocyclic ring opening step.  A 
unique advantage of the method is the ability to engage non-activated olefins as 
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4.3.2  ATTEMPTS TO ACHIEVE THE DESIRED [4 + 2] CYCLOADDITION 
In the forward direction, we began our studies with a pyridazine diene.  Coupling of 
3-pyridazine carboxylic acid (456) with tryptophol afforded ester 457, which was heated 
in diethylaniline in a microwave (Scheme 4.15A).  Unfortunately, no reaction was 
observed, which may be due to the preferred s-cis conformation of the ester linkage21 
preventing the substrate from adopting a reactive orientation.  Although we were unable 
to access a 3-hydroxymethylpyridazine building block to create the necessary ether 
linkage (which would require a subsequent allylic oxidation to install the ester functional 
group), we thought it would remain feasible to access the product from a substrate with a 
three-carbon ether tether, such as 462 (Scheme 4.15B).  To this end, we synthesized aryl 
ethers 460 and 461 by nucleophilic aromatic substitution reactions with readily avialable 
3,6-dichloropyridazine and heated them in diethylaniline.  Unsurprisingly, the Boc group 
of 460 was lost, but no further reactivity was observed.  In the case of the very electron-

















(70% yield) (97% yield)
220 °C
pentane
Chapter 4 – Progress toward the Total Synthesis of Calophyline A  538 
Scheme 4.15  Attempts to apply an indole-pyridazine [4 +2]/retro-[4 + 2] cycloaddition 
toward the synthesis of calophyline A 
 
 
Concurrently with our investigations into indole-pyridazine cycloadditions, we 
carried out studies of similar cycloadditions of thiophene-1,1-dioxides.  We initially 
synthesized an ester-linked substrate by coupling tryptophol with thiophene-2-carboxylic 
acid and subsequent oxidation of the thiophene sulfur using m-CPBA (Scheme 4.16A).  
While the oxidation was successful, the thiophene-1,1-dioxide was impossible to separate 
from excess reagent and benzoic acid byproduct.  The mixture was heated in 
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R = PMB, 459
R = Boc, 460
R = PMB, 461
R = Boc, 462




Chapter 4 – Progress toward the Total Synthesis of Calophyline A  539 
Scheme 4.16  A) An attempt to apply an ester-linked indole-thiophene-1,1-dioxide [4 
+2]/retro-[4 + 2] cycloaddition toward the synthesis of calophyline A.  B) Attempts to oxidize 
thiopene-2-carboxylic esters. 
 
To circumvent the issues with purification of the coupled thiophene-1,1-dioxide, we 
attempted to couple a tryptophol partner to the fully oxidized thiophene dioxide directly.  
A straightforwad approach would involve oxidation of a simpler thiophene-2-carboxylic 
ester, cleavage to the carboxylic acid, and coupling to tryptophol.  Unfortunately, 
attempts to access the necessary thiophene dioxides using several different conditions 
were not successful (Scheme 4.16B).  Oxidations of protected 2-hydroxymetylthiophenes 
were also unsuccessful. 
N
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2.  m-CPBA, MeOH
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Realizing that the ester linkage between the indole and diene fragments was 
likely problematic, we directed efforts toward the synthesis of an ether-linked substrate.  
Despite exploring a variety of bases, solvents, and leaving groups, efforts to couple 2-
hydroxymethylthiophene (473) with indole-containing electrophiles and efforts to couple 
2-bromomethylthiophene (476) with tryptophols were not successful (Scheme 4.17). 
 
Scheme 4.17  Attempted synthesis of an ether-linked indole-thiophene-1,1-dioxide cycloaddition 
substrate 
 
As an alternative to the intramolecular cycloadditions discussed above, we also 
briefly examined the possibility of an intermolecular reaction.  If known 2,5-
dibromothiophene-1,1-dioxide (477, Scheme 4.18) were used as the diene, a palladium-
catalyzed carbonylative esterification reaction would transform the cycloadduct (478) 
into a cyclohexadiene very similar to the desired intramolecular cycloaddition products 
(479).  Disappointingly, 477 failed to show any reactivity when heated with tryptophol or 
protected variants.  Diene 477 also failed to react with indole, suggesting it may not be 
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Scheme 4.18  Unsuccessful intermolecular cycloadditions with 2,5-dibromothiophene-1,1-
dioxide 
 
Despite only a single method for pyrone-indole [4 + 2] reactions, we briefly explored 
such an approach in our synthesis.  Perhaps unsurprisingly, the intermolecular reactions 
were unsuccessful, with no reactivity observed (Scheme 4.19). 
 
Scheme 4.19  Unsuccessful intermolecular cycloadditions with a pyrone diene 
 
Finding the [4 + 2]/retro-[4 + 2] step to be challenging, we turned our attention to a 
final [4 + 2] strategy: the use of a cyclobutadiene Diels–Alder/electrocyclic ring opening 
sequence.  Iron complex 487 was prepared from dimethyl malonate (485) and 1,1,3,3-
tetramethoxypropane (486) according to literature proceedures (Scheme 4.20A).22,23  The 
ester-linked cycloaddition substrate was available in a single step by DCC coupling, 
albeit in low yield.  Exposure to ceric ammonium nitrate (CAN) to promote oxidative 
unmasking of the cyclobutadiene moeity and cycloaddition resulted in only unidentifiable 
decomposition products, likely due to competitive oxidation or nitration of the indole ring 
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The preparation of an ether-linked substrate was briefly attempted, using 
known hydroxymethyl-substituted cyclobutadienyliron complex 49125 (Scheme 4.20C).  
We were disappointed to note that Brønsted or Lewis acid catalyzed methods were not 
able to successfully couple 491 to tryptophol.  Future studies could include reaction of a 
tryptophol derivative with the trichloroacetimidate 49325 or known bromomethyl-
substituted cyclobutadienyliron complex 494.26 
 
Scheme 4.20  Exploration of an indole-cyclobutadiene [4 + 2]/electrocyclic ring opening sequence 
 
 
4.4  INVESTIGATION OF A [2 + 2 + 2] CYCLOADDITION ROUTE 
TOWARD THE SYNTHESIS OF CALOPHYLINE A 
Despite our lack of success with a [4 + 2] cycloaddition strategy, we remained 










































CAN, acetone, 23 °C
















Brønsted or Lewis acid Fe(CO)3
X
X = C(NH)CCl3, 493
X = Br, 494
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such a compound by a different method.  We focused on an intramolecular [2 + 2 
+ 2] cycloaddition between two alkynes and an alkene, a method frequently used for the 
construction of complex cyclohexadienes from relatively simple precursors.27 
 
4.4.1  SYNTHETIC PRECEDENT AND RETROSYNTHETIC ANALYSIS 
We reasoned that engaging the indole C2–C3 bond as the alkene partner in an 
intramolecular alkene-alkyne-alkyne [2 + 2 + 2] cycloaddition could form a 
cyclohexadiene similar  to the desired intermediate of the [4 + 2] route previsouly 
discussed.  Examples of [2 + 2 + 2] cycloadditions utilizing the indole C2–C3 bond as a 
2π component are known, with Vollhardt reporting several examples.28  Substrates with 
the alkyne units tethered at either the indole nitrogen or at both the nitrogen and the C3 
position are known to be successful, and some intermolecular examples are shown as 
well.  One example from Vollhardt’s laboratory is shown in Scheme 4.21. 
 
Scheme 4.21  An example of a [2 + 2 + 2] cycloaddition engaging the indole C2–C3 bond28c 
 
Retrosynthetically, we envisioned that calophyline could be accessed from pentacycle 
497, itself formed from cyclohexadiene 498 by various olefin functionalizations (Scheme 
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cycloadditions of a substrate such as 499, which would be available from 
tryptophol (408).  
Scheme 4.22  Retrosynthetic analysis employing a [2 + 2 + 2] cycloaddition 
 
 
4.4.2  EXPLORATION OF A [2 + 2 + 2] STRATEGY 
Given that no examples existed of intramolecular [2 + 2 + 2] cycloadditions between 
an indole C2–C3 bond and a diyne fragment tethered at the indole 3-position, we chose to 
perform preliminary studies on a more readily available model system rather than the 
ynamide shown in Scheme 4.22.  To construct such a system, N-Boc tryptophol was O-
propargylated with bromide 500 to afford diyne 501 (Scheme 4.23).  A portion of this 
material was subjected to silylation of the terminal alkyne to install a group suitable for 
subsequent Tamao–Fleming oxidation.  With these two substrates in hand, a variety of 
catalysts were screened for activity in the desired cycloaddition reaction.  Unfortunately, 
only decomposition or a lack of reactivity were observed.  Given the difficulties in 
achieving the necessary reactivity in a simple model system, we elected to conclude 
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Scheme 4.23  Investigation of an intramolecular [2 + 2 + 2] cycloaddition toward the total 
synthesis of calophyline A 
 
 
4.5  FUTURE DIRECTION: CONSIDERATION OF A BROMOOXINDOLE 
ALKYLATION ROUTE TOWARD THE SYNTHESIS OF CALOPHYLINE A 
A potential future route to explore involves the creation of the quaternary stereocenter 
at the indole C3 position by using the bromooxindole alkylation methodology previously 
developed in our laboratory.  In 2007, our research group reported the facile reaction of 
unsubstituted malonates with 3-bromooxindoles to form all-carbon quaternary 
stereocenters,29 and the asymmetric variant was reported in 2009 (Scheme 4.24A).30  Our 
laboratory later applied the analogous reaction with a 2-aryl malonate in the formal 
syntheses of communesin F and perophoramidine (Scheme 4.24B).31  Although the 
conditions as presently optimized are not ideal for reactions of 2-alkylmalonate 
nucleophiles, an unpublished example with 2-allyl diethyl malonate is known, forming 3-
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Scheme 4.24  Reactions of 3-bromooxindoles with malonate nucleophiles 
 
The proposed route to calophyline A would commence with an alkylation product 
such as 512 (Scheme 4.24C).  Wacker oxidation would afford methyl ketone 513, which 
would then undergo an intramolecular condensation33 to furnish tricycle 514.  This 
intermediate could be converted to tetracycle 515 by hydroxyl deprotection and 
diastereoselective lactonization.  This compound could conceivably be advanced to 
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Scheme 4.25  A potential oxindole alkylation route to calophyline A 
 
 
4.6  CONCLUSIONS 
In summary, our efforts toward the total synthesis of calophyline A are described, 
including routes featuring a cyclopropanated indole (3 + 3) cycloaddition, an indole-vinyl 
diazoacetate (3 + 2) cycloaddition, an indole-diene [4 + 2]/retro-[4 + 2] or [4 + 
2]/electrocyclic ring opening cascade, and an indole-diyne [2 + 2 + 2] cycloaddition.  
Future studies may include consideration of a bromooxindole alkylation approach. 
 
4.7  EXPERIMENTAL SECTION 
4.7.1   MATERIALS AND METHODS 
Unless noted in the specific procedure, reactions were performed flame- or oven-
dried glassware under an argon or nitrogen atmosphere.  Dried and deoxygated solvents 
(Fisher Scientific) were prepared by passage through columns of activated aluminum 
before use.34 Triethylamine was distilled from calcium hydride immediated prior to use.  
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tryptophol (410),37 acid chloride 417,11 carboxylic acid 427,38 N-(4-
methoxybenzyl)tryptophol (459),37 thiophene 467,39 thiophene 470,40 thiophene dioxide 
477,41 pyrone 481,22 iron complex 487,23 iron complex 491,25 malonate 517,42 and 
dibromide 51843 were prepared according to literature procedures.  N,N’-ditosylhydrazine 
was prepared as described by Fukuyama.10  Tryptophol (408) is commercially available, 
but may also be synthesized according to a literature proceedure.44  Thiophene-2-
carboyxlic acid (454), pyridazine-3-carboxylic acid (456), dimethylmalonate (485), 
1,1,3,3,-tetramethoxypropane (486), and 3,6-dichloropyridazine were purchased from 
commercial suppliers and used as received, as were all other reagents.  Copper(I) 
trifluoromethanesulfonate benzene comples, copper(I) trifluoromethanesulfonate toluene 
complex, copper(II) acetylacetonate, copper(II) trifluoromethanesulfonate, copper(I) 
chloride, copper(I) bromide dimethylsulfide complex, tetrakis(acetonitrile)copper(I) 
hexafluorophosphate, copper(II) hexafluoroacetylacetonate, copper(II) isobutyrate, 
silver(I) trifluoromethanesulfonate, silver(I) hexafluorophosphate, silver(I) 
acetylacetonate, iron(III) acetylacetonate, rhodium(II) acetate, rhodium(II) 
trifluoroacetate, cyclooctadiene rhodium chloride dimer, cymeme ruthenium dichloride 
dimer, IPrAuCl, cyclopentadienylcobalt chloride dicarbonyl, dicobalt octacarbonyl, 
cobaltocene, decamethylcobaltocene, tetrakis(triphenylphosphine)palladium(0), 
cyclooctadiene iridium chloride dimer, and lithium hexamethyldisilazide were stored in a 
nitrogen-filled glovebox.  Brine is defined as a saturated aqueous solution of sodium 
chloride.  Reactions requiring external heat were modulated to the specified temperatures 
using an IKAmag temperature controller.  Reaction progress was monitored by thin-layer 
chromatography (TLC) or Agilent 1290 UHPLC-LCMS.  TLC was performed using E. 
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Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized by UV 
fluorescence quenching, potassium permanganate, or p-anisaldehyde staining.  SiliaFlash 
P60 Academic Silica gel (particle size 0.040–0.063 mm) was used for flash 
chromatography.  1H and 13C NMR spectra were recorded on a Varian Inova 500 
spectrometer (500 MHz and 126 MHz, respectively), a Bruker AV III HD spectrometer 
equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz and 101 MHz, 
respectively), or a Varian 300 spectrometer (300 MHz and 75 MHz, respectively) and are 
reported in terms of chemical shift relative to residual CDCl3 (δ 7.26 and δ 77.16 ppm, 
respectively).  Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) 
(multiplicity, coupling constant (Hz), integration).  Abbreviations are used as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, m = complex multiplet.  Infrared (IR) spectra 
were recorded on a Perkin Elmer Paragon 1000 spectrometer using thin film samples on 
NaCl plates, or a Thermo Scientific Nicolet iS5 attenuated total reflectance spectrometer 
using neat solid, neat oil, or CDCl3 or C6H6 solution samples, and are reported in 
frequency of absorption (cm–1).  High-resolution mass spectra (HRMS) were obtained 
from the Caltech Mass Spectral Facility using a JEOL JMS-600H High Resolution Mass 
Spectrometer with fast atom bombardment (FAB+) ionization mode. 
 
4.7.2   PROCEDURES AND CHARACTERIZATION DATA 
 
1-methyl 3-(2-(1-methyl-1H-indol-3-yl)ethyl) 2-diazomalonate (411): 
N
Me
OH 1. methyl malonyl chloride
    DMAP, Et3N, CH2Cl2, 0→23 °C







(74% yield, 2 steps)
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To a flame-dried round bottom flask equipped with a magnetic stir bar was 
added 409 (602 mg, 3.44 mmol).  The flask was capped with a rubber septum and 
evacuated and backfilled with nitrogen three times.  Dichloromethane (38 mL) was added 
by syringe.  The septum was quickly removed to allow for the addition of DMAP (42 mg, 
0.34 mmol).  Triethylamine (1.44 mL, 10.31 mmol) was added by syringe and the 
mixture was cooled to 0 °C in an ice water bath.  Methyl malonyl chloride (1.11 mL, 
10.31 mmol) was added slowly dropwise.  The mixture was allowed to warm to 23 °C 
and stir overnight.  Upon completion (as determined by TLC analysis), the reaction 
mixture was quenched with saturated aqueous ammonium chloride solution.  The 
aqueous layer was extracted with dichloromethane (1 x 30 mL) and the combined organic 
layers were washed with saturated sodium bicarbonate solution (1 x 30 mL).  The organic 
layers were dried over magensium sulfate, filtered, and concentrated to afford the crude 
product, which was purified by silica gel chromatography (20% ethyl acetate in hexanes) 
to afford 699 mg of the product malonate (74% yield). 
A solution of the malonate (699 mg, 2.54 mmol) in acetonitrile (2 mL) was added 
dropwise to a 0 °C stirring solution of p-ABSA (610 mg, 2.54 mmol) and triethlamine 
(375 μL) in acetonitrile (7 mL) in a flame-dried flask under nitrogen.  The mixture was 
allowed to warm to 23 °C and stir overnight.  Upon completion (as determined by TLC 
analysis), the reaction mixture was filtered through celite, washing with ether.  The 
filtrate was concentrated to afford the crude product, which was purified by silica gel 
chromatography (25% ethyl acetate in hexanes) to afford 781 mg of diazomaloante 411 
(quantitative yield, 74% over two steps).  1H NMR (400 MHz, CDCl3) δ = 7.61 (dt, J = 
7.9, 1.0, 1H), 7.30 (dt, J = 8.2, 0.9, 1H), 7.23 (ddd, J = 8.2, 6.9, 1.2, 1H), 7.12 (ddd, J = 
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8.0, 6.9, 1.1, 1H), 6.92 (d, J = 0.9, 1H), 4.48 (t, J = 7.2, 2H), 3.85 (s, 3H), 3.76 (s, 
3H), 3.14 (td, J = 7.2, 0.8, 2H); 13C NMR (101 MHz, CDCl3) δ 161.8, 161.0, 137.0, 
127.9, 127.2, 121.8, 119.1, 118.9, 110.0, 109.4, 66.0, 52.7, 32.8, 24.8; ATR-IR (CDCl3 
solution) 2954, 2134, 1754, 1731, 1475, 1438, 1328, 1270, 1086, 760, 740 cm–1; HRMS 
(FAB+) m/z calc’d for C15H16N3O4 [M+H]+: 302.1141, found 302.1136. 
 
 
1-(2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl) 3-methyl 2-diazomalonate (412): 
To a flame-dried round bottom flask equipped with a magnetic stir bar was added 410 
(1.369 g, 5.24 mmol).  The flask was capped with a rubber septum and evacuated and 
backfilled with nitrogen three times.  Dichloromethane (58 mL) was added by syringe.  
The septum was quickly removed to allow for the addition of DMAP (64 mg, 0.52 
mmol).  Triethylamine (2.19 mL, 15.72 mmol) was added by syringe and the mixture was 
cooled to 0 °C in an ice water bath.  Methyl malonyl chloride (1.69 mL, 15.72 mmol) was 
added slowly dropwise.  The mixture was allowed to warm to 23 °C and stir overnight.  
Upon completion (as determined by TLC analysis), the reaction mixture was quenched 
with saturated aqueous ammonium chloride solution.  The aqueous layer was extracted 
with dichloromethane (1 x 50 mL) and the combined organic layers were washed with 
saturated sodium bicarbonate solution (1 x 50 mL).  The organic layers were dried over 
magensium sulfate, filtered, and concentrated to afford the crude product, which was 
N
Boc
OH 1. methyl malonyl chloride
    DMAP, Et3N, CH2Cl2, 0→23 °C







(76% yield, 2 steps)
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purified by silica gel chromatography (15% ethyl acetate in hexanes) to afford 
1.5908 g of the product malonate (84% yield). 
A solution of the malonate (1.59 g, 4.40 mmol) in acetonitrile (3.5 mL) was added 
dropwise to a 0 °C stirring solution of p-ABSA (1.06 g, 4.40 mmol) and triethlamine 
(650 μL) in acetonitrile (12 mL) in a flame-dried flask under nitrogen.  The mixture was 
allowed to warm to 23 °C and stir overnight.  Upon completion (as determined by TLC 
analysis), the reaction mixture was filtered through celite, washing with acetonitrile.  The 
filtrate was concentrated to afford the crude product, which was purified by silica gel 
chromatography (20% ethyl acetate in hexanes) to afford 1.56 g of diazomaloante 412 
(91% yield, 76% over two steps).  1H NMR (500 MHz, CDCl3) δ = 8.13 (s, 1H), 7.58–
7.52 (m, 1H), 7.45 (s, 1H), 7.32 (ddd, J = 8.4, 7.2, 1.3, 1H), 7.27–7.23 (m, 1H), 4.51 (t, J 
= 7.0, 2H), 3.85 (s, 3H), 3.09 (td, J = 7.0, 1.0, 2H), 1.68 (s, 9H); 13C NMR (126 MHz, 
CDCl3) δ 166.7, 161.8, 161.0, 149.9, 130.5, 124.7, 123.7, 122.8, 119.0, 116.3, 115.5, 
83.8, 65.0, 52.8, 41.6, 28.4, 24.8; ATR-IR (CDCl3 solution) 2979, 2135, 1759, 1458, 
1369, 1324, 1270, 1255, 1158, 1089, 760 cm–1; HRMS (FAB+) m/z calc’d for C19H21N3O6 
[M•]+: 387.1430, found 387.1441. 
 
 
2-(1H-indol-3-yl)ethyl 2-diazoacetate (415): 
To a flame-dried round bottom flask equipped with a magnetic stir bar were added 
408 (950 mg, 5.89 mmol), sodium bicarbonate (1.49 g, 17.67 mmol), and acetonitrile (30 
N
H
OH 1. bromoacetyl bromide
    NaHCO3, MeCN, 0 °C
2. TsHN–NHTs, DBU







408 (72% yield, 2 steps) 415
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mL).  After cooling to 0 °C, bromoacetyl bromide (770 μL) was added dropwise 
and the reaction was stirred for 20 minutes.  After TLC analysis indicated consumption of 
the starting material, the mixture was quenched with water at 0 °C and the aqueous layer 
was extracted with dichloromethane (3 x 40 mL).  The organic layers were washed with 
brine (1 x 30 mL), dried over magnesium sulfate, and concentrated to give the crude 
product, which was used without further purification. 
To a flame-dried round bottom flask equipped with a magnetic stir bar were added the 
crude product from the previous step and N,N’-ditosylhydrazine (4.01 g, 11.78 mmol).  
THF (30 mL) was added and the mixture was cooled to 0 °C.  DBU was added dropwise 
and the mixture was stirred under nitrogen for 45 minutes.  After TLC analysis indicated 
consumption of the starting material, the mixture was quenched with saturated aqueous 
sodium bicarbonate solution and extracted with ether (3 x 50 mL).  The organic layers 
were washed with brine (1 x 50 mL), dried over magnesium sulfate, and concentrated to 
afford the crude product, which was purified by silica gel chromatography (25% ethyl 
acetate in hexanes) to afford 974 mg of diazoacetate 415 (72% yield over two steps).  1H 
NMR (300 MHz, CDCl3) δ = 8.01 (s, 1H), 7.63 (d, J = 7.8, 1H), 7.42–7.33 (m, 1H), 7.17 
(dddd, J = 21.6, 8.0, 7.1, 1.2, 2H), 7.05 (d, J = 2.4, 1H), 4.74 (s, 1H), 4.44 (t, J = 7.1, 2H), 
3.12 (td, J = 7.1, 0.8, 2H). 
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Diazoacetate 415 (974 mg, 4.28 mmol) was dissolved in dichloromethane (10 
mL).  Di-tert-butyl dicarbonate (1.02 g, 4.67 mmol) was added, followed by DMAP (53 
mg, 0.43 mmol).  The mixture was stirred for 7 hours at 23 °C.  TLC analysis showed 
incomplete conversion, so additional DMAP (50 mg) and di-tert-butyl dicarbonate (400 
mg) were added and the mixture was allowed to stir at 23 °C overnight.  Upon 
completion, the reaction solution was washed with brine (1 x 20 mL), dried over sodium 
sulfate, filtered, and evaporated to give the crude product, which was purified by silica 
gel chromatography (15% ethyl acetate in hexanes) to afford 1.23 g of diazoacetate 416 
(87% yield).  1H NMR (500 MHz, CDCl3) δ = 8.12 (s, 1H), 7.88–7.75 (m, 1H), 7.56–7.49 
(m, 1H), 7.48–7.40 (m, 1H), 7.32 (tdd, J = 7.0, 3.6, 1.9, 1H), 4.82–4.70 (m, 1H), 4.44 (t, J 
= 7.0, 2H), 3.05 (td, J = 7.0, 1.1, 2H), 1.74–1.60 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 
163.3, 149.8, 128.6, 124.6, 123.9, 123.5, 122.6, 119.0, 116.6, 115.4, 115.2, 64.2, 43.1, 
28.4, 24.8; ATR-IR (CDCl3 solution) 2979, 2112, 1729, 1698, 1458, 1368, 1253, 1151, 
1091, 737 cm–1. 
 
 
2-(1-methyl-1H-indol-3-yl)ethyl 2-diazoacetate (419): 
To a flame-dried round bottom flask equipped with a magnetic stir bar were added 
409 (500 mg, 2.85 mmol) and dichloromethane (22 mL) under argon.  Acid chloride 417 
(892 mg, 3.42 mmol) was added, and the mixture was cooled to 0 °C before 
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stir at 0 °C for 30 minutes, at which point triethylamine (1.99 mL, 14.3 mmol) was 
added.  The reaction was stirred at 0 °C for 30 minutes followed by 23 °C for 15 minutes.  
TLC analysis indicated the presence of starting material, so the mixture was allowed to 
stir overnight.  After a second TLC analysis showed no change in conversion, the mixture 
was concentrated and partitioned between water (30 mL) and ether (30 mL).  The 
aqueous layer was extracted with ether (1 x 30 mL), washed with saturated sodium 
bicarbonate solution (1 x 30 mL), dried over magnesium sulfate, filtered, and 
concentrated to give the crude product, which was purified by silica gel chromatography 
(10% ethyl acetate in hexanes) to afford 436 mg of diazoacetate 419 (63% yield).  1H 
NMR (500 MHz, CDCl3) δ = 7.61 (dt, J = 7.9, 1.0, 1H), 7.30 (dt, J = 8.2, 1.0, 1H), 7.26–
7.19 (m, 1H), 7.13 (ddd, J = 8.0, 6.9, 1.1, 1H), 6.90 (d, J = 0.8, 1H), 4.75 (s, 1H), 4.42 (t, 
J = 7.1, 2H), 3.77 (s, 3H), 3.11 (td, J = 7.1, 0.8, 2H); 13C NMR (126 MHz, CDCl3) δ 
142.7, 137.0, 129.7, 128.0, 127.0, 125.4, 121.8, 119.0, 110.4, 109.4, 65.3, 32.8, 25.0; 
ATR-IR (neat oil) 3100, 2951, 2105, 1684, 1394, 1333, 1237, 1126, 1011, 730 cm–1; 
HRMS (FAB+) m/z calc’d for C13H13N3O2 [M•]+: 243.1008, found 243.1004. 
 
 
2-(1-methyl-1H-indol-3-yl)ethyl (E)-2-diazo-4-phenylbut-3-enoate (428): 
To an oven-dried vial equipped with a magnetic stir bar were added, in order, 
carboxylic acid 427 (624 mg, 3.85 mmol), dichloromethane (4 mL), DMAP (30 mg), and 









    DCC, DMAP
    CH2Cl2, 0→23 °C
2. p-ABSA, DBU
    MeCN, 0→23 °C
427
CO2H
(47% yield, 2 steps)
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(874 mg, 4.24 mmol) was added.  The reaction was stirred for 5 minutes at 0 °C 
and then allowed to warm to 23 °C and stir overnight.  Upon completion (as determined 
by TLC analysis), the reaction mixture was filtered through Celite and concentrated.  The 
residue was suspended in dichloromethane and filtered through Celite again.  The filtrate 
was washed with 0.5 N aqueous hydrochloric acid (2 x 10 mL) and saturated aquous 
sodium bicarbonate (1 x 10 mL).  The organic layer was dried over magnesium sulfate, 
filtered, and concentrate to give the crude product, which was purified by silica gel 
chromatography (10% ethyl acetate in hexanes) to afford 870 mg of the ester product 
(71% yield). 
To a flame-dried round bottom flask equipped with a magnetic stir bar were added the 
ester (879 mg, 2.72 mmol), p-ABSA (784 mg, 3.26 mmol), and acetonitrile (72 mL) 
under argon.  The mixture was cooled to 0 °C and DBU (447 μL) was added rapidly by 
syringe.  The reaction was allowed to warm to 23 °C and stir overnight.  Upon 
completion (as determined by TLC analysis), the mixture was quenced with saturated 
aqueous ammonium chloride solution and extracted with ether (3 x 50 mL).  The 
combined organic layers were washed with brine (1 x 50 mL), dried over sodium sulfate, 
filtered, and concentrated to give the crude product, which was purified by silica gel 
chromatography (15% hexanes in ethyl acetate) to afford 617 mg of diazoester 428 (66% 
yield, 47% over two steps).  1H NMR (500 MHz, CDCl3) δ = 7.63 (dt, J = 7.9, 1.0, 1H), 
7.36–7.29 (m, 5H), 7.24–7.17 (m, 1H), 6.92 (d, J = 0.8, 1H), 6.47 (d, J = 16.3, 1H), 6.19 
(d, J = 16.3, 1H), 4.50 (t, J = 7.1, 2H), 3.77 (s, 3H), 3.16 (td, J = 7.1, 0.8, 2H). 
 




In a nitrogen-filled govebox, a dry vial equipped with a magnetic stir bar was charged 
with copper(I) trifluoromethanesulfonate (<1 mg) and sealed with a cap containing a 
septum, wrapping electrical tape around the cap to prevent the entry of oxygen.  The vial 
was then removed from the glovebox and put under a nitrogen atmosphere.  
Dichloromethane (1 mL) was added, and then a solution of diazoester 428 (24 mg, 0.07 
mmol) in dichloromethane (1 mL) was added by syringe pump over 1 hour.  After stirring 
for an additional 45 minutes, TLC analysis indicated the presence of starting material, but 
the reaction mixture was nevertheless adsorbed onto Celite and purified by silica gel 
chromatography (10% to 25% ethyl acetate in hexanes) to afford 7 mg of tetracycle 429 
(32% yield).  1H NMR (500 MHz, CDCl3) δ = 7.41–7.34 (m, 2H), 7.33–7.27 (m, 1H), 
7.23 (td, J = 7.7, 1.2, 1H), 7.20–7.16 (m, 2H), 7.10 (dd, J = 7.4, 1.2, 1H), 6.80 (d, J = 2.0, 
1H), 6.76 (td, J = 7.4, 1.0, 1H), 6.53 (d, J = 7.8, 1H), 4.86 (td, J = 12.1, 3.7, 1H), 4.59 
(ddd, J = 12.1, 5.5, 2.3, 1H), 4.13 (d, J = 6.0, 1H), 3.96 (dd, J = 6.0, 2.0, 1H), 2.80 (s, 
3H), 2.25 (ddd, J = 13.6, 12.1, 5.5, 1H), 2.17–2.08 (m, 1H); 13C NMR (126 MHz, CDCl3) 
δ 147.6, 144.4, 142.4, 135.1, 129.8, 129.4, 129.3, 128.3, 127.5, 124.3, 118.2, 110.4, 
110.2, 107.3, 88.4, 67.2, 55.6, 34.6, 33.4; ATR-IR (neat solid) 3050, 2945, 1593, 1521, 
1448, 1339, 1003, 818, 744 cm–1; HRMS (FAB+) m/z calc’d for C21H20NO2 [M+H]+: 
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X-ray quality single crystals of tetracycle 429 were produced by vapor diffusion of 
heptane (containing 2% benzene) into a solution of 429 in ethyl acetate. 
 
 
2-(1H-indol-3-yl)ethyl pyridazine-3-carboxylate (457): 
To an oven-dried vial equipped with a magnetic stir bar were added, in order, 
carboxylic acid 456 (100 mg, 0.81 mmol), dichloromethane (0.81 mL), DMAP (13 mg), 
and tryptophol (408, 131 mg, 0.81 mmol).  The mixture was cooled to 0 °C and DCC 
(183 mg, 0.87 mmol) was added.  The reaction was stirred for 5 minutes at 0 °C and then 
allowed to warm to 23 °C and stir overnight.  Upon completion (as determined by TLC 
analysis), the reaction mixture was filtered through Celite and concentrated.  The residue 
was suspended in dichloromethane and filtered through Celite again.  The filtrate was 
washed with 0.5 N aqueous hydrochloric acid (2 x 10 mL) and saturated aquous sodium 
bicarbonate (1 x 10 mL).  The organic layer was dried over magnesium sulfate, filtered, 
and concentrate to give the crude product, which was subjected to silica gel 
chromatography (10% methanol in dichloromethane) to afford 58 mg of ester 457 (27% 
yield), which was contaminated with dicyclohexylurea.  An attempt to purify further by 
colum chromatography (75% ethyl acetate in hexanes) was unsuccessful, so the material 
was carried on impure.  1H NMR (500 MHz, CDCl3) δ = 9.36 (ddt, J = 5.0, 1.7, 0.8, 1H), 
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(d, J = 8.1, 1H), 7.24–7.16 (m, 2H), 7.13 (tq, J = 7.0, 0.9, 1H), 4.76 (t, J = 7.3, 
2H), 3.33 (td, J = 7.4, 1.0, 2H). 
 
 
tert-butyl 3-(2-((6-chloropyridazin-3-yl)oxy)ethyl)-1H-indole-1-carboxylate (460): 
To an oven-dried vial equipped with a magnetic stir bar were added alcohol 410 (274 
mg, 1.05 mmol) and THF (750 μL).  The solution was cooled to 0 °C in an ice water bath 
and sodium hydride (60% dispersion in mineral oil, 50 mg, 1.25 mmol) was added.  The 
mixture was stirred at 0 °C for 10 minutes and 3,6-dichloropyridazine (150 mg, 1.00 
mmol) was added.  The reaction was allowed to warm to 23 °C and stir for 9 hours.  
Although TLC analysis revealed the presence of starting material, the mixture was 
quenched by pouring into saturated aqueous ammonium chloride solution.  The aqueous 
layer was extracted with ether (1 x 5 mL) and the organic layer was washed with water (1 
x 5 mL).  The organic layer was dried over magnesium sulfate, filtered, and concentrated 
to give the crude product, which was subjected to silica gel chromatography (25% ethyl 
acetate in hexanes).  Chromatography was not successful in proving pure 460, but the 
impure product was carried on as it was.  The yield was not determined.  1H NMR (300 
MHz, CDCl3) δ = 8.13 (d, J = 8.1, 1H), 7.65–7.58 (m, 1H), 7.52–7.46 (m, 2H), 7.39–7.27 
(m, 2H), 6.94 (dd, J = 9.2, 0.8, 1H), 4.79 (t, J = 6.9, 2H), 3.23 (td, J = 6.9, 1.0, 2H), 1.67 
















To an oven-dried vial equipped with a magnetic stir bar were added alcohol 459 (841 
mg, 2.99 mmol) and THF (3.1 mL).  The solution was cooled to 0 °C in an ice water bath 
and sodium hydride (60% dispersion in mineral oil, 143 mg, 3.56 mmol) was added.  The 
mixture was stirred at 0 °C for 10 minutes and 3,6-dichloropyridazine (425 mg, 2.85 
mmol) was added.  The reaction was allowed to warm to 23 °C and stir for 5 hours.  
Although LCMS analysis revealed the presence of a small amount of starting material, 
the mixture was quenched by pouring into saturated aqueous ammonium chloride 
solution.  The aqueous layer was extracted with ether (1 x 10 mL) and the organic layer 
was washed with water (1 x 10 mL).  The organic layer was dried over magnesium 
sulfate, filtered, and concentrated to give the crude product, which was purified by silica 
gel chromatography (25% ethyl acetate in hexanes) to afford 771 mg of arene 461 (69% 
yield).  1H NMR (500 MHz, CDCl3) δ = 7.68 (ddd, J = 7.8, 1.2, 0.7, 1H), 7.34 (d, J = 9.1, 
1H), 7.29 (dt, J = 8.2, 0.9, 1H), 7.18 (ddd, J = 8.2, 7.0, 1.2, 1H), 7.12 (ddd, J = 8.0, 7.0, 
1.1, 1H), 7.08–7.04 (m, 2H), 6.99 (d, J = 0.9, 1H), 6.92 (d, J = 9.1, 1H), 6.86–6.81 (m, 
2H), 4.77 (t, J = 7.1, 2H), 3.78 (s, 3H), 3.29 (td, J = 7.1, 0.9, 2H); 13C NMR (126 MHz, 
CDCl3) δ 164.5, 159.3, 151.1, 136.7, 131.0, 129.7, 128.5, 128.4, 126.3, 122.0, 120.5, 
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1585, 1442, 1377, 1278, 1246, 1148, 1029, 811, 733, 678 cm–1; HRMS (FAB+) 
m/z calc’d for C22H21ClN3O2 [M+H]+: 394.1322, found 394.1322. 
 
 
2-(1H-indol-3-yl)ethyl thiophene-2-carboxylate 1,1-dioxide (465): 
To an oven-dried vial equipped with a magnetic stir bar were added, in order, 
carboxylic acid 464 (397 mg, 3.10 mmol), dichloromethane (3.1 mL), DMAP (50 mg), 
and tryptophol (408, 500 mg, 3.10 mmol).  The mixture was cooled to 0 °C and DCC 
(704 mg, 3.41 mmol) was added.  The reaction was stirred for 5 minutes at 0 °C and then 
allowed to warm to 23 °C and stir for 5 hours.  Upon completion (as determined by TLC 
analysis), the reaction mixture was filtered through Celite and concentrated.  The residue 
was suspended in dichloromethane and filtered through Celite again.  The filtrate was 
washed with 0.5 N aqueous hydrochloric acid (2 x 20 mL) and saturated aquous sodium 
bicarbonate (1 x 20 mL).  The organic layer was dried over magnesium sulfate, filtered, 
and concentrated to give the crude product, which was purified by silica gel 
chromatography (25% ethyl acetate in hexanes) to afford 798 mg of thiophene 465 (95% 
yield). 
A solution of thiophene 465 (798 mg, 2.94 mmol) and m-CPBA (70–75% purity, 1.27 
g, 7.35 mmol) in methanol (12 mL) and chloroform (12 mL) was stirred at 23 °C for 2 
hours.  TLC analysis showed low conversion, so additional m-CPBA (635 mg) was added 
and the reaction mixture allowed to stir for an additional 15 hours.  TLC analysis still 
N
H














2.  m-CPBA, MeOH
     CHCl3, 23 °C
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revealed incomplete conversion, but the reaction mixture was poured into a 
seperatory funned and diluted with dichloromethane (10 mL).  The organic layer was 
washed with saturated aqueous sodium thiosulfate (1 x 20 mL) and saturated aqueous 
sodium bicarbonate (3 x 20 mL).  The organic layers were dried over sodium sulfate, 
filtered, and concentrated to give the crude product.  Attempts to purify by silica gel 
chromatography were only partially successful in removing the oxidation byproducts, so 
the material was carried on to the next step as it was.  A yield was not determined for this 
step.  1H NMR (300 MHz, CDCl3) δ = 8.77 (d, J = 8.4, 1H), 8.49 (d, J = 1.8, 1H), 7.96 
(dd, J = 8.1, 1.5, 1H), 7.78 (dd, J = 3.8, 1.3, 1H), 7.64–7.50 (m, 3H), 7.24–7.15 (m, 1H), 
7.08 (td, J = 4.7, 3.8, 1H), 4.73 (t, J = 6.3, 2H), 3.51 (t, J = 6.4, 2H). 
 
 
2-(1H-indol-3-yl)ethyl cyclobutadienylirontricarbonyl carboxylate (488): 
To an oven-dried vial equipped with a magnetic stir bar were added, in order, 
carboxylic acid 487 (100 mg, 0.42 mmol), dichloromethane (0.42 mL), DMAP (13 mg), 
and tryptophol (408, 68 mg, 0.42 mmol).  The mixture was cooled to 0 °C and DCC (93 
mg, 0.45 mmol) was added.  The reaction was stirred for 5 minutes at 0 °C and then 
allowed to warm to 23 °C and stir for 2 hours.  Upon completion (as determined by TLC 
analysis), the reaction mixture was filtered through Celite and concentrated.  The residue 
was suspended in dichloromethane and filtered through Celite again.  The filtrate was 
washed with 0.5 N aqueous hydrochloric acid (2 x 10 mL) and saturated aquous sodium 
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and concentrate to give the crude product, which was subjected to silica gel 
chromatography (20% ethyl acetate in hexanes) to afford 27 mg of ester 488 (16% yield).  
1H NMR (300 MHz, CDCl3) δ = 8.05 (s, 1H), 7.63 (dd, J = 7.4, 1.2, 1H), 7.37 (dt, J = 
8.0, 0.9, 1H), 7.21 (ddd, J = 8.1, 7.0, 1.4, 1H), 7.14 (ddd, J = 8.0, 7.1, 1.1, 1H), 7.03 (d, J 
= 2.2, 1H), 4.50 (s, 2H), 4.36 (t, J = 7.2, 2H), 4.27 (s, 1H), 3.08 (td, J = 7.2, 0.8, 2H); 13C 
NMR (126 MHz, CDCl3) δ 212.1, 167.2, 136.2, 127.5, 122.1, 119.4, 118.8, 111.7, 111.2, 
67.7, 65.3, 65.0, 64.9, 62.5, 24.6; HRMS (FAB+) m/z calc’d for C18H13FeNO5 [M•]+: 
379.0143, found 379.0154. 
 
 
dimethyl 2-(4-bromobut-2-yn-1-yl)-2-(prop-2-yn-1-yl)malonate (500): 
A flame-dried round bottom flask equipped with a magnetic stir bar was charged with 
sodium hydride (60% dispersion in mineral oil, 303 mg, 7.56 mmol) and THF (7.4 mL).  
Malonate 517 (1.00 mL, 6.58 mmol) was added neat dropwise by syringe and the mixture 
was stirred at 23 °C for 1 hour before being transferred by syringe to a solution of 
dibromide 518 (4.18 g, 19.74 mmol) in THF (30 mL).  This mixture was stirred at 23 °C 
for 3 hours.  Upon completion, the reaction was quenched with water (50 mL) and 
extracted with ether (3 x 40 mL).  The organic layers were washed with water (1 x 40 
mL) and brine (1 x 40 mL), dried over sodium sulfate, filtered, and concentrated to give 
the crude product, which was purified by silica gel chromatography (10% ethyl acetate in 
hexanes) to provide 1.92 g of malonate 500 (97% yield).  1H NMR (500 MHz, CDCl3) δ 
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2.7, 0.7, 2H), 2.05 (t, J = 2.7, 1H); 13C NMR (126 MHz, CDCl3) δ 169.1, 81.8, 
78.8, 78.4, 72.0, 56.7, 53.4, 23.3, 22.9, 14.7; ATR-IR (CDCl3 solution) 3291, 2955, 1737, 
1436, 1326, 1293, 1206, 1056, 977, 657 cm–1; HRMS (FAB+) m/z calc’d for C12H14BrO4 





To a flame-dried round bottom flask equipped with a magnetic stir bar were added 
sodium hydride (60% dispersion in mineral oil, 187 mg, 3.89 mmol) and DMF (4 mL).  A 
solution of alcohol 410 (1.02 g) in DMF (9.2 mL) was added dropwise by syringe and the 
mixture was stirred at 23 °C for 1 hour.  A solution of bromide 500 (1.17 g, 3.89 mmol) 
in DMF (2.8 mL) was added dropwise by syringe and the mixture was stirred at 23 °C for 
1 hour, until TLC analysis showed complete consumption of the starting material.  The 
reaction mixture was quenched with water (30 mL) and extracted with ethyl acetate (3 x 
30 mL).  The combined organic layers were washed with brine (1 x 30 mL), dried over 
sodium sulfate, filtered, and concentrated to give the crude product, which was purified 
by silica gel chromatography (20% ethyl acetate in hexanes) to provide 811 mg of diyne 
501 (43% yield).  Note that some material was lost during the workup, so the yield may 
be artificially low.  1H NMR (500 MHz, CDCl3) δ = 7.63–7.57 (m, 1H), 7.34–7.30 (m, 
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= 2.2, 2H), 4.38–4.27 (m, 2H), 3.68 (s, 6H), 3.12 (td, J = 7.6, 0.9, 2H), 3.01 (t, J = 
2.3, 2H), 2.96 (d, J = 2.6, 2H), 2.05 (t, J = 2.7, 1H), 1.49 (s, 9H); 13C NMR (126 MHz, 
CDCl3) δ 169.2, 153.7, 128.4, 125.5, 122.1, 119.6, 119.2, 110.9, 109.6, 109.4, 82.1, 79.9, 
78.4, 72.0, 67.0, 56.6, 53.3, 36.1, 29.9, 27.9, 25.0, 23.1, 23.0; IR (Neat Film, NaCl) 3286, 
2979, 1740, 1467, 1436, 1369, 1278, 1255, 1213, 1162, 1101, 1056, 963, 859, 794, 742, 





A flame-dried round bottom flask equipped with a magnetic stir bar was charged with 
diyne 501 (500 mg, 1.04 mmol) and placed under a nitrogen atmostphere.  THF (11.2 
mL) was added the the mixture cooled to –78 °C in a dry ice/acetone bath.  A solution of 
LiHMDS (263 mg, 1.57 mmol) in THF (1.5 mL) was added dropwise by syringe, and the 
mixture was stirred at –78 °C for 45 minutes.  A solution of phenyldimethylsilyl chloride 
(262 µL, 1.56 mmol) in THF (5.6 mL) was added dropwise by syringe, and the reaction 
nmixture was allowed to warm to 23 °C and stir overnight.  Upon completion (as 
determined by TLC analysis), the mixture was diluted with ether (50 mL) and poured into 
saturated aqueous ammonium chloride solution (50 mL).  The ether layer was separated 
and washed with brine (1 x 50 mL), dried over magnesium sulfate, filtered, and 















LiHMDS, THF, –78 °C;
PhMe2SiCl
THF, –78→23 °C
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deliver pure silane 502, and the material was carried forward impure.  A yield for 
the reaction was was not determined.  Integrals are approximate.  1H NMR (500 MHz, 
CDCl3) δ = 7.64–7.55 (m, 3H), 7.44–7.31 (m, 4H), 7.24 (ddd, J = 8.2, 7.1, 1.2, 1H), 7.14 
(ddd, J = 7.9, 7.0, 1.0, 1H), 7.04 (d, J = 0.8, 1H), 4.79 (t, J = 2.2, 2H), 4.33 (dd, J = 7.9, 
7.2, 2H), 3.65 (s, 6H), 3.12 (ddd, J = 8.1, 7.2, 0.9, 2H), 3.04 (s, 2H), 3.02 (t, J = 2.3, 2H), 
1.50 (s, 9H), 0.42 (s, 3H), 0.38 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 169.2, 153.6, 
139.2, 137.0, 136.1, 133.7, 133.7, 129.8, 129.5, 128.4, 128.0, 128.0, 125.5, 122.1, 119.5, 
119.1, 110.9, 109.6, 102.6, 86.8, 82.0, 80.0, 77.6, 67.0, 56.9, 53.1, 36.1, 27.9, 25.0, 24.5, 
23.2, 0.1, -0.7; ATR-IR (C6H6 solution) 2955, 2180, 1736, 1456, 1428, 1368, 1275, 1250, 
1208, 1158, 1026, 817, 782, 735, 702 cm–1; HRMS (FAB+) m/z calc’d for C35H41NO7Si 
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Reactions conducted on approx. 0.05 mmol scale by adding a solution of the substrate to a solution of the catalyst over one hour.
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Spectra Relevant to Chapter 4: 










































































































Figure A8.3 13C NMR (101 MHz, CDCl3) of compound 411. 
Figure A8.2 ATR-IR (CDCl3 solution) of compound 411. 
















































Figure A8.6 13C NMR (126 MHz, CDCl3) of compound 412. 
 
Figure A8.5 ATR-IR (CDCl3 solution) of compound 412. 
 






















































































Figure A8.10 13C NMR (126 MHz, CDCl3) of compound 416. 
 
Figure A8.9 ATR-IR (CDCl3 solution) of compound 416. 
 















































Figure A8.13 13C NMR (126 MHz, CDCl3) of compound 419. 
 
Figure A8.12 ATR-IR (neat oil) of compound 419. 
 


























































































Figure A8.17 13C NMR (126 MHz, CDCl3) of compound 429. 
 
Figure A8.16 ATR-IR (neat solid) of compound 429. 















































































































































































Figure A8.22 13C NMR (126 MHz, CDCl3) of compound 461. 
 
Figure A8.21 ATR-IR (neat solid) of compound 461. 
 


























































































Figure A8.25 13C NMR (126 MHz, CDCl3) of compound 488. 
 
















































Figure A8.28 13C NMR (126 MHz, CDCl3) of compound 500. 
 
Figure A8.27 ATR-IR (CDCl3 solution) of compound 500. 
 


















































Figure A8.31 13C NMR (126 MHz, CDCl3) of compound 501. 
 
Figure A8.30 Infrared spectrum (thin film/NaCl) of compound 501. 
 





















































Figure A8.34 13C NMR (126 MHz, CDCl3) of compound 502. 
 
Figure A8.33 ATR-IR (C6H6 solution) of compound 502. 
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Table A9.1.1 Experimental details for X-ray structure determination of tetracycle 429 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
D8 VENTURE KAPPA diffractometer coupled to a PHOTON 100 CMOS detector with 
Cu Kα radiation (λ = 1.54178 Å) from an IμS micro-source for the structure of tetracycle 
429. The structure was solved by direct methods using SHELXS and refined against F2 
on all data by full-matrix least squares with SHELXL-2014 using established refinement 
techniques. All non-hydrogen atoms were refined anisotropically. All hydrogen atoms 
were included into the model at geometrically calculated positions and refined using a 
riding model. The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups).  
Tetracycle 429 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. 
 
 
Table A9.1.2 Crystal data and structure refinement for tetracycle 429 
Identification code  P16006 
Empirical formula  C21 H19 N O2 
Formula weight  317.37 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 5.8176(2) Å a= 90°. 
 b = 9.2250(2) Å b= 90°. 
 c = 29.7053(8) Å g = 90°. 
Volume 1594.21(8) Å3 
Z 4 
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Density (calculated) 1.322 Mg/m3 
Absorption coefficient 0.673 mm-1 
F(000) 672 
Crystal size 0.250 x 0.100 x 0.050 mm3 
Theta range for data collection 2.975 to 74.451°. 
Index ranges -6<=h<=7, -10<=k<=11, -37<=l<=36 
Reflections collected 12810 
Independent reflections 3243 [R(int) = 0.0250] 
Completeness to theta = 67.679° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.6734 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3243 / 0 / 218 
Goodness-of-fit on F2 1.055 
Final R indices [I>2sigma(I)] R1 = 0.0258, wR2 = 0.0660 
R indices (all data) R1 = 0.0264, wR2 = 0.0665 
Absolute structure parameter -0.03(5) 
Extinction coefficient n/a 
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Table A9.1.3      Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 
103) for tetracycle 429.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 1980(2) 638(1) 7386(1) 25(1) 
C(1) 1514(3) 358(2) 6952(1) 19(1) 
O(2) 7(2) -500(1) 6862(1) 24(1) 
C(2) 2985(2) 1067(2) 6609(1) 18(1) 
C(3) 3162(2) 650(2) 6180(1) 18(1) 
C(4) 5049(2) 1452(2) 5935(1) 17(1) 
C(5) 6455(3) 2135(2) 6334(1) 17(1) 
C(15) 6456(2) 509(2) 5621(1) 18(1) 
C(16) 7614(3) -704(2) 5785(1) 20(1) 
C(17) 8944(3) -1561(2) 5500(1) 22(1) 
C(18) 9105(3) -1218(2) 5046(1) 24(1) 
C(19) 7952(3) -23(2) 4879(1) 25(1) 
C(20) 6632(3) 840(2) 5164(1) 22(1) 
C(6) 5386(3) 4518(2) 6388(1) 19(1) 
N(1) 7201(2) 3621(1) 6264(1) 19(1) 
C(21) 8635(3) 3957(2) 5880(1) 24(1) 
C(7) 5021(3) 5957(2) 6267(1) 22(1) 
C(8) 3088(3) 6656(2) 6444(1) 24(1) 
C(9) 1569(3) 5948(2) 6727(1) 23(1) 
C(10) 1937(3) 4492(2) 6842(1) 20(1) 
C(11) 3845(3) 3786(2) 6671(1) 17(1) 
C(12) 4709(2) 2228(2) 6729(1) 16(1) 
C(13) 5642(3) 1910(2) 7202(1) 20(1) 
C(14) 3647(3) 1736(2) 7525(1) 23(1) 
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Table A9.1.4      Bond lengths [Å] and angles [°] for tetracycle 429 
___________________________________________________________________________________  
O(1)-C(1)  1.3431(17) 
O(1)-C(14)  1.463(2) 
C(1)-O(2)  1.2107(19) 
C(1)-C(2)  1.4819(19) 
C(2)-C(3)  1.334(2) 
C(2)-C(12)  1.510(2) 
C(3)-C(4)  1.511(2) 
C(3)-H(3)  0.9500 
C(4)-C(15)  1.5160(19) 
C(4)-C(5)  1.5721(19) 
C(4)-H(4)  1.0000 
C(5)-N(1)  1.4527(18) 
C(5)-C(12)  1.5547(19) 
C(5)-H(5)  1.0000 
C(15)-C(16)  1.393(2) 
C(15)-C(20)  1.396(2) 
C(16)-C(17)  1.393(2) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.389(2) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.382(2) 
C(18)-H(18)  0.9500 
C(19)-C(20)  1.393(2) 
C(19)-H(19)  0.9500 
C(20)-H(20)  0.9500 
C(6)-N(1)  1.391(2) 
C(6)-C(7)  1.393(2) 
C(6)-C(11)  1.402(2) 
N(1)-C(21)  1.4477(18) 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
C(7)-C(8)  1.399(2) 
C(7)-H(7)  0.9500 
Appendix 9 – X-Ray Crystallography Report Relevant to Chapter 4  610
Table A9.1.4 (cont’d) 
C(8)-C(9)  1.384(2) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.402(2) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.383(2) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.5325(19) 
C(12)-C(13)  1.5336(18) 
C(13)-C(14)  1.514(2) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-H(14A)  0.9900 
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Symmetry transformations used to generate equivalent atoms:  
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Table A9.1.5  Anisotropic displacement parameters  (Å2x103) for tetracycle 429.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 26(1)  29(1) 19(1)  3(1) 4(1)  -3(1) 
C(1) 19(1)  17(1) 21(1)  2(1) 3(1)  4(1) 
O(2) 22(1)  21(1) 29(1)  2(1) 5(1)  -1(1) 
C(2) 16(1)  16(1) 21(1)  2(1) 1(1)  2(1) 
C(3) 16(1)  17(1) 22(1)  0(1) 0(1)  1(1) 
C(4) 17(1)  18(1) 16(1)  0(1) 0(1)  0(1) 
C(5) 17(1)  19(1) 16(1)  -1(1) 1(1)  1(1) 
C(15) 17(1)  19(1) 18(1)  -3(1) 1(1)  -3(1) 
C(16) 22(1)  20(1) 18(1)  0(1) 0(1)  -2(1) 
C(17) 21(1)  20(1) 26(1)  -2(1) -1(1)  1(1) 
C(18) 21(1)  29(1) 23(1)  -8(1) 3(1)  1(1) 
C(19) 27(1)  32(1) 17(1)  -2(1) 2(1)  1(1) 
C(20) 22(1)  25(1) 18(1)  0(1) -1(1)  2(1) 
C(6) 22(1)  21(1) 14(1)  -3(1) -2(1)  -3(1) 
N(1) 20(1)  19(1) 18(1)  -2(1) 3(1)  -3(1) 
C(21) 24(1)  26(1) 21(1)  -1(1) 6(1)  -6(1) 
C(7) 30(1)  19(1) 17(1)  1(1) -1(1)  -5(1) 
C(8) 36(1)  16(1) 21(1)  -1(1) -6(1)  2(1) 
C(9) 24(1)  22(1) 23(1)  -4(1) -3(1)  4(1) 
C(10) 21(1)  22(1) 17(1)  -1(1) -2(1)  0(1) 
C(11) 21(1)  18(1) 13(1)  -1(1) -2(1)  -2(1) 
C(12) 16(1)  18(1) 15(1)  -1(1) 1(1)  1(1) 
C(13) 21(1)  24(1) 17(1)  1(1) -1(1)  2(1) 
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Table A9.1.6     Hydrogen coordinates (x103) and isotropic displacement parameters (Å2x103)  
for tetracycle 429 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________   
H(3) 2213 -66 6045 21 
H(4) 4341 2254 5756 20 
H(5) 7787 1503 6416 21 
H(16) 7494 -949 6095 24 
H(17) 9740 -2378 5616 27 
H(18) 10005 -1803 4850 29 
H(19) 8060 211 4568 30 
H(20) 5846 1659 5046 26 
H(21A) 7684 3999 5608 35 
H(21B) 9807 3203 5845 35 
H(21C) 9384 4896 5927 35 
H(7) 6049 6448 6071 26 
H(8) 2810 7641 6367 29 
H(9) 274 6449 6844 28 
H(10) 891 3998 7033 24 
H(13A) 6570 1010 7197 25 
H(13B) 6642 2716 7302 25 
H(14A) 4257 1473 7825 28 
H(14B) 2849 2679 7555 28 
________________________________________________________________________________  
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Table A9.1.7 (cont’d) 
________________________________________________________________________________  
















Palladium(II)-Catalyzed Allylic C–H Oxidation of Hindered Substrates  
Featuring Tunable Selectivity Over Extent of Oxidation 
 
 
5.1   INTRODUCTION 
Recent developments in C–H functionalization have made major contributions to 
organic chemistry and are beginning to change the way chemists approach synthetic 
transformations.1 Allylic C–H acetoxylation2,3 and other functionalizations4 of terminal 
olefins have received considerable attention over the past decade as allyl groups are 
versatile and widespread in synthetic organic chemistry.  After the seminal report by 
White and co-workers of palladium-catalyzed allylic acetoxylation,3a numerous research 
groups have developed alternative conditions for this transformation, mainly differing in 
the identity of the terminal oxidant.3 
Complementing reports of the two-electron oxidation of allyl groups to allylic 
acetates, the four-electron oxidation of allyl groups to enones or enals has also been !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
† This work was performed in collaboration with Dr. Xiangyou Xing, alumnus of the Stoltz group.  
This work has been published, with portions of this chapter adapted with permission from Xing, X.; 
O’Connor, N. R.; Stoltz, B. M. Angew. Chem., Int. Ed. 2015, 54, 11186–11190.  Copyright 2015 WILEY-
VCH. 
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described.  While the oxidation of olefins, particularly cycloalkenes, to enones is well 
precedented,5 few examples exist of the transformation of allyl groups to enals.6,7  Of 
these limited cases, most produce the enals in low yield and with poor selectivity over 
other oxidation products, and/or require activated allylic C–H bonds (i.e. allylbenzenes).  
None of these methods are reported to be effective on complex or sterically hindered 
substrates. 
 
5.1.1   ENANTIOSELECTIVE SYNTHESIS OF QUATERNARY α-ALLYL 
LACTAMS AND ATTEMPTED ALLYLIC FUNCTIONALIZATION 
Our research group has had a longstanding interest in the asymmetric synthesis of α-
quaternary carbonyl compounds via catalytic decarboxylative enantioselective allylic 
alkylation.8,9  In 2012 we reported the construction of quaternary α-allyl lactams (529) in 
excellent yield and ee using this strategy (Scheme 5.1).8c   
 
Scheme 5.1  Enantioselective synthesis of α-quaternary lactams by palladium-catalyzed 
decarboxylative allylic alkylation 
 
Given our interest in C–H activation,10 the utility of allyl groups as functional 
handles, and the known status of allylic C–H bonds as a privileged motif in the C–H 
activation literature, we investigated the use of several reported procedures for the C–H 
functionalization of our lactam products (Scheme 5.2).11  Interestingly, use of classical 






Pd2(pmdba)3 (5 mol %)
(S)-(CF3)3-t-BuPHOX (12.5 mol %)




up to 97% yield
up to 99% ee528 529
n n
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Kharasch–Sosnovsky conditions14 resulted in either decomposition or no reaction.  Use of 
a palladium(II) catalyst with tert-butylhydroperoxide also resulted in no reaction.15  
Oxidation with chromium trioxide unexpectedly gave imide 531 in low yield.16  The 
conditions recently developed by White and co-workers (Pd(II), benzoquinone, DMSO, 
acetic acid)3a showed no reactivity, and those reported by Stahl and co-workers (Pd(II), 
oxygen, acetic acid)3i only produced the desired allylic acetates in low yields, leaving 
most of the starting materials unreacted. 
 
Scheme 5.2  Investigation into the allylic oxidation of lactam 530 
 
 
5.2   DEVELOPMENT OF A NOVEL PALLADIUM(II)-CATALYZED 
ALLYLIC ACETOXYLATION REACTION 
We attribute the absence of the desired reactivity to the sterically demanding 
quaternary center at the homoallylic position.  This hypothesis is corroborated by the 
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literature.  Realizing the amide functional group could act as an internal ligating group, 
we chose to develop conditions for the substrate-directed palladium-catalyzed allylic C–
H acetoxylation of these molecules.  We hoped that the use of a directing group, largely 
unknown in allylic C–H oxygenation reactions,17 would enable reactivity even in the most 
sterically hindered and challenging substrates. 
 
5.2.1   OPTIMIZATION OF THE ALLYLIC ACETOXYLATION 
We began our studies by screening various palladium(II) catalysts, oxidants, and 
solvents in the allylic acetoxylation of an N-benzoyl lactam (Scheme 5.3, entry 1), 
accessable via our allylic alkylation chemistry.8c  Gratifyingly, exposure of the substrate 
to palladium(II) acetate and Oxone in a mixture of acetonitrile and acetic acid produced 
trace amounts of allylic acetate 532 and enal 533.  We were pleased to find that Oxone 
was superior to other oxidants examined, as it is readily available, inexpensive, stable, 
relatively non-toxic, and environmentally safe.18  To our knowledge, this is the first report 
of Oxone as an oxidant for an allylic C–H functionalization reaction. 
Although the benzoyl-protected lactam was poorly reactive under our conditions, use 
of the free N–H lactam resulted in moderate conversion to a separable mixture of allylic 
acetate 532 and enal 533 products (Scheme 5.3, entry 2).  Further optimization revealed 
N-benzyl lactams to be superior to the free lactams, giving full conversion within a matter 
of hours (entries 3–6).  Subsequent experiments showed that the addition of acetic 
anhydride and molecular sieves was necessary to obtain the allylic acetate product in 
good yield.  An examination of other palladium(II) precursors (entries 4–6) led us to 
select palladium(II) hexafluoroacetylacetonate, as it resulted in the shortest reaction time 
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while maintaining a good ratio of the desired allylic acetate (532) to the undesired enal 
(533, entry 6).  With all substrates, we found that acetonitrile was necessary as a solvent, 
as its omission led to a significant decrease in reactivity.  In all cases, we observed little 
or no formation of the methyl ketone or aldehyde products expected from Wacker–Tsuji 
reactivity. 
 
Scheme 5.3  Optimization of the allylic acetoxylation 
 
 
5.2.2   SUBSTRATE SCOPE OF THE ALLYLIC ACETOXYLATION 
With the optimized conditions in hand, we investigated the substrate scope of the 
reaction.  We quickly found that the lactam nature of the substrate was critical to 
achieving good reactivity.  Interestingly, cyclic compounds lacking an amide functional 
group gave only low conversion under our conditions, as did a wide variety of linear 
amides investigated (see Appendix 10).  The scope of allylic acetoxylation of lactam 
substrates is shown in Scheme 5.4. Substrates incorporating alkyl groups at the α-position 
were well tolerated, furnishing the corresponding allylic acetates (537, 538, 540, 541) in 
Entry Catalyst (mol %) Oxone Equiv Conversion (%)a Products (532:533)c
1 Pd(OAc)2 (5.0) 1.5 31 6:1
2 Pd(OAc)2 (5.0) 1.5 100 8:1
3d Pd(OAc)2 (7.5) 2.5 100 8:1
4d Pd(TFA)2 (7.5) 2.5 100 9:1
5d Pd(acac)2 (7.5) 2.5 90 7:1







































Conditions: lactam 530 (0.10 mmol), catalyst (0.05 or 0.075 equiv; see table), Oxone (1.5 or 2.5 equiv; see table), MeCN (714 µL), 
and AcOH (286 µL) at 60 °C for 96 h or until full conversion by TLC.  a Conversion was determined from the yield of the isolated 
recovered starting material.  b Yield is that of isolated combined producs 532 and 533.  c Ratio determined by 1H NMR analysis 
of the crude reaction mixture.  d A solvent mixture of 5:1:1 MeCN/AcOH/Ac2O was used, and 4Å MS (80 mg) were added.
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good yields and selectivities.  Substrates with benzyl (539) or aryl (542) groups at the α-
position were also competent.19  The identity of the amide substituent is not limited to a 
benzyl group, and replacement with alkyl or aryl groups (543 and 546), or even olefin-
containing groups (547 and 548) did not reduce the yield or selectivity.19  The free N–H 
lactam was also a successful substrate (544).  A quaternary stereocenter was not found to 
be necessary, as an α-tertiary lactam underwent acetoxylation in good yield and exclusive 
selectivity over enal formation (545).  Finally, substrates derived from caprolactam (549, 
550) and butyrolactam (551–554), readily accessed via our decarboxylative allylic 
alkylation chemistry, also reacted smoothly.20 
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Scheme 5.4  Substrate scope of the allylic acetoxylation 
 
 
5.2.3   SYNTHETIC UTILITY OF ALLYLIC ACETATES 
The synthetic utility of allylic acetates is well known in the literature, and using 
standard conditions we were able to further derivatize products as sterically hindered as 
537 (Scheme 5.5).  Osmium-catalyzed dihydroxylation provided diol 555 in good yield 
and diastereoselectivity.21  Hydrogenation of the olefin proceeded smoothly, giving 
aliphatic acetate 556 in excellent yield.  Epoxidation was also facile, furnishing the 







































































































































Conditions: lactam 534 (0.2 mmol), Pd(hfacac)2 (0.075 equiv), Oxone (2.5 equiv), MeCN (1.43 mL), AcOH/Ac2O (1:1, 750 µL), and 4Å MS (160 mg) at 
60 °C for 3–6 h.  Yields are combined of the isolated separable acetate and enal products.  a Reaction time = 24 h.  b Reaction time = 11 h.
n n n
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reveal allylic alcohol 558 as well as global reduction of the amide and ester 
functionalities to afford amine 559 were also successful.  Finally, realizing the synthetic 
utility of allylic acetates in transition-metal-catalyzed allylic substitution reactions, we 
were pleased to find that ruthenium-mediated substitution with dimethyl malonate 
produced malonate 560 in good yield.23 
 
Scheme 5.5  Synthetic utility of an allylic acetate product 
 
 
5.3   DEVELOPMENT OF THE ALLYLIC OXIDATION REACTION TO 
FORM ENAL PRODUCTS 
 
5.3.1   OPTIMIZATION OF THE ENAL FORMATION 
After exploring the scope of the acetoxylation reaction, we were intrigued about the 
possibility of optimizing for the enal product seen in small amounts in most 
acetoxylations.  During early optimization studies of the allylic acetoxylation reaction, 
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degree of enal formation.  Using this as a starting point, we identified optimal conditions 
for enal formation (Scheme 5.6).  Remarkably, only simple changes to the reaction 
conditions allow for a significant change in the product ratio, allowing for facile control 
of the degree of oxidation.  Essentially, only the presence or absence of water controls 
switch between a two-electron oxidation of the allyl group to the allylic acetate (i.e. 
534→535) and a four-electron oxidation of the allyl group to the enal (i.e. 534→536). 
While palladium(II) hexafluoroacetylacetonate is an effective catalyst for oxidation to the 
enal, we opted to use the cheaper and more widely available palladium(II) acetate, as the 
results were similar.  We found the presence of small amounts of water to be necessary to 
achieve high conversion, and the presence of acetic acid aided in suppressing formation 
of the methyl ketone (i.e. standard Wacker–Tsuji oxidation).24 
 
5.3.2   SUBSTRATE SCOPE OF THE ENAL FORMATION 
The scope of the enal formation is shown in Scheme 5.6.  We found that N-benzyl 
valerolactams with a variety of alkyl groups at the α-position were well tolerated, 
furnishing the enal products (561, 562, 564, 565) in good yields and selectivities over the 
allylic acetates.  Substrates with α-benzyl and α-phenyl substituents were also 
successfully oxidized to enals 563 and 566, respectively.  As with the allylic 
acetoxylation reaction, we found that the benzyl-protected nitrogen was not critical, and 
that the N-methyl, N-aryl, and N–H substrates were also suitable (567, 568, and 569).  
Unfortunately, lactams of other ring sizes showed low conversion (570), and α-tertiary 
substrates gave predominately the methyl ketone product of a Wacker–Tsuji oxidation 
(not shown). 
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Scheme 5.6  Substrate scope of the enal formation 
 
 
5.3.3   SYNTHETIC UTILITY OF AN ENAL PRODUCT 
Similar to allylic acetates, enals are useful synthetic intermediates, and we were able 
to subject enal 561 to a variety of transformations (Scheme 5.7).  Reduction to the 
aliphatic aldehyde (571) by hydrogenation was facile, as was a one-carbon homologation 
to diene 572 under Wittig conditions.  We also found that the enal could be oxidized 
directly to the methyl ester (573) in excellent yield using a protocol developed by Thakur 
and coworkers.25  Finally, a Passerini multicomponent coupling with t-butyl isocyanide 





























































































Conditions: lactam 534 (0.2 mmol), Pd(OAc)2 (0.075 equiv), Oxone (2.5 equiv), AcOH (16.0 equiv), H2O (8.0 equiv), and MeCN (1.82 mL) at 50 °C for 
1–2 h.  Yields are combined of the isolated separable acetate and enal products.  a Starting material not fully consumed.
n n n
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Scheme 5.7  Synthetic utility of an enal product 
 
 
5.4   CONCLUSIONS AND FUTURE DIRECTIONS 
In summary, we have reported a novel protocol for palladium-catalyzed allylic C–H 
oxidation using inexpensive, non-toxic, and safe Oxone as the terminal oxidant.  This 
method is far more tolerant of steric bulk than previously known examples, possibly as a 
result of substrate-directed reactivity.  Furthermore, we have discovered that a minor 
change in conditions allows for access to either the allylic acetate products of a two-
electron oxidation or the enal products of a four-electron oxidation.  This reactivity 
switch demonstrates an unusual ability to selectively achieve different increases in 
oxidation state by a single palladium-catalyzed system.  The synthetic utility of the 
products resulting from these new C–H functionalization methods has been demonstrated 
by conversion of the prototypical products to a range of functionalized heterocycles. 
Although the allylic oxidation chemistry reported herein has certain scope limitations, 
the complete applicability of these new conditions for C–H functionalization is not yet 









































H2O, MeOH, 23 °C
(93% yield)
4-OMe-C6H4CO2H
t-BuNC, CH2Cl2, 40 °C
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resulted in selective allylic acetoxylation in moderate yield (Scheme 5.8).  Future 
directions may include further exploration of this reactivity. 
 
Scheme 5.8  Selective allylic acetoxylation of carvone 
 
 
5.5   EXPERIMENTAL SECTION 
5.5.1   MATERIALS AND METHODS 
Unless noted in the specific procedure, reactions were performed in non-dry 
glassware under an air atmosphere.  Dried and deoxygated solvents (Fisher Scientific) 
were prepared by passage through columns of activated aluminum before use.[ 27 ]  
Anhydrous carbon tetrachloride was purchased from Sigma Aldrich and used as received.  
Methanol (Fisher Scientific) was distilled from magnesium methoxide immediately prior 
to use.      Commercial reagents (Sigma Aldrich or Alfa Aesar) were used as received 
with the exception of δ-valerolactam (Oakwood Chemical), dichloro(p-
cymene)ruthenium(II) dimer (Strem Chemicals), triphenylphosphine (Sigma Aldrich) , 
lithium hexamethyldisilazide (Sigma Aldrich), zinc(II) chloride (Sigma Aldrich), and 
lithium tri-tert-butoxyaluminum hydride (Sigma Aldrich) which were stored in a 
nitrogen-filled govebox.  Diisopropylamine (Oakwood Chemical) and trimethylsilyl 
chloride (Alfa Aesar) were distilled from calcium hydride immediately prior to use.  The 
acetic acid (J. T. Baker) and acetic anhydride (Sigma Aldrich) used in the allylic 







Pd(OAc)2 (20 mol %)
Oxone (1.1 equiv)
AcOH, 95 °C
(40% yield based on 
recovered starting material)575 576
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defined as a saturated aqueous solution of sodium chloride.  Reactions requiring external 
heat were modulated to the specified temperatures using an IKAmag temperature 
controller.  Reaction progress was monitored by thin-layer chromatography (TLC) or 
Agilent 1290 UHPLC-LCMS.  TLC was performed using E. Merck silica gel 60 F254 
precoated plates (0.25 mm) and visualized by UV fluorescence quenching, potassium 
permanganate, or p-anisaldehyde staining.  SiliaFlash P60 Academic Silica gel (particle 
size 0.040-0.063 mm) was used for flash chromatography.  1H and 13C NMR spectra were 
recorded on a Varian Inova 500 spectrometer (500 MHz and 126 MHz, respectively) or a 
Bruker AV III HD spectrometer equipped with a Prodigy liquid nitrogen temperature 
cryoprobe (400 MHz and 101 MHz, respectively), and are reported in terms of chemical 
shift relative to residual CHCl3 (δ 7.26 and δ 77.16 ppm, respectively).  Data for 1H 
NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling 
constant (Hz), integration).  Abbreviations are used as follows: s = singlet, bs = broad 
singlet, d = doublet, t = triplet, q = quartet, m = complex multiplet.  Infrared (IR) spectra 
were recorded on a Perkin Elmer Paragon 1000 spectrometer using thin film samples on 
NaCl plates, and are reported in frequency of absorption (cm–1).  High-resolution mass 
spectra (HRMS) were obtained from the Caltech Mass Spectral Facility using a JEOL 
JMS-600H High Resolution Mass Spectrometer with fast atom bombardment (FAB+) 
ionization mode or were acquired using an Agilent 6200 Series TOF with an Agilent 
G1978A Multimode source in electrospray ionization (ESI+) mode.  Melting points were 
measured with a BÜCHI Melting Point B-545 apparatus. 
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5.5.2   GENERAL EXPERIMENTAL PROCEDURES 
 
General Procedure A.  Benzyl protection of lactams. 
To a flame-dried round-bottom flask with a magnetic stir bar were added sodium 
hydride (60% dispersion in mineral oil, 56.5 mmol, 1.13 equiv) and THF (16 mL).  The 
flask was capped with a rubber septum, put under a nitrogen atmosphere, and cooled to 0 
°C using an ice water bath.  A solution of lactam 577 (50.0 mmol, 1.00 equiv) in THF (75 
mL) was added rapidly dropwise by syringe, and the resulting mixture was allowed to 
warm to 23 °C and stir for 2 hours.  Benzyl bromide (53.5 mmol, 1.07 equiv) was added 
dropwise by syringe, and the mixture stirred for another 2 hours.  Upon completion (as 
determined by TLC analysis), the suspension was diluted with water (300 mL) and 
extracted with ethyl acetate (3 x 300 mL).  The combined organic layers were washed 
with brine (1 x 300 mL), dried over magnesium sulfate, filtered, and concentrated in 
vacuo.  The crude residue was purified by silica gel column chromatography, using 
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    R–X; –78→23 °C
2. LDA, THF, 0 °C;








Chapter 5 – Palladium-Catalyzed Allylic C–H Oxidation of Hindered Substrates  632
To a flame-dried round-bottom flask with a magnetic stir bar were added 
diisopropylamine (25.4 mmol, 1.2 equiv) and THF (13 mL) by syringe.  The solution was 
stirred under nitrogen and cooled to 0 °C using an ice water bath.  n-Butyllithium (2.5 M 
in hexane, 25.1 mmol, 1.19 equiv) was added rapidly dropwise by syringe, and the 
solution was allowed to stir at 0 °C for 20 minutes.  Meanwhile, lactam 578 (21.1 mmol, 
1.00 equiv) was dissolved in THF (200 mL) in a flame-dried round-bottom flask under 
nitrogen and cooled to 0 °C using an ice water bath.  The freshly prepared LDA solution 
was transferred to the lactam solution rapidly dropwise via syringe, and the mixture was 
allowed to stir at 0 °C for 45 minutes.  The solution was then cooled to –78 °C using a 
dry ice and acetone bath, and the appropriate alkyl halide (27.5 mmol, 1.30 equiv) was 
added dropwise by syringe.  The flask was placed in an ice water bath and allowed to 
gradually warm to 23 °C overnight.  Upon completion (as determined by TLC analysis), 
the reaction mixture was quenched by the addition of saturated aqueous ammonium 
chloride solution (400 mL), and the aqueous layer extracted with chloroform (3 x 300 
mL).  The combined organic layers were washed with brine (1 x 300 mL), dried over 
sodium sulfate, filtered, and concentrated in vacuo.  The crude residue was purified by 
silica gel column chromatography using mixtures of hexanes and ethyl acetate as eluent. 
To a flame-dried round-bottom flask with a magnetic stir bar were added 
diisopropylamine (29.3 mmol, 1.50 equiv) and THF (15 mL) by syringe.  The solution 
was stirred under nitrogen and cooled to 0 °C using an ice water bath.  n-Butyllithium 
(2.5 M in hexane, 29.1 mmol, 1.49 equiv) was added rapidly dropwise by syringe, and 
the solution was allowed to stir at 0 °C for 20 minutes.  Meanwhile, the mono-alkylated 
intermediate lactam (19.5 mmol, 1.00 equiv) was dissolved in THF (61 mL) in a flame-
Chapter 5 – Palladium-Catalyzed Allylic C–H Oxidation of Hindered Substrates  633
dried round-bottom flask under nitrogen and cooled to 0 °C using an ice water bath.  The 
freshly prepared LDA solution was transferred to the lactam solution rapidly dropwise 
via syringe, and the mixture was allowed to stir at 0 °C for 45 minutes.  The solution was 
then cooled to –78 °C using a dry ice and acetone bath, and allyl bromide (117.0 mmol, 
6.00 equiv) was added dropwise by syringe.  The flask was placed in an ice water bath 
and allowed to gradually warm to 23 °C overnight.  Upon completion (as determined by 
TLC analysis), the reaction mixture was quenched by the addition of saturated aqueous 
ammonium chloride solution (300 mL), and the aqueous layer extracted with chloroform 
(3 x 200 mL).  The combined organic layers were washed with brine (1 x 200 mL), dried 
over sodium sulfate, filtered, and concentrated in vacuo.  The crude residue was purified 
by silica gel column chromatography using mixtures of hexanes and ethyl acetate as 
eluent.  The products were obtained in 8–40% yield over two steps. 
 
 
General Procedure C.  Optimization of the allylic acetoxylation reaction. 
To a flame-dried 25 mL round-bottom flask with a magnetic stir bar were added, in 
order, the appropriate lactam 530 (0.10 mmol, 1.00 equiv), the appropriate palladium(II) 
catalyst (0.075 mmol or 0.05 mmol, 0.075 equiv or 0.05 equiv), Oxone (0.15 mmol or 
0.25 mmol, 1.50 equiv or 2.50 equiv), and (if indicated) hot, activated 4 Å molecular 
sieves (80 mg).  The flask was then capped with a rubber septum and evacuated and 
backfilled twice with nitrogen.  The appropriate solvent mixture (total volume 1 mL, 5:2 
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syringe.  The resulting suspension was stirred under nitrogen for 5 minutes at 23 °C and 
then heated to 60 °C in an oil bath.  Upon completion (as determined by TLC analysis), 
the flask was allowed to cool to 23 °C and the contents were filtered through a short plug 
of silica gel, rinsing with ethyl acetate.  The filtrate was adsorbed onto silica gel (approx. 
1 g), which was then flushed with ethyl acetate.  The eluent was concentrated to give the 
crude product as an oil.  After NMR analysis to determine the acetate:enal ratio, the crude 
residue was purified by silica gel column chromatography, using mixtures of hexanes and 
ethyl acetate as eluent. 
 
 
General Procedure D.  Allylic acetoxylation of α-allyl lactams. 
To a flame-dried 25 mL round-bottom flask with a magnetic stir bar were added, in 
order, lactam 534 (0.20 mmol, 1.00 equiv), palladium(II) hexafluoroacetylacetonate (8 
mg, 0.015 mmol, 0.075 equiv), Oxone (154 mg, 0.50 mmol, 2.50 equiv), and hot, 
activated 4 Å molecular sieves (160 mg).  The flask was then capped with a rubber 
septum and evacuated and backfilled twice with nitrogen.  Acetonitrile (1.43 mL) and 1:1 
acetic acid:acetic anhydride (571 μL) were added by syringe.  The resulting suspension 
was stirred under nitrogen for 5 minutes at 23 °C and then heated to 60 °C in an oil bath.  
Upon completion (as determined by TLC analysis), the flask was allowed to cool to 23 
°C and the contents were filtered through a short plug of silica gel, rinsing with ethyl 
acetate.  The filtrate was adsorbed onto silica gel (approx. 2 g), which was then flushed 
with ethyl acetate.  The eluent was concentrated to give the crude product as an oil.  After 
R1N
O
R2 Pd(hfacac)2 (7.5 mol %)
Oxone (2.5 equiv)
5:1:1 MeCN:AcOH:Ac2O
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NMR analysis to determine the acetate:enal ratio, the crude residue was purified by silica 
gel column chromatography, using mixtures of hexanes and ethyl acetate as eluent. 
 
 
General Procedure E.  Enal formation from α-allyl lactams. 
To a 25 mL round-bottom flask with a magnetic stir bar were added, in order, lactam 
534 (0.20 mmol, 1.00 equiv), palladium(II) acetate (3 mg, 0.015 mmol, 0.075 equiv), and 
Oxone (154 mg, 0.50 mmol, 2.50 equiv).  Acetonitrile (1.82 mL), acetic acid (183 μL, 
3.20 mmol, 16.00 equiv), and water (29 μL, 1.60 mmol, 8.00 equiv) were added by 
syringe.  The resulting suspension was stirred for 5 minutes at 23 °C and then heated to 
50 °C in an oil bath.  Upon completion (as determined by TLC analysis), the flask was 
allowed to cool to 23 °C and anhydrous magnesium sulfate (approx. 200 mg) was added.  
After stirring for 5 minutes the contents were filtered through a short plug of silica gel, 
rinsing with ethyl acetate.  The filtrate was adsorbed onto silica gel (approx. 2 g), which 
was then flushed with ethyl acetate.  The eluent was concentrated to give the crude 
product as an oil.  After NMR analysis to determine the acetate:enal ratio, the crude 
residue was purified by silica gel column chromatography, using mixtures of hexanes and 
ethyl acetate as eluent. 
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Compounds of the general structures 528 (not used in this work) and 529, including 
one used in this work (R1 = Bz, R2 = Et, n = 1; starting material for entry 1 of Scheme 1) 




Lactam 581 was prepared from δ-valerolactam (580) using General Procedure A.  




Lactam 583 was prepared from ε-caprolactam (582) using General Procedure A.  




Lactam 584 was prepared from 2-pyrrolidinone (584) using General Procedure A.  
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3-allyl-1-benzyl-3-ethylpiperidin-2-one (586): 
Lactam 586 was prepared from 581 using General Procedure B.  Rf = 0.40 (33% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.34–7.27 (m, 2H), 7.26–7.20 (m, 
3H), 5.78 (dddd, J = 16.7, 10.5, 8.1, 6.7 Hz, 1H), 5.10–5.05 (m, 1H), 5.06–5.03 (m, 2H), 
4.60 (d, J = 14.6 Hz, 1H), 4.56 (d, J = 14.6 Hz, 1H), 3.22–3.10 (m, 2H), 2.55 (ddt, J = 
13.5, 6.7, 1.3 Hz, 1H), 2.21 (ddt, J = 13.5, 8.0, 1.1 Hz, 1H), 1.83 (dq, J = 13.6, 7.5 Hz, 
1H), 1.78–1.63 (m, 3H), 1.52 (dq, J = 13.6, 7.5 Hz, 1H), 0.88 (t, J = 7.5 Hz, 3H); 13C 
NMR (CDCl3, 126 MHz) δ 174.5, 137.7, 135.0, 128.6, 128.1, 127.3, 117.8, 50.6, 47.8, 
45.3, 31.6, 28.9, 19.8, 8.9; IR (Neat Film, NaCl) 2938, 1633, 1488, 1453, 1352, 1196, 





Lactam 587 was prepared from 581 using General Procedure B.  Rf = 0.50 (33% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.32–7.27 (m, 2H), 2.26–2.20 (m, 
3H), 5.81–5.71 (m, 1H), 5.11–5.04 (m, 2H), 4.62 (d, J = 14.6 Hz, 1H), 4.50 (d, J = 14.6 
Hz, 1H), 3.24–3.10 (m, 2H), 2.57 (ddt, J = 13.5, 6.7, 1.3 Hz, 1H), 2.23 (ddt, J = 13.4, 8.1, 















Chapter 5 – Palladium-Catalyzed Allylic C–H Oxidation of Hindered Substrates  638
NMR (CDCl3, 126 MHz) δ 175.1, 137.7, 143.6, 128.6, 128.0, 127.3, 118.1, 50.5, 47.9, 
44.5, 41.6, 32.6, 26.0, 19.4; IR (Neat Film, NaCl) 2936, 1634, 1488, 1432, 1349, 1196, 





Lactam 588 was prepared from 581 using General Procedure B.  Rf = 0.40 (33% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) 7.32–7.13 (m, 10H), 5.82 (dddd, J = 
16.8, 10.6, 8.2, 6.5 Hz, 1H), 5.15–5.11 (m, 1H), 5.11–5.06 (m, 1H), 4.68 (d, J = 14.5 Hz, 
1H), 4.48 (d, J = 14.6 Hz, 1H), 3.38 (d, J = 13.0 Hz, 1H), 3.06 (ddd, J = 12.0, 7.4, 4.6 Hz, 
1H), 2.99–2.87 (m, 1H), 2.72 (ddt, J = 13.4, 6.5, 1.4 Hz, 1H), 2.61 (d, J = 13.1 Hz, 1H), 
2.21 (ddt, J = 13.4, 8.2, 1.0 Hz, 1H), 1.78–1.68 (m, 2H), 1.64 (qdd, J = 11.9, 5.9, 2.7 Hz, 
1H), 1.46–1.34 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 173.8, 138.3, 137.4, 134.5, 
130.8, 128.5, 128.1, 128.1, 127.3, 126.4, 118.5, 50.8, 47.8, 46.7, 44.8, 44.6, 28.6, 19.7; 
IR (Neat Film, NaCl) 3027, 2939, 1631, 1495, 1453, 1353, 1194, 916, 742 cm–1; HRMS 


















Chapter 5 – Palladium-Catalyzed Allylic C–H Oxidation of Hindered Substrates  639
Lactam 589 was prepared from 581 using General Procedure B.  Rf = 0.50 (33% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.35–7.29 (m, 2H), 7.27–7.20 (m, 
3H), 5.90–5.66 (m, 1H), 5.10–5.06 (m, 1H), 5.06–5.04 (m, 1H), 4.61 (d, J = 14.5 Hz, 
1H), 4.55 (d, J = 14.5 Hz, 1H), 3.16 (td, J = 5.4, 4.6, 2.2 Hz, 2H), 2.56 (ddt, J = 13.5, 6.7, 
1.3 Hz, 1H), 2.22 (ddt, J = 13.5, 8.1, 1.0 Hz, 1H), 1.83–1.57 (m, 5H), 1.55–1.41 (m, 1H), 
1.41–1.32 (m, 1H), 1.32–1.21 (m, 1H), 0.91 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 126 
MHz) δ 174.4, 137.7, 134.9, 128.5, 128.1, 127.2, 117.8, 50.5, 47.7, 45.1, 43.7, 41.4, 29.5, 
19.8, 17.6, 14.8; IR (Neat Film, NaCl) 2955, 1632, 1487, 1437, 1350, 1194, 913, 734 cm–




Lactam 590 was prepared from 581 using General Procedure B.  Rf = 0.3 (33% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.34–7.27 (m, 2H), 7.27–7.20 (m, 
3H), 5.86–5.65 (m, 1H), 5.08 (dtd, J = 13.3, 2.4, 1.1 Hz, 2H), 4.62 (d, J = 14.6 Hz, 1H), 
4.52 (d, J = 14.5 Hz, 1H), 3.56–3.37 (m, 2H), 3.29 (s, 3H), 3.24–3.12 (m, 2H), 2.56 (ddt, 
J = 13.6, 6.7, 1.3 Hz, 1H), 2.26 (ddt, J = 13.5, 8.0, 1.0 Hz, 1H), 2.09 (ddd, J = 14.1, 7.7, 
6.5 Hz, 1H), 1.83–1.63 (m, 5H); 13C NMR (CDCl3, 126 MHz) δ 173.9, 137.7, 134.4, 
128.6, 128.1, 127.3, 118.4, 69.7, 58.7, 50.7, 47.9, 44.0, 43.7, 38.0, 30.1, 19.7; IR (Neat 
Film, NaCl) 2925, 1632, 1487, 1452, 1195, 1114, 915, 736 cm–1; HRMS (ESI+) m/z 












Lactam 591 was prepared from 581 following a known procedure.2a  To a flame-dried 
round-bottom flask with a magnetic stir bar were added lactam 581 (662 mg, 3.50 mmol, 
2.20 equiv) and THF (6.4 mL).  The solution was stirred under nitrogen and cooled to –
20 °C using a dry ice and acetone bath.  A solution of lithium hexamethyldisilazide (532 
mg, 3.18 mmol, 2.00 equiv) in THF (1.4 mL) was added by syringe, and the reaction 
mixture was allowed to stir at –20 °C for 20 minutes.  A solution of zinc(II) chloride (477 
mg, 3.50 mmol, 2.20 equiv) in THF (7 mL) was added, and the reaction mixture was 
allowed to stir at –20 °C for another 20 minutes, after which it was transferred via syringe 
to a flame-dried round-bottom flask with a magnetic stir bar and a reflux condenser 
containing tris(dibenzylideneacetone)dipalladium(0) (23 mg, 0.025 mmol, 0.015 equiv), 
DavePhos (30 mg, 0.076 mmol, 0.048 equiv), bromobenzene (169 μL, 1.59 mmol, 1.00 
equiv), and THF (3.2 mL).  The mixture was heated to 65 °C for 10 hours.  Upon 
completion (as determined by TLC analysis), the reaction mixture was allowed to cool to 
23 °C, quenched by the addition of saturated aqueous ammonium chloride solution (100 
mL), and the aqueous layer was extracted with ether (3 x 200 mL).  The combined 
organic layers were dried over magnesium sulfate and concentrated in vacuo.  The crude 
residue was purified by silica gel column chromatography (20% ethyl aceate in hexanes 
to 25% ethyl acetate in hexanes) to provide lactam 591 as a colorless oil (141 mg, 15% 

















To a flame-dried round-bottom flask with a magnetic stir bar were added 
diisopropylamine (348 μL, 2.48 mmol, 1.50 equiv) and THF (1.3 mL) by syringe.  The 
solution was stirred under nitrogen and cooled to 0 °C using an ice water bath.  n-
Butyllithium (2.5 M in hexane, 983 μL, 2.46 mmol, 1.49 equiv) was added rapidly 
dropwise by syringe, and the solution was allowed to stir at 0 °C for 20 minutes.  
Meanwhile, lactam 591 (439 mg, 1.65 mmol, 1.00 equiv) was dissolved in THF (5.3 mL) 
in a flame-dried round-bottom flask under nitrogen and cooled to 0 °C using an ice water 
bath.  The freshly prepared LDA solution was transferred to the lactam solution rapidly 
dropwise via syringe, and the mixture was allowed to stir at 0 °C for 45 minutes.  The 
solution was then cooled to –78 °C using a dry ice and acetone bath, and allyl bromide 
(857 μL, 9.90 mmol, 6.00 equiv) was added dropwise by syringe.  The flask was placed 
in an ice water bath and allowed to gradually warm to 23 °C overnight.  Upon completion 
(as determined by TLC analysis), the reaction mixture was quenched by the addition of 
saturated aqueous ammonium chloride solution (100 mL), and the aqueous layer 
extracted with chloroform (3 x 75 mL).  The combined organic layers were washed with 
brine (1 x 100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo.  The 
crude residue was purified by silica gel column chromatography (5% ethyl aceate in 
hexanes) to provide lactam 592 as a colorless oil (332 mg, 66% yield).  Rf = 0.4 (10% 









LDA, THF, 0 °C;
allyl–Br, –78→23 °C
(66% yield)
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(m, 1H), 5.76 (dddd, J = 17.1, 10.2, 8.2, 6.1 Hz, 1H), 5.14–5.04 (m, 2H), 4.69 (s, 2H), 
3.28–3.16 (m, 1H), 3.12 (dddd, J = 12.1, 5.2, 3.7, 1.3 Hz, 1H), 2.96 (ddt, J = 13.5, 6.1, 
1.4 Hz, 1H), 2.53 (ddt, J = 13.6, 8.2, 1.0 Hz, 1H), 2.19 (dtd, J = 13.9, 4.0, 1.3 Hz, 1H), 
2.12–1.97 (m, 1H), 1.72–1.61 (m, 2H); 13C NMR (CDCl3, 126 MHz) δ 172.4, 144.0, 
137.6, 135.4, 128.7, 128.5, 128.3, 127.4, 126.8, 126.6, 118.2, 51.2, 50.8, 47.5, 45.8, 31.4, 
19.0; IR (Neat Film, NaCl) 3061, 2943, 1635, 1495, 1442, 1352, 1197, 916, 761, 699 cm–




To a flame-dried round-bottom flask with a magnetic stir bar were added sodium 
hydride (60% dispersion in mineral oil, 122 mg, 3.06 mmol, 1.10 equiv) and THF (5 
mL).  The flask was capped with a rubber septum, put under a nitrogen atmosphere, and 
cooled to 0 °C using an ice water bath.  A solution of lactam 593 (preparation described 
below, 465 mg, 2.78 mmol, 1.00 equiv) in THF (15 mL) was added rapidly dropwise by 
syringe, and the resulting mixture was allowed to warm to 23 °C and stir for 2 hours.  
Methyl iodide (191 μL, 3.06 mmol, 1.10 equiv) was added dropwise by syringe, and the 
mixture stirred for another 2 hours.  Upon completion (as determined by TLC analysis), 
the suspension was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 
mL).  The combined organic layers were washed with brine (1 x 100 mL), dried over 
magnesium sulfate, filtered, and concentrated in vacuo.  The crude residue was purified 









NaH, THF, 0→23 °C;
MeI, 23 °C
(97% yield)
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594 as a colorless oil (490 mg, 97% yield).  Rf = 0.4 (33% ethyl acetate in hexanes); 1H 
NMR (CDCl3, 500 MHz) δ 5.77–5.61 (m, 1H), 5.05–5.01 (m, 1H), 5.00 (t, J = 1.2 Hz, 
1H), 3.29–3.15 (m, 2H), 2.89 (s, 3H), 2.45 (ddt, J = 13.6, 6.7, 1.4 Hz, 1H), 2.15 (ddt, J = 
13.6, 8.1, 1.1 Hz, 1H), 1.84–1.58 (m, 5H), 1.46 (dq, J = 13.7, 7.4 Hz, 1H), 0.82 (t, J = 7.5 
Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 174.6, 135.1, 117.6, 50.5, 45.1, 43.0, 35.2, 31.3, 
28.9, 19.7, 8.0; IR (Neat Film, NaCl) 2938, 1635, 1499, 1458, 1398, 1357, 1201, 911 cm–




Lactam 595 was prepared from 580 following a known procedure.31  To a flame-dried 
round-bottom flask with a magnetic stir bar were added lactam 580 (2.25 g, 22.7 mmol, 
1.00 equiv) and THF (50 mL).  The solution was stirred under nitrogen and cooled to –78 
°C using a dry ice and acetone bath.  n-Butyllithium (2.5 M in hexane, 18.3 mL, 45.7 
mmol, 2.01 equiv) was added dropwise by syringe, and the reaction mixture was allowed 
to warm to 0 °C and stir for 1 hour.  Ethyl iodide (2.73 mL, 34.1 mmol, 1.50 equiv) was 
added dropwise by syringe, and the solution was stirred for 45 minutes at 0 °C.  Upon 
completion (as determined by TLC analysis), the mixture was quenched with saturated 
aqueous ammonium chloride solution (100 mL) and the aqueous layer was extracted with 
chloroform (3 x 200 mL).  The combined organic layers were washed with brine (1 x 200 
mL), dried over sodium sulfate, and concentrated in vacuo.  The crude residue was 
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Lactam 593 was prepared from 595 following a known procedure.6  To a flame-dried 
round-bottom flask with a magnetic stir bar were added lactam 595 (2.60 g, 20.4 mmol, 
1.00 equiv) and THF (60 mL).  The solution was stirred under nitrogen and cooled to –78 
°C using a dry ice and acetone bath.  n-Butyllithium (2.5 M in hexane, 8.24 mL, 20.6 
mmol, 1.01 equiv) was added dropwise by syringe, and the reaction mixture was allowed 
to warm to 0 °C and stir for 1.25 hours.  Trimethylsilyl chloride (3.77 mL, 22.5 mmol, 
1.10 equiv) was added rapidly by syringe, and the reaction mixture was allowed to stir for 
1.75 hours at 0 °C.  Meanwhile, to a flame-dried round-bottom flask with a magnetic stir 
bar were added diisopropylamine (4.29 mL, 30.6 mmol, 1.50 equiv) and THF (15 mL) by 
syringe.  The amine solution was stirred under nitrogen and cooled to 0 °C using an ice 
water bath.  n-Butyllithium (2.5 M in hexane, 12.2 mL, 30.4 mmol, 1.49 equiv) was 
added rapidly dropwise by syringe, and the solution was allowed to stir at 0 °C for 20 
minutes.  The freshly prepared LDA solution was then added to the reaction mixture 
rapidly by syringe, and the resulting solution was stirred for 45 minutes at 0 °C.  The 
solution was then cooled to –78 °C using a dry ice and acetone bath, and allyl bromide 
(21 mL, 250 mmol, 12.3 equiv) was added dropwise by syringe.  The reaction mixture 
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TLC analysis), the mixture was quenched with saturated aqueous ammonium chloride 
solution (100 mL) and the aqueous layer was extracted with chloroform (3 x 200 mL).  
The combined organic layers were washed with 1 M aqueous hydrochloric acid (2 x 100 
mL), water (1 x 100 mL), brine (1 x 100 mL), dried over sodium sulfate, and 
concentrated in vacuo.  The crude residue was purified by silica gel column 
chromatography (50% ethyl acetate in hexanes) to provide lactam 593 as a colorless oil 




To a flame-dried round-bottom flask with a magnetic stir bar were added 
diisopropylamine (2.91 mL, 20.8 mmol, 1.05 equiv) and THF (10 mL) by syringe.  The 
solution was stirred under nitrogen and cooled to 0 °C using an ice water bath.  n-
Butyllithium (2.5 M in hexane, 8.71 mL, 21.8 mmol, 1.10 equiv) was added rapidly 
dropwise by syringe, and the solution was allowed to stir at 0 °C for 30 minutes before 
being cooled to –78 °C in a dry ice and acetone bath.  A solution of lactam 581 (3.75 g, 
19.8 mmol, 1.00 equiv) in THF (60 mL) was added dropwise by cannula.  The reaction 
mixture was stirred at –78 °C for 4 hours.  Allyl bromide (1.79 mL, 20.8 mmol, 1.05 
equiv) was added dropwise by syringe, and the reaction mixture was allowed to gradually 
warm to 23 °C and stir for 16 h.  Upon completion (as determined by TLC analysis) the 
reaction mixture was quenched by the addition of saturated aqueous ammonium chloride 








LDA, THF, –78 °C;
allyl–Br, –78→23 °C
(61% yield)
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combined organic layers were washed with brine (1 x 200 mL), dried over sodium 
sulfate, filtered, and concentrated in vacuo.  The crude residue was purified by silica gel 
column chromatography (25% ethyl aceate in hexanes) to provide lactam 596 as a 
colorless oil (2.77 g, 61% yield).  Rf = 0.7 (50% ethyl acetate in hexanes); 




The conditions for this transformation were adapted from a known procedure.[33]  To a 
flame-dried round-bottom flask with a magnetic stir bar were added lactam 593 (1.00 g, 
5.98 mmol, 1.20 equiv) and DMF (6 mL).  The solution was stirred under nitrogen and 
copper(I) iodide (190 mg, 1.00 mmol, 0.20 equiv), potassium phosphate tribasic (2.12 g, 
10.0 mmol, 2.00 equiv), N,N’-dimethylethylenediamine (108 μL), and 4-bromoanisole 
(630 μL, 5.04 mmol, 1.00 equiv) were added.  The heterogeneous mixture was then 
heated to 110 °C under nitrogen for 20 hours.  Upon completion (as determined by 
LCMS analysis), the mixture was filtered through a plug of sodium sulfate, rinsing with 
dichloromethane.  The filtrate was washed with water (3 x 100 mL), dried over sodium 
sulfate, filtered, and concentrated in vacuo.  The crude residue was purified by silica gel 
column chromatography (20% ethyl acetate in hexanes) to provide lactam 597 as a 
colorless oil (203 mg, 12% yield).  Rf = 0.3 (20% ethyl acetate in hexanes); 1H NMR 
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5.10 (m, 1H), 5.10 (s, 1H), 3.80 (s, 3H), 3.58 (t, J = 5.9 Hz, 2H), 2.60 (ddt, J = 13.5, 6.7, 
1.3 Hz, 1H), 2.23 (ddt, J = 13.4, 8.1, 1.0 Hz, 1H), 2.00–1.77 (m, 5H), 1.57 (dq, J = 13.6, 
7.4 Hz, 1H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 174.9, 158.0, 137.0, 
135.1, 127.5, 118.0, 114.4, 55.6, 52.5, 45.7, 43.7, 31.9, 29.3, 20.6, 9.0; IR (Neat Film, 
NaCl) 3072, 2937, 1646, 1511, 1457, 1293, 1243, 1199, 1105, 1134, 913, 829 cm–1; 




To a flame-dried round-bottom flask with a magnetic stir bar were added lactam 593 
(400 mg, 2.40 mmol, 1.00 equiv) and THF (12 mL).  The flask was capped with a rubber 
septum, put under an argon atmosphere, and cooled to 0 °C using an ice water bath.  
Sodium hydride (60% dispersion in mineral oil, 192 mg, 4.80 mmol, 2.00 equiv) was 
then added in one portion, and the suspension was allowed to warm to 23 °C and stir for 
2 hours.  The suspension was then cooled to 0 °C using an ice water bath, and 3-bromo-2-
methylpropene (267 μL, 2.64 mmol, 1.10 equiv) was added by syringe.  The suspension 
was allowed to warm to 23 °C and stir for 1 hour.  Upon completion (as determined by 
TLC analysis), the reaction mixture was diluted with water (100 mL) and extracted with 
ethyl acetate (3 x 100 mL).  The combined organic layers were washed with brine (1 x 
100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo.  The crude 
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to provide lactam 598 as a colorless oil (531 mg, >99% yield).  Rf = 0.5 (20% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 5.86–5.62 (m, 1H), 5.07–5.04 (m, 
1H), 5.04–5.02 (m, 1H), 4.85 (q, J = 1.5 Hz, 1H), 4.76 (dt, J = 2.4, 1.1 Hz, 1H), 4.02–
3.80 (m, 2H), 3.24–3.08 (m, 2H), 2.58–2.38 (m, 1H), 2.18 (ddt, J = 13.5, 8.2, 1.1 Hz, 
1H), 1.89–1.68 (m, 5H), 1.67 (s, 3H), 1.56–1.45 (m, 1H), 0.87 (td, J = 7.4, 1.2 Hz, 3H); 
13C NMR (CDCl3, 126 MHz) δ 174.3, 140.9, 135.1, 117.8, 112.0, 52.7, 47.6, 45.3, 43.4, 
31.6, 29.0, 20.2, 19.9, 8.9; IR (Neat Film, NaCl) 3074, 2939, 1637, 1488, 1458, 1440, 
1346, 1285, 1197, 1000, 911 cm–1; HRMS (ESI+) m/z calc’d for C14H24NO [M+H]+: 




To a flame-dried round-bottom flask with a magnetic stir bar were added lactam 593 
(400 mg, 2.40 mmol, 1.00 equiv) and THF (12 mL).  The flask was capped with a rubber 
septum, put under an argon atmosphere, and cooled to 0 °C using an ice water bath.  
Sodium hydride (60% dispersion in mineral oil, 192 mg, 4.80 mmol, 2.00 equiv) was 
then added in one portion, and the suspension was allowed to warm to 23 °C and stir for 
2 hours.  The suspension was then cooled to 0 °C using an ice water bath, and 3-bromo-1-
phenyl-1-propene (520 mg, 2.64 mmol, 1.10 equiv) was added by syringe.  The 
suspension was allowed to warm to 23 °C and stir for 2 hours.  Upon completion (as 
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extracted with ethyl acetate (3 x 100 mL).  The combined organic layers were washed 
with brine (1 x 100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo.  
The crude residue was purified by silica gel column chromatography (20% ethyl acetate 
in hexanes) to provide lactam 599 as a colorless oil (676 mg, >99% yield).  Rf = 0.3 (20% 
ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.39–7.33 (m, 2H), 7.31 (ddd, J 
= 7.7, 6.7, 1.2 Hz, 2H), 7.26–7.20 (m, 1H), 6.48 (dt, J = 15.7, 1.5 Hz, 1H), 6.14 (dt, J = 
15.8, 6.5 Hz, 1H), 5.90–5.57 (m, 1H), 5.08 (ddt, J = 5.0, 2.3, 1.3 Hz, 1H), 5.06 (t, J = 1.2 
Hz, 1H), 4.14 (dd, J = 6.5, 1.4 Hz, 2H), 3.42–3.13 (m, 2H), 2.54 (ddt, J = 13.5, 6.7, 1.3 
Hz, 1H), 2.20 (ddt, J = 13.5, 8.1, 1.0 Hz, 1H), 1.95–1.65 (m, 5H), 1.52 (dq, J = 13.5, 7.4 
Hz, 1H), 0.89 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 174.3, 136.8, 135.1, 
132.6, 128.7, 127.7, 126.5, 125.0, 117.8, 49.5, 47.9, 45.4, 43.4, 31.6, 28.9, 20.0, 8.9; IR 
(Neat Film, NaCl) 2938, 1631, 1487, 1448, 1352, 1282, 1196, 965, 912, 746 cm–1; HRMS 




Lactam 600 was prepared from 583 using General Procedure B.  Rf = 0.4 (33% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.33–7.27 (m, 2H), 7.26–7.21 (m, 
3H), 5.94–5.72 (m, 1H), 5.12–5.07 (m, 1H), 5.06 (t, J = 1.2 Hz, 1H), 4.69 (d, J = 14.6 Hz, 
1H), 4.52 (d, J = 14.6 Hz, 1H), 3.42 (ddd, J = 15.2, 7.9, 4.0 Hz, 1H), 3.28 (ddd, J = 15.2, 
6.3, 3.9 Hz, 1H), 2.54–2.34 (m, 2H), 1.76–1.59 (m, 3H), 1.59–1.45 (m, 3H), 1.28 (s, 3H); 
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47.0, 46.3, 44.2, 34.9, 27.4, 26.2, 23.1; IR (Neat Film, NaCl) 2930, 1626, 1495, 1453, 





To a flame-dried round-bottom flask with a magnetic stir bar were added lactam 583 
(1.00 g, 4.92 mmol, 1.00 equiv) and THF (26 mL).  The solution was stirred under 
nitrogen and cooled to –78 °C using a dry ice and acetone bath.  n-Butyllithium (2.5 M in 
hexane, 2.16 mL, 5.41 mmol, 1.10 equiv) was added dropwise by syringe, and the 
solution was allowed to stir at –78 °C for 1 hour.  Allyl bromide (510 μL, 5.90 mmol, 
1.20 equiv) was then added dropwise by syringe, and the solution was allowed to 
gradually warm to 23 °C and stir for 17 hours.  Upon completion (as determined by 
LCMS analysis), the reaction mixture was quenched by the addition of saturated aqueous 
ammonium chloride solution (100 mL), and the aqueous layer extracted with ethyl 
acetate (3 x 100 mL).  The combined organic layers were dried over magnesium sulfate, 
filtered, and concentrated in vacuo.  The crude residue was purified by silica gel column 
chromatography (20% ethyl aceate in hexanes) to provide lactam 601 as a colorless oil 
(838 mg, 70% yield).  Rf = 0.2 (25% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 
MHz) δ 7.34–7.28 (m, 2H), 7.27–7.22 (m, 3H), 5.88 (dddd, J = 17.1, 10.2, 7.9, 5.6 Hz, 
1H), 5.14–4.95 (m, 2H), 4.75 (d, J = 14.6 Hz, 1H), 4.45 (d, J = 14.6 Hz, 1H), 3.56–3.40 







n-BuLi, THF, –78 °C;
allyl–Br, –78→23 °C
(70% yield)
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2.59 (dtd, J = 10.4, 6.7, 6.0, 1.5 Hz, 1H), 2.12 (dtt, J = 14.0, 7.6, 1.1 Hz, 1H), 1.92–1.83 
(m, 1H), 1.76 (dtd, J = 13.9, 4.7, 1.3 Hz, 1H), 1.64 (ddt, J = 13.9, 5.3, 4.0 Hz, 1H), 1.51 
(dtt, J = 13.8, 12.4, 3.9 Hz, 1H), 1.34 (dddd, J = 13.8, 12.5, 10.5, 3.1 Hz, 1H), 1.28–1.12 
(m, 1H); 13C NMR (CDCl3, 126 MHz) δ 176.7, 138.2, 137.5, 128.6, 128.3, 127.3, 116.3, 
51.2, 48.1, 43.5, 36.8, 29.5, 29.3, 27.6; IR (Neat Film, NaCl) 2929, 1646, 1477, 1430, 
1358, 1263, 1217, 912, 736 cm–1; HRMS (ESI+) m/z calc’d for C16H22NO [M+H]+: 




Lactam 602 was prepared from 584 using General Procedure B.  Rf = 0.4 (20% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.34–7.19 (m, 5H), 5.73 (dddd, J = 
16.8, 10.1, 8.3, 6.5 Hz, 1H), 5.16–4.97 (m, 2H), 4.47 (d, J = 14.6 Hz, 1H), 4.42 (d, J = 
14.6 Hz, 1H), 3.13–3.03 (m, 2H), 2.35 (ddt, J = 13.6, 6.5, 1.3 Hz, 1H), 2.19 (ddt, J = 
13.5, 8.3, 1.0 Hz, 1H), 1.97–1.86 (m, 1H), 1.86–1.77 (m, 1H), 1.64 (dq, J = 13.7, 7.5 Hz, 
1H), 1.52 (dq, J = 13.7, 7.4 Hz, 1H), 0.87 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 126 
MHz) δ 177.7, 136.8, 134.3, 128.7, 128.3, 127.6, 118.3, 48.2, 46.8, 43.9, 41.6, 30.0, 26.8, 
8.8; IR (Neat Film, NaCl) 3065, 2965, 1684, 1495, 1430, 1265, 1080, 1001, 916, 743 cm–
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3-allyl-1-benzyl-3-methylpyrrolidin-2-one (603): 
Lactam 603 was prepared from 584 using General Procedure B.  Rf = 0.4 (40% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.35–7.19 (m, 5H), 5.74 (dddd, J = 
16.9, 10.1, 8.1, 6.7 Hz, 1H), 5.15–4.98 (m, 2H), 4.46 (d, J = 14.7 Hz, 1H), 4.42 (d, J = 
14.6 Hz, 1H), 3.19–3.01 (m, 2H), 2.33 (ddt, J = 13.6, 6.6, 1.3 Hz, 1H), 2.21 (ddt, J = 
13.7, 8.1, 1.0 Hz, 1H), 1.99 (ddd, J = 12.8, 8.2, 6.4 Hz, 1H), 1.69 (ddd, J = 12.8, 7.9, 5.5 
Hz, 1H), 1.16 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 178.7, 136.9, 134.3, 128.8, 128.3, 
127.7, 118.5, 47.0, 44.2, 43.6, 42.4, 30.6, 23.3; IR (Neat Film, NaCl) 2962, 1685, 1495, 





Lactam 604 was prepared from 584 using General Procedure B.  Rf = 0.6 (33% ethyl 
acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.29–7.15 (m, 8H), 7.09–7.03 (m, 
2H), 5.79 (dddd, J = 16.7, 10.1, 8.5, 6.2 Hz, 1H), 5.18–5.07 (m, 2H), 4.47 (d, J = 14.7 
Hz, 1H), 4.16 (d, J = 14.7 Hz, 1H), 3.09 (d, J = 13.2 Hz, 1H), 2.86 (td, J = 9.2, 4.9 Hz, 
1H), 2.63 (d, J = 13.2 Hz, 1H), 2.52 (ddt, J = 13.6, 6.3, 1.4 Hz, 1H), 2.39–2.19 (m, 2H), 
1.98–1.78 (m, 2H); 13C NMR (CDCl3, 126 MHz) δ 177.0, 137.0, 136.4, 134.0, 130.3, 
128.6, 128.2, 128.2, 127.4, 126.6, 118.8, 49.5, 46.8, 43.8, 43.2, 42.8, 26.1; IR (Neat Film, 
NaCl) 2915, 1771, 1683, 1495, 1436, 1249, 917, 744 cm–1; HRMS (ESI+) m/z calc’d for 












To a flame-dried round-bottom flask with a magnetic stir bar were added 
diisopropylamine (479 μL, 3.42 mmol, 1.20 equiv) and THF (1.72 mL) by syringe.  The 
solution was stirred under nitrogen and cooled to 0 °C using an ice water bath.  n-
Butyllithium (2.5 M in hexane, 1.36 mL, 3.39 mmol, 1.19 equiv) was added rapidly 
dropwise by syringe, and the solution was allowed to stir at 0 °C for 20 minutes.  
Meanwhile, lactam 584 (500 mg, 2.85 mmol, 1.00 equiv) was dissolved in THF (9 mL) in 
a flame-dried round-bottom flask under nitrogen and cooled to 0 °C using an ice water 
bath.  The freshly prepared LDA solution was transferred to the lactam solution rapidly 
dropwise via syringe, and the mixture was allowed to stir at 0 °C for 45 minutes.  The 
solution was then cooled to –78 °C using a dry ice and acetone bath, and allyl bromide 
(321 μL, 3.71 mmol, 1.30 equiv) was added dropwise by syringe.  The flask was placed 
in an ice water bath, allowed to gradually warm to 23 °C, and stirred for 20 hours.  Upon 
completion (as determined by TLC analysis), the reaction mixture was quenched by the 
addition of saturated aqueous ammonium chloride solution (100 mL), and the aqueous 
layer extracted with chloroform (3 x 100 mL).  The combined organic layers were 
washed with 1 M aqueous hydrochloric acid (2 x 100 mL), water (1 x 100 mL), brine (1 x 
100 mL), dried over sodium sulfate, and concentrated in vacuo.  The crude residue was 








LDA, THF, 0 °C;
allyl–Br, –78→23 °C
(83% yield)
Chapter 5 – Palladium-Catalyzed Allylic C–H Oxidation of Hindered Substrates  654
lactam 605 as a colorless oil (509 mg, 83% yield).  Rf = 0.3 (20% ethyl acetate in 
hexanes); characterization data match those reported in the literature.[34] 
 
5.5.4   PROCEDURES FOR UNSUCCESSFUL ALLYLIC OXIDATIONS 
 
Allylic acetates 537 and 543 were prepared from 586 and 593 following a known 
procedure.3i To a round-bottom flask with a magnetic stir bar were added, in order, 
sodium acetate (3.5 mg, 0.043 mmol, 0.20 equiv), palladium(II) acetate (2.4 mg, 0.011 
mmol, 0.05 equiv), diazefluorenone ligand (1.9 mg, 0.011 mmol, 0.05 equiv), dioxane 
(600 μL), and acetic acid (190 μL).  The appropriate lactam substrate (586 or 593, 0.21 
mmol, 1.00 equiv) was added, and the flask was capped with a rubber septum.  The 
solution was stirred vigorously while oxygen was bubbled through for 15 minutes.  The 
solution was then stirred at 60 °C under an oxygen atmosphere for 41 hours.  TLC 
analysis throughout this time showed little conversion of the starting material.  After 41 
hours, the reaction mixture was filtered through a plug of silica gel, rinsing with ethyl 
acetate, and concentrated to give the crude residue.  In the case of either lactam substrate, 
NMR and LCMS analysis showed small amounts of the corresponding allylic acetate 










537  R = Bn
543  R = H
586  R = Bn
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To a 1 dram screw-top vial with a magnetic stir bar were added lactam 593 (25 mg, 
0.15 mmol, 1.00 equiv) and dioxane (1.5 mL). Selenium dioxide (83 mg, 5.00 equiv) was 
added and the reaction mixture was stirred at 80 ºC for 2h.  At this time, TLC analysis 
showed only baseline material, and the mixture was filtered through a plug of silica gel, 
rinsing with ethyl acetate.  The filtrate was concentrated and NMR and LCMS analysis 
showed complete decomposition of the starting material. 
 
 
The conditions for this transformation were adapted from a known procedure.35  To a 
1 dram screw-top vial with a magnetic stir bar were added lactam 593 (27 mg, 0.16 
mmol, 1.00 equiv) and dichlomethane (1.5 mL).  Selenium dioxide (9 mg, 0.08 mmol, 
0.50 equiv) and TBHP (5 M in decane, 160 μL, 0.80 mmol, 5.00 equiv) were added and 
the reaction mixture was stirred at 23 °C for 5 hours.  TLC analysis throughout this time 
showed no conversion of the starting material.  After 5 hours, the reaction mixture was 
filtered through a plug of silica gel, rinsing with ethyl acetate, and concentrated to give 




To a 1 dram screw-top vial with a magnetic stir bar were added lactam 586 (10 mg, 
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0.20 mmol, 5 mM in reaction solution) was added, the vial was capped with a septum, 
and oxygen was bubbled through the stirring solution for 2 minutes.  The vial was cooled 
to 0 °C using an ice water bath, and a 500 W halogen floodlight was placed at a distance 
d = 10 cm from the vial.  The solution was irradiated and allowed to gradually warm to 
23 °C over a period of 2 hours, and was further irradiated at 23 °C for an additional 12 
hours.  TLC analysis throughout this time showed no reactivity.  After 14 hours total 
reaction time, the mixture was filtered through a plug of silica gel, rinsing with ethyl 
acetate.  The filtrate was concentrated, and NMR and LCMS analysis showed only 




Imide 531 was prepared from 586 following a known procedure.[36]  Lactam 586 (20 
mg, 0.078 mmol, 1.00 equiv) was dissolved in 3.1 mL acetic acid in a 20 mL vial with a 
stir bar and heated to 77 °C.  A solution of chromium(VI) oxide (31 mg, 0.31 mmol, 4.00 
equiv) in acetic acid (1.6 mL) was added dropwise by pipette.  The vial was sealed with a 
Teflon-lined cap and stirred at 77 °C for 1 hour.  LCMS analysis at 1 hour showed full 
conversion of the starting material.  The mixture was cooled to 23 °C, and filtered 
through a plug of silica gel, rinsing with ethyl acetate.  The filtrate was diluted with 
heptanes and concentrated.  The crude residue was purified by silica gel column 
chromatography (20% ethyl aceate in hexanes) to provide imide 531 as a colorless oil 
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MHz) δ 7.34–7.26 (m, 4H), 7.25–7.20 (m, 1H), 5.66 (dddd, J = 17.0, 10.2, 7.8, 6.9 Hz, 
1H), 5.13–5.00 (m, 2H), 4.95 (s, 2H), 2.79–2.63 (m, 2H), 2.49 (ddt, J = 13.8, 6.9, 1.3 Hz, 
1H), 2.29 (ddt, J = 13.9, 7.8, 1.1 Hz, 1H), 1.92–1.77 (m, 2H), 1.72 (dq, J = 14.0, 7.5 Hz, 
1H), 1.68–1.58 (m, 1H), 0.84 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 176.5, 
172.2, 137.7, 133.0, 128.7, 128.5, 127.4, 119.3, 45.2, 43.2, 40.2, 29.3, 28.7, 24.8, 8.3; IR 
(Neat Film, NaCl) 2967, 1722, 1676, 1455, 1345, 1164 cm–1; HRMS (ESI+) m/z calc’d 
for C17H22NO2 [M+H]+: 272.1645, found 272.1632. 
 
 
The conditions for this transformation were adapted from a known procedure.15 To an 
oven-dried 1 dram screw-top vial with a magnetic stir bar were added, in order, lactam 
586 (35 mg, 0.14 mmol, 1.00 equiv) potassium carbonate (5 mg, 0.036 mmol, 0.26 
equiv), and dichloromethane (750 μL).  Palladium hydroxide on carbon (20 wt. %, 11 
mg) and tert-butyl hydroperoxide (5.0 M in decane, 137 μL, 0.69 mmol, 5.00 equiv) were 
added.  The vial was sealed with a Teflon-lined cap and the reaction mixture was stirred 
at 23 °C for 48 hours.  TLC analysis throughout this time showed very little conversion 
of the starting material.  After 48 hours, the mixture was filtered through Celite, rinsing 
first with dichloromethane and later with ethyl acetate.  The filtrate was concentrated and 
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The conditions for this transformation were adapted from a known procedure.37 To a 
1 dram screw-top vial with a magnetic stir bar were added lactam 593 (17 mg, 0.10 
mmol, 1.00 equiv) and benzene (1 mL).  Copper(I) bromide (16 mg, 0.11 mmol, 1.10 
equiv) and tert-butyl peroxybenzoate (110 μL, 0.60 mmol, 6.00 equiv) were added and 
the reaction mixture was heated to 80 °C and stirred for 5 hours.  TLC and LCMS 
analysis throughout this time showed no conversion of the starting material.  After 5 
hours, the mixture was filtered through a plug of silica gel, rinsing with ethyl acetate.  




The conditions for this reaction were adapted from a known procedure.3a To a round-
bottom flask with a magnetic stir bar were added, in order, palladium(II) acetate (5.5 mg, 
0.025 mmol, 0.10 equiv), benzoquinone (53 mg, 0.50 mmol, 2.00 equiv), and activated 4 
Å molecular sieves (53 mg).  DMSO (740 μL), lactam 593 (41 mg, 0.25 mmol, 1.00 
equiv), and acetic acid (740 μL) were added.  The vial was sealed with a Teflon-lined cap 
and heated to 40 °C for 15 hours.  TLC analysis throughout this time showed no 
conversion of the starting material.  After 15 hours, the reaction mixture was quenched 
with saturated aqueous ammonium chloride (10 mL) and extracted with dichloromethane 
(3 x 10 mL).  The combined organic layers were washed with water (1 x 10 mL), dried 
over sodium sulfate, filtered, and concentrated in vacuo.  NMR and LCMS analysis of the 
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5.5.5   ALLYLIC ACETATE CHARACTERIZATION DATA 
 
(E)-3-(1-benzyl-3-ethyl-2-oxopiperidin-3-yl)allyl acetate (597): 
Acetate 537 was prepared from 586 using General Procedure D.  56% isolated yield, 
63% combined yield with enal.  Rf = 0.3 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.34–7.28 (m, 2H), 7.28–7.20 (m, 3H), 5.88 (dt, J = 16.0, 1.3 Hz, 
1H), 5.61 (dt, J = 15.9, 6.2 Hz, 1H), 4.65 (d, J = 14.5 Hz, 1H), 4.59–4.54 (m, 2H), 4.51 
(d, J = 14.6 Hz, 1H), 3.26–3.04 (m, 2H), 2.06 (s, 3H), 1.95–1.84 (m, 1H), 1.84–1.70 (m, 
4H), 1.70–1.59 (m, 1H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 172.7, 
171.0, 139.5, 137.6, 128.7, 128.1, 127.4, 123.7, 65.2, 50.7, 48.5, 47.8, 31.9, 29.1, 21.2, 
19.3, 8.6; IR (Neat Film, NaCl) 2939, 1738, 1634, 1495, 1453, 1361, 1231, 1028, 969, 
736 cm–1; HRMS (ESI+) m/z calc’d for C19H26NO3 [M+H]+: 316.1907, found 316.1913. 
 
 
(E)-3-(1-benzyl-3-methyl-2-oxopiperidin-3-yl)allyl acetate (538): 
Acetate 538 was prepared from 587 using General Procedure D.  67% isolated yield, 
74% combined yield with enal.  Rf = 0.2 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.35–7.26 (m, 3H), 7.26–7.20 (m, 2H), 5.91 (dt, J = 15.8, 1.3 Hz, 
1H), 5.63 (dt, J = 15.8, 6.2 Hz, 1H), 4.62 (d, J = 14.6 Hz, 1H), 4.56 (dt, J = 6.3, 1.5 Hz, 
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1.78 (m, 1H), 1.78–1.69 (m, 2H), 1.36 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 173.1, 
170.9, 140.5, 137.6, 128.7, 128.1, 127.4, 123.2, 65.1, 50.6, 47.9, 44.7, 34.2, 26.6, 21.2, 
19.5; IR (Neat Film, NaCl) 2936, 1738, 1634, 1489, 1453, 1361, 1232, 1028, 976, 736 
cm–1; HRMS (ESI+) m/z calc’d for C18H24NO3 [M+H]+: 302.1751, found 302.1755. 
 
 
(E)-3-(1,3-dibenzyl-2-oxopiperidin-3-yl)allyl acetate (539): 
Acetate 529 was prepared from 588 using General Procedure D.  54% isolated yield, 
62% combined yield with enal.  Rf = 0.3 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.30–7.26 (m, 2H), 7.26–7.12 (m, 8H), 5.88 (dt, J = 15.9, 1.4 Hz, 
1H), 5.63 (dt, J = 15.9, 6.1 Hz, 1H), 4.76 (d, J = 14.6 Hz, 1H), 4.68–4.52 (m, 2H), 4.43 
(d, J = 14.6 Hz, 1H), 3.38 (d, J = 13.2 Hz, 1H), 3.16–2.99 (m, 2H), 2.79 (d, J = 13.2 Hz, 
1H), 2.08 (s, 3H), 1.87–1.53 (m, 4H); 13C NMR (CDCl3, 126 MHz) δ 171.8, 171.0, 139.4, 
137.4, 137.3, 131.2, 128.6, 128.1, 128.0, 127.4, 126.6, 124.4, 65.0, 50.9, 49.8, 47.9, 45.0, 
29.8, 21.2, 19.2; IR (Neat Film, NaCl) 2940, 1738, 1634, 1495, 1453, 1360, 1233, 1193, 
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Acetate 540 was prepared from 589 using General Procedure D.  58% isolated yield, 
66% combined yield with enal.  Rf = 0.3 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.34–7.26 (m, 3H), 7.26–7.20 (m, 2H), 5.89 (dt, J = 16.0, 1.4 Hz, 
1H), 5.61 (dt, J = 16.0, 6.2 Hz, 1H), 4.62 (d, J = 14.5 Hz, 1H), 4.57 (dt, J = 6.3, 1.5 Hz, 
2H), 4.53 (d, J = 14.6 Hz, 1H), 3.30–3.01 (m, 2H), 2.06 (s, 3H), 1.89–1.76 (m, 4H), 1.76–
1.69 (m, 1H), 1.61 (ddd, J = 13.4, 12.3, 4.4 Hz, 1H), 1.39–1.14 (m, 2H), 0.91 (t, J = 7.3 
Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 172.7, 171.0, 139.8, 137.6, 128.7, 128.2, 127.4, 
123.5, 65.3, 50.7, 48.4, 47.8, 41.6, 29.9, 21.2, 19.4, 17.5, 14.7; IR (Neat Film, NaCl) 
2955, 1739, 1635, 1495, 1453, 1360, 1230, 1027, 979, 736 cm–1; HRMS (ESI+) m/z 
calc’d for C20H28NO3 [M+H]+: 330.2064, found 330.2067. 
 
 
(E)-3-(1-benzyl-3-(2-methoxyethyl)-2-oxopiperidin-3-yl)allyl acetate (541): 
Acetate 541 was prepared from 590 using General Procedure D.  55% isolated yield, 
61% combined yield with enal.  Rf = 0.2 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.40–7.31 (m, 3H), 7.30–7.25 (m, 2H), 5.91 (dt, J = 15.9, 1.3 Hz, 
1H), 5.68 (dt, J = 15.9, 6.2 Hz, 1H), 4.69 (d, J = 14.5 Hz, 1H), 4.67–4.59 (m, 2H), 4.57 
(d, J = 14.6 Hz, 1H), 3.57–3.45 (m, 2H), 3.34 (s, 3H), 3.30–3.17 (m, 2H), 2.24–2.14 (m, 
1H), 2.12 (s, 3H), 2.02–1.71 (m, 5H); 13C NMR (CDCl3, 126 MHz) δ 172.0, 170.8, 139.0, 
137.4, 128.6, 128.0, 127.3, 124.0, 69.5, 64.9, 58.5, 50.6, 47.7, 47.3, 38.4, 30.8, 21.0, 
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(E)-3-(1-benzyl-2-oxo-3-phenylpiperidin-3-yl)allyl acetate (541): 
Acetate 542 was prepared from 592 using General Procedure D.  62% isolated yield, 
70% combined yield with enal.  Rf = 0.8 (50% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.38–7.27 (m, 8H), 7.25–7.18 (m, 2H), 6.38 (dt, J = 16.0, 1.4 Hz, 
1H), 5.69 (dt, J = 16.0, 6.2 Hz, 1H), 4.82 (d, J = 14.4 Hz, 1H), 4.64 (dt, J = 6.2, 1.2 Hz, 
2H), 4.54 (d, J = 14.4 Hz, 1H), 3.34–3.12 (m, 2H), 2.32–2.13 (m, 2H), 2.08 (s, 3H), 1.83–
1.71 (m, 1H), 1.71–1.59 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 171.4, 171.0, 143.3, 
139.3, 137.4, 128.8, 128.6, 128.5, 127.6, 127.5, 126.9, 123.7, 65.2, 53.9, 51.0, 47.6, 33.3, 
21.2, 18.9; IR (Neat Film, NaCl) 2934, 1737, 1636, 1494, 1445, 1352, 1231, 1195, 1027, 




(E)-3-(3-ethyl-1-methyl-2-oxopiperidin-3-yl)allyl acetate (543): 
Acetate 543 was prepared from 594 using General Procedure D.  59% isolated yield, 
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(CDCl3, 500 MHz) δ 5.83 (dt, J = 16.0, 1.4 Hz, 1H), 5.55 (dt, J = 16.0, 6.2 Hz, 1H), 
4.70–4.32 (m, 2H), 3.35–3.26 (m, 1H), 3.25–3.15 (m, 1H), 2.92 (s, 3H), 2.05 (s, 3H), 
1.91–1.76 (m, 5H), 1.64 (dq, J = 13.7, 7.5 Hz, 1H), 0.80 (t, J = 7.4 Hz, 3H); 13C NMR 
(CDCl3, 126 MHz) δ 172.8, 171.0, 139.4, 123.5, 65.2, 50.5, 48.3, 35.3, 31.7, 29.1, 21.2, 
19.3, 8.5; IR (Neat Film, NaCl) 2940, 1739, 1636, 1500, 1446, 1362, 1242, 1026, 981 
cm–1; HRMS (ESI+) m/z calc’d for C13H21NO3 [M+H]+: 240.1594, found 240.1598. 
 
 
(E)-3-(3-ethyl-2-oxopiperidin-3-yl)allyl acetate (544): 
Acetate 544 was prepared from 593 using General Procedure D.  51% isolated yield, 
56% combined yield with enal.  Rf = 0.1 (67% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 6.00 (s, 1H), 5.82 (dt, J = 16.0, 1.3 Hz, 1H), 5.62 (dt, J = 15.9, 6.2 
Hz, 1H), 4.68–4.41 (m, 2H), 3.28 (qd, J = 4.2, 3.6, 1.7 Hz, 2H), 2.05 (s, 3H), 1.96–1.70 
(m, 5H), 1.63 (dq, J = 13.7, 7.5 Hz, 1H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 
MHz) δ 175.0, 171.0, 138.9, 123.9, 65.1, 48.2, 42.8, 31.4, 29.0, 21.2, 19.2, 8.5; IR (Neat 
Film, NaCl) 3203, 2941, 1740, 1657, 1490, 1361, 1231, 1027, 980 cm–1; HRMS (ESI+) 
m/z calc’d for C12H20NO3 [M+H]+: 226.1438, found 226.1430. 
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Acetate 545 was prepared from 596 using General Procedure D.  61% isolated yield.  
Rf = 0.2 (33% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.37–7.19 (m, 
5H), 6.06 (dd, J = 15.7, 6.4 Hz, 1H), 5.71 (dt, J = 15.2, 6.3 Hz, 1H), 4.78–4.38 (m, 4H), 
3.22 (t, J = 5.9 Hz, 2H), 3.16 (q, J = 7.0 Hz, 1H), 2.07 (d, J = 1.6 Hz, 3H), 2.06–1.70 (m, 
4H); 13C NMR (CDCl3, 126 MHz) δ 171.0, 170.3, 137.3, 134.2, 128.7, 128.3, 127.5, 
125.6, 65.1 50.5, 47.5, 44.7, 27.2, 21.4, 21.2; IR (Neat Film, NaCl) 3225, 2936, 1738, 
1618, 1494, 1453, 1361, 1234, 1028, 737 cm–1; HRMS (ESI+) m/z calc’d for C17H22NO3 
[M+H]+: 288.1594, found 288.1607. 
 
 
(E)-3-(3-ethyl-1-(4-methoxyphenyl)-2-oxopiperidin-3-yl)allyl acetate (546): 
Acetate 546 was prepared from 597 using General Procedure D.  54% isolated yield, 
61% combined yield with enal.  Rf = 0.2 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.15–7.06 (m, 2H), 6.96–6.84 (m, 2H), 5.91 (dt, J = 15.9, 1.3 Hz, 
1H), 5.68 (dt, J = 15.9, 6.2 Hz, 1H), 4.71–4.52 (m, 2H), 3.80 (s, 3H), 3.70–3.48 (m, 2H), 
2.08 (s, 3H), 2.04–1.82 (m, 5H), 1.69 (dq, J = 13.6, 7.4 Hz, 1H), 0.90 (t, J = 7.4 Hz, 3H); 
13C NMR (CDCl3, 126 MHz) δ 173.1, 171.0, 158.2, 139.5, 136.7, 127.6, 123.7, 114.5, 
65.3, 55.6, 52.5, 48.8, 32.0, 29.4, 21.2, 20.0, 8.7; IR (Neat Film, NaCl) 2939, 1739, 1645, 
1607, 1511, 1464, 1294, 1243, 1030, 825 cm–1; HRMS (ESI+) m/z calc’d for C19H26NO4 
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(E)-3-(3-ethyl-1-(2-methylallyl)-2-oxopiperidin-3-yl)allyl acetate (547): 
Acetate 547 was prepared from 598 using General Procedure D.  50% isolated yield, 
56% combined yield with enal.  Rf = 0.2 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 5.85 (dt, J = 15.9, 1.3 Hz, 1H), 5.60 (dt, J = 15.9, 6.2 Hz, 1H), 4.86 
(h, J = 1.3 Hz, 1H), 4.74 (qt, J = 1.6, 0.7 Hz, 1H), 4.63–4.49 (m, 2H), 4.02–3.95 (m, 1H), 
3.94–3.87 (m, 1H), 3.32–3.05 (m, 2H), 2.06 (s, 3H), 1.95–1.74 (m, 5H), 1.73–1.49 (m, 
4H), 0.84 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 172.5, 171.0, 140.7, 139.6, 
123.6, 112.0, 65.2, 52.7, 48.6, 47.7, 31.9, 29.3, 21.2, 20.2, 19.4, 8.7; IR (Neat Film, 
NaCl) 2939, 1740, 1636, 1489, 1441, 1362, 1230, 1198, 1025, 967, 896 cm–1; HRMS 
(ESI+) m/z calc’d for C16H26NO3 [M+H]+: 280.1907, found 280.1914. 
 
 
(E)-3-(1-cinnamyl-3-ethyl-2-oxopiperidin-3-yl)allyl acetate (548): 
Acetate 548 was prepared from 599 using General Procedure D.  51% isolated yield, 
60% combined yield with enal.  Rf = 0.3 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.39–7.28 (m, 4H), 7.26–7.19 (m, 1H), 6.48 (dd, J = 15.9, 1.4 Hz, 
1H), 6.14 (dt, J = 15.8, 6.5 Hz, 1H), 5.87 (dt, J = 15.9, 1.3 Hz, 1H), 5.60 (dt, J = 15.9, 6.2 
Hz, 1H), 4.65–4.48 (m, 2H), 4.21–4.07 (m, 2H), 3.37–3.20 (m, 2H), 2.06 (s, 3H), 1.91–
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δ 172.5, 171.0, 139.5, 136.7, 132.9, 128.7, 127.8, 126.5, 124.7, 123.6, 65.3, 49.6, 48.5, 
47.9, 31.8, 29.1, 21.2, 19.4, 8.6; IR (Neat Film, NaCl) 2939, 1740, 1636, 1490, 1448, 
1361, 1232, 1026, 967, 750, 694 cm–1; HRMS (ESI+) m/z calc’d for C21H28NO3 [M+H]+: 
342.2066, found 342.2077. 
 
 
(E)-3-(1-benzyl-3-methyl-2-oxoazepan-3-yl)allyl acetate (549): 
Acetate 549 was prepared from 600 using General Procedure D.  40% isolated yield.  
Rf = 0.3 (33% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.34–7.28 (m, 
2H), 7.26–7.22 (m, 3H), 5.94 (dt, J = 16.0, 1.4 Hz, 1H), 5.54 (dt, J = 16.0, 6.3 Hz, 1H), 
4.80 (d, J = 14.6 Hz, 1H), 4.55 (dt, J = 6.1, 1.3 Hz, 2H), 4.45 (d, J = 14.6 Hz, 1H), 3.51 
(ddt, J = 15.2, 11.3, 1.1 Hz, 1H), 3.08 (ddd, J = 15.2, 5.7, 2.1 Hz, 1H), 2.03 (s, 3H), 1.84–
1.64 (m, 4H), 1.64–1.52 (m, 2H), 1.35 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 176.4, 
170.9, 138.9, 138.4, 128.6, 128.3, 127.3, 123.3, 65.1, 53.0, 48.5, 47.6, 36.6, 27.9, 25.3, 
21.1; IR (Neat Film, NaCl) 2925, 1740, 1636, 1419, 1363, 1236, 1028, 965, 745 cm–1; 
HRMS (ESI+) m/z calc’d for C19H26NO3 [M+H]+: 316.1907, found 316.1921. 
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Acetate 550 was prepared from 601 using General Procedure D.  53% isolated yield, 
63% combined yield with enal.  Rf = 0.2 (33% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 400 MHz) δ 7.35–7.22 (m, 5H), 6.18 (ddt, J = 15.6, 8.4, 1.3 Hz, 1H), 5.58 (dtd, 
J = 15.6, 6.3, 1.0 Hz, 1H), 4.71 (d, J = 14.6 Hz, 1H), 4.65–4.51 (m, 2H), 4.47 (d, J = 14.6 
Hz, 1H), 3.44 (dd, J = 15.3, 11.1 Hz, 1H), 3.37–3.12 (m, 2H), 2.06 (s, 3H), 1.90 (dd, J = 
11.1, 4.6 Hz, 1H), 1.84–1.71 (m, 1H), 1.71–1.57 (m, 2H), 1.36–1.17 (m, 2H); 13C NMR 
(CDCl3, 101 MHz) δ 175.5, 171.0, 137.9, 135.7, 128.7, 128.5, 127.5, 123.8, 65.2, 51.4, 
48.0, 47.7, 31.1, 28.8, 27.6, 21.2; IR (Neat Film, NaCl) 2931, 1740, 1639, 1442, 1364, 




(E)-3-(1-benzyl-3-ethyl-2-oxopyrrolidin-3-yl)allyl acetate (551): 
Acetate 551 was prepared from 602 using General Procedure D.  66% isolated yield.  
Rf = 0.1 (25% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.35–7.26 (m, 
3H), 7.23–7.17 (m, 2H), 5.87 (dt, J = 15.9, 1.3 Hz, 1H), 5.64 (dt, J = 15.9, 6.2 Hz, 1H), 
4.61–4.52 (m, 2H), 4.50 (d, J = 14.7 Hz, 1H), 4.41 (d, J = 14.7 Hz, 1H), 3.23–3.02 (m, 
2H), 2.11–2.02 (m, 1H), 2.07 (s, 3H), 2.00–1.92 (m, 1H), 1.78–1.63 (m, 1H), 0.88 (t, J = 
7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 176.2, 170.9, 136.7, 136.6, 128.8, 128.2, 
127.7, 123.9, 65.0, 50.9, 46.9, 43.6, 29.7, 28.2, 21.1, 8.8; IR (Neat Film, NaCl) 2925, 
1740, 1636, 1419, 1363, 1236, 1028, 965, 745 cm–1; HRMS (ESI+) m/z calc’d for 
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(E)-3-(1-benzyl-3-methyl-2-oxopyrrolidin-3-yl)allyl acetate (552): 
Acetate 552 was prepared from 603 using General Procedure D.  48% isolated yield, 
54% combined yield with enal.  Rf = 0.1 (40% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.35–7.26 (m, 3H), 7.24–7.18 (m, 2H), 5.89 (dt, J = 15.8, 1.3 Hz, 
1H), 5.66 (dt, J = 15.8, 6.2 Hz, 1H), 4.56 (dt, J = 6.2, 1.5 Hz, 2H), 4.46 (d, J = 3.3 Hz, 
2H), 3.26–3.05 (m, 2H), 2.12 (ddd, J = 12.8, 7.5, 5.5 Hz, 1H), 2.07 (s, 3H), 1.89 (ddd, J = 
12.7, 7.7, 6.4 Hz, 1H), 1.31 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 176.7, 170.9, 137.5, 
136.6, 128.8, 128.2, 127.7, 123.4, 64.9, 47.1, 46.7, 43.3, 32.5, 32.1, 21.1; IR (Neat Film, 
NaCl) 2927, 1738, 1689, 1495, 1428, 1361, 1233, 1028, 972, 740 cm–1; HRMS (ESI+) 
m/z calc’d for C17H22NO3 [M+H]+: 288.1594, found 288.1593. 
 
 
(E)-3-(1,3-dibenzyl-2-oxopyrrolidin-3-yl)allyl acetate (553): 
Acetate 553 was prepared from 604 using General Procedure D.  50% isolated yield, 
58% combined yield with enal.  Rf = 0.2 (40% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.29–7.26 (m, 1H), 7.26–7.20 (m, 5H), 7.20–7.14 (m, 2H), 7.11–
7.06 (m, 2H), 5.97 (dt, J = 15.9, 1.4 Hz, 1H), 5.63 (dt, J = 15.8, 6.1 Hz, 1H), 4.63–4.51 
(m, 2H), 4.45 (d, J = 14.7 Hz, 1H), 4.27 (d, J = 14.7 Hz, 1H), 3.15 (d, J = 13.3 Hz, 1H), 
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Hz, 1H), 2.07 (s, 3H), 2.06–1.99 (m, 1H), 1.94 (ddd, J = 13.0, 8.0, 4.9 Hz, 1H); 13C NMR 
(CDCl3, 126 MHz) δ 175.4, 170.9, 137.0, 137.0, 136.3, 130.5, 128.7, 128.2, 128.2, 127.6, 
126.8, 124.1, 64.8, 51.8, 47.0, 43.5, 43.0, 28.0, 21.1; IR (Neat Film, NaCl) 2920, 1740, 
1685, 1495, 1437, 1361, 1230, 1028, 973, 743 cm–1; HRMS (ESI+) m/z calc’d for 
C23H26NO3 [M+H]+: 364.1907, found 364.1931. 
 
 
(E)-3-(1-benzyl-2-oxopyrrolidin-3-yl)allyl acetate (555): 
Acetate 555 was prepared from 605 using General Procedure D.  57% isolated yield, 
61% combined yield with enal.  Rf = 0.3 (50% ethyl acetate in hexanes); 1H NMR 
(CDCl3, 500 MHz) δ 7.36–7.27 (m, 3H), 7.25–7.19 (m, 2H), 5.92 (ddt, J = 15.5, 6.6, 1.3 
Hz, 1H), 5.76 (dtd, J = 15.6, 6.1, 1.4 Hz, 1H), 4.59 (dq, J = 6.3, 1.2 Hz, 2H), 4.49 (d, J = 
14.6 Hz, 1H), 4.44 (d, J = 14.7 Hz, 1H), 3.28–3.12 (m, 3H), 2.26 (dddd, J = 12.8, 8.8, 
6.7, 4.1 Hz, 1H), 2.08 (s, 3H), 1.91 (dq, J = 12.7, 8.5 Hz, 1H); 13C NMR (CDCl3, 126 
MHz) δ 174.2, 170.9, 136.5, 132.2, 128.9, 128.3, 127.8, 126.7, 64.8, 47.1, 45.0, 44.9, 
25.0, 21.1; IR (Neat Film, NaCl) 2923, 1735, 1685, 1430, 1363, 1238, 1027, 971 cm–1; 
HRMS (ESI+) m/z calc’d for C16H20NO3 [M+H]+: 274.1438, found 274.1447. 
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To a flame-dried 25 mL round-bottom flask with a magnetic stir bar were added, in 
order, (S)-carvone (575, 30 mg, 0.2 mmol, 1.00 equiv), palladium(II) acetate (9 mg, 0.04 
mmol, 0.20 equiv), and Oxone (68 mg, 0.22 mmol, 1.10 equiv).  The flask was then 
capped with a rubber septum and evacuated and backfilled twice with nitrogen.  Acetic 
acid (1.00 mL) was added by syringe.  The resulting suspension was stirred under 
nitrogen for 5 minutes at 23 °C and then heated to 95 °C in an oil bath.  Although TLC 
analysis did not show full consumption of 575, the reaction was stopped at 16 hours.  The 
flask was allowed to cool to 23 °C and the contents were filtered through a short plug of 
silica gel, rinsing with ethyl acetate.  The filtrate was adsorbed onto silica gel (approx. 2 
g), which was then flushed with ethyl acetate.  The eluent was concentrated to give the 
crude product as an oil.  The crude residue was purified by silica gel column 
chromatography (15% ethyl acetate in hexanes) to provide recovered (S)-carvone (14 mg, 
0.096 mmol, 48% yield, 52% conversion) and acetate 576 as a colorless oil (8.7 mg, 21% 
yield, 40% yield based on recovered starting material).  Rf = 0.3 (25% ethyl acetate in 
hexanes); 1H NMR (CDCl3, 500 MHz) δ 6.75 (ddq, J = 5.6, 2.8, 1.4 Hz, 1H), 5.18 (q, J = 
0.9 Hz, 1H), 5.05 (dd, J = 1.3, 0.7 Hz, 1H), 4.61 (dd, J = 12.8, 1.0 Hz, 1H), 4.59–4.53 (m, 
1H), 2.87–2.74 (m, 1H), 2.64 (ddd, J = 16.0, 3.7, 1.6 Hz, 1H), 2.53 (dddt, J = 18.2, 6.0, 
4.5, 1.5 Hz, 1H), 2.40 (dd, J = 16.1, 13.2 Hz, 1H), 2.35–2.26 (m, 1H), 2.10 (s, 3H), 1.80 
(dt, J = 2.6, 1.4 Hz, 3H).; 13C NMR (CDCl3, 126 MHz) δ 199.3, 170.8, 145.4, 144.3, 
135.8, 113.8, 65.9, 43.2, 38.6, 31.5, 21.1, 15.9; IR (Neat Film, NaCl) 2923, 1741, 1673, 
1433, 1371, 1227, 1109, 1029, 903 cm–1; HRMS (FAB+) m/z calc’d for C12H17O3 
[M+H]+: 209.1178, found 209.1187. 
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5.5.6   ENAL CHARACTERIZATION DATA 
 
(E)-3-(1-benzyl-3-ethyl-2-oxopiperidin-3-yl)acrylaldehyde (591): 
Enal 591 was prepared from 586 using General Procedure E.  50% isolated yield, 
56% combined yield with allylic acetate.  Rf = 0.2 (33% ethyl acetate in hexanes); 1H 
NMR (CDCl3, 500 MHz) δ 9.57 (d, J = 7.6 Hz, 1H), 7.37–7.27 (m, 3H), 7.25–7.18 (m, 
2H), 7.06 (d, J = 16.2 Hz, 1H), 6.13 (dd, J = 16.2, 7.7 Hz, 1H), 4.70 (d, J = 14.5 Hz, 1H), 
4.49 (d, J = 14.5 Hz, 1H), 3.45–3.05 (m, 2H), 2.03–1.89 (m, 3H), 1.85–1.69 (m, 3H), 
0.88 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 194.2, 171.4, 161.9, 137.1, 
131.6, 128.8, 128.1, 127.7, 50.9, 49.8, 47.7, 31.6, 28.5, 19.5, 8.6; IR (Neat Film, NaCl) 
2940, 1713, 1689, 1634, 1606, 1495, 1453, 1356, 1262, 1198, 982, 735 cm–1; HRMS 




Enal 562 was prepared from 587 using General Procedure E.  67% isolated yield.  Rf 
= 0.1 (33% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 9.57 (d, J = 7.6 Hz, 
1H), 7.37–7.27 (m, 3H), 7.25–7.17 (m, 2H), 7.08 (d, J = 16.1 Hz, 1H), 6.15 (dd, J = 16.1, 
7.6 Hz, 1H), 4.61 (d, J = 14.5 Hz, 1H), 4.56 (d, J = 14.5 Hz, 1H), 3.33–3.10 (m, 2H), 
2.09–1.94 (m, 1H), 1.94–1.71 (m, 3H), 1.47 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 
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IR (Neat Film, NaCl) 2931, 1689, 1638, 1488, 1453, 1351, 1198, 1106, 978, 735, 702 




Enal 563 was prepared from 588 using General Procedure E.  50% isolated yield, 
56% combined yield with allylic acetate.  Rf = 0.4 (33% ethyl acetate in hexanes); 1H 
NMR (CDCl3, 500 MHz) δ 9.59 (d, J = 7.6 Hz, 1H), 7.32–7.26 (m, 4H), 7.26–7.23 (m, 
2H), 7.20–7.10 (m, 4H), 7.04 (d, J = 16.2 Hz, 1H), 6.10 (dd, J = 16.1, 7.6 Hz, 1H), 4.79 
(d, J = 14.5 Hz, 1H), 4.41 (d, J = 14.5 Hz, 1H), 3.46 (d, J = 13.3 Hz, 1H), 3.22–3.00 (m, 
2H), 2.88 (d, J = 13.3 Hz, 1H), 1.99–1.77 (m, 2H), 1.79–1.61 (m, 2H); 13C NMR (CDCl3, 
126 MHz) δ 194.0, 170.4, 161.6, 136.8, 136.2, 132.0, 131.0, 128.8, 128.3, 128.1, 127.6, 
127.1, 51.2, 51.1, 47.8, 44.5, 29.3, 19.5; IR (Neat Film, NaCl) 2924, 1689, 1636, 1494, 
1453, 1355, 1194, 982, 743 cm–1; HRMS (ESI+) m/z calc’d for C22H24NO2 [M+H]+: 




Enal 564 was prepared from 589 using General Procedure E.  55% isolated yield, 
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NMR (CDCl3, 500 MHz) δ 9.57 (d, J = 7.7 Hz, 1H), 7.36–7.26 (m, 3H), 7.25–7.19 (m, 
2H), 7.06 (d, J = 16.2 Hz, 1H), 6.12 (dd, J = 16.2, 7.6 Hz, 1H), 4.67 (d, J = 14.5 Hz, 1H), 
4.51 (d, J = 14.6 Hz, 1H), 3.40–3.03 (m, 2H), 1.93 (dd, J = 7.3, 4.6 Hz, 2H), 1.91–1.84 
(m, 1H), 1.84–1.68 (m, 3H), 1.38–1.15 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H); 13C NMR 
(CDCl3, 126 MHz) δ 194.2, 171.4, 162.1, 137.1, 131.4, 128.8, 128.2, 127.7, 51.0, 49.7, 
47.7, 41.1, 29.2, 19.6, 17.5, 14.5; IR (Neat Film, NaCl) 2957, 1688, 1634, 1489, 1453, 





Enal 565 was prepared from 590 using General Procedure E.  54% isolated yield.  Rf 
= 0.3 (50% ethyl acetate in hexanes); 9.57 (d, J = 7.6 Hz, 1H), 7.36–7.27 (m, 3H), 7.25–
7.21 (m, 2H), 7.03 (d, J = 16.1 Hz, 1H), 6.16 (dd, J = 16.2, 7.6 Hz, 1H), 4.71 (d, J = 14.5 
Hz, 1H), 4.48 (d, J = 14.5 Hz, 1H), 3.46 (td, J = 6.4, 1.7 Hz, 2H), 3.28 (s, 3H), 3.26–3.16 
(m, 2H), 2.22 (dt, J = 14.1, 6.6 Hz, 1H), 2.13–2.02 (m, 2H), 1.97 (dddd, J = 13.8, 6.7, 
3.3, 1.1 Hz, 1H), 1.83 (ddtd, J = 13.5, 6.7, 5.0, 3.4 Hz, 1H), 1.79–1.66 (m, 1H); 13C NMR 
(CDCl3, 126 MHz) δ 194.1, 170.9, 161.6, 137.1, 131.6, 128.8, 128.2, 127.7, 69.2, 58.7, 
51.0, 48.7, 47.8, 38.2, 30.2, 19.6; IR (Neat Film, NaCl) 2927, 1685, 1636, 1490, 1452, 
1355, 1196, 1112, 979, 736 cm–1; HRMS (ESI+) m/z calc’d for C18H24NO3 [M+H]+: 















Enal 566 was prepared from 592 using General Procedure E.  48% isolated yield, 
54% combined yield with allylic acetate.  Rf = 0.2 (20% ethyl acetate in hexanes); 1H 
NMR (CDCl3, 500 MHz) δ 9.61 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 16.2 Hz, 1H), 7.42–
7.26 (m, 8H), 7.25–7.21 (m, 2H), 6.17 (dd, J = 16.2, 7.7 Hz, 1H), 4.83 (d, J = 14.3 Hz, 
1H), 4.59 (d, J = 14.3 Hz, 1H), 3.38–3.17 (m, 2H), 2.37 (ddd, J = 13.5, 5.5, 3.3 Hz, 1H), 
2.30–2.07 (m, 1H), 1.83–1.61 (m, 2H); 13C NMR (CDCl3, 126 MHz) δ 194.4, 169.9, 
161.3, 140.8, 137.0, 130.5, 128.9, 128.5, 127.8, 127.6, 127.3, 54.6, 51.1, 47.4, 32.0, 18.7; 
IR (Neat Film, NaCl) 2937, 1683, 1634, 1494, 1446, 1352, 1196, 763 cm–1; HRMS 




Enal 567 was prepared from 594 using General Procedure E.  59% isolated yield.  Rf 
= 0.2 (33% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 9.55 (d, J = 7.6 Hz, 
1H), 7.01 (d, J = 16.2 Hz, 1H), 6.09 (dd, J = 16.2, 7.7 Hz, 1H), 3.35 (ddd, J = 11.9, 8.7, 
5.0 Hz, 1H), 3.25 (ddd, J = 12.1, 5.8, 4.9 Hz, 1H), 2.95 (s, 3H), 1.97–1.72 (m, 6H), 0.84 
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35.5, 31.4, 28.5, 19.5, 8.5; IR (Neat Film, NaCl) 2939, 1688, 1635, 1506, 1456, 1257, 





Enal 568 was prepared from 597 using General Procedure E.  53% isolated yield, 
58% combined yield with allylic acetate.  Rf = 0.2 (33% ethyl acetate in hexanes); 1H 
NMR (CDCl3, 500 MHz) δ 9.58 (d, J = 7.6 Hz, 1H), 7.14–7.10 (m, 2H), 7.07 (d, J = 16.2 
Hz, 1H), 6.94–6.87 (m, 2H), 6.19 (dd, J = 16.2, 7.6 Hz, 1H), 3.81 (s, 3H), 3.66 (ddd, J = 
12.1, 8.7, 5.0 Hz, 1H), 3.62–3.52 (m, 1H), 2.16–1.89 (m, 5H), 1.83 (dq, J = 13.7, 7.5 Hz, 
1H), 0.94 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 194.2, 171.7, 161.9, 158.4, 
136.2, 131.6, 127.5, 114.6, 55.6, 52.5, 50.1, 31.7, 28.7, 20.1, 8.6; IR (Neat Film, NaCl) 
2938, 1685, 1647, 1510, 1295, 1243, 1130, 1032, 982, 827 cm–1; HRMS (ESI+) m/z 




Enal 569 was prepared from 593 using General Procedure E.  44% isolated yield, 
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NMR (CDCl3, 500 MHz) δ 9.55 (d, J = 7.6 Hz, 1H), 6.98 (d, J = 16.1 Hz, 1H), 6.14 (dd, 
J = 16.2, 7.6 Hz, 1H), 5.85 (s, 1H), 3.46–3.26 (m, 2H), 2.01–1.90 (m, 3H), 1.90–1.84 (m, 
1H), 1.84–1.73 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 194.1, 
173.4, 161.1, 131.8, 49.4, 42.8, 31.1, 28.3, 19.3, 8.4; IR (Neat Film, NaCl) 3287, 2941, 
1687, 1662, 1489, 1464, 1354, 1107, 983 cm–1; HRMS (ESI+) m/z calc’d for C10H16NO2 




Enal 570 was prepared from 604 using General Procedure E.  30% isolated yield.  Rf 
= 0.4 (33% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 9.58 (d, J = 7.6 Hz, 
1H), 7.30–7.26 (m, 3H), 7.26–7.22 (m, 3H), 7.20–7.14 (m, 2H), 7.12–7.04 (m, 3H), 6.12 
(dd, J = 16.0, 7.6 Hz, 1H), 4.45 (d, J = 14.7 Hz, 1H), 4.26 (d, J = 14.6 Hz, 1H), 3.24 (d, J 
= 13.4 Hz, 1H), 3.07–2.88 (m, 1H), 2.83 (d, J = 13.4 Hz, 1H), 2.69–2.52 (m, 1H), 2.18 
(ddd, J = 13.3, 8.2, 5.2 Hz, 1H), 2.11–1.98 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 
193.8, 173.8, 158.9, 135.9, 131.7, 130.4, 128.9, 128.6, 128.3, 127.9, 127.4, 53.1, 47.3, 
43.5, 42.8, 27.4; IR (Neat Film, NaCl) 2921, 1738, 1683, 1495, 1454, 1246, 981, 745, 
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5.5.7   ALLYLIC ACETATE DERIVATIZATION PROCEDURES AND 
CHARACTERIZATION DATA 
 
3-(1-benzyl-3-ethyl-2-oxopiperidin-3-yl)-2,3-dihydroxypropyl acetate (555): 
To a 1 dram screw-top vial with a magnetic stir bar were added, in order, acetate 537 
(18 mg, 0.057 mmol, 1.00 equiv), acetone (reagent grade, 540 μL), deionized water (180 
μL), potassium osmate(VI) dehydrate (2 mg, 0.006 mmol, 0.10 equiv), and 4-
methylmorpholine N-oxide (13 mg, 0.144 mmol, 2.00 equiv).  The vial was sealed with a 
Teflon-lined cap and the purple solution was stirred at 23 °C for 3 hours.  Upon 
completion (as determined by TLC analysis), the reaction mixture was adsorbed onto 
Celite and purified by silica gel column chromatography (50% ethyl acetate in hexanes) 
to provide the major diastereomer 555 as colorless crystals (16.5 mg, 83% yield).  Rf = 
0.3 (50% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.36–7.30 (m, 2H), 
7.29–7.26 (m, 2H), 7.26–7.23 (m, 1H), 5.96 (d, J = 8.5 Hz, 1H), 4.60 (d, J = 14.7 Hz, 
1H), 4.56 (d, J = 14.8 Hz, 1H), 4.28 (dd, J = 11.5, 7.5 Hz, 1H), 4.22 (dd, J = 11.5, 4.8 Hz, 
1H), 3.96 (dddd, J = 9.6, 7.5, 4.8, 1.5 Hz, 1H), 3.52 (dd, J = 8.5, 1.4 Hz, 1H), 3.31–3.07 
(m, 2H), 2.27 (d, J = 9.7 Hz, 1H), 2.10 (s, 3H), 2.03–1.93 (m, 1H), 1.93–1.85 (m, 1H), 
1.85–1.77 (m, 2H), 1.77–1.63 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 
MHz) δ 176.9, 171.3, 136.7, 128.8, 128.1, 127.6, 75.8, 69.8, 67.5, 50.5, 47.1, 45.4, 30.2, 
27.3, 21.2, 20.0, 8.1; IR (Neat Film, NaCl) 3382, 2936, 2878, 1736, 1606, 1495, 1453, 
1362, 1248, 1206, 1039, 737 cm–1; HRMS (ESI+) m/z calc’d for C19H28NO5 [M+H]+: 













4:1 acetone:H2O, 23 °C
(83% yield)
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Colorless, translucent X-ray quality crystals of diol 555 were obtained by slow diffusion 
of 2% benzene in pentane into a solution of 555 in ether at –20 °C, mp: 86–88 °C. 
 
 
3-(1-benzyl-3-ethyl-2-oxopiperidin-3-yl)propyl acetate (556): 
To a round-bottom flask with a magnetic stir bar were added acetate 537 (40 mg, 0.13 
mmol, 1.00 equiv) and ethyl acetate (750 μL).  Palladium on carbon (10 wt. %, 2 mg) 
was added, and the suspension was stirred vigorously while the air atmosphere was 
replaced with hydrogen by three evacuation/back-fill cycles.  The reaction mixture was 
then stirred at 23 °C under an atmosphere of hydrogen (supplied by a balloon) for 5 
hours.  As TLC analysis showed remaining starting material, an additional 5 mg of 
palladium on carbon (10 wt. %) was added.  After letting the reaction mixture stir for an 
additional 19 hours, TLC analysis showed full conversion.  The mixture was filtered 
through Celite, rinsing with ethyl acetate.  The filtrate was concentrated and the crude 
residue was purified by silica gel column chromatography (25% ethyl acetate in hexanes) 
to provide aliphatic acetate 556 as a colorless oil (34.0 mg, 99% yield).  Rf = 0.7 (50% 
ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.37–7.27 (m, 2H), 7.25–7.19 
(m, 3H), 4.66 (d, J = 14.5 Hz, 1H), 4.50 (d, J = 14.5 Hz, 1H), 4.22–3.85 (m, 2H), 3.29–
3.13 (m, 2H), 2.05 (s, 3H), 1.94–1.50 (m, 10H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR 
(CDCl3, 126 MHz) δ 174.6, 171.3, 137.8, 128.7, 128.2, 127.4, 65.1, 50.7, 47.8, 44.9, 
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1362, 1241, 1038, 738, 701 cm–1; HRMS (ESI+) m/z calc’d for C19H28NO3 [M+H]+: 
318.2064, found 318.2051. 
 
 
(3-(1-benzyl-3-ethyl-2-oxopiperidin-3-yl)oxiran-2-yl)methyl acetate (557): 
To a 1 dram screw-top vial with a magnetic stir bar were added, in order, acetate 537 
(10 mg, 0.032 mmol, 1.00 equiv), 3-chloroperbezoic acid (54 mg, 0.32 mmol, 10.00 
equiv), and dichloromethane (320 μL).  The vial was sealed with a Teflon-lined cap and 
the pale yellow solution was stirred at 23 °C for 12 hours.  Upon completion (as 
determined by TLC analysis), the reaction mixture was diluted with dichloromethane (3 
mL) and quenched with saturated aqueous sodium thiosulfate (3 mL).  The organic layer 
was separated and washed with saturated aqueous sodium bicarbonate solution (3 x 3 
mL), dried over sodium sulfate, filtered, and concentrated in vacuo.  NMR analysis of the 
crude reaction mixture showed a single diasteromer.  The crude was residue purified by 
silica gel column chromatography (25% ethyl acetate and 1% triethylamine in hexanes) 
to provide epoxide 557 as a colorless oil (9.9 mg, 93% yield, single diastereomer).  Rf = 
0.5 (50% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.36–7.27 (m, 3H), 
7.24 (ddt, J = 7.6, 1.4, 0.7 Hz, 2H), 4.67 (d, J = 14.6 Hz, 1H), 4.56 (d, J = 14.6 Hz, 1H), 
4.42 (dd, J = 12.2, 3.1 Hz, 1H), 3.97 (dd, J = 12.3, 6.3 Hz, 1H), 3.46 (d, J = 2.3 Hz, 1H), 
3.20–3.15 (m, 2H), 3.13 (ddd, J = 6.3, 3.1, 2.4 Hz, 1H), 2.11 (s, 3H), 1.90 (dq, J = 13.8, 
7.5 Hz, 1H), 1.85–1.72 (m, 1H), 1.68 (dt, J = 13.8, 7.5 Hz, 1H), 1.61–1.51 (m, 2H), 0.91 













Chapter 5 – Palladium-Catalyzed Allylic C–H Oxidation of Hindered Substrates  680
127.5, 64.8, 60.9, 52.2, 50.9, 47.6, 45.4, 28.9, 24.2, 20.9, 19.8, 8.7; IR (Neat Film, NaCl) 
2940, 1744, 1632, 1494, 1453, 1364, 1232, 1037, 907, 735 cm–1; HRMS (ESI+) m/z 




To a 1 dram screw-top vial with a magnetic stir bar were added, in order, acetate 537 
(102 mg, 0.32 mmol, 1.00 equiv), freshly powdered potassium hydroxide (27 mg, 0.49 
mmol, 1.50 equiv), methanol (1.3 mL), and water (300 μL).  The vial was sealed with a 
Teflon-lined cap and the solution was stirred at 23 °C for 4 minutes.  Upon completion 
(as determined by TLC analysis), the reaction mixture was adsorbed onto Celite and 
purified by silica gel column chromatography (50% ethyl acetate in hexanes) to provide 
allylic alcohol 558 as a colorless oil (88.0 mg, >99% yield).  Rf = 0.2 (50% ethyl acetate 
in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.35–7.26 (m, 3H), 7.25–7.21 (m, 2H), 5.83 
(dt, J = 15.9, 1.4 Hz, 1H), 5.75–5.65 (m, 1H), 4.68 (d, J = 14.5 Hz, 1H), 4.50 (d, J = 14.6 
Hz, 1H), 4.26–4.05 (m, 2H), 3.35–3.06 (m, 2H), 1.97–1.86 (m, 1H), 1.86–1.64 (m, 6H), 
0.86 (td, J = 7.4, 1.2 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 173.1, 137.6, 136.6, 128.8, 
128.7, 128.2, 127.4, 63.9, 50.7, 48.4, 47.9, 32.0, 29.3, 19.4, 8.7; IR (Neat Film, NaCl) 
3402, 2936, 2863, 1617, 1494, 1452, 1353, 1196, 981, 734, 701 cm–1; HRMS (ESI+) m/z 
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(E)-3-(1-benzyl-3-ethylpiperidin-3-yl)prop-2-en-1-ol (559): 
To an oven-dried 1 dram screw-top vial with a magnetic stir bar were added, in order, 
acetate 537 (30 mg, 0.095 mmol, 1.00 equiv), lithium aluminum hydride (72 mg, 1.90 
mmol, 20.00 equiv), and THF (500 μL).  The vial was sealed with a Teflon-lined cap and 
the suspension was stirred at 70 °C for 10 hours.  Upon completion (as determined by 
TLC analysis), the reaction mixture cooled to 0 °C using an ice water bath.  1.5 mL water 
was added slowly dropwise, followed by 1.5 mL NaOH (15 wt. %), followed by 4.5 mL 
water.  The suspension was stirred until the color turned white (45 minutes), after which 
it was filtered through Celite, rinsing with ether.  The filtrate was concentrated and the 
crude residue was purified by silica gel column chromatography (50% ethyl acetate and 
1% triethylamine in hexanes with) to provide amine 559 as a colorless oil (23.9 mg, 97 % 
yield).  Rf = 0.3 (50% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.33–
7.27 (m, 4H), 7.26–7.21 (m, 1H), 5.58 (dt, J = 16.0, 5.7 Hz, 1H), 5.50 (dt, J = 15.9, 1.0 
Hz, 1H), 4.12 (d, J = 5.6 Hz, 2H), 3.44 (s, 2H), 2.51–1.95 (m, 4H), 1.75 (s, 1H), 1.59 (m, 
1H), 1.50 (d, J = 15.5 Hz, 3H), 1.37 (dt, J = 13.8, 7.2 Hz, 2H), 0.70 (t, J = 7.5 Hz, 3H); 
13C NMR (CDCl3, 126 MHz) δ 139.7, 139.0, 129.1, 128.2, 127.6, 127.0, 64.5, 63.7, 62.8, 
54.8, 39.3, 33.4, 22.3, 7.9; IR (Neat Film, NaCl) 3326, 2934, 1453, 1349, 1091, 974, 739, 
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dimethyl (E)-2-(3-(1-benzyl-3-ethyl-2-oxopiperidin-3-yl)allyl)malonate (560): 
The conditions for the transformation were adapted from a known procedure.23 In a 
nitrogen-filled glovebox, an oven-dried 1 dram screw-top vial with a magnetic stir bar 
was charged with dichloro(p-cymene)ruthenium(II) dimer (12 mg, 0.019 mmol, 0.50 
equiv), triphenylphosphine (10 mg, 0.038 mmol, 1.00 equiv), and toluene (150 μL).  To 
this solution was added a solution of acetate 537 (12 mg, 0.038 mmol, 1.00 equiv) in 
toluene (100 μL).  Dimethyl malonate (7 μL, 0.057 mmol, 1.50 equiv) was then added, 
followed by a solution of lithium hexamethyldisilazide (9 mg, 0.052 mmol, 1.40 equiv) in 
THF (100 μL).  The vial was sealed with a Teflon-lined cap and heated at 60 °C for 90 
hours.  Upon completion (as determined by LCMS analysis) the reaction was removed 
from the glovebox, adsorbed onto Celite, and purified by silica gel column 
chromatography (20% ethyl acetate in hexanes) to provide malonate 560 as a colorless oil 
(12.1 mg, 82% yield.  Rf = 0.2 (25% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 
MHz) δ 7.35–7.28 (m, 3H), 7.25–7.20 (m, 2H), 5.65 (dt, J = 15.8, 1.3 Hz, 1H), 5.44 (dt, J 
= 15.8, 7.0 Hz, 1H), 4.62 (d, J = 14.6 Hz, 1H), 4.53 (d, J = 14.5 Hz, 1H), 3.71 (s, 3H), 
3.71 (s, 3H), 3.45 (t, J = 7.6 Hz, 1H), 3.32–3.04 (m, 2H), 2.66 (ddd, J = 7.5, 7.0, 1.3 Hz, 
2H), 1.84 (dq, J = 13.5, 7.4 Hz, 1H), 1.80–1.67 (m, 4H), 1.67–1.58 (m, 1H), 0.83 (t, J = 
7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 173.0, 169.5, 169.5, 138.1, 137.7, 128.7, 
128.1, 127.4, 125.0, 52.6, 52.6, 52.0, 50.6, 48.6, 47.8, 32.3, 32.1, 29.3, 19.3, 8.6; IR (Neat 
Film, NaCl) 2952, 1734, 1635, 1437, 1350, 1261, 1195, 1153, 740 cm–1; HRMS (ESI+) 
m/z calc’d for C22H30NO5 [M+H]+: 388.2118, found 388.2110. 
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To a round-bottom flask with a magnetic stir bar were added enal 561 (30 mg, 0.11 
mmol, 1.00 equiv) and ethyl acetate (320 μL).  Palladium on carbon (10 wt. %, 2 mg) 
was added, and the suspension was stirred vigorously while the air atmosphere was 
replaced with hydrogen by three evacuation/back-fill cycles.  The reaction mixture was 
then stirred at 23 °C under one atmosphere of hydrogen (supplied by a balloon) for 1.25 
hours.  After completion (as determined by TLC analysis), the mixture was filtered 
through Celite, rinsing with ethyl acetate.  The filtrate was concentrated and the crude 
residue was purified by silica gel column chromatography (25% ethyl acetate in hexanes) 
to provide aliphatic aldehyde 571 as a colorless oil (29.3 mg, 97% yield).  Rf = 0.5 (50% 
ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 9.77 (t, J = 1.5 Hz, 1H), 7.37–
7.27 (m, 3H), 7.25–7.18 (m, 2H), 4.65 (d, J = 14.5 Hz, 1H), 4.48 (d, J = 14.5 Hz, 1H), 
3.36–3.06 (m, 2H), 2.59 (dddd, J = 17.4, 10.1, 5.7, 1.6 Hz, 1H), 2.49 (dddd, J = 17.3, 
10.1, 5.6, 1.5 Hz, 1H), 1.98 (ddd, J = 14.0, 10.1, 5.6 Hz, 1H), 1.93–1.85 (m, 1H), 1.85–
1.71 (m, 3H), 1.67–1.50 (m, 3H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 126 MHz) 
δ 202.6, 174.1, 137.7, 128.7, 128.1, 127.5, 50.7, 47.8, 44.4, 39.8, 31.1, 30.3, 29.9, 19.7, 
8.6; IR (Neat Film, NaCl) 2937, 1722, 1628, 1494, 1452, 1351, 1194, 736, 701 cm–1; 
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(E)-1-benzyl-3-(buta-1,3-dien-1-yl)-3-ethylpiperidin-2-one (572): 
To a flame-dried round-bottom flask with a magnetic stir bar were added methyl 
triphenylphosphonium bromide (64 mg, 0.18 mmol, 1.25 equiv) and THF (0.9 mL).  The 
white suspension was cooled to 0 °C using an ice water bath and n-butyllithium (2.5 M in 
hexanes, 72 μL, 1.25 equiv) was added dropwise by syringe.  The mixture was stirred for 
15 minutes at 0 °C and a solution of enal 561 (40 mg, 0.15 mmol, 1.00 equiv) in THF 
(180 μL) was added dropwise by syringe.  The mixture was stirred for 1 hour at 0 °C and 
20 hours at 23 °C.  As the reaction was not progressing, additional ylide (1.25 equiv, 
generated as described above) was added by syringe at 0 °C.  The reaction was allowed to 
stir at 23 °C for 5 hours, at which point additional ylide (2.50 equiv, generated as 
described above) was added at 0 °C.  After stirring for 3 hours at 23 °C, TLC analysis 
showed complete consumption of the starting material.  The reaction was quenched by 
addition of saturated aqueous ammonium chloride solution (5 mL).  The mixture was 
extracted with ether (3 x 5 mL), and the combined organic layers were washed with brine 
(1 x 5 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo.  The crude 
residue was purified by silica gel column chromatography (20% ethyl aceate in hexanes) 
to provide diene 572 as a colorless oil (32.1 mg, 79% yield).  Rf = 0.5 (25% ethyl acetate 
in hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.34–7.26 (m, 2H), 7.26–7.21 (m, 3H), 6.35 
(dtd, J = 16.9, 10.2, 0.7 Hz, 1H), 6.10 (ddd, J = 15.7, 10.2, 0.7 Hz, 1H), 5.81 (dd, J = 
15.7, 0.8 Hz, 1H), 5.14 (ddt, J = 17.0, 1.6, 0.7 Hz, 1H), 5.03 (ddt, J = 10.1, 1.6, 0.7 Hz, 
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= 13.6, 7.5 Hz, 1H), 1.86–1.78 (m, 3H), 1.78–1.64 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H); 13C 
NMR (CDCl3, 126 MHz) δ 172.9, 139.0, 137.7, 137.3, 130.3 128.7, 128.2, 127.4, 116.4, 
50.7, 48.8, 47.9, 32.2, 29.4, 19.5, 8.8; IR (Neat Film, NaCl) 2966, 1635, 1600, 1488, 
1452, 1352, 1196, 1007, 733, 701 cm–1; HRMS (ESI+) m/z calc’d for C18H24NO [M+H]+: 




The conditions for the transformation were adapted from a known procedure.25 To a 1 
dram screw-top vial with a magnetic stir bar were added, in order, vanadyl 
acetylacetonate (1 mg, 0.001 mmol, 0.04 equiv) and hydrogen peroxide (35 wt. % in 
water, 50 μL).  A solution of enal 561 (10 mg, 0.04 mmol, 1.00 equiv) in methanol (200 
μL) was then added.  The vial was sealed with a Teflon-lined cap and the solution was 
stirred at 23 °C for 17 hours.  Upon completion (as determined by TLC analysis), the 
reaction mixture was diluted with dichloromethane (3 mL), adsorbed onto Celite and 
purified by silica gel column chromatography (25% ethyl acetate in hexanes) to provide 
enoate 573 as a colorless oil (11.2 mg, 93% yield).  Rf = 0.4 (10% ethyl acetate in 
hexanes); 1H NMR (CDCl3, 500 MHz) δ 7.37–7.26 (m, 3H), 7.25–7.18 (m, 2H), 7.04 (d, 
J = 16.1 Hz, 1H), 5.90 (d, J = 16.1 Hz, 1H), 4.68 (d, J = 14.5 Hz, 1H), 4.51 (d, J = 14.5 
Hz, 1H), 3.74 (s, 3H), 3.32–3.09 (m, 2H), 1.95 (dq, J = 13.5, 7.4 Hz, 1H), 1.91–1.82 (m, 
2H), 1.82–1.67 (m, 3H), 0.88 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 171.4, 
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8.7; IR (Neat Film, NaCl) 2946, 1723, 1631, 1434, 1341, 1273, 1197, 1020, 701 cm–1; 





The conditions for the transformation were adapted from a known procedure.26 To a 
0.5 dram screw-top vial with a magnetic stir bar were added, in order, enal 561 (10 mg, 
0.037 mmol, 1.00 equiv), tert-butyl isocyanide (42 μL, 0.37 mmol, 10.0 equiv), 4-
methoxybenzoic acid (56 mg, 0.37 mmol, 10.0 equiv), and dichloromethane (50 μL).  
The vial was sealed with a Teflon-lined cap and the white suspension was stirred at 23 °C 
for 21 hours, and then at 40 °C for 12 additional hours.  Upon completion (as determined 
by LCMS analysis), the reaction mixture was diluted with dichloromethane (2 mL) and 
washed with saturated aqueous sodium bicarbonate solution (1 x 2 mL).  The organic 
layer was dried over sodium sulfate, filtered, and concentrated in vacuo.  The crude 
residue was purified by silica gel column chromatography (25% ethyl acetate in hexanes) 
to provide the product (574) as an inseparable 1:1 mixture of diastereomers (12.1 mg, 
64% yield).  Rf = 0.3 (25% ethyl acetate in hexanes); 1H NMR (CDCl3, 500 MHz) δ 8.04 
(dd, J = 2.1, 1.5 Hz, 1H), 8.03 (dd, J = 2.1, 1.5 Hz, 1H), 7.35–7.27 (m, 1H), 7.25–7.16 
(m, 3H), 6.96 (d, J = 2.5 Hz, 1H), 6.94 (t, J = 2.4 Hz, 1H), 6.07 (ddd, J = 15.9, 9.9, 1.2 


















t-BuNC, CH2Cl2, 40 °C
(64% yield)
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6.9, 3.3, 1.2 Hz, 1H), 4.64 (dd, J = 26.6, 14.6 Hz, 1H), 4.52 (dd, J = 14.6, 6.6 Hz, 1H), 
3.88 (d, J = 1.1 Hz, 3H), 3.33–3.02 (m, 2H), 1.96–1.80 (m, 3H), 1.80–1.61 (m, 1H), 1.35 
(d, J = 1.7 Hz, 9H), 0.86 (td, J = 7.4, 5.8 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 172.7, 
172.7, 167.8, 167.7, 164.8, 163.9, 163.9, 140.0, 139.8, 137.5, 132.4, 132.0, 132.0, 128.7, 
128.7, 128.0, 128.0, 127.4, 127.4, 124.2, 124.0, 121.9, 121.9, 114.0, 114.0, 113.8, 75.0, 
74.8, 55.7, 51.5, 51.5, 50.7, 50.6, 48.7, 48.6, 47.8, 47.8, 36.8, 32.0, 31.7, 29.1, 29.1, 28.8, 
24.8, 19.4, 19.3, 8.6, 8.6; IR (Neat Film, NaCl) 3320, 2965, 1691, 1606, 1453, 1256, 
1168, 1102, 1028 cm–1; HRMS (ESI+) m/z calc’d for C30H39N2O5 [M+H]+: 507.2853, 
found 507.2857. 
 
5.5.9   MECHANISTIC INVESTIGATION EXPERIMENTS 
 
Oxidation of allylic alcohol 558 to enal 561: 
To a 0.5 dram vial with a magnetic stir bar were added, in order, allylic alcohol 558 
(11 mg, 0.04 mmol, 1.00 equiv), palladium(II) acetate (1 mg, 0.03 mmol, 0.075 equiv), 
and Oxone (31 mg, 0.10 mmol, 2.5 equiv).  Acetonitrile (400 μL), acetic acid (37 μL, 3.2 
mmol, 16.00 equiv), and water (6 μL, 1.6 mmol, 8.00 equiv) were added by syringe.  The 
resulting suspension was stirred for 5 minutes at 23 °C and then heated to 50 °C in an oil 
bath.  Upon completion (as determined by TLC analysis), the flask was allowed to cool to 
23 °C.  The reaction mixture was filtered through a plug of silica gel, rinsing with ethyl 
acetate, and concentrated to give the crude product, which was identical to 561 by 1H 
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Oxidation of aliphatic aldehyde 571 to enal 561: 
To a 0.5 dram vial with a magnetic stir bar were added, in order, aliphatic aldehyde 
571 (3 mg, 0.011 mmol, 1.00 equiv), palladium(II) acetate (<1 mg, 0.015 mmol, 0.075 
equiv), and Oxone (8 mg, 0.028 mmol, 2.5 equiv).  Acetonitrile (100 μL), acetic acid (10 
μL, 3.2 mmol, 16.00 equiv), and water (2 μL, 1.6 mmol, 8.00 equiv) were added by 
syringe.  The resulting suspension was stirred for 5 minutes at 23 °C and then heated to 
50 °C in an oil bath.  Upon completion (as determined by TLC analysis), the flask was 
allowed to cool to 23 °C.  The reaction mixture was filtered through a plug of silica gel, 
rinsing with ethyl acetate, and concentrated to give the crude product, which was 















H Pd(OAc)2 (7.5 mol %)Oxone (2.5 equiv)
AcOH (16.0 equiv)
H2O (8.00 equiv)
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Supplementary Synthetic Information Relevant to Chapter 5 
 
 
A10.1  INTRODUCTION 
This section presents poor substrates for the C–H allylic acetoxylation and enal 
formation reactions.  The substrates were either unreactive, gave low yields of the desired 
products as the only isolable material, afforded primarily Wacker–Tsuji oxidation 
products, or decomposed. 
 
A10.2  UNSUCCESSFUL SUBSTRATES IN THE ALLYLIC ACETOXYLATION 
REACTION 
Figure A10.1 presents those substrates that performed poorly under the allylic 
acetoxylation conditions.  The decomposition observed with 622 suggests amide 
coordination may play a role in the allylic C–H functionalization. 
 
                                                
† This work was performed in collaboration with Dr. Xiangyou Xing, alumnus of the Stoltz group.  This 
work has been published, with selected data in this appendix reproduced with permission from Xing, X.; 
O’Connor, N. R.; Stoltz, B. M. Angew. Chem., Int. Ed. 2015, 54, 11186–11190.  Copyright 2015 WILEY-
VCH. 
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Figure A10.1  Poor substrates in the allylic acetoxylation reaction 
 
 
A10.3  UNSUCCESSFUL SUBSTRATES IN THE ENAL FORMATION 
REACTION 
Under the optimized conditions for the formation of enals, many attempted substrates 
instead underwent Wacker–Tsuji oxidation to afford the methyl ketones.  A selection of 
these substrates is shown in Figure A10.2. 
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Figure A10.2  Poor substrates in the enal formation reaction 
 
 
A10.4  CONCLUSIONS 
These problematic substrates illustrate the limitations of this palladium(II)/Oxone 
catalyst system in the realm of allylic C–H functionalization reactions.  Further 
exploration of this system might involve substrates with strongly coordinating directing 
groups (similar to 615) or examination of the role of olefin directing groups, which may 
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Figure 11.3 13C NMR (126 MHz, CDCl3) of compound 586. 
Figure A11.2 Infrared spectrum (thin film/NaCl) of compound 586. 












































Figure A11.6 13C NMR (126 MHz, CDCl3) of compound 587. 
 
Figure A11.5 Infrared spectrum (thin film/NaCl) of compound 587. 
 











































Figure A11.9 13C NMR (126 MHz, CDCl3) of compound 588. 
 
Figure A11.8 Infrared spectrum (thin film/NaCl) of compound 588. 
 












































Figure A11.11 Infrared spectrum (thin film/NaCl) of compound 589. 
 
Figure A11.12 13C NMR (126 MHz, CDCl3) of compound 589. 
 












































Figure A11.15 13C NMR (126 MHz, CDCl3) of compound 590. 
 
Figure A11.14 Infrared spectrum (thin film/NaCl) of compound 590. 
 














































Figure A11.18. 13C NMR (126 MHz, CDCl3) of compound 592. 
 
Figure A11.17 Infrared spectrum (thin film/NaCl) of compound 592. 
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Figure A11.21 13C NMR (126 MHz, CDCl3) of compound 594. 
 
Figure A11.20 Infrared spectrum (thin film/NaCl) of compound 594. 
 











































Figure A11.24 13C NMR (126 MHz, CDCl3) of compound 597. 
 
Figure A11.23 Infrared spectrum (thin film/NaCl) of compound 597. 
 












































































































Figure A11.27 13C NMR (126 MHz, CDCl3) of compound 598. 
 
Figure A11.26 Infrared spectrum (thin film/NaCl) of compound 598. 
 











































Figure A11.30 13C NMR (126 MHz, CDCl3) of compound 599. 
 
Figure A11.29 Infrared spectrum (thin film/NaCl) of compound 599. 
 













































Figure A11.33 13C NMR (126 MHz, CDCl3) of compound 600. 
 
Figure A11.32 Infrared spectrum (thin film/NaCl) of compound 600. 
 












































Figure A11.36 13C NMR (126 MHz, CDCl3) of compound 601. 
 
Figure A11.35 Infrared spectrum (thin film/NaCl) of compound 601. 
 












































Figure A11.39 13C NMR (126 MHz, CDCl3) of compound 602. 
 
Figure A11.38 Infrared spectrum (thin film/NaCl) of compound 602. 
 













































Figure A11.42 13C NMR (126 MHz, CDCl3) of compound 603. 
 
Figure A11.41 Infrared spectrum (thin film/NaCl) of compound 603. 
 












































Figure A11.45 13C NMR (126 MHz, CDCl3) of compound 604. 
 
Figure A11.44 Infrared spectrum (thin film/NaCl) of compound 604. 
 













































Figure A11.48 13C NMR (126 MHz, CDCl3) of compound 531. 
 
Figure A11.47 Infrared spectrum (thin film/NaCl) of compound 531. 
 













































Figure A11.51 13C NMR (126 MHz, CDCl3) of compound 537. 
 
Figure A11.50 Infrared spectrum (thin film/NaCl) of compound 537. 
 














































Figure A11.54 13C NMR (126 MHz, CDCl3) of compound 538. 
 
Figure A11.53 Infrared spectrum (thin film/NaCl) of compound 538. 
 













































Figure A11.57 13C NMR (126 MHz, CDCl3) of compound 539. 
 
Figure A11.56 Infrared spectrum (thin film/NaCl) of compound 539. 
 














































Figure A11.60 13C NMR (126 MHz, CDCl3) of compound 540. 
 
Figure A11.59 Infrared spectrum (thin film/NaCl) of compound 540. 
 














































Figure A11.63 13C NMR (126 MHz, CDCl3) of compound 541. 
 
Figure A11.62 Infrared spectrum (thin film/NaCl) of compound 541. 
 













































Figure A11.66 13C NMR (126 MHz, CDCl3) of compound 542. 
 
Figure A11.65 Infrared spectrum (thin film/NaCl) of compound 542. 
 













































Figure A11.69 13C NMR (101 MHz, CDCl3) of compound 543. 
 
Figure A11.68 Infrared spectrum (thin film/NaCl) of compound 543. 
 












































Figure A11.72 13C NMR (101 MHz, CDCl3) of compound 544. 
Figure A11.71 Infrared spectrum (thin film/NaCl) of compound 544. 
 













































Figure A11.75 13C NMR (126 MHz, CDCl3) of compound 545. 
 
Figure A11.74 Infrared spectrum (thin film/NaCl) of compound 545. 
 













































Figure A11.78 13C NMR (126 MHz, CDCl3) of compound 546. 
 
Figure A11.77 Infrared spectrum (thin film/NaCl) of compound 546. 
 














































Figure A11.81 13C NMR (126 MHz, CDCl3) of compound 547. 
 
Figure A11.80 Infrared spectrum (thin film/NaCl) of compound 547. 
 














































Figure A11.84 13C NMR (126 MHz, CDCl3) of compound 548. 
 
Figure A11.83 Infrared spectrum (thin film/NaCl) of compound 548. 
 















































Figure A11.87 13C NMR (126 MHz, CDCl3) of compound 549. 
 
Figure A11.86 Infrared spectrum (thin film/NaCl) of compound 549. 
 














































Figure A11.90 13C NMR (101 MHz, CDCl3) of compound 550. 
 
Figure A11.89 Infrared spectrum (thin film/NaCl) of compound 550. 
 














































Figure A11.93 13C NMR (126 MHz, CDCl3) of compound 551. 
 
Figure A11.92 Infrared spectrum (thin film/NaCl) of compound 551. 
 















































Figure A11.96 13C NMR (126 MHz, CDCl3) of compound 552. 
 
Figure A11.95 Infrared spectrum (thin film/NaCl) of compound 552. 
 














































Figure A11.99 13C NMR (126 MHz, CDCl3) of compound 553. 
 
Figure A11.98 Infrared spectrum (thin film/NaCl) of compound 553. 
 















































Figure A11.102 13C NMR (126 MHz, CDCl3) of compound 554. 
 
Figure A11.101 Infrared spectrum (thin film/NaCl) of compound 554. 
 

















































Figure A11.105 13C NMR (126 MHz, CDCl3) of compound 555. 
 
Figure A11.104 Infrared spectrum (thin film/NaCl) of compound 555. 
 















































Figure A11.108 13C NMR (126 MHz, CDCl3) of compound 556. 
 
Figure A11.107 Infrared spectrum (thin film/NaCl) of compound 556. 
 
















































Figure A11.111 13C NMR (126 MHz, CDCl3) of compound 557. 
 
Figure A11.110 Infrared spectrum (thin film/NaCl) of compound 557. 
 













































Figure A11.114 13C NMR (126 MHz, CDCl3) of compound 558. 
 
Figure A11.113 Infrared spectrum (thin film/NaCl) of compound 558. 
 













































Figure A11.117 13C NMR (126 MHz, CDCl3) of compound 559. 
 
Figure A11.116 Infrared spectrum (thin film/NaCl) of compound 559. 
 



















































Figure A11.120 13C NMR (126 MHz, CDCl3) of compound 560. 
 
Figure A11.119 Infrared spectrum (thin film/NaCl) of compound 560. 
 














































Figure A11.123 13C NMR (126 MHz, CDCl3) of compound 561. 
 
Figure A11.122 Infrared spectrum (thin film/NaCl) of compound 561. 
 















































Figure A11.126 13C NMR (126 MHz, CDCl3) of compound 562. 
 
Figure A11.125 Infrared spectrum (thin film/NaCl) of compound 562. 
 














































Figure A11.129 13C NMR (126 MHz, CDCl3) of compound 563. 
 
Figure A11.128 Infrared spectrum (thin film/NaCl) of compound 563. 
 















































Figure A11.132 13C NMR (126 MHz, CDCl3) of compound 564. 
 
Figure A11.131 Infrared spectrum (thin film/NaCl) of compound 564. 
 















































Figure A11.135 13C NMR (126 MHz, CDCl3) of compound 565. 
 
Figure A11.134 Infrared spectrum (thin film/NaCl) of compound 565. 
 














































Figure A11.138 13C NMR (126 MHz, CDCl3) of compound 566. 
 
Figure A11.137 Infrared spectrum (thin film/NaCl) of compound 566. 
 














































Figure A11.141 13C NMR (126 MHz, CDCl3) of compound 567. 
 
Figure A11.140 Infrared spectrum (thin film/NaCl) of compound 567. 
 













































Figure A11.144 13C NMR (126 MHz, CDCl3) of compound 569. 
 
Figure A11.143 Infrared spectrum (thin film/NaCl) of compound 569. 
 














































Figure A11.147 13C NMR (126 MHz, CDCl3) of compound 568. 
 
Figure A11.146 Infrared spectrum (thin film/NaCl) of compound 568. 
 















































Figure A11.150 13C NMR (126 MHz, CDCl3) of compound 570. 
 
Figure A11.149 Infrared spectrum (thin film/NaCl) of compound 570. 
 















































Figure A11.153 13C NMR (126 MHz, CDCl3) of compound 571. 
 
Figure A11.152 Infrared spectrum (thin film/NaCl) of compound 571. 
 













































Figure A11.156 13C NMR (126 MHz, CDCl3) of compound 572. 
 
Figure A11.155 Infrared spectrum (thin film/NaCl) of compound 572. 
 
















































Figure A11.159 13C NMR (126 MHz, CDCl3) of compound 573. 
 
Figure A11.158 Infrared spectrum (thin film/NaCl) of compound 573. 
 



























































Figure A11.162 13C NMR (126 MHz, CDCl3) of compound 574. 
 
Figure A11.161 Infrared spectrum (thin film/NaCl) of compound 574. 
 














































Figure A11.165 13C NMR (126 MHz, CDCl3) of compound 576. 
 
Figure A11.164 Infrared spectrum (thin film/NaCl) of compound 576. 
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Table A12.1.1 Experimental Details 
Table A12.1.2 Crystal Data 
Table A12.1.3 Atomic Coordinates  
Table A12.1.4 Full Bond Distances and Angles 
Table A12.1.5 Anisotropic Displacement Parameters 
Table A12.1.6 Hydrogen Atomic Coordinates 
Table A12.1.7 Torsion Angles 
Table A12.1.8 Hydrogen Bond Distances and Angles 
 
 
Figure A12.1.1     X-ray crystal structure of diol 555 
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Table A12.1.1 Experimental details for X-ray structure determination of diol 555 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
D8 VENTURE KAPPA diffractometer coupled to a PHOTON 100 CMOS detector with 
Cu Kα radiation (λ = 1.54178 Å) from an IμS micro-source for the structure of diol 555. 
The structure was solved by direct methods using SHELXS and refined against F2 on all 
data by full-matrix least squares with SHELXL-2014 using established refinement 
techniques. All non-hydrogen atoms were refined anisotropically. Unless otherwise 
noted, all hydrogen atoms were included into the model at geometrically calculated 
positions and refined using a riding model. The isotropic displacement parameters of all 
hydrogen atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 
times for methyl groups).  
Diol 555 crystallizes in the orthorhombic space group P212121 with one molecule in 
the asymmetric unit. The coordinates for the hydrogen atoms bound to O2 and O3 were 
located in the difference Fourier synthesis and refined semi-freely with the help of a 
restraint on the O-H distance (0.84(4) Å).  
 
Table A12.1.2 Crystal data and structure refinement for diol 555 
CCDC deposition number 1057691 
Empirical formula  C19 H27 N O5 
Formula weight  349.41 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
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Table A12.1.2 (cont’d) 
 
Unit cell dimensions a = 7.8598(4) Å a= 90°. 
 b = 11.0342(6) Å b= 90°. 
 c = 20.5656(13) Å g = 90°. 
Volume 1783.58(17) Å3 
Z 4 
Density (calculated) 1.301 Mg/m3 
Absorption coefficient 0.767 mm-1 
F(000) 752 
Crystal size 0.150 x 0.100 x 0.100 mm3 
Theta range for data collection 4.299 to 74.529°. 
Index ranges -9<=h<=9, -8<=k<=13, -25<=l<=25 
Reflections collected 12461 
Independent reflections 3592 [R(int) = 0.0553] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.6907 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3592 / 2 / 234 
Goodness-of-fit on F2 1.056 
Final R indices [I>2sigma(I)] R1 = 0.0368, wR2 = 0.0729 
R indices (all data) R1 = 0.0470, wR2 = 0.0765 
Absolute structure parameter 0.00(14) 
Extinction coefficient n/a 
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Table A12.1.3      Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 
103) for diol 555.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N(1) 3370(3) 3133(2) 986(1) 16(1) 
C(13) 1612(3) 3420(2) 809(1) 18(1) 
C(21) 831(3) 4438(2) 1206(1) 16(1) 
C(22) 282(3) 5492(2) 901(1) 18(1) 
C(23) -554(3) 6393(2) 1254(1) 21(1) 
C(24) -825(3) 6248(2) 1914(1) 23(1) 
C(25) -244(3) 5205(2) 2224(1) 22(1) 
C(26) 579(3) 4304(2) 1873(1) 19(1) 
C(1) 3702(3) 2140(2) 1342(1) 14(1) 
O(1) 2533(2) 1498(1) 1558(1) 17(1) 
C(2) 5551(3) 1718(2) 1435(1) 13(1) 
C(6) 5875(3) 1416(2) 2158(1) 14(1) 
O(2) 4694(2) 530(1) 2395(1) 16(1) 
C(7) 5905(3) 2505(2) 2618(1) 14(1) 
O(3) 4348(2) 3153(2) 2569(1) 17(1) 
C(8) 6201(3) 2075(2) 3309(1) 17(1) 
O(4) 6995(2) 3075(1) 3653(1) 17(1) 
O(5) 6468(3) 2166(2) 4609(1) 26(1) 
C(9) 7090(3) 2982(2) 4303(1) 18(1) 
C(10) 8103(4) 4004(2) 4588(1) 23(1) 
C(11) 5664(3) 524(2) 1031(1) 18(1) 
C(12) 7406(4) -94(2) 1031(2) 25(1) 
C(3) 6887(3) 2629(2) 1183(1) 16(1) 
C(4) 6245(3) 3928(2) 1163(1) 19(1) 
C(5) 4663(3) 3988(2) 751(1) 18(1) 
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Table A12.1.4      Bond lengths [Å] and angles [°] for diol 555 
___________________________________________________________________________________  
N(1)-C(1)  1.343(3) 
N(1)-C(13)  1.464(3) 
N(1)-C(5)  1.469(3) 
C(13)-C(21)  1.519(3) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(21)-C(22)  1.390(3) 
C(21)-C(26)  1.394(4) 
C(22)-C(23)  1.395(4) 
C(22)-H(22)  0.9500 
C(23)-C(24)  1.384(4) 
C(23)-H(23)  0.9500 
C(24)-C(25)  1.392(4) 
C(24)-H(24)  0.9500 
C(25)-C(26)  1.388(4) 
C(25)-H(25)  0.9500 
C(26)-H(26)  0.9500 
C(1)-O(1)  1.241(3) 
C(1)-C(2)  1.539(3) 
C(2)-C(3)  1.543(3) 
C(2)-C(6)  1.544(3) 
C(2)-C(11)  1.560(3) 
C(6)-O(2)  1.434(3) 
C(6)-C(7)  1.530(3) 
C(6)-H(6)  1.0000 
O(2)-H(2O)  0.83(2) 
C(7)-O(3)  1.421(3) 
C(7)-C(8)  1.517(3) 
C(7)-H(7)  1.0000 
O(3)-H(3O)  0.83(2) 
C(8)-O(4)  1.452(3) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
O(4)-C(9)  1.344(3) 
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Table A12.1.4 (cont’d) 
O(5)-C(9)  1.203(3) 
C(9)-C(10)  1.499(4) 
C(10)-H(10A)  0.9800 
C(10)-H(10B)  0.9800 
C(10)-H(10C)  0.9800 
C(11)-C(12)  1.529(4) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
C(3)-C(4)  1.521(3) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-C(5)  1.505(4) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-H(5A)  0.9900 
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Symmetry transformations used to generate equivalent atoms:  
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Table A12.1.5  Anisotropic displacement parameters  (Å2x103) for diol 555.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
N(1) 16(1)  15(1) 16(1)  2(1) -1(1)  0(1) 
C(13) 19(1)  20(1) 16(1)  -1(1) -5(1)  3(1) 
C(21) 12(1)  16(1) 21(1)  -2(1) -2(1)  -2(1) 
C(22) 15(1)  21(1) 19(1)  0(1) -1(1)  -4(1) 
C(23) 18(1)  14(1) 31(2)  1(1) -2(1)  -1(1) 
C(24) 18(1)  21(1) 31(2)  -9(1) 3(1)  -2(1) 
C(25) 18(1)  31(1) 18(2)  -4(1) 1(1)  -5(1) 
C(26) 17(1)  21(1) 20(1)  2(1) -1(1)  -2(1) 
C(1) 17(1)  13(1) 11(1)  -4(1) -1(1)  -1(1) 
O(1) 14(1)  17(1) 21(1)  0(1) 2(1)  -3(1) 
C(2) 11(1)  14(1) 14(1)  -1(1) 1(1)  -1(1) 
C(6) 12(1)  11(1) 17(1)  0(1) 1(1)  0(1) 
O(2) 20(1)  11(1) 19(1)  2(1) 1(1)  -2(1) 
C(7) 14(1)  12(1) 16(1)  0(1) -1(1)  1(1) 
O(3) 18(1)  10(1) 22(1)  -1(1) -1(1)  3(1) 
C(8) 22(1)  11(1) 17(1)  -2(1) -2(1)  0(1) 
O(4) 22(1)  15(1) 14(1)  -1(1) -4(1)  -1(1) 
O(5) 30(1)  31(1) 18(1)  3(1) 2(1)  -5(1) 
C(9) 17(1)  21(1) 15(1)  -1(1) -2(1)  4(1) 
C(10) 22(1)  25(1) 21(1)  -6(1) -2(1)  2(1) 
C(11) 20(1)  16(1) 18(1)  -1(1) 2(1)  0(1) 
C(12) 29(2)  20(1) 27(2)  -4(1) 5(1)  6(1) 
C(3) 14(1)  18(1) 17(1)  1(1) 2(1)  -2(1) 
C(4) 20(1)  16(1) 20(1)  1(1) 1(1)  -4(1) 
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Table A12.1.6     Hydrogen coordinates (x103) and isotropic displacement parameters (Å2x103)  
for diol 555 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________   
H(13A) 908 2683 862 22 
H(13B) 1579 3649 343 22 
H(22) 477 5599 449 22 
H(23) -936 7107 1040 25 
H(24) -1403 6857 2155 28 
H(25) -414 5109 2678 27 
H(26) 972 3595 2089 23 
H(6) 7029 1037 2181 16 
H(2O) 3780(30) 710(30) 2213(14) 25 
H(7) 6860 3054 2489 17 
H(3O) 4550(40) 3884(19) 2621(15) 25 
H(8A) 5108 1855 3517 20 
H(8B) 6954 1356 3312 20 
H(10A) 7558 4284 4989 34 
H(10B) 8156 4674 4275 34 
H(10C) 9258 3723 4685 34 
H(11A) 4815 -56 1203 22 
H(11B) 5347 708 576 22 
H(12A) 8281 495 905 38 
H(12B) 7400 -766 719 38 
H(12C) 7654 -405 1467 38 
H(3A) 7903 2591 1467 20 
H(3B) 7241 2385 740 20 
H(4A) 5988 4211 1609 22 
H(4B) 7132 4463 977 22 
H(5A) 4197 4821 763 22 
H(5B) 4954 3793 295 22 
________________________________________________________________________________  
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Table A12.1.8    Hydrogen bonds for diol 555 [Å and °] 
________________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________________  
 O(2)-H(2O)...O(1) 0.83(2) 1.88(2) 2.645(2) 152(3) 
 O(3)-H(3O)...O(2)#1 0.83(2) 1.91(2) 2.730(2) 169(3) 
 C(10)-H(10C)...O(5)#2 0.98 2.47 3.374(3) 153.9 
 C(4)-H(4A)...O(2)#1 0.99 2.57 3.530(3) 163.7 
 C(4)-H(4A)...O(3) 0.99 2.63 3.364(3) 131.0 
________________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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